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Abstract 
The Water Framework Directive (WFD) was created and adopted as an operational tool 
for quality recovery, protection and assurance of the sustainable use of all water bodies in 
the European Union (EU). Recently, special focus has been paid to the so-called “emerging 
pollutants” (EPs), many of which are ubiquitously distributed in the aquatic compartment. 
Among them, pharmaceutically active substances have generated rising awareness owing 
to their huge variety and consumption, recognised (eco)toxicity, as well as their 
unpredictable environmental impact, even at low concentration levels.  
Pharmaceutical compounds reach the aquatic environment mainly through effluent 
discharges in wastewater treatment plants (WWTPs). Given their high consumption and 
the increasing amount of identified metabolites and transformation products (TPs), 
complex mixtures or “cocktails” of these pollutants are expected to be found in the aquatic 
compartment. Therefore, the first stage of this work consisted on the development and 
validation of an offline solid-phase extraction with simultaneous cleanup capability, 
followed by liquid chromatography–(electrospray ionisation)–ion trap mass spectrometry, 
enabling the concurrent determination of 23 pharmaceuticals of diverse chemical nature, 
among the most consumed in Portugal, in wastewater samples. Several cleanup strategies 
were assayed, exploiting the physical and chemical properties of the analytes vs. 
interferences. After testing all combinations of adsorbents and elution solvents, the best 
results were achieved with the mixed-anion exchange Oasis MAX cartridges. They 
provided recovery rates generally higher than 60%. The precision of the method ranged 
from 2% to 18% and 4% to 19% (except for diclofenac (22%) and simvastatin (26%)) for 
intra- and inter-day analyses, respectively. Method detection limits varied between 1 and 
20 ng L−1 (excluding ibuprofen).  
The developed analytical method was further applied to evaluate the impact caused by the 
discharge of a municipal WWTP on Febros river, a small tributary of Douro river, located 
in the northern region of Portugal, regarding pharmaceutical content only. Febros WWTP 
implication on the pharmaceutical input to Febros river was evidenced by the higher 
pharmaceutical load in samples collected immediately downstream the WWTP discharge 
point, when compared to upstream sampling sites. Moreover, the performance of the 
method was assessed through the participation in two European level inter-laboratory 
exercises (ILEs), promoted by EU-JRC and PHARMAS FP7. Most of our results fell in a 
satisfactory z-score range, which demonstrated the reliability of the developed procedure 
for monitoring pharmaceuticals in water samples. 
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Since the conventional treatment processes employed in most WWTPs seem to be 
inefficient for pharmaceuticals’ complete removal, a tremendous amount of research has 
been recalled in the field of robust new water treatment technologies, leading to the 
complete mineralization of organic pollutants at lower cost and with less energy. In this 
field, advanced oxidation processes (AOPs) have been regarded as promising tools.  
Thus, our following work was mainly focused on advanced photocatalytic treatment 
processes, primarily tested on lorazepam (LZP), a recalcitrant drug, frequently quantified 
in WWTPs’ effluents and surface waters. In a preliminary study, LZP photolytic and 
photocatalytic degradation kinetics were comparatively evaluated using three 
experimental systems: two lab-scale photochemical reactors, one provided with an UV 
medium pressure mercury lamp (LsAUVP) and the other with a blacklight blue lamp 
(LsBLBUV), and a solar pilot plant with compound parabolic collectors (SPP-CPCs). 
Results showed that the best degradation performance was achieved using the SPP-CPCs 
system, by photocatalysis with a TiO2 concentration of 200 mg L-1 (pseudo-first order 
degradation kinetic constant k=1.49±0.03 L kJ-1). Subsequently, LZP phototransformation 
pathways were assessed using ultra-high performance liquid chromatography–
quadrupole-time-of-flight–mass spectrometry (UHPLC/QToF-MS). Six major lorazepam 
by-products (LBPs) were identified and elucidated, with nominal [M+H]+ masses of 337, 
303, 319, 275, 291 and 293 Da.  
Afterwards, the optimized photocatalytic treatment method was further applied to the 
treatment of a real municipal WWTP effluent, containing 22 pharmaceutical compounds 
in moderate concentrations (maximum of 680 ng L-1, except for diclofenac ~24 µg L-1 and 
hydrochlorothiazide ~3 µg L-1). A pseudo-first order kinetic model was able to successfully 
predict all pharmaceuticals’ degradation kinetics. The overall treatment was considered 
efficient, with a complete removal of the majority of these micropollutants, except for 
ciprofloxacin (35%), ketoprofen (61%) and bisoprolol (77%). Finally, V. fischeri acute 
toxicity test showed that the effluent itself presented no significant toxicity and that the 
intermediate oxidation compounds, possibly formed during phototreatment, did not 
reflect any significant increase of toxicity. Therefore, photocatalysis with TiO2 was 
proposed as a viable, green, low cost decontamination method of EPs in domestic 
wastewaters. 
 
Keywords: emerging pollutants; pharmaceutical compounds; liquid chromatography-
mass spectrometry; wastewater treatment plants; advanced oxidation processes 
 xi 
 
Resumo 
A Diretiva-Quadro da Água (DQA) constitui uma ferramenta operacional para a 
recuperação da qualidade de todos os cursos de água na União Europeia (UE), sua 
proteção e garantia do uso sustentável. Recentemente tem sido dado especial ênfase aos 
designados “poluentes emergentes” (PEs), muitos dos quais se encontram distribuídos de 
forma ubíqua no meio aquático. De entre eles, as substâncias farmacêuticas geram 
crescente preocupação, dada a sua grande variedade e consumo, reconhecida 
(eco)toxicidade, além do seu impacto ambiental imprevisível, mesmo em baixos teores. 
Os compostos farmacêuticos atingem o meio aquático principalmente através da descarga 
de efluentes em estações de tratamento de águas residuais (ETARs). Juntamente com 
estas substâncias tem sido identificado um crescente número de metabolitos e produtos de 
transformação (PTs), sendo esperadas misturas complexas ou “cocktails” destes poluentes 
no ambiente. Assim, numa primeira etapa deste trabalho procedeu-se ao desenvolvimento 
e validação de um método de extração em fase sólida offline com cleanup simultâneo, 
seguida de cromatografia líquida-(ionização em electrospray)-espectrometria de massa 
(ion trap), permitindo a determinação concomitante de 23 fármacos, de entre os mais 
consumidos em Portugal, em águas residuais. Testaram-se diferentes estratégias de 
cleanup, explorando as propriedades físico-químicas dos analitos vs. interferências. Após 
o ensaio de várias combinações de adsorventes e solventes de eluição, os melhores 
resultados foram obtidos com os cartuchos de troca iónica mistos Oasis MAX (mixed-
anion exchange). Estes cartuchos permitiram a obtenção de taxas de recuperação, em 
geral, superiores a 60%. A precisão do método variou entre os 2-18% e os 4-19% (exceto 
para a sinvastatina (26%) e o diclofenac (22%)), expressa em repetibilidade e precisão 
intermédia, respectivamente. Os limites de detecção variaram entre 1-20 ng L-1 (exceto o 
ibuprofeno). 
O método analítico desenvolvido foi posteriormente aplicado na avaliação do impacto 
causado pela descarga de uma ETAR municipal no rio Febros, um afluente do rio Douro. A 
contribuição da ETAR de Febros para a contaminação daquele rio com compostos 
farmacêuticos foi evidenciada pela elevada carga destes compostos nas amostras colhidas 
imediatamente a jusante do ponto de descarga da ETAR, quando comparadas com os 
pontos a montante. A performance do método foi também avaliada pela participação em 
dois ensaios interlaboratoriais (EILs), promovidos pelo EU-JRC e pelo projeto PHARMAS 
FP7. A maioria dos resultados obtidos foi classificada com z-score satisfatório 
demonstrando assim a fiabilidade do método desenvolvido para a monitorização de 
fármacos em amostras de água. 
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Dado que os processos de tratamento convencionais utilizados na maioria das ETARs se 
têm revelado ineficazes na remoção completa dos fármacos, tem-se assistido a um 
aumento exponencial da investigação em novas tecnologias de tratamento de águas, 
capazes de promover a completa mineralização dos poluentes orgânicos, com baixo custo e 
reduzido consumo energético. Neste campo, os processos avançados de oxidação (PAOs) 
têm-se revelado ferramentas bastante promissoras. 
Assim, a etapa seguinte deste trabalho centrou-se nos processos de tratamento 
fotocatalítico avançados, usando o lorazepam (LZP) como modelo, um fármaco 
recalcitrante presente em efluentes de ETARs e águas superficiais. Compararam-se as 
cinéticas de degradação fotolítica e fotocatalítica do LZP, utilizando três sistemas 
experimentas: dois reatores fotoquímicos à escala laboratorial, um constituído por uma 
lâmpada UV de mercúrio de média pressão (LsAUVP) e outro por uma lâmpada de luz 
negra (LsBLBUV), e ainda uma instalação solar piloto com coletores parabólicos 
compostos (SPP-CPCs). Os resultados obtidos mostraram que o maior rendimento de 
degradação se obteve com o sistema SPP-CPCs, por fotocatálise com TiO2, na 
concentração de 200 mg L-1 (cinética de pseudo-primeira ordem, k=1.49±0.03 L kJ-1). De 
seguida, estudaram-se os mecanismos de fototransformação do LZP, utilizando a técnica 
de cromatografia líquida de ultra performance–espectrometria de massa por “tempo-de-
vôo” (time-of-flight) (UHPLC/QToFMS). Identificaram-se seis produtos de degradação do 
LZP com massas nominais [M+H]+ de 337, 303, 319, 275, 291 e 293 Da. 
Por último, o método de tratamento fotocatalítico otimizado foi posteriormente aplicado 
no tratamento de efluente de uma ETAR municipal, contaminado com 22 compostos 
farmacêuticos em concentrações moderadas (máximo de 680 ng L-1, exceto diclofenac ~24 
µg L-1 e hidroclorotiazida ~24 µg L-1). A degradação dos fármacos seguiu uma cinética de 
pseudo-primeira ordem. Em geral, o tratamento foi considerado bastante eficiente, 
conseguindo-se uma remoção completa destes micropoluentes, com a exceção da 
ciprofloxacina (35%), do cetoprofeno (61%) e do bisoprolol (77%). Finalmente, foram 
realizados testes de toxicidade aguda ao V. fischeri, tendo-se revelado a ausência de 
toxicidade significativa no efluente inicial. Verificou-se ainda que os compostos 
intermediários potencialmente formados durante o fototratamento não contribuíram para 
o aumento da toxicidade. Assim sendo, o processo fotocatalítico com TiO2 foi proposto 
como um processo viável, amigo do ambiente e de baixo custo para a descontaminação de 
águas residuais com poluentes emergentes. 
Palavras-chave: poluentes emergentes; compostos farmacêuticos; cromatografia 
líquida–espectrometria de massa; estações de tratamento de águas residuais; processos 
avançados de oxidação 
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Chapter 1 
General Introduction  
 
1.1. Water Quality Policy and Legislation 
Nowadays, one of the most relevant topics in the environmental field is water quality. It 
has been evident for a considerable time now the increasing demand by citizens and 
environmental organizations for cleaner rivers, lakes, groundwater and coastal beaches. 
This demand was precisely one of the main reasons why the European Commission (EC) 
has made water protection one of its top work priorities. Whilst some actions taken in the 
past by the European Union (EU), such as the Drinking Water Directive (DWD) and the 
Urban Waste Water Directive (UWWD), can properly be considered milestones, a renewed 
European Water Policy was mandatory to address the increasing awareness of citizens and 
other involved parties. Consequently, and as the outcome of a consultation process 
involving all interested parties, the Commission presented a Proposal for a Water 
Framework Directive, with the following key aims (1):  
i) expanding the scope of water protection to all waters, surface waters and 
groundwater;   
ii) achieving “good status” for all waters by a set deadline; 
iii) water management based on river basins;  
iv) “combined approach” of emission limit values and quality standards;  
v) getting the prices right;  
vi) getting the citizens involved more closely;  
vii) streamlining legislation. 
Hence, the Water Framework Directive (WFD, Directive 2000/60/EC) was created and 
adopted as an operational tool, setting the objectives for water protection. It presented a 
huge breakthrough in the EU water policy, aiming to achieve a good ecological and 
chemical status for all surface waters at the latest 15 years from the date of entry into 
force, i.e., 22 December 2000. Furthermore, the WFD was later amended by Decision no. 
2455/2001/EC, that established a list of 33 priority substances given their significant risk 
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to the aquatic environment, and even more recently by Directive 2008/105/EC, which laid 
down environmental quality standards (EQS) for priority substances and other certain 
pollutants, as provided for in Article 16 of the WFD (1, 2). 
In order to accomplish the co-ordination of the objectives and achieve a good status for all 
waters by the set deadline, it became necessary to define the best model for a single system 
of water management. As a result, the management by river basin – the natural 
geographical and hydrological unit – was adopted, instead of according to administrative 
or political boundaries. Meanwhile, though several Member States are already 
undertaking “the river basin approach”, some national and international river basin 
districts are still not established (Fig. 1.1). Furthermore, all river basin districts must be 
updated every six years, in order to provide the context for all co-ordination requirements 
aforementioned (1).   
 
1.2. Emerging Environmental Pollutants 
Over the last few decades, the focus of environmental research has been extended from the 
conventional “priority pollutants”, such as polycyclic aromatic hydrocarbons (PAHs), 
polychlorinated biphenyls (PCBs), dioxins and pesticides, to the so called “emerging 
pollutants” (EPs), many of which are ubiquitously distributed in the aquatic compartment. 
EPs are not necessarily new chemicals; they also include substances that have long been 
present in the environment but whose presence and significance are only now being 
elucidated. Therefore, the rising interest on such organic micropollutants is not only 
concomitant with their increased diversity, widespread and growing use, but also with the 
development of new highly sensitive analytical tools, namely liquid chromatography (LC) 
coupled with mass spectrometry (MS). Such analytical hyphenated technique led to a 
“revolution” in environmental analysis, enabling the identification and quantification of 
polar organic pollutants down to relatively low concentrations, in all kinds of waters 
(wastewater, surface water, ground water, drinking water) and in solid matrices (sewage 
sludge, manure, sediment) (3-5). 
However, emerging pollutants correspond in most cases to unregulated contaminants and 
are generally not included in the monitoring campaigns enforced by EU legislation. 
Consequently, there is the need to build knowledge on their occurrence, levels and fate in 
the environment, as well as to elucidate their long-term risks,  ecotoxicity  and  human 
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Fig. 1.1. Map presenting the national and international river basin districts, as designated 
by Member States (1). 
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health impact, which might be used as evidence for future regulation (2, 6). Emerging 
pollutants are considered “pseudo-persistent” compounds, since their 
transformation/removal rates can be compensated by their continuous introduction into 
the environment. Moreover, their recalcitrant character, together with their polarity, 
favour their spread along the aquatic compartment (7). 
The NORMAN Network, established since 2009 as a permanent self-sustaining network of 
reference laboratories, research centres and related organizations for the monitoring and 
biomonitoring of emerging environmental substances, started its activities in September 
2005, with the financial support of the European Commission (NORMAN project – 6th 
Framework Programme – Priority 6.3). Currently, it proposes a preliminary list of 
emerging substances, built upon the results collected by Member States, after several 
European surveys. Herein, different classes of compounds are included, from algal toxins 
to anticorrosives, antifoaming agents, antifouling compounds, antioxidants, biocides, bio-
terrorism/sabotage agents, complexing agents, detergents, disinfection by-products 
(drinking water), drugs of abuse, flame retardants, food additives, fragrances, gasoline 
additives, industrial chemicals, nanoparticles, perfluoroalkylated substances and their 
transformation products, personal care products, pesticides, pharmaceuticals, plasticizers, 
trace metals and their compounds, wood preservatives, among others (for individual 
substances, please refer to Annex I) (8).  
Furthermore, the NORMAN Association has also created an interactive database – 
EMPODAT, designed to assemble the geo-referenced monitoring and bio-monitoring data 
collected by its members on emerging substances in air, water and soil. Each contact point 
across the Member States is requested to provide information concerning data sources, 
sample matrices and analytical methods employed to obtaining the results. In conclusion, 
the EMPODAT database allows access to the latest information on emerging pollutants, 
with an overview of benchmark values on the occurrence of emerging substances across 
Europe, as well as the identification of gaps in data relating to time, geographical areas 
and/or environmental matrices.  
Among all emerging substances in water, special attention has been given to 
pharmaceutical products and residues. This rising awareness is attributed to their growing 
variety and consumption, recognised (eco)toxicity, as well as their unpredictable 
environmental impact, even at low concentration levels (9, 10). 
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1.2.1. Pharmaceutical Compounds 
1.2.1.1. Definition and Classification by Therapeutic Group 
The European Medicines Agency (EMEA) is responsible for establishing the rules 
governing human and veterinary medicinal products in the EU. According to Directive 
2001/83/EC, of November 6, on the Community code relating to medicinal products for 
human use, later amended by Directive 2004/27/EC, of March 31, a medicinal product is 
(11): 
i) any substance or combination of substances presented as having properties for 
treating or preventing disease in human beings; or 
ii) any substance or combination of substances which may be used in or administered 
to human beings either with a view to restoring, correcting or modifying 
physiological functions by exerting a pharmacological, immunological or metabolic 
action, or to making a medical diagnosis. 
In Portugal, there is an annual edition of the Therapeutic Handbook, mainly addressed to 
medical doctors, pharmacists and other health care professionals, which sets the 
guidelines for the therapeutic use of drugs and constitutes an essential tool for the rational 
use of medicines, providing guidance during prescription. It contains the monographs of 
all medicines marketed in Portugal and available in pharmacies, as well as some that, 
although available only in hospitals, are of particular interest for patients continuing the 
treatment process at the clinic. In the Therapeutic Handbook, medicines are grouped by 
pharmaceutically active substance, according to the respective therapeutic group. The first 
10 therapeutic groups and respective sub-groups included in this Handbook are displayed 
in Table 1.1, since they include the pharmaceutical compounds most widely studied as 
environmental pollutants (12). 
According to NORMAN, Table 1.2 shows a list of pharmaceutical pollutants which are 
object of study by EU Member States, as well as all over the world. Moreover, at the 
NORMAN Association website, further information including the systematic name 
(IUPAC), CAS number and therapeutic sub-class of every pharmaceutical compound can 
be found (8). 
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Table 1.1. Therapeutic groups according to the Portuguese Therapeutic Handbook (12) 
THERAPEUTIC HANDBOOK                               
Therapeutic Groups                                                           Edition 2011 
GROUP 1 - Anti-infective Medicines 
1.1. Antibacterials 
1.2. Antifungals 
1.3. Antivirals 
1.4. Antiparasitics 
 
 
GROUP 2 - Central Nervous System (CNS) 
2.1. General Anesthetics 
2.2. Local Anesthetics 
2.3. Muscle Relaxing Agents 
2.4. Antimyasthenia Agents 
2.5. Antiparkinsonian Agents 
2.6. Antiepileptics and Anticonvulsivants 
2.7. Antiemetics and Antivertigo Agents 
2.8. Unspecific Stimulants of CNS 
2.9. Psychopharmaceuticals 
2.10. Analgesics and Antipyretics 
2.11. Medicines for Headache 
2.12. Narcotics 
2.13. Others 
 
 
GROUP 3 - Cardiovascular System 
3.1. Cardiotonics 
3.2. Antiarrhythmics 
3.3. Sympathomimetics  
3.4. Antihypertensives  
3.5. Vasodilators 
3.6. Venotropics 
3.7. Lipid Regulators 
 
 
GROUP 4 - Blood 
4.1. Antianemic Agents 
4.2. Hematopoietic Growth Factors 
4.3. Anticoagulant and Antithrombotic Agents 
4.4. Antihemorrhagic Agents 
 
 
GROUP 5 - Respiratory System 
5.1. Antiasthmatics and Bronchodilators 
5.2. Antitussives and Expectorants 
5.3. Pulmonary Tensoactive Agents (Surfactants) 
GROUP 6 - Digestive System 
6.1. Medicines acting on Mouth and Orofaringe 
6.2. Antacids and Anti-ulcer Agents 
6.3. Modifiers of Gastrointestinal Motility 
6.4. Antispasmodics 
6.5. Enzyme Inhibitors 
6.6. Enzyme Suplements and Analogs  
6.7. Antihemorrhoid Agents 
6.8. Intestinal Anti-inflammatory Agents 
6.9. Medicines acting on Liver and Biliary 
 
 
GROUP 7 - Genitourinary System 
7.1. Vaginal Medicines 
7.2. Medicines acting on Uterus 
7.3. Urinary Anti-infective and Antiseptic Agents 
7.4. Others 
 
 
GROUP 8 - Hormones and Medicines for 
Endocrine Diseases 
8.1. Hypothalamus and Pituitary Hormones, their 
Analogs and Antagonists  
8.2. Corticosteroids  
8.3. Thyroid Hormones and Antagonists 
8.4. Insulins, Oral Antidiabetics and Glucagon 
8.5. Sex Hormones 
8.6. Ovulation Stimulants and Gonadotropins 
8.7. Anti-hormones 
 
 
GROUP 9 - Locomotor System 
9.1. Non-Steroidal Anti-inflammatory Drugs 
9.2. Rheumatism Modifiers 
9.3. Medicines used for Arthritis 
9.4. Medicines used for Arthrosis 
9.5. Anti-inflammatory Enzymes 
9.6. Medicines acting on Bones and Calcium Metabolism 
 
 
GROUP 10 - Antialergics 
10.1. Antihistamines  
10.2. Corticosteroids 
10.3. Sympathomimetics 
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Table 1.2. Pharmaceutical emerging pollutants, according to the NORMAN Network (8) 
 
(R)-O-Desmethyl Naproxen 
17-alpha-Estradiol 
17-alpha-Ethinylestradiol 
17-beta-Estradiol 
Acebutolol 
Acecarbromal 
Aceclofenac 
Acemetacin 
Acetaminophen (paracetamol) 
Acetazolamide 
Acetylsalicylic acid (aspirin) 
Acyclovir 
Albuterol 
Albuterol sulfate 
Alclofenac 
Allobarbital 
Alprazolam 
Amitryptiline 
Amobarbital 
Amoxicillin 
Ampicillin 
Anthracen-1,4-dione 
Apramycin 
Aprobarbital 
Atenolol 
Azithromycin 
Baclofen 
Baquiloprim 
Betamethasone 
Beta-sitosterol 
Betaxolol 
Bezafibrate 
Bisoprolol 
Bromazepam 
Butalbital 
Caffeine 
Carazolol 
Carbamazepine 
Cefacetrile 
Cefalexin 
Cefalonium 
Cefapirin 
Cefazolin 
Cefoperazone 
Chloral hydrate 
Chloramphenicol 
Chlorobutanol 
Chlortetracycline 
Cholesterol 
Ciprofloxacin 
Citalopram 
Clarithromycin 
Clenbuterol 
Clofibric acid 
Clotrimazole 
Cloxacillin 
Codeine 
Cotrimoxazole 
Crotamiton 
Cyclophosphamide 
Cyclophosphamide (anhydrous) 
Danofloxacin 
Dantrolene 
Dapsone 
Daunorubicin 
Dexamethasone 
Diatrizoate 
Diazepam 
Diclofenac 
Dicloxacillin 
Diethylstilbestrol 
Difloxacin 
Diphenhydramine 
Domperidone 
Doxepine 
Doxorubicin 
Doxycycline (anhydrous) 
Doxycycline (monohydrate) 
Enoxacin 
Enrofloxacin 
Epirubicin 
Erythromycin 
Escitalopram 
Esomeprazole 
Estriol 
Estrone 
Estrone sulphate 
Ethosuximide 
Etofibrate 
Famotidine 
Fenfluramine 
Fenofibrate 
Fenofibric acid 
Fenoprofen 
Fenoprofen calcium salt dihydrate 
Fenoterol 
Flucloxacillin 
Flumequine 
Fluorouracil 
Fluoxetine 
Fluvoxamine 
Furosemide 
Gemfibrozil 
Gentamicin 
Glyburide (glibenclamid; glybenzcyclamide) 
Hexobarbital 
Hydrochlorothiazide 
Hydrocodone 
Ibuprofen 
Ibuprofen 1-hydroxy 
Ibuprofen 2-hydroxy 
Ifosfamide 
Imapramine 
Iminostilbene 
Indomethacin 
Iohexol 
Iomeprol 
Iopamidol 
Iopromide 
Ivermectin 
Josamycin 
Kanamycin sulfate 
Ketoprofen 
Lamotrigine 
Lansoprazole 
Levetiracetam 
Lidocaine 
Lincomycin 
Lithium carbonate 
Loratadine 
Lorazepam 
Lovastatin 
Marbofloxacin 
Mebeverine 
Meclofenamic acid 
Medazepam 
Mefenamic acid 
Meprobamate 
Mestranol 
Metformin 
Methicillin 
Methylphenobarbital 
Metoprolol 
Mevastatin 
Minocycline 
Nadolol 
Nafcillin 
Nandrolone 
Naproxen 
Neomycin B 
N-Methylphenacetine 
Nordiazepam 
Norfloxacin 
Novobiocin 
Ofloxacin 
Oleandomycin 
Omeprazole 
Oxacillin 
Oxalinic acid 
Oxazepam 
Oxprenolol 
Oxytetracycline 
Paroxetine 
Penicillin G 
Penicillin V 
Pentobarbital 
Pentoxifylline 
Phenazone 
Phenobarbital 
Phenylbutazone 
Phenytoine 
Pindolol 
Pipamperon 
Pravastatin 
Prednisolone 
Primidone 
Propranolol 
Propyphenazone 
Ranitidine 
Roxithromycin 
Salbutamol 
Sarafloxacin 
Secobarbital 
Secobarbital sodium 
Sertraline 
Simvastatin 
Sotalol 
Spectinomycin 
Spiramycin 
Streptomycin 
Sulfadiazine 
Sulfadimethoxine 
Sulfadoxine 
Sulfamerazine 
Sulfamethazine 
Sulfamethoxazole 
Sulfapyridine 
Taloxa 
Temazepam 
Terbutaline 
Tetracycline 
Tiamulin 
Tilmicosin 
Timolol 
Tolfenamic acid 
Tramadol 
Trimethoprime 
Tylosin 
Valnemulin 
Valproic acid 
Verapamil 
Zolpidem 
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1.2.1.2. Consumption: Worldwide, in Europe and in Portugal 
Still in 2004, the global consumption of drugs (as total pharmaceutical formulation) 
produced and used by humans was estimated to be 100,000 metric tons (t) per year, 
corresponding to a worldwide average per capita consumption of approximately 15 g.cap-
1.a-1 (13). However, according to statistical studies conducted in the United States of 
America (USA) and in Sweden regarding industrialized countries, it was foreseen that the 
consumption of active pharmaceutical substances would still rise up to the range between 
50 and 150 g.cap-1.a-1. Moreover, these two surveys showed that ca. 95% of the total 
consumption of pharmaceutical substances corresponded to less than 50 of the 130 
compounds investigated (14, 15).  
The trends on pharmaceuticals use clearly vary between different countries. For instance, 
in Germany, the amount of active compounds in use was estimated to be around 3,000, 
though this number is certainly underestimated due to over-the-counter (OTC) drugs, i.e., 
drugs acquired without medical prescription, besides those procured illegally. Likewise, 
prescription drugs are generally sold in quantities at least one order of magnitude lower 
than non-prescription drugs (5). In contrast to Germany, sales in the USA for compounds 
such as carbamazepine and ciprofloxacin have shown a trend of decreasing use between 
the years 1995 and 2001, whereas metoprolol use has been increasing in both countries 
(16). Several publications regarding consumption data in England, Denmark and 
Australia, have also displayed an intensive use of pharmaceutical products. Nonetheless, 
despite being possible to establish a similar consumption pattern for many 
pharmaceuticals between several EU countries, obvious differences can also be spotted 
when comparing specific pharmaceutical products among different countries (17, 18). 
Besides the considerable variation over different countries, pharmaceuticals consumption 
also varies over time, with the introduction of new products in the market, and according 
to the season. For example, the use of compounds such as metoprolol, carbamazepine, 
diclofenac, iomeprol and ciprofloxacin, has been increasing in Germany between 1996 and 
2001. On the contrary, the consumption of drugs such as gemfibrozil, naproxen and 
erythromycin has been decreasing over the same time period (5). Regarding seasonal 
differences, a study in Switzerland has shown that, during the winter season, loads of 
macrolide antibiotics in sewage treatment plants (STPs) were two times higher than in 
summer. Nevertheless, these differences can be attributed to either lower elimination 
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rates of pharmaceuticals in STPs and/or sewer, due to minor biological activity, or to the 
higher input in winter (19). 
As far as veterinary medicines are concerned, according to the European Federation of 
Animal Health (FEDESA), the annual consumption of antibiotics in the EU (including 
Switzerland) in the year 1999 was in total 13,288 t with 29% (3,850 t) for veterinary 
medicine (therapy and prophylaxis), 6% (800 t) as antibiotic feed additives and 65% 
(8,600 t) in human medicine. In the particular case of Switzerland, in 1997, before the 
banning of veterinary growth promoters, approximately 90 t of antibiotics were used, with 
38% (34 t) in human medicine and 62% (56 t) in veterinary medicine. In 1999, after the 
banning of the growth promoters, antibiotics consumption dropped 33% in feeds, between 
1995 and 2000, to a level of 17.3 t annually. On the other hand, the annual volume of 
antibiotics used in human medicine remained fairly constant (19). 
In Portugal, the data on the environmental prevalence and distribution of pharmaceutical 
compounds is still quite scarce. However, there are clear trends concerning 
pharmaceuticals consumption over the last few years, as corroborated by the results 
provided by INFARMED – the Portuguese National Authority of Medicines and Health 
Products, IP. INFARMED is a Government agency accountable to the Health Ministry, 
whose objective is to monitor, assess and regulate all activities relating to human 
medicines and health products for the protection of Public Health (20). 
Table 1.3 presents a list of the 30 most marketed pharmaceutical compounds in Portugal, 
over the years 2005, 2007 and 2009. As one can observe, paracetamol highlights in the 
first position of the ranking for the three years, while alprazolam, simvastatin and 
metformin also find place in the “top 10” for the three years. Moreover, all other 26 
pharmaceutically active substances remain in the group of the 30 most commercialized 
over the studied years, with slight modifications in position. A few exceptions include 
alendronic acid, amlodipine, ambroxol, glibenclamide and nifedipine, which from 2005 to 
2007 were replaced in this ranking by acetylsalicylic acid, glucosamine, clopidogrel, 
irbesartan and perindopril. On the other hand, from 2007 to more recently in 2009, the 
association ethinylestradiol+gestodene, glucosamine, acarbose and atorvastatin were also 
outpaced by levothyroxine, tamsulosin, betahistine and rosuvastatin. 
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 Table 1.3. Pharmaceutical compounds ordered from the highest to the lowest sales 
amount in Portugal, over the years 2005/2007/2009, according to INFARMED (20) 
Ranking 
                    2005                     2007                     2009 
Active 
Substance Packages 
Active 
Substance Packages 
Active 
Substance Packages 
1 Paracetamol 3 863 422 Paracetamol 3 520 490 Paracetamol 3 642 302 
2 Alprazolam 2 801 120 Alprazolam 2 208 290 Simvastatin 2 941 467 
3 Nimesulide 2 155 332 Simvastatin 2 144 523 Metformin 2 429 287 
4 Diclofenac 2 019 393 Amoxicillin + Clavulanic acid 2 091 167 Alprazolam 2 280 686 
5 Trimetazidine 1 974 870 Metformin 2 011 843 Amoxicillin + Clavulanic acid 2 239 124 
6 Amoxicillin + Clavulanic acid 1 897 584 Trimetazidine 1 992 384 Trimetazidine 2 102 559 
7 Simvastatin 1 787 970 Diclofenac 1 947 175 Omeprazole 2 029 495 
8 Metformin 1 745 421 Lorazepam 1 888 586 Ibuprofen 2 016 009 
9 Indapamide 1 724 022 Indapamide 1 775 043 Lorazepam 1 909 169 
10 Lorazepam 1 665 454 Omeprazole 1 650 237 Diclofenac 1 817 520 
11 Omeprazole 1 459 827 Ibuprofen 1 633 842 Acetylsalicylic acid 1 778 370 
12 Bromazepam 1 452 038 Nimesulide 1 622 152 Indapamide 1 743 762 
13 Ibuprofen 1 438 448 Gliclazide 1 342 691 Nimesulide 1 510 441 
14 Diazepam 1 364 734 Bromazepam 1 207 555 Gliclazide 1 355 017 
15 Ethinylestradiol + Gestodene 1 199 641 Diazepam 1 146 901 
Influenza 
vaccines 1 343 266 
16 Gliclazide 1 187 588 Furosemide 1 146 044 Furosemide 1 312 465 
17 Alendronic acid 1 122 161 Ethinylestradiol + Gestodene 1 125 664 Bromazepam 1 196 396 
18 Influenza vaccines 1 004 026 
Acetylsalicylic 
acid 1 107 377 Flavonoids 1 170 030 
19 Zolpidem 981 630 Influenza vaccines 1 028 351 Clopidogrel 1 153 693 
20 Furosemide 968 630 Flavonoids 1 017 510 Losartan + 
Hydrochlorothiazide 1 139 107 
21 Amlodipine 957 691 Zolpidem 980 308 Diazepam 1 130 220 
22 Acarbose 945 264 Glucosamine 969 137 Bisoprolol 1 126 119 
23 Azithromycin 938 614 Losartan + 
Hydrochlorothiazide 943 100 Zolpidem 1 078 175 
24 Ambroxol 935 946 Clopidogrel 942 154 Irbesartan + 
Hydrochlorothiazide 1 021 011 
25 Flavonoids 932 684 Bisoprolol 901 661 Levothyroxine 963 390 
26 Glibenclamide 907 202 Acarbose 893 544 Tamsulosin 951 188 
27 Atorvastatin 778 436 Azithromycin 892 528 Perindopril 941 067 
28 Nifedipine 764 028 Irbesartan + 
Hydrochlorothiazide 884 087 Betahistine 934 658 
29 Losartan + 
Hydrochlorothiazide 763 278 Atorvastatin 842 300 Rosuvastatin 913 081 
30 Bisoprolol 717 100 Perindopril 823 971 Azithromycin 912 055 
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In conclusion, all these results indicate that there are significant seasonal and regional 
differences of pharmaceutical loads, which consequently affect their concentrations in the 
aquatic compartment. Thus, such variations must be always considered for a proper 
environmental risk assessment, without ever disregarding the fact that, in the water cycle, 
the variety of chemical compounds is further enlarged by metabolites formed in the 
human body, through microbial activity or via diverse environmental and/or artificial 
transformation processes (21, 22).  
 
1.2.1.3. Pollution Sources, Environmental Occurrence and Fate 
Pharmaceutical compounds are ubiquitary substances, often persistent and 
bioaccumulable in the environment, namely in the aquatic compartment. As the majority 
of organic micropollutants, the environmental contamination by pharmaceuticals is 
mainly of anthropogenic origin (10). 
 
 
Fig. 1.2. Representative sources and routes of pharmaceutical compounds in the 
environment (from Mompelat et al. (10)). 
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As according to Fig. 1.2, after intake pharmaceuticals can be partially metabolized and 
both the native compound and/or its metabolites are excreted via urine and/or faeces, 
through the sewer network as urban wastewater, until reaching the wastewater treatment 
plants (WWTPs), or they can be also released directly into septic tanks, as it is usual in 
countryside households (23). Direct release can occur as well by improper disposal of 
unused or expired drugs, thrown directly in toilets, from manufacture spill accidents or, in 
the case of veterinary pharmaceuticals, via application in aquaculture (24). On the other 
hand, indirect release may happen by way of animals topically treated and mainly via run-
off and leaching through fields from manure spreading to agricultural fields and livestock 
wastes (25, 26). 
However, it is consensual that the most significant entry route for pharmaceuticals into 
the aquatic environment is the release from WWTPs. Since there is no unit specifically 
designed to remove these compounds, the treatment processes used by most WWTPs 
seems to be inefficient and, along with the treated wastewater, these pollutants are 
released to the aquatic environment (27, 28). Afterwards, and once surface waters can be 
physically closely linked to groundwaters, they can contaminate one another, even after 
soil or bank filtration (29). Finally, and before drinking water distribution, the ultimate 
elimination step of pharmaceuticals in raw water may take place during the treatment 
processes at water treatment plants (WTPs) (Fig. 1.2).  
Hence, large amounts of pharmaceuticals can be discharged into the aquatic environment 
after being used, which will further enable their detection in wastewater, surface water, 
groundwater and even drinking water, at ng L-1 to several µg L-1 levels (30, 31). 
Nonetheless, and since the occurrence patterns of pharmaceuticals in WWTPs are related 
to local production and/or sales figures, as previously described in section 1.2.1.2., 
regional surveys need to be conducted (32). Furthermore, environmental conditions in the 
receiving body vary a lot across latitudes. 
According to data in already published literature, the main therapeutic classes drawing the 
attention of the scientific community are non-steroidal anti-inflammatory drugs 
(NSAIDs), lipid regulators, antibiotics and sex hormones, as presented in Fig. 1.3. For 
example, Brown et al. (33) studied the environmental fate of ofloxacin, a fluoroquinolone 
antibiotic, first detected at 35.5 µg L-1 in an Albuquerque (New Mexico, USA) hospital 
effluent, while in the Albuquerque WWTP only 410 ng L-1 and 110 ng L-1 were found, in the 
influent and effluent, respectively.  Finally, in the Rio Grande River, which receives the 
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WWTP effluent, ofloxacin was already below the detection limit. On the other hand, 
NSAIDs usually present the higher concentrations in surface waters, ranging from few ng 
L-1 up to ca. 20 µg L-1, being diclofenac, paracetamol and ibuprofen the most quantitatively 
found (34). 
 
 
Fig. 1.3. Therapeutic classes of pharmaceuticals detected in the environment (expressed 
in relative percentage). Data collected from 134 articles published between 1997 and 2009 
(adapted from Santos et al. (9)). 
 
Groundwater contamination by pharmaceutical compounds is much less reported. 
However, few were already detected, such as paracetamol at 211 ng L-1 in French wells and 
carbamazepine up to 465 ng L-1 between 5-10 m below ground in bank filtration transects 
in Germany (35, 36). Besides, ibuprofen, salicylic acid, gemfibrozil, naproxen, 
indomethacin and bezafibrate were also found in effluents of septic tanks in Ontario, 
Canada, up to 2150, 480, 430, 300, 4 and 12 ng L-1, respectively (23). 
With regard to drinking water, results are even scarcer and most countries (if any) do not 
have monitoring programs to routinely test drinking water for pharmaceuticals, due to 
practical difficulties. Thus, the majority of the occurrence data comes from targeted 
research projects/investigations and ad hoc surveys (37). For instance, studies in the USA 
conducted by Benotti et al. (38) have detected very low concentrations of pharmaceuticals 
in finished drinking water, with the highest value of 40 ng L-l reported for meprobamate. 
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In the Netherlands, however, antibiotics, antiepileptics and β-blockers have been detected 
at concentrations up to 100 ng L-1 in the drinking water supply (39). It is estimated that, to 
date, there have been detected between 15 and 25 pharmaceutical compounds in drinking 
water all over the world (37). 
As previously stated, pharmaceutical compounds can be metabolized in humans or 
animals organism, then both native compounds and metabolites can reach the 
environment and originate different transformation products, under various physico-
chemical and biological processes, as in WWTPs or waterworks. Thus, the designation of 
“by-products” (BPs) was created to comprise both the excreted metabolites and the 
environmental transformation products (10). The fate and behaviour of pharmaceuticals 
and their BPs in the environment still requires further elucidation. Nevertheless, it is 
understandable that their concentration levels in receiving waters can be attenuated first 
by dilution and then adsorption on suspended solids and sediments, colloids or other 
organic matter. They may also undergo biotic and/or physico-chemical transformations, 
namely direct and indirect photodegradation reactions, besides, hydrolysis, 
oxidation/reduction, isomerisation, etc.  (40, 41). These phototransformation processes 
will be further discussed on chapter 4 of the present thesis.  
 
1.2.1.4. Risk Assessment and (Eco)Toxicity 
Results of toxicology studies have revealed that some pharmaceuticals are suspected to 
have direct toxicity towards certain aquatic organisms. Moreover, their continual but 
undetectable effects can slowly accumulate, finally leading to irreversible changes on both 
wildlife and human beings (42, 43). It is essential to foster the study on ecotoxicological 
hazards, to go through a comprehensive evaluation of the toxicity effects on non-target 
organisms, using tests for both acute effects (e.g., measuring mortality rate) and chronic 
effects (e.g., exposing to different concentrations of a chemical over a prolonged period of 
time and measuring growth index or reproduction rate) (44). These latter are particularly 
scarce, possibly owing to their complex experimental procedure (45). 
There is a huge concern associated to the environmental contamination with antibiotics 
and the possible development of resistance mechanisms by bacteria. This could 
subsequently compromise public health in terms of treatment effectiveness. Chemical risk 
assessment methods for substances found in water involve establishing different points of 
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departure (PoD) or toxicological endpoints such as the predicted environmental 
concentration (PEC), predicted no-effect concentration (PNEC), no-observed effect 
concentration (NOEC), lowest observed effect concentration (LOEC), half-maximal lethal 
concentration (LC50) and/or half-maximal effective concentration (EC50) (9, 37). For 
instance, Yamashita et al. (46) evaluated the inhibition of the algae P. subcapitata by 
levofloxacin and clarithromycin and the results obtained showed that the latter presented 
higher toxicity, with an EC50 of 11 µg L-1 and a LOEC and a NOEC of 6.3 and 3.1 µg L-1, 
respectively. On the other hand, Isidori et al. (47) tested five antibiotics (oxytetracyclin, 
sulfamethoxazole, ofloxacin, lincomycin and clarithromycin) on aquatic organisms from 
different trophic levels (bacteria, algae, rotifers, crustaceans and fish). Results showed that 
the antibiotics were less active against rotifers, crustaceans and fish, and that while acute 
toxicity levels were in the order of mg L-1, chronic toxicity became visible at concentrations 
in the order of µg L-1, mainly for algae.  
Another therapeutic class raising great awareness is sex hormones, extremely active 
biological compounds capable of inducing intense therapeutic effect at very low doses. 
Within this group, estrogens are the most commonly found in the environment, existing 
either as natural or synthetic substances and acting as endocrine-disrupting compounds 
(48). For example, Kidd et al. (49) developed a 7-year experiment which demonstrated 
that the chronic exposure of fathead minnow to 5-6 ng L-1 of ethinylestradiol (EE2) led to 
feminization of males fish and altered oogenesis in females. EE2 is a synthetic estrogen 
present in oral contraceptive pills with proved estrogenic effects in fish. 
In the group of NSAIDs, 28-days chronic toxicity tests conducted on the rainbow trout 
(Oncorhynchus mykiss) by exposure to only 1 µg L-1 of diclofenac resulted in cytological 
changes in the liver, kidneys and gills (50). Regarding the toxicity of lipid regulators such 
as statins, larval and adult grass shrimp (Palaemonetes pugio) 96-hours exposure to 
simvastatin resulted in a LC50 of 1.18 and 10 mg L-1, respectively (51). Also the widely used 
antiepileptic carbamazepine showed to be carcinogenic to rats, though not presenting 
mutagenic properties in mammals. Furthermore, it proved to be lethal to zebrafish at 43 
µg L-1 and induce sub-lethal changes in Daphnia sp. at 92 µg L-1 (52). 
Finally, it must be highlighted that pharmaceutical compounds do not occur alone in the 
environment, but in mixtures of different active substances, their metabolites and 
transformation products, which may display potentially additive, antagonistic and even 
synergistic effects among them and with other naturally occurring compounds (53).  
Chapter 1 
16 
 
1.2.1.5. Legislation 
Nowadays, there is still a big hiatus in legislation concerning the environmental 
contamination by pharmaceutical compounds. This gap is probably due to the scarcity of 
studies and available data which could allow a coherent profiling and a precise approach 
to this issue. 
Up until 1992, there were no requirements imposed by the EU legislation towards the 
pharmaceutical industry, demanding the inclusion of environmental risk assessment data 
to obtain the Marketing Authorization of a new pharmaceutical product. This was first 
achieved through Directive 92/18/EEC (54), but only regarding veterinary products. 
Consequently, EMEA published a Note for Guidance (55), establishing the guidelines for 
the accurate risk assessment of veterinary medicinal products. The extension of this 
procedure to pharmaceutical products for human use was performed by the EC through 
Directive 2001/83/EC, later amended by Directive 2004/27/EC (11). These documents 
required the Marketing Authorization of a new pharmaceutical product for human use to 
be accompanied by a proper environmental risk assessment study, according to the 
guidelines set out by EMEA. Evaluation of the environmental impact of both human and 
veterinary medicines embraced two phases: Phase I, concerning the environmental 
exposure assessment to pharmaceutical compounds and/or their metabolites; Phase II, 
comprising the study of their effects and fate in the environment. This second phase was 
still sub-divided into two parts:  Tier A, regarding the evaluation of potential effects and 
fate of the respective pharmaceuticals and/or metabolites, and Tier B, focusing on their 
potential effects on fauna and flora within specific environmental compartments. 
However, only pharmaceutical products for human use presenting a PEC in surface waters 
equal to or above 0.01 µg L-1 are requested to undergo Phase II studies (56) (Fig. 1.4). 
In the USA, concerns over the environmental presence of pharmaceutical compounds have 
long been raised. At the moment, regulation established by the USA Food and Drug 
Administration (FDA) requires the inclusion of the environmental risk assessment study 
in order to obtain the Marketing Authorization, according to the Guidance for Industry - 
Environmental Assessment of Human Drug and Biologic Applications (57). Nonetheless, 
this study is only mandatory for pharmaceuticals with PEC superior to 1 µg L-1 (Fig. 1.5). 
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Fig. 1.4. Graphical representation of EMEA guidelines (58). 
 
* Committee for Proprietary Medicinal Products (CPMP) was the former designation for the 
EMEA Committee. 
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Fig. 1.5. FDA tiered approach to fate and effects testing (58). 
 
    * Expected Introductory Concentration (EIC);  
  ** Maximum Expected Environmental Concentration (MEEC);  
*** Centre for Drug Evaluation and Research (CDER)/ Centre for Biologics Evaluation 
and Research (CBER). 
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1.3. Thesis 
1.3.1. Main Objectives 
Considering the state-of-the-art a priori, as well as the main knowledge gaps and 
analytical obstacles, briefly exposed in the preceding sections, the ultimate purpose of this 
Ph.D. work was to significantly contribute to the enlightening of the problematic 
concerning the aquatic compartment contamination by pharmaceutical residues. This 
implies the development of novel analytical and experimental approaches to streamlining 
the detection, quantification and removal of pharmaceuticals from water samples, 
consequently providing new data on the impact and fate of these compounds in the 
environment. Research holds an important role in the support of new legal decisions, 
helping to reach a balance between all the actors involved, including official authorities, 
environmental managers and industry officers. The restrictive legislation that will be 
adopted at EU level will oblige to spend huge financial budgets and technical resources. 
Bearing it in mind, a multidisciplinary strategy was adopted with the aim of help finding 
answers to the key-topics in environmental studies: occurrence, behaviour and toxicity. 
Hence, the following tasks were addressed within this Ph.D. project: 
1) Development of a multiresidue method for the analysis of pharmaceutical compounds 
in water, using an adequate sample preparation/extraction procedure, followed by the 
analysis through liquid chromatography–tandem mass spectrometry (LC-tandem MS 
or LC-MS/MS or LC-MS2). 
Sample preparation processes are crucial for a good separation of target analytes from 
the remaining sample compounds. Basically, they comprise the following steps: i) 
extraction; ii) concentration; iii) cleansing; iv) extract injection. Nowadays, a wide 
variety of adsorbents/coatings is commercially available, allowing the efficient and 
selective extraction of compounds, within a broad range of polarities. These solid-
phase adsorbents will be thoroughly studied during this work. 
One of the biggest limitations in the analysis of emerging pollutants relies on the lack 
of analytical methodologies able to detect and quantify contaminants present in low 
concentrations. One prerequisite for the quality assessment and monitoring of 
wastewaters, surface and drinking waters, is the capability to develop multiresidue 
methods, capable of providing rapid and accurate results. Even though there has been 
an increase of such methodologies reported in literature over the past few years, there 
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is still the need to improve both sensitivity and selectivity in the case of more complex 
matrices as wastewaters. 
2) Participation in inter-laboratory exercises (ILEs) promoted by the Joint Research 
Centre (JRC) and organized under the scope of European projects, with the purpose 
of establishing a valid system for quality control and methods’ harmonization. 
3) Monitoring campaigns encompassing WWTP samples and receiving surface water 
bodies, impact assessment and further evaluation of the constraints influencing a 
representative sampling plan. 
During the last few decades, the scientific community has started reporting the 
presence and concentrations of pharmaceutical residues in WWTP effluents, surface 
waters, its fauna and flora. In the case of WWTPs, the great variability of results 
achieved is usually attributed to the type of treatment process employed, as well as its 
location, social/economic factors, most commercialized medicines and other 
demographic parameters. 
Regarding sampling processes, either grab or composite samples can be collected 
using automatic samplers, according to the results obtained after preliminary 
exploratory examinations. Recently, passive sampling is considered a very promising 
technique. However, it is still in a preliminary experimental phase. 
4) Study of the photodegradation kinetic of several pharmaceutical compounds, at lab-
scale and pre-industrial pilot scale. 
The influence of several factors must be taken into consideration, such as 
temperature, pH, presence of dissolved and particulate material and radiation source. 
The results attained may be of great relevance for the conception and design of future 
WTPs and WWTPs. 
5) Identification of phototreatment by-products and elucidation of the involved 
photo(cata)lytic degradation mechanisms. 
Herein, there is the need to take profit of advanced high-resolution techniques, such 
as ultra-performance liquid chromatography coupled to quadrupole time-of-flight 
mass spectrometry (UPLC-QToF-MS), which enable an accurate highly sensitive non-
target screening approach. 
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1.3.2. Organization 
The presented Ph.D. thesis is organized in chapters, each one dealing with a different topic 
and including its own bibliographic references. 
In Chapter 1, “General Introduction”, a broad overview is presented concerning water 
quality policy and the recent problematic of emerging water micropollutants. Special 
emphasis is given to pharmaceutical compounds, including their therapeutic classification 
and identification of main environmental contamination sources. Moreover, a brief review 
on pharmaceuticals’ environmental distribution, occurrence and fate, as well as their 
consequent (eco)toxicological effects, already demonstrated in different species, is also 
displayed. A final note regarding the still incomplete legislation on this issue is presented 
in the end. 
In Chapter 2, “Analytical Method Development for Detection and Quantification of 
Pharmaceuticals in Waters”, the different stages of a multiresidue analytical method for 
pharmaceuticals’ quantification are approached. From the optimization of the cleanup and 
extraction procedure, to the selection of the most suitable separation and detection 
techniques, different aspects are taken into consideration, according to the specific target 
analytes and the nature and complexity of samples’ matrix. This chapter also includes the 
publication “Cleanup strategies and advantages in the determination of several 
therapeutic classes of pharmaceuticals in wastewater samples by SPE-LC-MS/MS”, 
which reports on the work conducted during the development, optimization and 
validation of the analytical method, applied to the detection and quantification of diverse 
pharmaceutical compounds in wastewater samples. 
In Chapter 3, “Monitoring of Pharmaceuticals in Municipal Wastewaters and Surface 
Waters”, the monitoring results achieved with the developed method on Febros WWTP, 
and its impact on Febros river and later on Douro river, are assessed regarding the 
pharmaceutical content. Furthermore, different sampling methodologies are 
comparatively evaluated. This chapter also includes the scientific paper in Portuguese 
language “Effects of treated domestic effluents and tributaries on the contamination of 
Douro river with pharmaceutical compounds – Mitigation processes”, concerning the 
results aforementioned. Finally, the participation in two inter-laboratory exercises, 
achieved results and withdrawn conclusions regarding the method reliability are also 
reported. 
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In Chapter 4, “Photo-Remediation of Contaminated Waters using Advanced Oxidation 
Processes (AOPs)”, various advanced oxidation processes for pharmaceuticals’ mitigation 
in water samples are described. Special attention is given to heterogeneous photocatalytic 
processes, while the influence of different experimental variables on the overall treatment 
is also studied. This chapter also includes two published papers “Photolytic and TiO2-
Assisted Photocatalytic Oxidation of the Anxiolytic Drug Lorazepam (Lorenin® pills) 
under Artificial UV Light and Natural Sunlight: A Comparative and Comprehensive 
Study” and “Suspended TiO2-Assisted Photocatalytic Degradation of Emerging 
Contaminants in a Municipal WWTP Effluent using a solar Pilot Plant with CPCs”, 
concerning the optimization of TiO2-assisted photocatalytic degradation processes of 
lorazepam, a recalcitrant anxiolytic drug, and later application to the treatment of a 
municipal WWTP effluent, contaminated with diverse pharmaceuticals. 
In Chapter 5, “Phototreatment Mechanisms and By-Products Structural Elucidation”, 
lorazepam photo(cata)lytic degradation mechanisms are enlightened, while the resulting 
by-products are also identified and structurally elucidated. This chapter is mostly 
composed by the publication “Lorazepam Photofate under Photolysis and TiO2-assisted 
Photocatalysis: By-products’ Identification and Evolution Profiles during 
Phototreatment of a Contaminated WWTP Effluent”. 
In Chapter 6, “Occurrence of Emerging Pollutants’ By-Products in Water Resources”, a 
résumé of a broad review regarding emerging pollutants’ by-products environmental 
occurrence in different water sources is presented. 
In Chapter 7, “Final Conclusions and Remarks: Work Novelty, Knowledge Gaps and 
Future Research”, the key achievements of the work are presented, as well as the main 
knowledge lacunas and missing scientific evidences which may be filled in and enlightened 
during some future experiments’ proposals.  
 
 
 
 
 
 
 
 
 
General Introduction 
23 
 
1.4. References 
1. The EU Water Framework Directive - integrated river basin management for Europe. Online at: 
http://ec.europa.eu/environment/water/water-framework/index_en.html (last accessed on 
December 12, 2012). 
2. Barceló D. Emerging pollutants in water analysis. Trends in Analytical Chemistry. 
2003;22(10):xiv-xvi. 
3. Richardson SD. Environmental mass spectrometry: Emerging contaminants and current issues. 
Analytical Chemistry. 2002;74(12):2719-41. 
4. Richardson SD. Water analysis: Emerging contaminants and current issues. Analytical 
Chemistry. 2007;79(12):4295-323. 
5. Ternes TA, Joss A. Human Pharmaceuticals, Hormones and Fragrances - The challenge of 
micropollutants in urban water management. London, U.K.2006. 
6. Kot-Wasik A, Debska J, Namieśnik J. Analytical techniques in studies of the environmental fate 
of pharmaceuticals and personal-care products. Trends in Analytical Chemistry. 
2007;26(6):557-68. 
7. Rodil R, Quintana JB, López-Mahía P, Muniategui-Lorenzo S, Prada-Rodríguez D. Multi-
residue analytical method for the determination of emerging pollutants in water by solid-phase 
extraction and liquid chromatography–tandem mass spectrometry. Journal of Chromatography 
A. 2009;1216(14):2958-69. 
8. Why do we need to address emerging substances? Online at: http://www.norman-
network.net/index_php.php?module=public/about_us/comment_substances&menu2=public/
about_us/about_us (last accessed on December 12, 2012). 
9. Santos LHMLM, Araújo AN, Fachini A, Pena A, Delerue-Matos C, Montenegro MCBSM. 
Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. 
Journal of Hazardous Materials. 2010;175(1-3):45-95. 
10. Mompelat S, Le Bot B, Thomas O. Occurrence and fate of pharmaceutical products and by-
products, from resource to drinking water. Environ Int. 2009;35(5):803-14. 
11. EudraLex – Pharmaceutical Legislation Medicinal Products for Human Use, Online at: 
http://ec.europa.eu/health/human-use/legal-framework/index_en.htm (last accessed on 
December 12, 2012). 
12. Prontuário terapêutico - 10, Março 2011. Online at: 
http://www.infarmed.pt/portal/page/portal/INFARMED/PUBLICACOES/PRONTUARIO/pt1
0_web.pdf (last accessed on December 12, 2012). 
13. Kummerer K, editor. Pharmaceuticals in the environment - Sources, fate, effects and risks. 
Berlin, Heidelberg, New York: Springer; 2004. 
14. Sedlak DL, Pinkston K, Huang CH. Occurence survey of pharmaceutically active compounds. 
Denver, CO: Awwa Research Foundation. 2005. 
15. Stockholm County Council 2005. Environmentally Classified Pharmaceuticals, Department of 
the Environment, Stockholm, Sweden. 
16. Sedlak DL, Huang CH, Pinkston K. Strategies for selecting pharmaceuticals to assess 
attenuation during indirect potable water reuse. In: Kummerer K, editor. Pharmaceuticals in the 
environment - Sources, fate, effects and risks. Berlin, Heidelberg, New York: Springer; 2004. p. 
107-20. 
17. Jørgensen SE, Halling-Sørensen B. Drugs in the environment. Chemosphere. 2000;40(7):691-9. 
18. Khan SJ, Ongerth JE. Estimation of pharmaceutical residues in primary and secondary sewage 
sludge based on quantities of use and fugacity modelling. Water Science and Technology. 
2002;46:105-13. 
19. McArdell CS, Molnar E, Suter MJF, Giger W. Occurence and Fate of Macrolide Antibiotics in 
Wastewater Treatment Plants and in the Glatt Valley Watershed, Switzerland. Environmental 
Science and Technology. 2003;37:5479-86. 
Chapter 1 
24 
 
20. INFARMED - Estatística do Medicamento. Online at: 
http://www.infarmed.pt/portal/page/portal/INFARMED/PUBLICACOES/TEMATICOS/ESTA
TISTICA_MEDICAMENTO (last accessed on December 12, 2012). 
21. Quintana JB, Rodil R, Cela R. Reaction of β-blockers and β-agonist pharmaceuticals with 
aqueous chlorine. Investigation of kinetics and by-products by liquid chromatography 
quadrupole time-of-flight mass spectrometry. Analytical and Bioanalytical Chemistry. 
2012;403(8):2385-95. 
22. Marco-Urrea E, Pérez-Trujillo M, Vicent T, Caminal G. Ability of white-rot fungi to remove 
selected pharmaceuticals and identification of degradation products of ibuprofen by Trametes 
versicolor. Chemosphere. 2009;74(6):765-72. 
23. Carrara C, Ptacek CJ, Robertson WD, Blowes DW, Moncur MC, Sverko E, et al. Fate of 
pharmaceutical and trace organic compounds in three septic system plumes, Ontario, Canada. 
Environmental Science and Technology. 2008;42(8):2805-11. 
24. Reddersen K, Heberer T, Dünnbier U. Identification and significance of phenazone drugs and 
their metabolites in ground- and drinking water. Chemosphere. 2002;49(6):539-44. 
25. Sanderson H, Laird B, Pope L, Brain R, Wilson C, Johnson D, et al. Assessment of the 
environmental fate and effects of ivermectin in aquatic mesocosms. Aquatic Toxicology. 
2007;85(4):229-40. 
26. Boxall ABA, Fogg LA, Blackwell PA, Kay P, Pemberton EJ, Croxford A. Veterinary medicines in 
the environment. Rev Environ Contam Toxicol. 2004;180:1-91. 
27. Castiglioni S, Bagnati R, Fanelli R, Pomati F, Calamari D, Zuccato E. Removal of 
pharmaceuticals in sewage treatment plants in Italy. Environmental Science and Technology. 
2006;40(1):357-63. 
28. Vieno N, Tuhkanen T, Kronberg L. Elimination of pharmaceuticals in sewage treatment 
plants in Finland. Water Research. 2007;41(5):1001-12. 
29. Jux U, Baginski RM, Arnold HG, Krönke M, Seng PN. Detection of pharmaceutical 
contaminations of river, pond, and tap water from Cologne (Germany) and surroundings. Int J 
Hyg Environ Health. 2002;205(5):393-8. 
30. Matamoros V, Bayona JM. Elimination of pharmaceuticals and personal care products in 
subsurface flow constructed wetlands. Environmental Science and Technology. 
2006;40(18):5811-6. 
31. Pedrouzo M, Reverté S, Borrull F, Pocurull E, Marcé RM. Pharmaceutical determination in 
surface and wastewaters using high-performance liquid chromatography-(electrospray)-mass 
spectrometry. Journal of Separation Science. 2007;30(3):297-303. 
32. Radjenović J, Petrović M, Barceló D. Advanced mass spectrometric methods applied to the 
study of fate and removal of pharmaceuticals in wastewater treatment. Trends in Analytical 
Chemistry. 2007;26(11):1132-44. 
33. Brown KD, Kulis J, Thomson B, Chapman TH, Mawhinney DB. Occurrence of antibiotics in 
hospital, residential, and dairy effluent, municipal wastewater, and the Rio Grande in New 
Mexico. Science of the Total Environment. 2006;366(2-3):772-83. 
34. Möder M, Braun P, Lange F, Schrader S, Lorenz W. Determination of endocrine disrupting 
compounds and acidic drugs in water by coupling of derivatization, gas chromatography and 
negative-chemical ionization mass spectrometry. Clean - Soil, Air, Water. 2007;35(5):444-51. 
35. Rabiet M, Togola A, Brissaud F, Seidel JL, Budzinski H, Elbaz-Poulichet F. Consequences of 
treated water recycling as regards pharmaceuticals and drugs in surface and ground waters of a 
medium-sized mediterranean catchment. Environmental Science and Technology. 
2006;40(17):5282-8. 
36. Heberer T, Mechlinski A, Fanck B, Knappe A, Massmann G, Pekdeger A, et al. Field studies on 
the fate and transport of pharmaceutical residues in bank filtration. Ground Water Monit 
Remed. 2004;24(2):70-7. 
37. WHO/HSE/WSH/11.05. World Health Organization - Pharmaceuticals in Drinking-water. 
Geneva, Switzerland: WHO Press; 2011. 
38. Benotti MJ, Trenholm RA, Vanderford BJ, Holady JC, Stanford BD, Snyder SA. Pharmaceuticals 
and endocrine disrupting compounds in U.S. drinking water. Environmental Science and 
Technology. 2009;43(3):597-603. 
General Introduction 
25 
 
39. Mons MN, Hoogenboom AC, Noij THM. Pharmaceuticals and drinking water supply in the 
Netherlands. Nieuwegein, Kiwa Water Research (Kiwa Report No BTO 2003040). 2003. 
40. Osenbrück K, Gläser H-R, Knöller K, Weise SM, Möder M, Wennrich R, et al. Sources and 
transport of selected organic micropollutants in urban groundwater underlying the city of Halle 
(Saale), Germany. Water Research. 2007;41(15):3259-70. 
41. Sammartino MP, Bellanti F, Castrucci M, Ruiu D, Visco G, Zoccarato T. Ecopharmacology: 
Deliberated or casual dispersion of pharmaceutical principles, phytosanitary, personal health 
care and veterinary products in environment needs a multivariate analysis or expert systems for 
the control, the measure and the remediation. Microchemical Journal. 2008;88(2):201-9. 
42. Jjemba PK. Excretion and ecotoxicity of pharmaceutical and personal care products in the 
environment. Ecotoxicology and Environmental Safety. 2006;63(1):113-30. 
43. Daughton CG, Ternes TA. Pharmaceuticals and personal care products in the environment: 
agents of subtle change? Environmental Health Perspectives. 1999;107(S6):907-38. 
44. Crane M, Watts C, Boucard T. Chronic aquatic environmental risks from exposure to human 
pharmaceuticals. Science of the Total Environment. 2006;367(1):23-41. 
45. Fent K, Weston AA, Caminada D. Ecotoxicology of human pharmaceuticals. Aquatic Toxicology. 
2006;76(2):122-59. 
46. Yamashita N, Yasojima M, Miyajima K, Suzuki Y, Tanaka H. Effects of antibacterial agents, 
levofloxacin and clarithromycin, on aquatic organisms. Water Science and Technology. 
2006;53:65–72. 
47. Isidori M, Lavorgna M, Nardelli A, Pascarella L, Parrella A. Toxic and genotoxic evaluation of six 
antibiotics on non-target organisms. Science of the Total Environment. 2005;346(1–3):87-98. 
48. Larsson DGJ, Adolfsson-Erici M, Parkkonen J, Pettersson M, Berg AH, Olsson PE, et al. 
Ethinyloestradiol — an undesired fish contraceptive? Aquatic Toxicology. 1999;45(2–3):91-7. 
49. Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, Lazorchak JM, et al. Collapse of a fish 
population after exposure to a synthetic estrogen. Proceedings of the National Academy of 
Sciences. 2007;104:8897–901. 
50. Triebskorn R, Casper H, Heyd A, Eikemper R, Köhler HR, Schwaiger J. Toxic effects of the non-
steroidal anti-inflammatory drug diclofenac: Part II. Cytological effects in liver, kidney, gills and 
intestine of rainbow trout (Oncorhynchus mykiss). Aquatic Toxicology. 2004;68(2):151-66. 
51. Key PB, Hoguet J, Reed LA, Chung KW, Fulton MH. Effects of the statin antihyperlipidemic 
agent simvastatin on grass shrimp, Palaemonetes pugio. Environmental Toxicology. 
2008;23:153–60. 
52. Thacker PD. Pharmaceutical data elude researchers. Environmental Science and Technology. 
2005;39:193A–4A. 
53. Farré Ml, Pérez S, Kantiani L, Barceló D. Fate and toxicity of emerging pollutants, their 
metabolites and transformation products in the aquatic environment. Trends in Analytical 
Chemistry. 2008;27(11):991-1007. 
54. Comission Directive 92/18/EEC, Modifying the Annex to Council Directive 81/852/EEC on the 
Approximation of the Laws of Member States Relating to Analytical, Pharmacotoxicological and 
Clinical Standards and Protocols in Respect of the Testing of Veterinary Medicinal Products, 
1992. 
55. EMEA, Note for Guidance: Environmental Risk Assessment for Veterinary Medicinal Products 
Other Than GMO-Containing and Immunological Products, The European Agency for the 
Evaluation of Medicinal Products: Veterinary Medicines Evaluation Unit, 
EMEA/CVMP/055/96-FINAL,1998. 
56. EMEA, Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use, 
The European Agency for the Evaluation of Medicinal Products: Committee for Medicinal 
Products for Human Use, EMEA/CHMP/SWP/4447/00, 2006. 
57. FDA, Guidance for Industry: Environmental Assessment of Human Drug and Biologics 
Applications, Food and Drug Administration (Center for Drug Evaluation and Research), CMC 
6, Revision 1, 1998. 
58. Bound JP, Voulvoulis N. Pharmaceuticals in the aquatic environment – a comparison of risk 
assessment strategies. Chemosphere. 2004;56(11):1143-55. 
Chapter 1 
26 
 
 
 
 
 
 
 
 
 
Analytical Method Development for Detection and Quantification of Pharmaceuticals in Waters 
 
27 
 
Chapter 2 
Analytical Method Development for 
Detection and Quantification of 
Pharmaceuticals in Waters  
 
2.1. Multiresidue Methods for the Analysis of 
Pharmaceutical Compounds 
Given the hundreds of tonnes of pharmacologically active substances consumed per year, 
the exponentially increasing amount of identified metabolites and transformation 
products (TPs) resulting from different natural and/or artificial physico-chemical and 
biological degradation processes, the hypothesis of finding complex mixtures or 
“cocktails” of these pollutants in the environmental aquatic compartment seems well-
founded. Consequently, there is a strong need to search for a wide range of 
pharmaceuticals and respective by-products, potentially contaminating different 
environmental matrixes. Taking into account all the resources and time expenses 
involving this task, the newly developed analytical methods must be capable to 
simultaneously determine trace levels of the largest amount of compounds possible, thus 
allowing to reduce the number of cleanups and extraction steps. Such methods are 
addressed as multiresidue or multiclass methods, contrary to analytical methods 
encompassing only one class of pollutants, or eventually specific to one compound only 
(1). Therefore, multiresidue analytical methods constitute a prerequisite to provide 
reliable figures on the occurrence, partition, removal and fate of pharmaceutical 
contaminants in the environment, reducing monitoring costs and simultaneously enabling 
to increase its frequency and spread (2). 
In the attempt to simplify the analytical work, the rational selection of target analytes to be 
included in the multiresidue method also constitutes one extremely important criterion. In 
this Ph.D. work, and since pharmaceuticals’ environmental occurrence is highly 
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conditioned by their consumption levels, region- and time-specificity were two significant 
factors considered during the selection process. It would obviously be a waste of time and 
resources to monitor the presence of pharmaceuticals little or not at all commercialized in 
our country, whose environmental occurrence in real matrices would thus be unlikely. 
Hence, the pharmaceutical compounds encompassed in our study (Paper 1) were chosen 
according to data provided by the Portuguese National Authority of Medicines and Health 
Products, IP (INFARMED), belonging to the list of the 30 most marketed pharmaceuticals 
in Portugal, over the last few years (please refer to section 1.2.1.2). They represent 9 
different therapeutic classes, including analgesic and antipyretic drugs, anti-
inflammatories, lipid regulators, antibiotics, anxiolytics, antidepressives, diuretics, 
cardiotonics and anti-ulcer agents. These therapeutic groups are also within the most 
studied, reported and consumed worldwide. 
Several multiresidue analytical methods have already been described in literature, some 
for the detection of specific therapeutic categories (3, 4), others aiming at a wider range of 
compounds (5, 6). Nevertheless, the set-up of a multiresidue method implies taking into 
consideration all different stages of the analytical process, i.e., not only assuring that the 
separation and detection systems allow the identification of all target analytes, but also 
that these can undergo a common pre-treatment process (e.g., preservation and sample 
extraction), more complicated when applied to complex matrixes such as wastewater 
samples. 
 
2.2. Extraction and Concentration of Water Samples 
According to a review study by Liska (7), two major target areas of interest can be 
distinguished during the development of a method for environmental organic trace 
analysis: i) sample preparation and ii) analytical separation and detection. While 
remarkable progress has been achieved during several decades concerning the second 
area, sample preparation has been in the shadow for quite longer time. Only after highly 
sensitive analytical systems became common standard for environmental analysts did they 
realise that samples’ preparation was an important breaking factor in the general progress 
of environmental analysis. Nonetheless, this stage is usually highly time-consuming (8), 
comprising less automated processes during which many errors can take place, carrying 
along more or less significant deviations on the accuracy and precision of the results (9). 
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The use of an appropriate sample handling technique is thus a must in an analysis of 
organic micropollutants in water. The main goal is to achieve a sample extract enriched in 
target analytes and free of other matrix components, as far as possible. To do so, three 
key-steps must be conducted: i) extraction of trace amounts of target analytes from the 
sample matrix, ii) concentration of those analytes, and iii) removal of other substances 
which may be co-extracted and simultaneously concentrated, consequently hampering the 
efficiency of the method (7, 10). 
Every effort concerning the improvement of this analytical stage may result in significant 
increases in the yield and quality of the results obtained (9). The most relevant sample 
pre-treatment techniques, some of which employed during this Ph.D. work, will be 
discussed in the following sections. 
 
2.2.1. Solid-Phase Extraction 
2.2.1.1. Fundamentals and Applications 
The first experimental applications of solid-phase extraction (SPE) started approximately 
five decades ago (7). From then on, hundreds of scientific papers have described various 
developments and applications of SPE in water analysis (11-13), being currently one of the 
most frequently used techniques for cleanup and pre-concentration of pharmaceuticals 
from water samples (14-17). 
The isolation process comprises the selective retention of analytes in a solid adsorbent, 
which can in turn be eluted with an organic solvent. Analytes are selectively trapped on 
the adsorbent mainly through hydrogen bonds, Van der Waals forces, hydrophobic effects, 
π-electron interactions and cation- or anion-exchange processes (18). A scheme of SPE 
procedure is shown in Fig. 2.1. 
SPE major goals are the extraction, concentration and elimination of interfering 
components. Nevertheless, other advantageous uses of SPE have been found out: i) 
storage of analytes in the adsorbed stage, most useful for less stable compounds in the 
aqueous phase or volatile substances, ii) fractionation of the sample extract in different 
groups of compounds and iii) derivatization of analytes in the cartridge (10). However, 
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SPE also has several drawbacks, such as the loss of more polar compounds during sample 
percolation, the co-extraction of matrix interferences, filters clogging, a noticeable time 
consumption for the extraction of large water volume, a significant consumption of 
organic solvents, an incomplete desorption of target analytes, the loss of volatile 
compounds and the incomplete recovery of the dry extract (1, 18).  
 
Fig. 2.1. Illustration of the SPE process:  - interferences;  - target analytes.                    
1) Retention of the analyte: analyte molecules are enriched on the adsorbent > interfering 
components and solvent molecules (matrix) are not retained > remaining interfering 
components are washed from the adsorbent > the analyte is removed from the adsorbent 
by elution with a suitable solvent (e.g., methanol, tetrahydrofuran (THF), -propanol);  
2) Retention of interfering components: analyte molecules show no interaction with the 
adsorbent > interfering components and solvent molecules (matrix) are retained > analyte 
molecules are “washed” from the adsorbent > the solid phase is simply used to “filter” the 
sample (19). 
 
 
2.2.1.2. Adsorbents 
Several SPE adsorbents have been developed. Among them, the most adequate for the 
extraction of organic compounds are the reverse phase sorbents, from the conventional 
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alkyl-modified silica materials (C8 and C18 non-polar phase), to the more recent 
polymeric sorbents, which improve the retention of polar compounds due to the high 
surface area and cross-links (e.g., poly(styrene-divinylbenzene) (PS-DVB)), and carbon 
materials (e.g.,  graphitised carbon black (GCB)) (18, 20).  
Polymeric sorbents present different functional groups combined with a polymeric 
skeleton, allowing more than one kind of interaction between analytes and the sorbent 
(hydrophilic, hydrophobic and π- π interactions) (18). Some examples of these sorbents 
are displayed in Table 2.1. 
 
Table 2.1. Commercial brands of SPE extraction columns constituted by polymeric 
adsorbents, frequently utilized in the extraction of pharmaceutical compounds from water 
samples 
Cartridge 
commercial 
designation 
Adsorbent composition Application Reference 
Strata-X Polydivinylbenzene resin 
chemically modified with 
piperidone groups 
Extraction of non-steroidal anti-
inflammatory drugs (NSAIDs) 
from surface and groundwaters 
(21) 
Evolute ABN Surface modified polystyrene 
divinylbenzene polymer 
Extraction of human 
pharmaceuticals from river 
waters 
(22) 
Oasis HLB 
(Hydrophilic-
lipophilic-balanced 
reversed-phase 
sorbent for acids, 
bases and neutrals) 
Hydrophobic-lipophilic 
copolymer of divynilbenzene 
and vinylpirrolidone 
Extraction of veterinary 
pharmaceuticals from 
wastewaters 
(23) 
Oasis MCX 
(Mixed-mode cation 
exchange sorbent for 
bases) 
Poly(divynilbenzeneco-N-
vinylpirrolidone) copolymer on 
which strong-cation exchanging 
sulfonic groups are convalently 
bonded 
Extraction of basic/neutral 
pharmaceuticals and illicit drugs 
from surface waters 
 
(15) 
Oasis MAX 
(Mixed-mode anion 
exchange sorbent for 
acids) 
Poly(divynilbenzeneco-N-
vinylpirrolidone) copolymer on 
which strong-anion exchanging 
quaternary ammonium groups 
are convalently bonded 
Extraction of human 
pharmaceuticals from 
wastewaters 
(24) 
(Paper 1) 
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The recent trends in the development of SPE (and cleanup) adsorbents contemplate the 
extraction of increasingly polar compounds and wider polarity ranges, thus extending the 
scope of SPE and further supporting the improvement of multiresidue methods. Some 
recent developments in this field will now be presented. 
Monolithic (particle free) SPE is a recent strategy to deal with selectivity and sensitivity 
issues regarding liquid chromatography-mass spectrometry (LC-MS) bio-analytical 
methods. In contrast to SPE cartridges, monolithic stationary phases are presented in the 
format of SPE discs (available in 15 different sorbent chemistries, such as C2,C8 and C18) 
(25) and 96-wells plates, more easily automated. These materials present several 
advantages: i) low cost, ii) mechanical robustness and high stability, iii) no void volumes, 
iv) easy control of the porous properties of adsorbents, v) high hydraulic permeability  and 
vi) dominance of the convection over the diffusion mechanism of mass-exchange under 
dynamic conditions that allow the separation at extremely high flow rates (26). 
Extraction selectivity may also be increased using molecularly imprinted SPE (MISPE). 
Molecularly imprinted polymers (MIPs) are synthetic polymers with a predetermined 
selectivity for a given analyte or group of structurally related compounds. They enclose 
specific recognition sites which are complementary in shape, size and functional group, to 
the analyte or analytes of interest (18, 26). MIPs have already been synthesised for several 
emerging pollutants, including pharmaceuticals and endocrine disrupting compounds 
(EDCs) (27). 
Immuno-affinity chromatography (IAC) is a technique based on the affinity between 
antibodies and antigens, mainly applied as a cleanup technique in food and biological 
analyses. Although presenting high selectivity and enabling the better cleanup attained for 
polar compounds in complex matrices, its main drawbacks include small breakthrough 
volumes and low stability against solvents, strong pH and temperature (26, 28).   
Restricted access materials (RAMs) are frequently used as pre-columns in column-
switching LC systems. They consist on a support type which allows direct injection of 
complex samples by limiting the accessibility of interaction sites within the pores only to 
small molecules (26). 
Most recently, new nanomaterials have been exploited as well to integrate new extraction 
and cleanup technologies (29). 
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Besides being used for sample extraction (Fig. 2.1 -1)), SPE can also be applied to sample 
cleanup (Fig.2.1-2)); in this case, normal phase adsorbents such as silica, alumina and 
florisil are usually preferred (10) (Paper 1).  
It must also be noticed that pH control plays an important role in SPE, since it governs the 
dissociation of ionisable compounds, therefore affecting their hydrophobicity and 
interaction with the sorbent. For instance, when using a reverse phase sorbent, the 
retention of a compound increases for pH values favouring their non-ionised form (21).  
Lately, the development of on-line SPE coupled to LC-MS/MS methodologies has further 
increased the overall method robustness. Besides saving time on the analysis, it offered an 
alternative as a more environmentally friendly method for pharmaceutical determinations 
in waters. In fact, on-line SPE requires low sample and solvent volumes (14). 
 
2.2.2. Solid-Phase Microextraction 
Solid-phase microextraction (SPME) was introduced by Pawliszyn and co-workers (30), in 
1989, representing a significant step forward in terms of simplification and 
miniaturization of the analytic process. 
SPME represents a solvent-free sampling technique, often used in the extraction of 
organic micropollutants from water samples. It employs a fused-silica fibre coated on the 
outside with an appropriate stationary phase. SPME fibres are commercially available in a 
“syringe-like” format, which allows its protection during septum puncture (30). Volatile 
analytes can be emitted from the sample and isolated from the headspace or adsorbed by 
direct immersion into the liquid sample and concentrated in the fibre coating. SPME 
association with gas chromatography-mass spectrometry (GC-MS) is overwhelming 
comparatively to LC-MS (31, 32). Therefore, after the extraction, thermal desorption in the 
hot GC injection port usually follows (33). 
Fig. 2.2 shows a schematic representation of a SPME set-up and operating modes, as well 
as the composition of a SPME fibre. 
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Fig. 2.2. SPME components: on the left – scheme of a SPME set-up; in the centre – detail 
of a SPME fibre; on the right – operating modes of SPME: A – immersion, B – headspace. 
 
SPME is associated with strong matrix effects and, consequently, complications in 
quantification. Moreover, the variability of detection limits for several analytes in 
dependent upon the equilibrium between the fibre coating and the matrix (33). Different 
factors can influence the efficiency of the SPME process: i) the type of adsorbent polymer 
(34), ii) sample stirring (35), iii) sample temperature (9), iv) sample pH (34), v) sample 
ionic strength (36) and vi) the duration of the extraction (37). 
On the other hand, SPME presents as main advantages its simplicity, low cost and low 
time consumption, high selectivity and sensitivity, when coupled to adequate detection 
methods (37). It integrates, in only one continuous process, sampling, extraction, 
concentration and introduction of target analytes in the chromatographic system for 
separation and detection. All these pros, along with its “solventless” character, make of 
SPME a rather promising extraction technique (37, 38).  
SPME successful application on the extraction of various emerging contaminants, 
including pharmaceuticals, from water samples has also been reported in several studies 
(39-42). 
 
Analytical Method Development for Detection and Quantification of Pharmaceuticals in Waters 
 
35 
 
2.2.3. Other Extraction Techniques 
Apart from SPE, which is the most used technique in pharmaceutical analyses, SPME has 
also earned great acknowledgment in this field, presenting further increasing development 
potential. On the contrary, more conventional techniques are now less employed. Such is 
the case of liquid-liquid extraction (LLE), which presents several drawbacks, including the 
emulsion formation, the use of large volumes of solvents, environmentally unfriendly, 
high time consumption and high cost. Liquid-phase microextraction (LPME) is a solvent-
minimised sample pre-treatment modality of LLE, requiring some µL of organic solvent to 
concentrate analytes (43). Nevertheless, LPME shows a low precision (44).  
Other more recent extraction techniques include dispersive liquid-liquid microextraction 
(DLLME) and stir membrane liquid-liquid microextraction (SM-LLME), both presenting 
high extraction efficiencies (18).  
 
2.3. Separation and Detection of Pharmaceutical 
Compounds 
In order to determine very low concentration levels of pharmaceutical compounds in 
waters, the appropriate sample pre-treatment is fundamental. Afterwards, separation, 
detection, quantification and confirmation of analytes follow. The separation of organic 
compounds is usually achieved either by liquid or gas chromatography, according to 
analytes’ polarity, volatility and decomposition at high temperatures. While volatile or 
semi-volatile compounds may be analysed by GC, more polar or thermolable non-polar 
compounds are analysed by LC, with no need of prior derivatization. Generally, every 
compound is amenable to LC, although not all are directly and easily detected by the 
available detectors (10).  
Fast and high resolution LC systems have been developed, without compromising 
resolution and separation efficiency. They include liquid chromatography at ultra high 
pressures, using sub-2-µm particle packed columns (UHPLC) (Paper 5), the use of 
monolith columns, the use of fused core columns and high-temperature liquid 
chromatography (HTLC) (26).  
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Nowadays, the detection at sub-ppt concentrations is practically routine for many organic 
contaminants, including pharmaceutical compounds in water and wastewater, whereas 
some methods can even detect few hundred fentograms of some analytes (45). These 
impressive improvements in method detection limits are mostly attributed to the use of 
hyphenated chromatography-mass spectrometry techniques, which currently constitute 
the methods of election for the analysis of trace organic contaminants in environmental 
samples (26). Fig. 2.3. presents some examples of pharmaceutical compounds usually 
detected in water and wastewater, using these advanced analytical methods (46). 
 
Fig. 2.3. Analytical methods applied for the most common pharmaceutical compounds 
present in water and wastewater (from Fatta et al. (46)). 
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Regarding mass spectrometry (MS), it is an instrumental technique based on the 
separation of ions according to their mass-to-charge ratios (m/z), in vacuum, in the gas 
phase. After ionization, the (pseudo)molecular ions formed can undergo further 
fragmentation and all these formed ions are then separated in the mass spectrometer 
according to their m/z and are detected. A mass spectrometer is composed by three 
fundamental parts: an ion source, a mass analyser and a detector (Fig. 2.4) (33).  
Several ionisation methods are available. Hence, the fitness of the ion source will depend 
on the polarity, molecular weight and thermal lability of the analytes, as well as the 
complexity of the sample to be analysed. Concerning mass analysers, they can vary from 
quadrupole, quadrupole ion trap, linear quadrupole ion trap and magnetic sector, 
representing scanning instruments, to other type of mass analysers, such as time-of-flight 
(ToF) (Fig. 2.5), Fourier-transform ion cyclotron resonance analyser and orbitrap, which 
belong to the group of non-scanning instruments. Afterwards, the detector allows to 
monitor the ion current and finally records the data as mass spectra (33).  
 
 
 
Fig. 2.4. Overview of mass spectrometric techniques (from Cajka et al. (33)). 
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Fig. 2.5. Time-of-flight mass analyser. (1) Pulse of ions from the orthogonal accelerator 
(spatial focusing); (2) separation of ions according to their flight times; (3) focusing of the 
kinetic energy of ions; (4) separation of focused ions according to their flight times, 
dependent on their weight (adapted from Cajka et al. (33)).  
 
Full-scan sensitivity, a low-femtomole level of sensitivity, high-mass resolution and mass 
accuracy (mass errors below 2 mDa or 5 ppm) can be achieved with QqToF-MS (47). 
Consequently, these instruments are often the first choice in studies devoted to the 
elucidation of degradation mechanisms of organic emerging pollutants, under 
environmental conditions. Several strategies can be employed for the identification of 
degradation products, taking profit of exact mass measurements, tandem mass 
fragmentation and typical “diagnostic ions”. This subject will be further addressed in 
Chapter 5, applied to the photo(cata)lytic degradation of the anxiolytic drug lorazepam 
(Paper 5). 
 
Herein follows Paper 1, which reports on the analytical approaches and obtained results 
during the optimization of a multiresidue method for the determination of several 
pharmaceutical compounds in wastewaters, giving particular emphasis to the cleanup 
step. Another work on this topic was also published by our group, although this one more 
specifically oriented to cleaner river waters (Annex II). 
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2.4. Paper 1 – Cleanup strategies and advantages in the 
determination of several therapeutic classes of 
pharmaceuticals in wastewater samples by SPE-LC-
MS/MS 
 
Published Scientific Paper: 
 
Sousa, M.A., Gonçalves, C., Cunha, E., Hajšlová, J. and Alpendurada, M.F., Cleanup 
strategies and advantages in the determination of several therapeutic classes of 
pharmaceuticals in wastewater samples by SPE–LC–MS/MS. Analytical and 
Bioanalytical Chemistry, 2011. 399: 807-822. 
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Chapter 3 
Monitoring of Pharmaceuticals in 
Municipal Wastewaters and     
Surface Waters 
 
As previously mentioned, not many emerging pollutants (EPs) are regulated or included in 
monitoring programs. In this process, the new legislature within the European Union 
(EU) – the registration, evaluation and authorisation of chemicals (REACH) system, 
among other legislative frameworks, will have great importance.  In order to acquire the 
necessary scientific evidence for EPs to be included in such frameworks and future 
directives, it became necessary to launch several monitoring programs and develop cost-
effective and user-friendly strategies for their monitoring in water resources (1). 
 
Since wastewater treatment plants (WWTPs) are considered major contamination sources 
by EPs, in this Ph.D. work we attempted to evaluate the impact caused by the discharge of 
a municipal WWTP on Febros river, a small tributary of Douro river, located in the 
northern region of Portugal, in terms of pharmaceutical content only. To achieve this goal, 
we employed the developed and optimized methods described in the previous chapter. 
Afterwards, we further assessed Febros river contribution to the contamination with 
pharmaceutical residues of Douro river, where it debouches. Douro river constitutes an 
important water source for the production of drinking water. 
This study resulted in the publication of Paper 2 (please refer to the end of Section 3.4), 
in Portuguese language. Therefore, its content, main results and conclusions will be 
displayed along the present chapter. 
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3.1. Water Sampling 
Sampling could be defined as the process of selecting a representative water sample with 
the appropriate volume to be conveniently transported and handled in the laboratory. It is 
an integral part of the analytical process, often representing the main contribution to the 
error of the analytical result (2). 
Proper sampling and analytical techniques are of fundamental importance in the 
characterization of water samples. Firstly, it is essential to ensure that the analysed sample 
is truly representative of the environment sampled. Once this requirement is met, it is 
then necessary to adopt the appropriate analytical procedures, specifically developed for 
water or wastewater analyses (3).  
The data collected during the sampling plan must be useful, thus meeting the objectives of 
the monitoring plan (4), reproducible and defensible, i.e., have associated documentation 
which validates the sampling procedure and provides information concerning the degree 
of accuracy and precision of the acquired data. While accuracy measures the closeness 
of results to the true value, precision measures the reproducibility of the results when the 
same sample is repeatedly analysed (3, 5). 
 
3.1.1. Sampling Protocol 
A detailed sampling protocol must be developed, along with a quality assurance project 
plan (QAPP) (previously known as quality assurance/quality control - QA/QC), 
encompassing the following items (4, 5): 
i) sampling plan: including the number of sampling locations, number and type of 
samples, frequency and time intervals (e.g., real-time and/or time-delayed 
samples); 
ii) sample types and size: catch or grab samples, composite samples, integrated 
samples, separate samples for different analyses, sample volume, etc.; 
iii) sample labelling and chain of custody; 
iv)  sampling methods: indicating the techniques and equipment to be used (e.g., 
manual, automatic, passive sampling); 
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v) sampling storage and preservation: referring the type of containers and 
preservation methods; 
vi)  sample constituents: consisting of a list of parameters to be measured; 
vii) analytical methods: consisting of a list of field and laboratory test methods and 
procedures to be used. 
When designing a sampling plan, it is essential to clearly specify the objective of the 
exercise. For instance, one may aim to estimate maximum or mean concentrations, to 
detect changes or trends or even to provide a basis for industrial effluent charges. 
Nevertheless, to attain an accurate assessment of the scenario, it is usually necessary to 
generate composite samples. Integrated composite samples can be obtained by bulking 
individual samples collected at known time intervals and in proportion to the appropriate 
flow of the stream, along a certain period of time. Likewise, in cases when sampling rivers 
with large channel sections, it is desirable to collect samples at different points across the 
section and at several depths. 
Furthermore, it is always necessary to bear in mind the resources available for both 
sampling and analysis procedures. Consequently, a realistic level of uncertainty of the 
results must be set, based upon the established goals (3). Whether high levels of 
uncertainty lead to unacceptable levels of reliability in the decisions based upon them 
depends on a rigorous evaluation of the fitness for purpose (6-8). 
The potential sources of error during sampling procedures are of diverse origin. Table 3.1 
displays some error sources which should be taken into consideration, according to a 
review study by Madrid and Zayas (2): 
 
Table 3.1. Error sources during sampling procedures 
Sampling stage (decision making) Possible sources of error 
Definition and sub-division of the field Heterogeneity of the sample; spatial and/or temporal 
change of pollutants: “hot spots” 
Sampling method No representative statistics; skew distribution; 
contamination or analyte loss 
Number of samples Few replicates; absence of representativeness 
Sample mass Absence of representativeness 
Moment of sampling Seasonal changes; climatic conditions 
Experimental conditions Matrix effects; lixiviation or irreproducible deposits 
Bottling Contamination or extraction by the equipment or 
container material; volatilization 
Storage during sampling Contamination or losses by volatilization; chemical 
reactions (change of species) 
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3.1.2. Materials and Equipments 
Ideally, all analyses should be conducted immediately after sample collection, so that the 
obtained results are a true assessment of the nature of the water sample in situ. In the real 
world, only some analytical determinations are viable on site, such as temperature, pH, 
conductivity, dissolved oxygen (DO), salinity, among others. These parameters cannot be 
adequately determined after transportation to the laboratory (9), thus multiparameter 
probes are usually taken to the field (Fig. 3.1 (a)). 
In the case of surface waters, samples are often collected by direct filling of the sample 
bottle, at ca. 0.5 m depth. For deep water bodies or in places of difficult access, special 
sampling flasks can be used: these are lowered in a closed state, on a rope or steel cable, 
and then remotely triggered to open (Fig. 3.1 (b)). Various automatic devices are also 
available to collect composite samples, being operated on either a time basis or on a flow-
proportional basis (Fig. 3.1 (c)). These instruments are of particular interest during the 
sampling of WWTP effluent discharges, since these are often intermittent in nature. In 
such circumstances, it is fundamental to fully understand the nature of the operations 
producing the discharge, in order to draw an appropriate sampling programme and 
consequently obtain a true picture of the discharge.  
 
Fig. 3.1. Sampling devices. (a) multiparameter field probe; (b) sampling flask with 
remotely triggered opening; (c) automatic sampler used to collect and refrigerate grab or 
composite samples over a 24-h period. 
 
In the last two decades, passive sampling methods have shown much promise as tools for 
measuring aqueous concentrations of a wide variety of pollutants. In its broadest sense, 
passive sampling includes any sampling technique based on free flow of analyte molecules 
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from the sampled medium to a receiving phase in a sampling device, due to a difference 
between the chemical potentials of the analyte in the two media. Thus, there is no need of 
any energy source other than this chemical potential difference. The net flow of analyte 
molecules between both media continues until reaching the equilibrium state or until the 
sampling period is stopped (10). The main advantages of passive sampling compared to 
active water sampling, regarding the collection of organic pollutants, include the following 
aspects: i) it is based on diffusion processes (no power supply), ii) it occurs in situ 
(selective analyte isolation and pre-concentration (11)) and it is often time-integrative, iii) 
it shows low variability, due to a standardised configuration of the synthetic samplers, and 
finally iv) it mimics the respiratory exposure for aquatic organisms, since, traditionally, it 
includes a mass transfer and rate limiting membrane(s) in their design (12). Summing up, 
passive samplers simplify the operations performed at the sampling site.  
Table 3.2 presents an overview of some of the most used passive samplers for monitoring 
of organic pollutants, as reviewed by Namiesnik et al. (13). 
 
Table 3.2. Passive sampling devices for organic contaminants 
Sampler Full Name Analytes References 
Chemcatcher  Universal passive sampler using 
Empore disk 
Polar and non-polar organics (14) 
Ecoscope A sampler based on solvent-
filled dialysis membranes and 
chelating sorbent discs 
Non-polar organics (15) 
MESCO Membrane-enclosed sorptive 
coating 
PAHs, PCBs, organochlorine 
pesticides 
(16) 
PDB Passive diffusion bag samplers Polar organic compounds, 
VOCs, metals, trace elements 
(17) 
PISCES Passive in situ concentration-
extraction sampler 
PCBs (18) 
POCIS Polar organic chemical 
integrative sampler 
Herbicides and pharmaceuticals 
with log KOW < 3 
(19) 
SPATT Solid-phase adsorption toxin 
tracking 
Polar phytotoxins (20) 
SPMD Semi-permeable membrane 
devices 
Hydrophobic semi-volatile 
organic compounds 
(21) 
 
Lastly, it must be highlighted that the physical, chemical and biological integrity of 
samples during interim periods between sampling and analysis shall be preserved. 
Changes in sample composition can be retarded by storage at low temperatures (4 ºC), in 
the dark. The more polluted a sample is, the shorter the time which can be allowed 
between sampling and analysis, in order to avoid significant errors (3).  
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3.2. A Portuguese Case Study 
3.2.1. Monitoring Sites 
Monitoring water quality is carried out for various purposes and its design will depend on 
its later uses. Obviously the cost of monitoring has to be related to the ultimate benefit. In 
our study, both wastewater and surface water samples were analysed in terms of 
pharmaceutical content. While the first were collected at Febros WWTP, the latter were 
sampled in Febros river and Douro river. 
 
3.2.1.1. Febros WWTP 
Febros WWTP was built in 2003, in the city of Vila Nova de Gaia. It was dimensioned for 
80 000 inhabitants, designed to treat a wastewater flow of 39 605 m3 per day and a load 
corresponding to 5 334 kg per day in terms of biochemical oxygen demand (BOD5). Febros 
WWTP (Fig. 3.2) comprises: an harrowing/sieving, desanding and degreasing 
system; 2 aeration tanks with a capacity of 6 053 m3 each; 3 secondary clarifiers 
with a 25 m diameter; 1 thickener with a diameter of 14 m; sludge mechanical 
dehydration with 2 centrifuges; sludge storage silo of 50 m3 capacity; and, finally, an 
odour deodorizing treatment step using a column of activated carbon for 6 380 
m3 h-1.     
 
Fig. 3.2. Image of Febros WWTP, which discharges to Febros river, flowing on the right-
hand side. In the top-right part of the image one can identify Douro river, dividing the city 
of Vila Nova de Gaia (left bank) from the city of Porto (right bank) (22). 
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3.2.1.2. Febros River and Douro River 
 
 
Fig. 3.3. Geographical location of the case study – Portuguese hydrographical region no. 
3: Douro.  
 
Table 3.3. GPS coordinates of the sampling spots in Febros river, identified in Fig. 3.3  
 Sampling Spots Latitude Longitude 
Upstream WWTP F1 41° 7'2.92" N 8°34'11.48" W 
Downstream 
WWTP 
F2 41° 7'8.75" N 8°34'14.42" W 
F3 41° 7'15.52" N 8°34'13.24" W 
F4 41° 7'21.04" N 8°34'9.41" W 
F5 41° 7'24.65" N 8°34'9.72" W 
 
* Sampling Spot H (latitude 41º08’00.89’’ N; longitude 8º34’20.77’’ W): located in Douro River, 
after the debouching site of Febros River. The remaining sampling spots in Douro River were not 
part of the present work, but were included in the monitoring campaigns addressed in the study by 
Gonçalves et al. (Annex II). 
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The study area is situated in the hydrographical region no. 3 – Douro (Fig. 3.3).  
Douro river (Fig. 3.4) is the third longest river in the Iberian Peninsula, with a total length 
of 927 km. Douro riverhead is located in Sierra de Urbión, Sória (Spain), at 2 080 m of 
altitude, the Portuguese river basin is 18 643 km2 (total 97 603 km2) and has an average 
flow of 450 m3 s-1 (ranging between 200 and 710 m3 s-1). It crosses the northern region of 
Portugal, flowing towards the Atlantic Ocean, with the river mouth close to the cities of 
Vila Nova de Gaia and Porto. 
 
Fig. 3.4. Image of Douro river. 
 
In contrast, Febros river (Fig. 3.5) is a small tributary on the left bank of Douro river. 
Febros riverhead is located in Seixezelo and the river mouth is in the Esteiro de Avintes. 
This river also crosses the Natural Park of Vila Nova de Gaia.  
 
Fig. 3.5. Image of Febros river, close to the river mouth. 
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Hence, due to Febros river low flow and small basin area, a high impact caused by the 
discharge of the WWTP effluents was predictable from the beginning. Nonetheless, the 
construction of Febros WWTP proved to be quite advantageous in the remediation of the 
river. The removal of contaminants of both domestic and industrial origin, in collaboration 
with the natural city park, allowed Febros river repopulation with a mammal species long 
disappeared in this river - the otter. On the other hand, a strong dilution effect occurs 
during Febros river debouching into Douro river. Therefore, its potential impact on Douro 
river, in terms of pharmaceutical content, was expected to be negligible.  
 
3.2.2. Methodology 
3.2.2.1. Sampling 
At Febros WWTP, both grab and composite (400 mL per hour, over 24-h) influent and 
treated effluent samples were collected from May 2009 to March 2011. Concerning surface 
waters, grab samples were collected in 5 sampling spots in Febros river (1 upstream 
Febros WWTP and 4 downstream Febros WWTP) and 12 sampling spots in Douro river (7 
upstream the debouching point of Febros river and 5 others downstream this point), 
during two sampling campaigns conducted in 2010 (spring and winter) (please refer to 
Fig. 3.3 and Table 3.3). 
The sampling plan included the collection of 2.5 L sample for wastewaters and 1 L for 
surface waters (in this case, collected at 1 m of depth), transport to the laboratory in ice-
packed containers and subsequent preservation at 4 ºC until analysis (max. 3 days after 
sampling). Moreover, influent and effluent wastewater samples were filtered using glass 
fibre filters (Ø 1.2 µm), immediately after arrival to the laboratory. 
 
3.2.2.2. Analytical Method – SPE-LC-MS/MS 
The analytical methods developed and optimised for the determination of 23 
pharmaceutical compounds potentially present in the collected samples were described in 
the previous chapter. Briefly, they consisted on an initial cleanup step (optional in the case 
of surface water samples), followed by a solid-phase extraction (SPE) procedure, in order 
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to remove most interferences and concentrate the target analytes, and subsequent 
analysis/quantification by high performance liquid chromatography coupled to mass 
spectrometry (HPLC-MS). 
For wastewater samples, the cleanup and SPE processes were simultaneously carried out 
using Oasis MAX columns. Oasis MAX is a mixed-mode sorbent consisting of a strong 
anion exchanger (quaternary amine) and a non-polar N-vinylpyrrolidone/divinylbenzene 
polymer. It has been optimised to achieve higher selectivity and sensitivity for extracting 
acidic compounds with anion exchange groups, while basic and neutral compounds are 
retained by the polymeric sorbent. In the case of surface water samples, whenever 
necessary, cleanup was achieved using Bakerbond 1º,2º-Amino (weak-anion exchange, 
WAX) cartridges, while SPE procedure was conducted with JTBaker H2Ophilic extraction 
columns (23). Besides the sorbent, other extraction parameters were as well optimised, 
including the pH (pH 2), percolation flow (10 mL min-1) and the breakthrough volume of 
50 mL for WWTP influents, 100 mL for WWTP effluents and 200 mL for river waters.  
The separation, identification and quantification of pharmaceuticals was performed by 
HPLC-ESI-MS/MS (ion-trap detector), assuring the unequivocal confirmation of each 
compound through the comparison with reference spectra obtained for the respective 
standards. 
The final validated analytical method proved to be sensitive, selective, precise, accurate 
and robust for the determination of the 23 pharmaceuticals in water and wastewater 
samples. In specific cases, definitive identification was achieved by MS/MS/MS (MS3). 
 
3.2.3. Results and Discussion 
3.2.3.1. Wastewaters from Febros WWTP 
Table 3.4 summarises the results obtained after analysis of Febros WWTP composite 
influent and effluent samples, using the developed pharmaceutical multiresidue method. 
Pharmaceuticals like paracetamol and hydrochlorothiazide highlighted in significantly 
high concentrations in the WWTP influent (> 5 µg L-1). Nonetheless, their removal along 
the treatment processes showed to be quite efficient, as one can confirm by the 
concentration values in the corresponding WWTP effluent (below the respective method 
quantification limit). On the contrary, the removal percentage of other pharmaceutical 
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compounds, such as azithromycin, bisoprolol, furosemide and ibuprofen, was rather low.  
Moreover, another very important aspect relates to the cases of lorazepam, ketoprofen, 
naproxen, bezafibrate, diclofenac and gemfibrozil, whose concentrations detected in 
influent samples were below those obtained in the corresponding WWTP effluents. This 
apparent incongruence can be justified considering: i) the difficulty to establish an 
accurate correspondence between the sample collected at the intake of the WWTP 
(influent) and that collected after the treatment, at the exit of the WWTP (effluent) – 
related to the WWTP typical hydraulic retention time (HRT)); ii) the conversion of 
conjugated metabolites (present in influent samples) to the original substances, over the 
treatment processes (24). 
 
 
Table 3.4. Target pharmaceuticals quantified in Febros WWTP influent and effluent  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Concentration below the method quantification limit. 
 
With the purpose of better assessing the concentration levels of pharmaceuticals over the 
WWTP daily cycle, and possibly identifying potentially critical discharge periods, grab 
effluent samples were collected each hour, for 21-h, using the aforementioned automatic 
sampler device (Fig. 3.1 (c)), and further analysed.  
Pharmaceuticals 
Concentration (ng L-1) 
Influent Effluent 
Hydrochlorothiazide 6 022 <58* 
Paracetamol 20 074 <22 
Ciprofloxacin <6 <4 
Zolpidem <3 <2 
Azithromycin 571 530 
Bisoprolol 239 187 
Omeprazole - - 
Furosemide 2 675 2 430 
Indapamide <65 <57 
Paroxetine 105 60 
Bromazepam <7 <6 
Fluoxetine <5 <4 
Alprazolam <5 <4 
Lorazepam <7 240 
Nimesulide <4 <3 
Ketoprofen 122 562 
Naproxen 2 583 2 748 
Diazepam <3 <3 
Bezafibrate 1 348 1 797 
Diclofenac 431 1 107 
Ibuprofen 1 992 1 527 
Gemfibrozil 307 753 
Simvastatin 976 197 
Chapter 3 
72 
 
 
 
 
Fig. 3.6. Grab samples of WWTP effluent, collected hourly for a 21-h period, analysed 
individually. Graphics represent concentration variations for each pharmaceutical over the 
sampling period. AVG – theoretical average value calculated for a composite sample; MIN 
– minimum value; MAX – maximum value; LOQ – limit of quantification. 
Monitoring of Pharmaceuticals in Municipal Wastewaters and Surface Waters 
 
73 
 
The results obtained, and displayed in Fig. 3.6 revealed that, for the majority of the 
pharmaceuticals detected in the different effluent grab samples, there were no significant 
variations in terms of concentration. Hence, we confirmed that composite samples were 
accurate and representative. The HRT of this WWTP was allowing a proper 
homogenisation of influent wastewaters and the consequent attenuation of any eventual 
pharmaceutical discharge peak. Only the anti-inflammatory compound naproxen and the 
lipid regulator bezafibrate were indicated as <LOQ by analysis of the composite sample, 
while quantifiable concentration levels were achieved for some grab samples (max. 288 ng 
L-1 and 28 ng L-1, respectively). However, besides being rather low environmental 
concentrations, these results may denote punctual situations, with no substantial 
consequence whatsoever on the representativeness of composite samples.  
 
3.2.3.2. Surface Waters from Febros River and Douro River 
Concerning Febros river, a significant increase in the concentration levels of bisoprolol 
and furosemide was observed (approximately 2 and 6 times, respectively – Paper 2), 
when comparing sampling spot F1 (upstream the WWTP discharge point) with spot F2 
(immediately downstream the WWTP discharge point) (Fig. 3.3). Moreover, 
hydrochlorothiazide, azithromycin, diclofenac, gemfibrozil and simvastatin became 
quantifiable in F2, in concentrations ranging from 40 to 360 ng L-1. These results, in 
addition to those previously obtained for Febros WWTP effluent (Table 3.4), demonstrate 
the contribution of the WWTP to Febros river contamination with pharmaceutical 
compounds. Furthermore, the case of paracetamol must also be given particular attention. 
Its concentrations in Febros river upstream and downstream the WWTP discharge point 
were rather similar, which indicted the presence of another anthropogenic contamination 
source, possibly domestic untreated effluents. It is known that paracetamol is highly 
degraded over the treatment processes taking place in WWTPs (24).  
With regard to Douro river, the potential contribution of Febros river (its left bank 
tributary) to its contamination with pharmaceutical compounds was not confirmed. In 
fact, the results achieved for the sampling spots F5 and H (Fig. 3.3) revealed no 
pharmaceutical residue above its respective LOQ, most likely due to the already predicted 
high dilution effect, given Douro river huge dimensions. 
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3.2.4. Conclusions 
The main conclusions withdrawn from the present work relate to the importance of 
WWTPs’ role in the environmental dissemination of pharmaceutical compounds. 
Specifically regarding Febros WWTP, its implication on the pharmaceutical input to 
Febros river was evidenced by the higher pharmaceutical load in samples collected 
downstream the WWTP discharge point, when compared to upstream sampling sites. On 
the other hand, no significant increase in the pharmaceutical content was observed in 
Douro river after the mouth of Febros river, most likely due to the great dilution factor. 
Owing to the overall low removal efficiency attained by most WWTPs regarding 
pharmaceuticals in particular and emerging organic micropollutants in general, the 
development and application of more advanced treatment techniques became essential. 
This matter will be extensively discussed in the following chapter. 
 
Herein follows Paper 2 (in Portuguese language), concerning the Portuguese monitoring 
case study presented along this chapter. 
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3.3. Paper 2 – Effects of treated domestic effluents and 
tributaries on the contamination of Douro river with 
pharmaceutical compounds – Mitigation processes 
 
Published Scientific Paper: 
 
Sousa, M.A., Gonçalves, C., Vilar, V.J.P., Boaventura, R.A.R. e Alpendurada, M.F., Efeitos 
dos efluentes domésticos tratados e rios tributários no pool de resíduos farmacêuticos 
do Rio Douro - Processos de Mitigação [Effects of treated domestic effluents and 
tributaries on the contamination of Douro river with pharmaceutical compounds – 
Mitigation processes]. Submitted for publication in Recursos Hídricos (APRH - 
Associação Portuguesa de Recursos Hídricos), June 2011. 
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Resumo 
A presença de compostos farmacêuticos no meio aquático tem vindo a ser motivo de crescente preocupação por parte da 
comunidade científica, um pouco por todo o mundo. As ETARs são vistas como importantes fontes de contaminação. 
Neste trabalho procurou-se avaliar o impacto causado pela descarga do efluente tratado numa ETAR municipal num pequeno 
afluente do Rio Douro – o Rio Febros – e, em última análise, a contribuição destas duas fontes para o aporte de resíduos 
farmacêuticos ao Rio Douro (fonte de captação de água destinada ao consumo humano). 
O impacto causado pela descarga deo efluente da ETAR no Rio Febros foi notório dado o aumento significativo dos níveis de 
diversos fármacos no rio, a jusante do ponto de descarga da ETAR. Já a implicação do Rio Febros na contaminação do Rio 
Douro com fármacos não foi observada, o que se atribuiu ao elevado efeito de diluição verificado.  
Finalmente, e como tentativa de prevenção da contaminação do meio aquático com compostos farmacêuticos, foi testada a 
fotocatálise solar com TiO2, recorrendo à utilização de uma Instalação Solar Piloto com Colectores Parabólicos compostos 
(CPCs). Este processo revelou-se bastante promissor uma vez que, além do aumento significativo das taxas de remoção de 
diversos fármacos, se baseia no uso de uma fonte de energia renovável, tornando-se assim economicamente mais atractivo e 
amigo do ambiente. 
Palavras-chave: fármacos; contaminação aquática; ETARs; instalação solar piloto com CPCs; fotocatálise solar com TiO2.  
 
Abstract 
The aquatic environmental occurrence of pharmaceutical compounds has been increasingly concerning the scientific 
community worldwide. Wastewater treatment plants (WWTPs) are seen as important contamination sources. 
Therefore, in this work we attempted to evaluate the impact caused by the discharge of a municipal WWTP on a small 
tributary of Douro River – Febros River – and afterwards their overall contribution to the contamination of Douro River (water 
source for the production of drinking water) with pharmaceutical residues. 
The role of Febros’ WWTP on pharmaceutical aquatic dissemination was confirmed by the significant increase of several 
pharmaceutical compounds in Febros water body, downstream the WWTP discharge point. On the other hand, no significant 
contribution of these potential sources to Douro River’s contamination was observed, probably due to the high dilution effect.  
As a promising strategy for the mitigation of pharmaceuticals in the aquatic compartment, a solar photocatalysis experiment 
with TiO2 was performed and proved to be quite efficient. With the use of a Solar Pilot Plant with Compound Parabolic 
Collectors (CPCs), besides increasing removal rates, we make use of a renewable energy source, thus becoming more 
economically attractive and environmentally friendly.   
Keywords: pharmaceuticals; water contamination; WWTPs; solar pilot plant with CPCs; solar photocatalysis with TiO2.  
 
 
1. Introdução  
 
1.1. Poluentes Emergentes – Grupo dos Compostos 
Farmacêuticos 
A Directiva-Quadro da Água (DQA, Directiva 
2000/60/CE), que entrou em vigor a 22 de Dezembro de 
2000, mantém-se actualmente como o principal instrumento 
da Política da União Europeia relativa à Água. Através do 
estabelecimento de um quadro de acção comunitária, são 
indicados os protocolos a seguir com vista à obtenção do 
“Bom Estado Químico e Ecológico de todas as Águas até 
2015” e subsequente uso sustentado a longo termo. Esta 
Directiva salienta também a necessidade de identificação de 
“Outras Substâncias descarregadas em quantidades 
significativas na massa de água” e que constituam um 
potencial perigo para a qualidade da água, além das já 
conhecidas Substâncias Prioritárias [http://dqa.inag.pt/]. 
É exactamente neste grupo de “Outras Substâncias” que 
podemos incluir os designados Poluentes Emergentes 
(PEs), compostos actualmente não abrangidos por 
programas de monitorização a nível Europeu, mas que 
podem ser candidatos a regulamentação futura, 
dependendo dos resultados de ensaios de ecotoxicidade, 
___________ Monitoring of Pharmaceuticals in Municipal Wastewaters and Surface Waters _______________
77
M.A. Sousa, C. Gonçalves, V. Vilar, R. Boaventura & M.F. Alpendurada 
 2 
potenciais efeitos sobre a saúde e dados de monitorização 
da sua ocorrência em diversos compartimentos ambientais. 
Entre a grande variedade de compostos abrangidos sob esta 
designação incluem-se os Compostos Farmacêuticos (CFs), 
cujas diversas acções terapêuticas podem originar desde o 
desenvolvimento de resistências bacterianas (ex. 
antibióticos), a interferências com a reprodução, fisiologia e 
crescimento de espécies aquáticas (ex. desreguladores 
endócrinos – esteróides, hormonas). Além do mais, trata-se 
de compostos que podem apresentar baixa toxicidade 
aguda mas elevada toxicidade crónica, com potencial 
bioacumulação em diferentes tecidos animais. 
Estes poluentes são considerados emergentes não pela 
emergência do seu aparecimento mas da sua detecção, 
dada a cada vez maior capacidade analítica, viabilizada por 
associações de métodos cromatográficos a processos de 
detecção avançados, nomeadamente a Espectrometria de 
Massa, possibilitando a obtenção de limites de detecção na 
ordem dos µg-ng L-1 [Sousa et al., 2011]. 
1.2. Processos Avançados de Oxidação (PAOs)  
O uso crescente de xenobióticos como fármacos, fragrâncias 
sintéticas, pesticidas, drogas de abuso e outros 
contaminantes está a conduzir ao aumento das 
concentrações destas substâncias nas águas residuais e 
superficiais. Os CFs são considerados poluentes “pseudo-
persistentes” dado que as suas taxas de 
transformação/eliminação (0-100%, dependendo do 
composto e do processo de remoção natural/artificial) são 
compensadas pela sua re-introdução contínua no meio 
ambiente [Petrović et al., 2003]. 
A ocorrência e destino destes contaminantes têm sido 
objecto de vários estudos ao longo dos últimos anos (Fig. 1). 
Em Portugal começaram já a surgir registos da presença 
ambiental aquática de CFs. Desde efluentes hospitalares 
contendo, por vezes, elevadas concentrações de antibióticos 
(quinolonas) como ciprofloxacina, enrofloxacina, ofloxacina 
e norfloxacina, a efluentes domésticos tratados [Seifrtová et 
al., 2008 e Pena et al., 2010], bem como cursos de água 
superficiais, incluindo os rios Douro, Leça e Febros, tem 
sido reportada a presença de diversos CFs, pertencentes a 
vários grupos terapêuticos, entre eles analgésicos, 
antipiréticos e anti-inflamatórios, reguladores lipídicos, 
antibióticos, anti-epilépticos, etc. [Sousa et al., 2011]. 
 
 
 
Figura 1. Percurso cíclico dos compostos farmacêuticos nos 
diferentes compartimentos aquáticos [adaptado de 
Mompelat et al., 2009]. 
Dado que a reutilização de água tratada poderá, no futuro, 
ser a melhor solução para uma gestão sustentada em países 
mais desprovidos de água, e que uma das preocupações 
básicas no seu reuso é a presença de microcontaminantes 
(muitas vezes provenientes das descargas de ETARs 
municipais), são requeridos processos alternativos e/ou 
complementares aos tratamentos convencionais, capazes de 
permitir o aumento da qualidade dos efluentes eliminados 
e prevenir a contaminação ambiental com CFs. 
Neste contexto, os PAOs são considerados processos de 
tratamento bastante competitivos para a remoção destes 
compostos, mais ou menos recalcitrantes dada a sua 
elevada estabilidade química e/ou baixa 
biodegradabilidade. Os PAOs têm em comum a formação 
do radical hidroxilo (•OH), altamente reactivo e 
responsável pela degradação da componente orgânica. 
Dado o seu poder oxidante não-selectivo, estes radicais são 
capazes de oxidar e mineralizar quase todas as moléculas 
orgânicas, originando CO2, H2O e iões inorgânicos como 
produtos finais. Todavia, alguns deles podem apresentar 
também alguns inconvenientes, tais como altos consumos 
energéticos (ex. lâmpadas UV, geradores de ozono), 
quantidades elevadas de oxidantes e catalisadores (ex. 
H2O2, TiO2), ou ainda a necessidade de ajuste do pH de 
grandes volumes de amostra (ex. Fenton e foto-Fenton) 
[Miranda-Garcia et al., 2011 e Oller et al., in press]. 
2. Fármacos no Rio Douro 
2.1. Compostos Farmacêuticos 
Os fármacos englobados no presente estudo pertencem a 
doze classes terapêuticas diferentes, incluindo analgésicos e 
antipiréticos (paracetamol), anti-inflamatórios não 
esteróides (cetoprofeno, diclofenac, ibuprofeno, naproxeno, 
nimesulida), reguladores lipídicos (bezafibrato, gemfibrosil, 
sinvastatina), antibióticos (azitromicina, ciprofloxacina), 
ansiolíticos (alprazolam, bromazepam, diazepam, 
lorazepam, zolpidem), antidepressivos (fluoxetina, 
paroxetina), diuréticos (furosemida, hidroclorotiazida, 
indapamida), cardiotónicos (bisoprolol) e anti-ulcerosos 
(omeprazol), entre outros. 
Estes CFs encontram-se entre os mais comercializados em 
Portugal ao longo dos últimos anos, segundo dados 
fornecidos pelo INFARMED – Instituto Nacional da 
Farmácia e do Medicamento, e as correspondentes classes 
terapêuticas fazem parte do grupo das mais estudadas, 
reportadas e consumidas mundialmente [Sousa et al., 2011]. 
 
2.2. Possíveis Fontes de Contaminação – ETAR 
Municipal e Rio Tributário 
O local em estudo situa-se na Região Hidrográfica 3 – Rio 
Douro (RH3 – Douro, Fig. 2), sendo um dos principais 
objectivos a avaliação do impacto, no que se refere apenas 
ao conteúdo em fármacos, da descarga de efluentes 
tratados pela ETAR de Febros (concelho de V. N. Gaia) no 
Rio Febros e deste, posteriormente, no Rio Douro, onde 
desagua.  
Enquanto que o Rio Douro é o segundo rio mais extenso da 
Península Ibérica (com 927 km no total, nasce em Espanha 
na província de Sória, nos picos da Sierra de Urbión, a 2.080 
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m de altitude, apresentando uma área da bacia de 97.603 
km2 e um débito médio de 450 m3 s-1, atravessa o norte de 
Portugal, sendo a foz no Oceano Atlântico, junto das 
cidades do Porto e V. N. Gaia), já o Rio Febros é um 
pequeno afluente da margem esquerda do Rio Douro 
(nasce em Seixezelo e desagua no Esteiro de Avintes, 
passando também pelo Parque Biológico de Gaia). Assim, é 
expectável que o possível impacto causado pela ETAR seja 
mais notório no Rio Febros do que no Rio Douro, onde se 
prevê um grande efeito de diluição. Todavia, a construção 
da ETAR mostrou-se desde logo vantajosa na despoluição 
do Rio Febros de resíduos de origem doméstica e industrial, 
permitindo inclusivamente a sua repovoação, em 
colaboração com o Parque Biológico, com uma espécie de 
mamíferos marinhos há já 20 anos desaparecida deste rio – 
a lontra [http://www.dn.pt/inicio/ciencia/interior.aspx? 
content_id=1576557&seccao=Biosfera]. 
Assim, e como segundo principal objectivo deste estudo, 
pretende-se também aumentar a taxa de remoção de CFs 
em efluentes aplicando uma etapa adicional com PAO. 
Como modelo experimental, usou-se um efluente da ETAR 
de Febros e uma Instalação Solar com Colectores 
Parabólicos Compostos (CPCs), à escala piloto, para 
desenvolver um tratamento de Fotocatálise Solar com TiO2. 
 
 
 
Figura 2. Localização geográfica do local/caso em estudo – Região 
Hidrográfica 3: Douro. 
3. Metodologia Experimental 
3.1. Amostragem e Pré-Tratamento das Amostras 
O plano de monitorização da ocorrência de CFs em 
amostras ambientais incluíu, por um lado,  
afluentes/efluentes da ETAR de Febros (amostras 
compostas), e por outro lado, águas superficiais dos rios 
Febros e Douro (amostras simples).  Efectuou-se a análise 
de diversas amostras de água residual à entrada e saída da 
referida ETAR, desde Maio de 2009 a Março de 2011, bem 
como de amostras colhidas em 5 pontos do Rio Febros (1 a 
montante e 4 a jusante do ponto de descarga da ETAR) e 12 
pontos do Rio Douro (7 a montante e 5 a jusante da 
confluência com o Rio Febros), ao longo de 2 campanhas de 
amostragem realizadas em 2010 (Fig. 2). 
O plano de amostragem incluíu a colheita de 2,5 L para 
águas residuais e 1 L para águas superficiais (neste caso 
colhida a 1 m de profundidade), transporte até ao 
laboratório em malas térmicas e posterior conservação a 4 
ºC até realização da análise (máx. 3 dias após a colheita). 
No caso das amostras de afluente/efluente da ETAR de 
Febros, estas foram filtradas por filtros de fibra de vidro (Ø 
1,2 µm) imediatamente após chegada ao laboratório, 
previamente à conservação a 4 ºC. 
 
3.2. Método Analítico – SPE-LC-MS/MS 
Com vista à análise e quantificação dos 23 CFs 
seleccionados, que pudessem estar presentes nas amostras 
de água incluídas no programa de monitorização, havia já 
sido desenvolvido e optimizado pelos autores um método 
analítico, cf. descrito por Sousa et al. (2011). Sumariamente, 
o método consiste numa primeira etapa de cleanup 
(facultativo no caso das águas superficiais), seguido de 
extracção em fase sólida (SPE – Solid-Phase Extraction), para 
remoção de interferências e concentração dos analitos em 
estudo, e posterior análise/quantificação por cromatografia 
líquida associada a espectrometria de massa (LC-MS – 
Liquid Chromatography-Mass Spectrometry). 
Para as águas residuais, ambos os passos de cleanup e SPE 
foram efectuados simultaneamente com o uso de um 
adsorvente sólido misto (colunas de extracção Oasis MAX – 
Mixed-Anion Exchange), constituído por uma mistura entre 
uma amina quaternária (SAX - Strong-Anion Exchange) e 
uma fase apolar (polímero divinilbenzeno/N-
vinilpirrolidona). Este adsorvente misto foi optimizado de 
forma a possibilitar uma elevada selectividade e 
sensibilidade na extracção de compostos ácidos pelos 
grupos de troca aniónica, enquanto que os compostos 
básicos e neutros são retidos na fracção polimérica. 
No caso das águas superficiais, o cleanup é realizado, 
sempre que necessário, recorrendo a colunas Bakerbond 1º, 
2º - Amino (WAX – Weak-Anion Exchange), tendo o SPE sido 
optimizado com uso de um adsorvente hidrofílico (JTBaker 
H2Ophilic) [Gonçalves et al., 2011]. 
A par da optimização do adsorvente de extracção, foram 
igualmente optimizados outros parâmetros como pH (pH 
2), fluxo de percolação (10 mL min-1) e volume de rotura de 
50 mL para afluentes de ETAR, 100 mL efluentes de ETAR e 
200 mL para águas superficiais. 
A separação, identificação e quantificação dos CFs foi 
conseguida com recurso à cromatografia líquida de alta 
performance, ionização por Electrospray (ESI) e detecção 
por espectrometria de massa (detector ion-trap), em modo 
de operação MS-MS, garantido assim a confirmação 
inequívoca de cada composto por comparação com os 
espectros de referência obtidos para os respectivos padrões.  
Uma vez optimizadas todas as variáveis experimentais, o 
método analítico obtido foi validado em termos de 
sensibilidade, selectividade, precisão, exactidão e 
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calibração, tendo-se revelado robusto para a determinação 
de CFs em amostras de água [Sousa et al., 2011]. 
 
3.3.  Fotocatálise Solar Heterogénea (TiO2) como 
Tratamento Terciário de Efluentes Municipais 
A versatilidade dos processos avançados de oxidação deve-
se à existência de múltiplas reacções capazes de gerar 
radicais hidroxilo, tais como TiO2/UV, H2O2/UV, Fenton 
(Fe2+/H2O2)/foto-Fenton (Fe2+/H2O2/UV)/electro-Fenton 
/electro-foto-Fenton e ozono (O3, O3/UV e O3/H2O2). 
Todas estas metodologias se tornam economicamente mais 
atractivas quando existe a possibilidade de utilização da 
radiação solar como fonte de fotões UV.  
Entre os diferentes PAOs, a fotocatálise heterogénea com 
UV/TiO2 tem-se revelado bastante promissora na 
destoxificação de águas residuais. A fotocatálise 
heterogénea é um processo que ocorre na presença de 
radiação UV e de um catalisador na fase sólida (fixo ou em 
suspensão). Na maioria dos métodos, o catalisador 
utilizado é um semicondutor. A estrutura electrónica destes 
semicondutores é caracterizada por uma banda de valência 
completa, de energia mais baixa, e uma banda de condução 
vazia, de energia mais alta. Estas duas bandas são 
separadas por uma quantidade de energia que se denomina 
gradiente energético. Ao absorver um fotão com uma 
quantidade de energia igual ou superior à do gradiente 
energético, um electrão da banda de valência ganha energia 
suficiente para passar ao nível da banda de condução, 
gerando um par electrão/lacuna (“electron/hole pair” – e-
/h+). Contudo, por este ser um estado instável, em que o 
electrão se encontra excitado, o par electrão/lacuna tem 
tendência a anular-se, recombinando-se para o estado 
inicial  numa  questão  de  nanosegundos.  No  entanto,   na  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
presença de H2O e O2 na superfície do semicondutor, estes 
podem reagir com o par electrão/lacuna, ocorrendo 
reacções de oxidação/redução em vez da recombinação, 
dando origem à formação dos radicais hidroxilo.  
O interesse particular no TiO2 (BGE – Band Gap Energy = 3 
eV) deve-se às propriedades fotocatalíticas, elevada 
hidrofilia e reactividade, baixa toxicidade, baixo custo e 
estabilidade química [Miranda-García et al., 2011 e Oller et 
al., 2011]. 
Neste estudo foi utilizada uma Instalação Solar Piloto com 
Colectores Parabólicos Compostos (CPCs) (Fig. 3) para o 
tratamento fotocatalítico de um efluente proveniente da 
ETAR de Febros, usando como catalisador o TiO2.  
A planta encontra-se instalada no terraço do Departamento 
de Engenharia Química da Faculdade de Engenharia, 
Universidade do Porto (FEUP). O colector solar é 
constituído por uma unidade CPC (0,91 m2) de 4 tubos de 
vidro borossilicatado (Schott-Duran type 3.3, Alemanha, com 
cut-off a 280 nm, diâmetro externo de 50 mm, comprimento 
de 1500 mm e espessura de 1,8 mm), ligados em série por 
junções em polipropileno, com reflectores parabólicos em 
alumínio anodizado, suportados por uma estrutura em 
alumínio e com uma inclinação de 41º (correspodente à 
latitude local). A planta solar possui ainda 2 tanques de 
recirculação (10 L e 20 L), 2 bombas de recirculação (máx. 
20 L min-1) e 2 rotâmetros, 5 válvulas em polipropileno e 
um quadro eléctrico para controlo. A instalação pode ser 
usada de dois modos: utilizando a área total dos CPCs (0,91 
m2) ou 0,455 m2 de cada par de tubos individualmente, 
permitindo a execução em simultâneo de duas experiências 
independentes, sob as mesmas condições de irradiação 
solar [Pintor et al., 2011]. 
A intensidade da radiação UV solar é medida por um 
radiómetro  (ACADUS 85-PLS),  instalado   com   o   mesmo  
 
 
 
Figura 3. Plantas de Desinfecção Solar à Escala Piloto 
A – Planta Solar Piloto com radiómetro: (a) Vista Frente, (b) Vista Trás; 1- Radiómetro, 2- Painel Fotovoltáico, 3- Bateria; 
B – Planta Solar Piloto utilizada na experiência: (c) CPCs com efluente da ETAR de Febros, (d) CPCs com efluente da 
ETAR de Febros e 200 mg L-1 TiO2, (e) Vista Trás; 4- Colectores Parabólicos Compostos (CPCs), 5- Tanques de 
Recirculação, 6- Bombas de Recirculação, 7- Quadro Eléctrico, 8- Rotâmetros. 
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 5 
ângulo de inclinação. As medições da radiação ultravioleta 
instantânea (W m-2) são obtidas com intervalos de 1 min. e 
usadas no cálculo da energia UV acumulada (QUV,n , kJ L-1), 
durante um determinado intervalo de tempo (∆t), através 
da equação: 
 
11 −− −=+= nnn
t
r
n,Gnn,UVn,UV ttt;V
AUVtQQ ∆∆
 
 
 
onde tn é o tempo correspondente a n-alíquota (s), Vt,n o 
volume total de efluente em n-alíquota (L), Ar a superfície 
iluminada do colector e nGUV ,  o valor médio de radiação 
UV solar (W m-2) medida no intervalo de tempo ∆tn [Pintor 
et al., 2011].  
A amostra de efluente da ETAR de Febros foi caracterizada 
antes do início do tratamento por fotocatálise solar. Os 
resultados obtidos são apresentados na Tabela 2 (secção 
4.3.).  
A concentração óptima de TiO2 determinada foi de 200 mg 
L-1. As várias alíquotas colhidas ao longo da experiência 
foram analisadas segundo o método descrito na secção 3.2., 
com o objectivo de obter as cinéticas de degradação dos 
diversos fármacos presentes na amostra ao longo das várias 
horas de exposição solar. 
Podem ser encontrados detalhes adicionais sobre o modo 
de funcionamento e utilização da Instalação Solar Piloto 
com CPCs, bem como sobre as determinações analíticas 
seleccionadas/efectuadas para caracterização da amostra 
em Pintor et al., 2011. 
4. Resultados e Discussão 
4.1. Águas Residuais – Afluente e Efluente da ETAR 
de Febros 
O método analítico multi-resíduo desenvolvido foi 
utilizado na análise rigorosa de amostras compostas de 
afluente e efluente da ETAR de Febros, cujos resultados 
obtidos se encontram sumariados na Tabela 1. 
Compostos como o paracetamol e a hidroclorotiazida 
destacam-se em concentrações bastante significativas no 
afluente da ETAR (>5 µg L-1). Todavia, a eficácia dos 
processos de tratamento utilizados é bastante elevada para 
ambos os compostos, como se pode comprovar pelos 
valores obtidos à saída da ETAR (concentrações inferiores 
aos respectivos limites de quantificação). Já para outros 
compostos a eficiência de remoção na ETAR não é tão 
elevada, enquanto que em alguns casos se verifica mesmo 
um aumento da concentração no efluente, 
comparativamente ao afluente. Tal pode dever-se, 
sobretudo, à dificuldade de correlação entre a amostra 
colhida antes e após o tratamento na ETAR (relacionado 
com tempo de retenção hidráulica), mas também à 
possibilidade de não quantificação de alguns compostos à 
entrada da ETAR pelo facto de se encontrarem na forma 
conjugada (metabolitos), sendo que à saída se poderão já 
encontrar na forma original não-conjugada, reconvertida ao 
longo das etapas de tratamento [Gros et al., 2010]. 
 
Tabela 1. Concentrações dos compostos farmacêuticos-alvo 
detectadas no afluente e efluente da ETAR de Febros 
* Concentração abaixo do Limite de Quantificação do Método 
 
No sentido de conhecer a evolução dos teores de fármacos 
ao longo do ciclo diário e identificar momentos críticos de 
descarga destes poluentes, foram realizadas análises, em 
separado de amostras simples de efluente da ETAR, 
colhidas de hora em hora, ao longo de 21h consecutivas.  
Da análise dos gráficos (Fig. 4) podemos concluir que, para 
a generalidade dos compostos detectados nas diferentes 
amostras de efluente da ETAR, não existem variações 
significativas nas concentrações determinadas, daí que a 
amostragem composta seja considerada adequada e 
representativa. O tempo de retenção hidraúlica da ETAR 
permite uma homogenização do afluente e consequente 
atenuação de eventuais picos de concentração dos 
fármacos. Apenas o anti-inflamatório naproxeno e o 
regulador lipídico bezafibrato são indicados como <LOQ 
por análise da amostra composta, enquanto que foram 
obtidos valores quantificáveis para algumas amostras 
simples (máximos de 288 ng L-1 e 28 ng L-1, 
respectivamente). Todavia, além destas concentrações 
serem bastante baixas, tratar-se-ão de casos pontuais, sem 
consequências significativas no que respeita à 
representatividade da amostragem composta. 
 
4.2. Águas Superficiais – rios Febros e Douro 
Um resultado típico obtido nas campanhas de 
monitorização do Rio Febros encontra-se representado na 
Fig. 5. 
Pode constatar-se que no rio Febros a jusante do ponto de 
descarga da ETAR (ponto F2, Fig. 2) se verifica um 
aumento significativo dos níveis de bisoprolol (ca. dobro) e 
furosemida (ca. 6 vezes superior), enquanto que a 
hidroclorotiazida,  azitromicina,  diclofenac,  gemfibrosil   e  
Concentração (ng L-1) Composto 
Farmacêutico Afluente Efluente 
Hidroclorotiazida 6.022 <58* 
Paracetamol 20.074 <22 
Ciprofloxacina <6 <4 
Zolpidem <3 <2 
Azitromicina 571 530 
Bisoprolol 239 187 
Omeprazol - - 
Furosemida 2.675 2.430 
Indapamida <65 <57 
Paroxetina 105 60 
Bromazepam <7 <6 
Fluoxetina <5 <4 
Alprazolam <5 <4 
Lorazepam <7 240 
Nimesulida <4 <3 
Cetoprofeno 122 562 
Naproxeno 2.583 2.748 
Diazepam <3 <3 
Bezafibrato 1.348 1.797 
Diclofenac 431 1.107 
Ibuprofeno 1.992 1.527 
Gemfibrosil 307 753 
Sinvastatina 976 197 
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Figura 4. Amostras simples de efluente da ETAR de Febros, colhidas de hora em hora durante um período de 21h, analisadas 
individualmente. Os gráficos representam a variação da concentração de cada composto durante o período de colheitas. O valor médio 
indicado corresponde ao valor teoricamente obtido na amostra composta. LOQ – Limit of Quantification 
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sinvastatina se tornaram quantificáveis, em concentrações 
entre os 40 e 360 ng L-1. Tais resultados, em complemento 
com os já obtidos para a análise de efluente da ETAR 
(Tabela 1), apontam para a contribuição da ETAR na 
contaminação do Rio Febros com resíduos farmacêuticos. 
De notar que no caso do paracetamol os níveis detectados 
no Rio Febros a montante e a jusante da ETAR são 
semelhantes, indiciando a existência de outra fonte de 
contaminação antropogénica. È sabido que o paracetamol 
se degrada durante o tratmento nas ETARs. 
Já relativamente ao Rio Douro, o possível impacto do Rio 
Febros (seu afluente, margem esquerda) no aporte de 
compostos farmacêuticos ao seu estuário não é visível. De 
facto, os resultados não revelaram a presença de qualquer 
um dos fármacos pesquisados acima do respectivo LOQ, 
provavelmente devido ao grande efeito de diluição 
verificado, dado o elevado caudal do Rio Douro.  
Concluindo, dada a reduzida eficácia de remoção de alguns 
fármacos por parte da ETAR em estudo, e de outras ETARs 
em geral, é urgente a aplicação de processos de tratamento 
mais eficientes na remoção de poluentes emergentes nestas 
Estações de Tratamento de Água. 
 
4.3. Tratamento do Efluente da ETAR de Febros por 
Fotocatálise Solar numa Planta Piloto com CPCs 
Com o propósito de avaliar a aplicabilidade dos PAOs no 
tratamento terciário de águas residuais numa ETAR, usou-
se como amostra um efluente da ETAR de Febros (Tabela 2) 
e seleccionou-se a fotocatálise solar com dióxido de titânio 
como processo de fototratamento. 
Nas condições experimentais descritas (secção 3.3.), os 
resultados obtidos são traduzidos nos gráficos da Fig. 6. 
Da análise desta Figura pode concluir-se que o tratamento 
por fotocatálise com TiO2 foi eficaz na remoção completa da 
maioria dos compostos farmacêuticos quantificados no 
efluente original, recolhido à saída da ETAR de Febros. 
Exceptuam-se os seguintes compostos: ciprofloxacina, 
cetoprofeno, losartan1 e carvedilol1, cujas concentrações no  
 
1NOTA: Alguns dos compostos farmacêuticos representados na 
Fig. 6 não estão incluídos no método descrito na secção 
experimental. Todavia, a sua inclusão no método foi relativamente 
simples, seguindo a metodologia de optimização usada para os 
restantes fármacos. 
 
 
 
 
final do tratamento, embora não inferiores aos respectivos 
LOQ, eram já significativamente inferiores às concentrações 
correspondentes iniciais. Nestes casos, o processo 
fotocatalítico teria de ser ainda optimizado, a nível da 
concentração do catalisador e/ou da quantidade de energia 
UV acumulada total necessária. 
 
Tabela 2. Caracterização físico-química da amostra de efluente da 
ETAR de Febros usada na experiência de fotocatálise solar 
Parâmetro (unidades) 
Efluente da 
ETAR Febros 
(18.03.2011) 
Côr n.d.* (dil. 1/20) 
Cheiro n.d. (dil. 1/20) 
pH 7,3 
Temperatura (º C) 20,0 
Turvação (NTU) 115 
Condutividade (µS cm-1) 555 
Oxigénio Dissolvido (mg L-1) 2,2 
Oxidabilidade (mg L-1) 56,2 
Carbono Total Dissolvido (mg L-1) 37,5 
Absorvância a 254 nm (UA) 0,07 
Sólidos Suspensos Totais (mg L-1) 363 
Sólidos Suspensos Voláteis (mg L-1) 223 
Azoto amoniacal - NH4+ (mg L-1) 1,2 
Nitrato - NO3- (mg L-1) 23,3 
Nitrito - NO2- (mg L-1) <0,5 
Brometo - Br- (mg L-1) <0,5 
Cloreto - Cl- (mg L-1) 78,5 
Fluoreto - F- (mg L-1) <0,5 
Fosfato - PO43- (mg L-1) 7 
Sulfato - SO42- (mg L-1) 59,8 
Fósforo - 31P (mg L-1) 
Metais 
Sódio - 23Na (mg L-1) 
Potássio - 39K (mg L-1) 
Cálcio - 44Ca (mg L-1) 
3,0 
 
78,8 
21,1 
274,8 
* n.d. – não detectável 
 
Figura 5. Representação gráfica comparativa dos fármacos quantificados no Rio Febros a montante e a jusante do ponto de descarga da 
ETAR de Febros. 
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5. Conclusões 
Do presente trabalho podemos concluir que os compostos 
farmacêuticos se encontram bastante disseminados no 
compartimento ambiental aquático, sendo as ETARs uma 
importante fonte de contaminação. 
No caso particular da ETAR de Febros, a sua provável 
implicação no input dum conjunto de fármacos no Rio 
Febros foi posta em evidência através da comparação dos 
níveis dos vários compostos em amostras colhidas a 
montante e a jusante do ponto de descarga da ETAR, sendo 
estes superiores no segundo caso. 
Já no que respeita à contribuição do Rio Febros para os 
níveis de compostos farmacêuticos no Rio Douro, tal não foi 
considerada significativa, provavelmente devido ao grande 
efeito de diluição resultante do elevado caudal deste rio. 
Em última análise, este trabalho demonstra ainda a 
aplicabilidade dos PAOs, em particular da fotocatálise solar 
com TiO2, como processo de tratamento terciário com 
potencial aplicação em ETARs (Fig. 7), surgindo como um 
método promissor no aumento das taxas de remoção de 
poluentes emergentes antropogénicos como os compostos 
farmacêuticos. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 6. Representação gráfica do decréscimo de concentração 
dos diferentes fármacos quantificados na amostra de efluente da 
ETAR de Febros, sujeita ao tratamento fotocatalítico. 
 
 
 
 
 
 
 
 
Figura 7. Representação esquemática da possível instalação de 
uma planta solar com CPCs numa ETAR, como processo de 
tratamento terciário, precedente à descarga do efluente.  
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3.4. Inter-laboratory Exercises: Method Validation and 
Quality Control 
There is currently no standardised practice or protocol for the sampling and analytical 
determination of pharmaceuticals in water, or any other environmental media, to ensure 
the comparability and quality of the data generated.  
The participation in inter-laboratory exercises (ILEs) allows withdrawing information 
concerning the overall cycle of the sample, including its reception, analysis and data 
treatment, ultimately leading to a quality improvement of the results. ILEs can be carried 
out with three purposes: i) to assess the performance of an analytical method, ii) to 
evaluate the competence of a laboratory, or iii) to enable the certification of reference 
materials (25).  
Nowadays, European level ILEs, regarding the analysis of frequently used pharmaceuticals 
in environmental waters, are still scarce. Nevertheless, some joint efforts have already 
been reported (26, 27).  
During this Ph.D. work, we participated in two European inter-laboratory studies, the first 
promoted by the Joint Research Centre (JRC), a Directorate-General of the European 
Commission for research, innovation and science (herein addressed as ILE-FATE_SEES), 
and a second one organized under the PHARMAS EU project, by the Advanced School of 
Public Health (EHESP) (ILE-PHARMAS).  
ILE-FATE_SEES presented as main goal the evaluation of the reproducibility of analytical 
methods employed in the determination of a list of emerging pollutants (pharmaceuticals 
included) in WWTP effluents. After 1 L sampling of municipal effluents from two WWTP 
located in the northern region of Portugal (WWTP from Viana do Castelo (VC) and 
WWTP from Parada, Maia (PM)), a certain volume of each sample was shipped to the 
organizing laboratory in Italy, while the remaining was analysed in our facilities, using the 
aforedescribed method conceived for the determination of pharmaceutical compounds in 
wastewaters. Only 12 out of the 23 pharmaceuticals included in our method were present 
in the list proposed by ILE-FATE_SEES organization: diclofenac, ketoprofen, naproxen, 
ibuprofen, bezafibrate, gemfibrozil, ciprofloxacin, bisoprolol, fluoxetine, paroxetine, 
alprazolam and zolpidem. Afterwards, the attained results by both laboratories were 
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statistically evaluated in terms of z-scores. Z values were calculated according to the 
following expression:  
  σ
Χ−
= lab
X
Z
       
(1) 
where: 
Xlab = result for a laboratory; 
X = mean values between all laboratories; 
σ = standard deviation in the corresponding population. 
The most commonly accepted classification establishes that: │z-score│< 2 – satisfactory 
result; 2 < │z-score│< 3 – questionable result; │z-score│> 3 – unsatisfactory result (28). 
In a total of 24 analytical determinations (12 pharmaceuticals for WWTP-VC and for 
WWTP-PM), our results included: 
 11 determinations with │z-score│< 2: satisfactory results; 
 4 determinations with 2 < │z-score│< 3: dubious results; 
 3 determinations with │z-score│> 3: unsatisfactory results; 
 6 results with pharmaceutical below the respective LOQ. 
Even though, the attained results relied on the comparison between two laboratories only. 
Consequently, more accurate conclusions on the performance of the employed 
methodologies could only be withdrawn after enlarging the comprehensiveness of the 
study. 
In the ILE-PHARMAS exercise, the goal was to evaluate the reproducibility of analytical 
methods for the measurement of antibiotics in waters (Table 3.5). It was the first initiative 
organised in Europe in this type of exercises, using different kind of analytical methods 
and devices. Fourteen laboratories from five countries (Canada, France, Italy, the 
Netherland and Portugal) participated and a total number of 78 samples were distributed. 
During the exercise, 2 testing samples (3 bottles of each) prepared from tap water (series 
A) and river water (series B) were spiked with antibiotics and sent to the participants to be 
analysed along one month. 
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Table 3.5. Antibiotics included in the ILE-PHARMAS exercise  
Class of Antibiotic Compound Acronym CAS number 
Fluoroquinolones Ofloxacin OFL 83380-47-6 
Ciprofloxacin CIP 85721-33-1 
Sulfonamide Sulfamethoxazole SMX 723-46-6 
Pyrimidin (associated to sulphonamide) Trimethoprim TMP 738-70-5 
Macrolide Erythromycin ERY 114-07-8 
 
 
Part of the report of this exercise is displayed in Annex III. In our laboratory, therein 
identified as Lab. 5, both sample series A and B (tap water and river water, respectively – 
3 replicates each) were analysed using the aforedescribed method primarily developed for 
surface waters, i.e., beginning with 200 mL sample acidification to pH 2, followed by an 
optional cleanup step using Bakerbond 1º,2º-Amino cartridges and subsequent solid-
phase extraction with JTBaker H2Ophilic extraction columns (23). Chromatographic and 
mass spectrometric conditions were optimised for OFL, SMX and TMP, and further 
included in the analytical method already comprising CIP, whereas ERY was not analysed 
at our laboratory, due to the unavailability of analytical standard.  
The concentrations determined in the 3 replicates of each sample series, A and B, are 
presented in Tables 3.6 and 3.7. 
 
Table 3.6. Concentration (ng L-1) of antibiotics determined in the three replicates of 
sample series A (spiked tap water). Each extract was injected twice for LC-MS/MS analysis 
Antibiotics 
Extraction 1 Extraction 2 Extraction 3 
Injection 1 Injection 2 Injection 1 Injection 2 Injection 1 Injection 2 
Erythromycin n.a.* n.a. n.a. n.a. n.a. n.a. 
Ciprofloxacin <33 <33 <33 <33 <33 <33 
Ofloxacin 41.878 38.478 41.611 37.170 45.051 37.958 
Sulfamethoxazole 15.766 13.261 - - 11.517 12.508 
Trimethoprim 31.845 32.998 32.659 36.364 33.525 39.222 
* n.a. – not analysed 
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Table 3.7. Concentration (ng L-1) of antibiotics determined in the three replicates of 
sample series B (spiked river water). Each extract was injected twice for LC-MS/MS 
analysis 
Antibiotics 
Extraction 1 Extraction 2 Extraction 3 
Injection 1 Injection 2 Injection 1 Injection 2 Injection 1 Injection 2 
Erythromycin n.a. n.a. n.a. n.a. n.a. n.a. 
Ciprofloxacin 135.034 127.366 121.843 110.450 133.801 154.607 
Ofloxacin 259.210 226.503 231.983 209.912 191.808 212.723 
Sulfamethoxazole 74.250 86.567 71.857 82.690 68.715 78.851 
Trimethoprim 135.034 127.366 121.843 110.450 133.801 154.607 
* n.a. – not analysed 
 
The attained z-scores of all participants are illustrated in Fig. 3.7. 
 
 
Fig. 3.7. Z-score absolute values (outliers excluded). Sample A – spiked tap water;  
sample B – spiked river water. 
 
All our results fell in the satisfactory z-score range, which demonstrates the reliability of 
the developed procedure for monitoring pharmaceuticals in water samples.  
In conclusion, ILEs constitute a clear strategy to demonstrate analytical capability (29), 
which is fundamental to obtain good quality data for future inclusion in framework 
directives. 
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Chapter 4 
Photo-Remediation of Contaminated 
Waters using Advanced Oxidation 
Processes (AOPs) 
 
Up till this moment, the work herein described consisted on: i) the development, 
optimization and validation of the cleanup–SPE–HPLC-tandem MS multiresidue method 
for detection and quantification of pharmaceutical compounds in waters (Chapter 2); ii) 
its further application to the analysis of contaminated water samples collected over 
monitoring campaigns and acquired during inter-laboratory exercises (ILEs) (Chapter 3). 
Hence, it came the time to tackle the study of remediation procedures aiming for water 
decontamination. This study resulted in the publication of Paper 3 and Paper 4 (please 
refer to the end of Section 4.2). 
As previously mentioned, wastewater treatment plants (WWTPs) are considered the major 
source of environmental pollution by pharmaceuticals, since the employed conventional 
treatment processes are inefficient for their complete removal or degradation (1). Once in 
the environment, such micropollutants can undergo a series of chemical reactions, mainly 
divided into four types: biotics, photochemicals, hydrolysis and oxidation/reduction (2).  
Photochemical processes result from the absorption of the energy contained in solar 
radiation by organic molecules. This is influenced by factors such as chemical structure, 
latitude, season and day time. When a compound undergoes a chemical transformation in 
result of the direct absorption of solar radiation, the process is called direct photolysis. On 
the other hand, if the photodegradation occurs by means of another compound (e.g., 
photosensitive natural compounds such as nitrates and humic acids), that absorbs the 
energy, originating reactive species which will in turn react with the first compound, then 
the process is entitled indirect photolysis (Fig. 4.1) (2). These are the main processes 
involved in the degradation of pharmaceutical compounds on shallow surface waters. 
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However, total mineralization is far from being achieved. Thus, there is an absolute need 
to develop effective methods for handling these contaminants and potentially toxic 
compounds, widely dispersed in the environment. 
Conventional drinking water decontamination processes involve the combination of 
flocculation, filtration, sterilization and conservation, with the addition of a limited 
number of chemicals. On the contrary, normal human sewage water is usually treated in 
conventional biological processing plants. Despite the fact that biological treatment 
techniques are well established and relatively cheap, they are often susceptible to toxic 
compounds which inactivate the degrading microorganisms, thus becoming unable to 
remove the contaminants. In order to solve this issue, besides reducing emissions, a 
chemical treatment of contaminated drinking, surface and groundwaters should be 
pursued, as well as a chemical treatment of wastewaters containing biocides or non-
biodegradable compounds (3). 
Addressing this problem has recently recalled a tremendous amount of research in the 
field of robust new water treatment technologies, leading to the complete mineralization 
of organic pollutants at lower cost and with less energy, while at the same time minimizing 
the use of chemicals and their subsequent impact on the environment (4). Special 
attention has been given to advanced oxidation treatment processes. 
 
4.1. Advanced Oxidation Processes 
4.1.1. Definition 
Advanced oxidation processes (AOPs) are defined as oxidation methods occurring in the 
aqueous phase and based upon the generation of highly reactive species such as hydroxyl 
radicals (●OH). These radicals present a high oxidation potential (E0 = 2.80 V relatively to 
the normal hydrogen electrode) and are responsible for the oxidation and mineralization 
of almost any organic molecule, yielding CO2, H2O and inorganic ions as final products, 
due to their strong, unselective oxidative power. Thus, AOPs can be used to chemically 
decompose pollutants into harmless end-products, otherwise not removed by 
conventional treatment processes (3, 5). Moreover, these oxidation processes have the 
increased interest of taking place at room temperature. 
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Nevertheless, there are species such as CO32-, HCO3-, SO42-, Cl- and humic acids, which can 
act as free radicals’ inhibitors and significantly reduce the degradation process efficiency, 
depending on their concentration in the medium. For that reason, some pre-treatment 
may be required to reduce these species concentration or even eliminate them. In case the 
treatment process is occurring under acidic conditions, the problem concerning the 
presence of carbonates or bicarbonates is automatically solved (6). 
 
 
 
Fig. 4.1. Reactions involved in the processes of direct photolysis, indirect photolysis, 
heterogeneous photocatalysis and formation of oxygen radical reactive species (adapted 
from Burrows et al. (2)).  
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4.1.2. Classification and Applications to Water Treatment 
According to the number of phases of the reaction system, AOPs can be divided in 
homogeneous (single-phase system) or heterogeneous (more than one phase system) 
processes. Moreover, they can also be classified in compliance with the method used to 
generate the reactive radical species as chemical, photochemical, electrochemical, 
sonochemical or thermochemical (Fig. 4.2). 
HOMOGENEOUS 
 
CHEMICAL                                                                                                                                              Ref. 
Ozone in basic medium (O3/OH–)                                                                                                         (7) 
Ozone and hydrogen peroxide (O3/H2O2) and (O3/H2O2/OH–)                                                        (8) 
Homogeneous catalytic ozonation (O3/catalyst)                                                                               (9)              
Fenton (H2O2/Fe2+)                                                                                                                                (10) 
 
PHOTOCHEMICAL                                                                                                                                 Ref. 
Ozone and ultraviolet radiation (O3/UV)                                                                                          (11) 
Hydrogen peroxide and ultraviolet radiation (H2O2/UV)                                                         (12, 13) 
Ozone, hydrogen peroxide and ultraviolet radiation (O3/H2O2/UV)                                            (14) 
Photo-Fenton (H2O2/ Fe2+/UV)                                                                                                            (15) 
 
ELECTROCHEMICAL                                                                                                                              Ref. 
Electrochemical oxidation                                                                                                                   (16) 
Electro-Fenton and photo-electro-Fenton                                                                                 (17, 18) 
 
SONOCHEMICAL                                                                                                                                   Ref. 
Ultrasounds (US)                                                                                                                                   (19) 
Ozone and ultrasounds (O3/US)                                                                                                         (20) 
Hydrogen peroxide and ultrasounds (H2O2/US)                                                                              (21) 
 
THERMOCHEMICAL                                                                                                                              Ref. 
Wet air oxidation (WAO)                                                                                                                     (22) 
Supercritical wet air oxidation (SWAO)                                                                                            (23) 
Catalytic wet air oxidation (CWAO)                                                                                            (24, 25) 
 
HETEROGENEOUS 
CHEMICAL                                                                                                                                              Ref. 
 Heterogeneous catalytic ozonation (O3/catalyst)                                                                    (26, 27) 
PHOTOCHEMICAL                                                                                                                                 Ref. 
Heterogeneous photocatalysis (TiO2/UV), (TiO2/UV/H2O2) and (O3/TiO2/UV)              (12, 28, 29) 
 
 
Fig. 4.2. AOPs classification, possible combinations and some relevant references.  
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Many AOPs have recently earned great interest in the field of water decontamination 
processes, each one presenting its own advantages and disadvantages. Polluted waters 
vary from industrial effluents with different origins (e.g., agriculture, textile, tannery, etc.), 
to hazardous effluents from hospitals or pharmaceuticals production facilities, or even to 
municipal WWTP effluents contaminated with pathogenic agents and recalcitrant 
pollutants, such as pharmaceuticals and endocrine disrupting compounds (7, 30, 31). 
In particular, over the last few decades there has been a paramount increase of studies 
concerning the use of photochemical AOPs for the effective and sustainable treatment of 
waters contaminated with pharmaceutical compounds, as one can observe in Fig. 4.3. 
Indeed, owing to some technological/engineering developments, this growth may also 
have been propelled by the possibility of using solar radiation as the photon source. 
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Fig. 4.3. Number of publications relative to photodegradation treatment processes of 
waters contaminated with pharmaceutical compounds, between 2000 and 2012 (source: 
www.sciencedirect.com, using “photodegradation” and “pharmaceuticals” and “water 
treatment” as keywords).  
 
Amongst all photochemical oxidation processes that could be chosen, in the herein 
described Ph.D. work we opted for the heterogeneous photocatalysis, using titanium 
dioxide (TiO2) as catalyst (Paper 3 and Paper 4). 
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4.1.2.1. Heterogeneous Photocatalysis 
4.1.2.1.1. Fundamentals 
In a photochemical process, light is always a reagent, never a catalyst. The term 
photocatalysis implies the combination of photochemical process with the use of a 
catalyst, i.e., it is the “acceleration of a photoreaction by the presence of a catalyst” (3). In 
the case of heterogeneous processes, the catalyst employed is a semiconductor material 
like metal oxides. 
When a semiconductor (SC) is exposed to radiation with higher energy than the band gap 
between its valence band (VB – filled electronic band with the highest energy) and its 
conduction band (CB - empty electronic band with the lowest energy), there is an electron 
transfer from VB to CB, resulting in the formation of a hole in the valence band (h+): 
 SC + hν  →  SC (h+ VB  + e- CB)     (1) 
If the semiconductor is in contact with a liquid electrolyte solution containing redox 
couple, the formed electron/hole (e- and h+) pairs migrate to the surface of the 
semiconductor particle and charge transfer occurs across the interface, in order to balance 
the potentials of the two phases (3, 32).  
Hydroxyl radicals can be formed by two ways: the valence band hole (h+ VB) can either 
react with the adsorbed water or the surface OH- groups on the semiconductor particle: 
 SC (h+ VB) + H2Oads  →  SC + HO● ads + H+   (2) 
 SC (h+ VB) + OH- ads  →  SC + HO● ads    (3) 
The semiconductor is recovered when acceptor molecules (A) such as O2 are adsorbed and 
react with an electron in the conduction band, while donor molecules (D) such as H2O are 
adsorbed and react with a hole in the valence band: 
 SC (e- CB) + Aads  →  SC + A- ads     (4) 
 SC (h+ VB) + Dads  →  SC + D+ ads     (5) 
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It is widely accepted that O2 plays an important role in these reactions. O2 can trap 
conduction band electrons to originate superoxide radicals (O2● -) (Eq. 6). These radicals 
can react as well with hydrogen ions (H+) from water splitting process to form HO2● -. 
 SC (e- CB) + O2 ads + H+  →  SC + HO2● -  →  O2● - + H+  (6) 
H2O2 can also be formed from HO2● – species: 
 SC (e- CB) + HO2● - + H+  →  H2O2    (7) 
and hydroxyl radicals may be originated by cleavage of H2O2 via one of the following 
reactions: 
 H2O2 + hν  →  2 HO●       (8) 
 H2O2 + O2● -  →  HO● + O2 + HO-    (9) 
 H2O2 + SC (e- CB)  →  HO● + HO- + SC             (10) 
Finally, highly reactive hydroxyl radicals will act as oxidants in the degradation of organic 
compounds (33, 34). A resume of the photocatalytic process detailed by Eqs. (1)-(10) is 
illustrated in Fig. 4.4. 
 
Fig. 4.4. Schematic diagram illustrating the principle of heterogeneous photocatalysis 
(adapted from Ahmed et al. (33)). 
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4.1.2.1.2. Catalysts 
By definition, a catalyst remains unaltered and can be recovered unchanged after many 
turnovers of the reaction process. In the case of photocatalytic treatment processes, metal 
oxides and sulphides constitute a large class of suitable semiconductor materials (Table 
4.1.).  
 
Table 4.1. Properties of some semiconductor materials (from Galvez et al. (3)) 
Material 
Band gap  
(eV) 
Wavelength corresponding to band 
gap (nm) 
BaTiO3 3.3 375 
CdO 2.1 590 
CdS 2.5 497 
CdSe 1.7 730 
Fe2O3 2.2 565 
GaAs 1.4 887 
GaP 2.3 540 
SnO2 3.9 318 
SrTiO3 3.4 365 
TiO2 3.0 390 
WO3 2.8 443 
ZnO 3.2 390 
ZnS 3.7 336 
 
Titanium dioxide (TiO2; white powder; BGE = 3.0 eV) is one of the most commonly used 
catalysts. As aforementioned, it was also the catalyst chosen for our experimental work 
(Paper 3 and Paper 4) due to its high reactivity, low toxicity, low price, chemical 
stability and, above all, its capability of using natural and renewable solar UV energy (λ ≤ 
390 nm). TiO2 has an adequate energetic separation between the valence and the 
conduction bands, which can be surpassed by the energy content of a solar photon, thus 
reducing the cost associated with UV radiation production (3, 35). More specifically, we 
opted for TiO2 P25-Degussa (80% anatase and 20% rutile), which is as well the most 
frequently employed on photocatalytic tests. Anatase and rutile are two distinct crystalline 
forms of TiO2, presenting a density of 3.9 and 4.2 g cm-3, respectively. 
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Titanium dioxide can be used in suspension or, alternatively, immobilized in different 
supports, such as glass spheres, Teflon or glass fibre. Though in our work TiO2 was 
employed in suspension, the immobilized form has proved to be quite efficient, mainly at 
the industrial scale, where suspended TiO2 has revealed some problems concerning its 
separation and regeneration. Due to the small particle dimensions (usually < 0.5 µm), the 
filtration process becomes rather expensive, thus hindering its application (36). 
Studies on the use of this catalyst have also showed that its efficiency can be improved by 
either increasing the active surface area, redimensioning it to the nanoscopic scale or 
through the addition of some co-adsorbent materials (e.g., silica, alumina, zeolites or 
activated carbon) (37-39). 
 
4.1.2.1.3. Variables affecting Photocatalysis 
The kinetic behaviour of the photocatalytic degradation reactions of organic pollutants in 
general, and pharmaceutical compounds in particular, depends on several experimental 
parameters, which shall be optimized in order to maximize the process efficiency. Such 
parameters include: i) contaminant initial concentration; ii) concentration of the catalyst; 
iii) radiation source; iv) pH of the reaction medium; v) temperature; vi) dissolved organic 
matter (DOM); vii) dissolved O2; viii) presence of sensitizers and radical scavengers (3, 
40). 
 
i) Influence of Contaminant Initial Concentration 
Most authors agree that, for the majority of the contaminants, the influence of the initial 
concentration of substrate on the photocatalytic degradation rate follows a pseudo-first 
order kinetic, according to the Langmuir-Hinshelwood (L-H) law. 
The photocatalytic reaction rate (r) is proportional to the catalyst covered surface fraction 
(θ), according to Eq. (11): 
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where k represents the pseudo-first order kinetic constant, C the initial concentration of 
the substrate and K  the constant of the adsorption balance of substrate at the surface of 
the catalyst (41).  
As oxidation proceeds, less and less surface of TiO2 particles is covered, as the 
contaminant is degraded. At total decomposition, the degradation rate equals zero and a 
decreased photocatalytic rate is to be expected with the increase of accumulated UV 
energy. 
 
ii) Influence of Catalyst Concentration 
The concentration of TiO2 which maximizes the reaction rate is that corresponding to a 
maximal particle surface exposed to radiation. When the catalyst concentration is too 
high, turbidity also rises and hampers the further penetration of light in the reactor. On 
the other hand, by increasing the number of suspended particles, the probability they 
agglomerate is higher, leading to a decrease of surface area available for the reaction (3, 
41, 42). 
In every practical application, the optimum catalyst load must be determined to prevent 
its excess and ensure the maximal absorption of efficient photons. Therefore, in our 
experimental work (Paper 3), some preliminary tests were conducted comprising a wide 
range of TiO2 concentrations (from absence, corresponding to photolysis, to 400 mg L-1), 
according to the set of different experimental systems employed. 
 
iii) Influence of Radiation Source 
The radiation source can affect photocatalysis kinetic according to three factors: the 
radiation photon flux, the radiation wavelength and the quantum yield.  
Regarding the photon flux, an increase of radiation intensity generally results in the 
improvement of the photocatalytic reaction rate, i.e., in the proportional increase of the 
substrate degradation rate. However, above a certain threshold, the reaction rate becomes 
independent of the radiation flux, which can be attributed to the recombination of the 
electron/hole pairs at high radiation intensities (3, 32).  
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Concerning the radiation wavelength, and according to what was previously explained, 
the adsorption spectrum of the catalyst will condition the useful wavelength range for a 
certain photocatalytic reaction. In our case-study, TiO2 just absorbs radiation with λ ≤ 390 
nm (please refer to Table 4.1), thus being photo-activated only in the UV spectral region. 
As regard to the quantum yield, its influence on the photocatalytic process will be later 
assessed on Section 4.2.2.1.4. 
In our initial work (Paper 3), two different radiation sources were comparatively tested 
and optimized: an UV medium pressure mercury lamp (Heraeus TQ 150W) vs. natural 
solar radiation.  
 
iv) Influence of pH 
It is well known that TiO2 surface is amphoteric and, consequently, its charge is pH-
dependent. For TiO2-P25, used in our work, the zero charge point (pHzcp) is located in the 
range 5.6 < pH < 6.4 (pH ≈ 6.3) (42). For that reason, at lower pH values TiO2 surface is 
positively charged, as represented in the following equation: 
   TiOH + H+  ↔  TiOH2 +     (12) 
On the contrary, if the medium pH is above TiO2 pHzcp, then the catalyst surface will be 
negatively charged: 
   TiOH + HO  ↔  TiO‒ + H2O     (13) 
In conclusion, pH will affect both the ionization state of the substrate and TiO2 surface, 
thus promoting or hampering the adsorption of organic compounds to the catalyst surface 
in case they present different or equal charges, respectively. Moreover, it must be 
highlighted that, under acidic conditions, TiO2 particles are prone to agglomerate, which 
will lead to a reduction of active surface area available for the absorption of radiation and 
adsorption of contaminants. 
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v) Influence of Temperature 
Photocatalytic systems do not require heating and can operate at room temperature, 
owing to the photonic activation.  
The true activation energy (Et) is null, while the apparent activation energy (Ea) is often 
very low (a few kJ mol-1) for temperatures in the range of 20ºC to 80°C. However, at very 
low temperatures (-40°C to 0°C), activity decreases and the apparent activation energy 
increases. On the contrary, at high temperatures (>70-80°C) approaching the water 
boiling point, the activity decreases for several types of photocatalytic reactions and the 
apparent activation energy becomes negative (3). 
Summing up, the optimal temperature range for photocatalytic processes is located 
between 20 and 80ºC. 
 
vi) Influence of DOM 
Apart from contaminants, water samples may contain other dissolved natural organic 
matter, like humic substances (HS – a class of naturally existing biogenic heterogeneous 
organic substances, with high molecular weights) (43). These substances will compete for 
the oxidizing reactive species, such as hydroxyl radicals, and consequently decrease the 
removal rate of target polluting compounds. The amount of dissolved organic matter is 
indirectly given by determining the dissolved organic carbon (DOC). 
 
vii) Influence of Dissolved Oxygen 
Oxygen is necessary for achieving complete mineralization at the end of photodegradation 
treatments. Also, it does not seem to compete with other reactives for adsorption onto 
TiO2 particles, since oxidation and reduction loci are separate. In addition, oxygen may 
prevent as well the electron/hole recombination process, taking place after TiO2 
irradiation, through the acceptance of the electrons originating from the conduction band. 
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Oxygen concentration also affects the reaction rate: the photocatalytic reaction occurs 
faster when oxygen partial pressure increases, and vice-versa. In any case, the difference is 
not drastic (3). 
 
viii) Influence of Sensitizers vs. Radical Scavengers 
Besides the oxidation/reduction reactions taking place at the surface of the catalyst 
particles, highly reactive radical species can have a different origin. As aforementioned, it 
is known that nitrates, humic and fulvic acids, often present in fresh waters, may act as 
sensitizers, giving rise to reactive species such as hydroxyl radicals, singlet oxygen or 
hydrogen peroxide, which promote indirect photolysis (Fig. 4.1) (44, 45).  
On the contrary, there are other substances which can act as radicals’ quenchers or 
scavengers, thus reducing the photocatalytic process efficiency (e.g., CO32-, HCO3-, SO42-, 
Cl-) (46). 
 
4.1.2.1.4. Photochemical Reactors 
Another major factor affecting waters photocatalytic treatment is the choice of the 
photochemical reactor. Here, several aspects have to be taken into consideration, 
including the material structure, the reactor geometry and the system for temperature 
control. 
In our work, three distinct experimental systems were used (Paper 3, Paper 4 and 
Paper 5). The first lab-scale experimental apparatus consisted of a glass immersion 
photochemical reactor with a water column of 8 cm diameter and 16 cm height. The 
reactor was loaded with 850 mL of solution, with constant stirring for the total reaction 
period. It was equipped with a medium pressure mercury lamp Heraeus TQ 150W, with a 
dominant emission line at 366 nm, placed axially and held in a quartz immersion tube 
with a surface contact area of ~233 cm2 - LsTQUV (Lab-scale TQ150W-UV prototype) 
(Fig. 4.5). This system was refrigerated by a continuous tap water flow, which allowed 
temperature to be properly controlled below 30 ºC.  
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Fig. 4.5. Lab-scale photochemical reactor equipped with a medium pressure mercury 
lamp Heraeus TQ150W (LsTQUV). 
 
The second employed lab-scale prototype was composed by a 5 L beaker, loaded with 4.5 L 
of solution constantly stirred, and an immersed pyrex glass cylinder placed axially, 
holding a LYNX S11W blacklight blue lamp with maximal emission at 365 nm. The surface 
contact area between the pyrex cylinder and the solution was approximately 456 cm2. The 
water column was 23.5 cm high with 11 cm diameter - LsBLBUV (Lab-scale Blacklight 
Blue-UV system) (Fig. 4.6).  
 
Fig. 4.6. Lab-scale photochemical reactor equipped with a LYNX S11W blacklight blue 
lamp (LsBLBUV). 
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Furthermore, photocatalytic experiments were also performed, during sunny days, in a 
Solar Pilot Plant with Compound Parabolic Collectors (CPCs) installed in the roof of the 
Chemical Engineering Department of the Faculty of Engineering, University of Porto 
(FEUP), Portugal. This CPC solar collector (0.91 m2) was composed of four borosilicate 
tubes (Schott-Duran type 3.3, Germany, cut-off at 280 nm, external diameter 50 mm, 
length 1500 mm and thickness 1.8 mm) connected in series by polypropylene junctions 
with their CPC mirrors in anodized aluminum, supported by an aluminum structure and 
tilted 41º (local latitude) - SPP-CPCs (Solar Pilot Plant with CPCs) (Fig. 4.7). The pilot 
plant has also two recirculation tanks (10 L and 20 L), two recirculation pumps (maximum 
20 L min-1), two rotameters, five polypropylene valves and an electric board for process 
control. It operates in batch mode and can be used in two ways: using the total CPCs area 
(0.91 m2) or using 0.455 m2 of the CPCs area individually, giving the possibility to carry 
out two distinct experiments at the same time and at the same solar radiation conditions. 
 
 
 
Fig. 4.7. Solar Pilot Plant with CPCs (SPP-CPCs). 
 
First of all, and regarding both lab-scale systems, it must be noticed that while one 
immersion tube was made of quartz (LsTQUV), the other one had a borosilicate 
composition (LsBLBUV). This feature is of extreme importance, taking into account the 
radiation spectral region able to photo-activate TiO2 (λ ≤ 390 nm). As displayed in Fig. 
4.8, quartz transmittance is higher than 80% even for wavelengths as low as ~250 nm. On 
the other hand, UV radiation does not cross common borosilicate glass. Therefore, the 
borosilicate used in these experiments had a special treatment, in order to present a cut-
off at 280 nm. For the same reason, this borosilicate glass (Schott-Duran type 3.3, 
Germany, cut-off at 280 nm) was also used for the CPC units of the solar pilot plant (SPP-
CPCs). 
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Fig. 4.8. Transmittance spectra of quartz and borosilicate (Schott-Duran type 3.3, 
Germany, cut-off at 280 nm). 
 
The photocatalytic performance of a heterogeneous system can be evaluated by 
the quantum yield (quantum efficiency) of the reaction or through its apparent kinetic 
constant. 
The quantum yield (Φ) is defined as the ratio between the number of reacting molecules 
(Δn) and the quantity of photons absorbed by the system (Na): 
  Φ = (Δn/Na)       (14) 
Experimentally, the quantum yield represents the number of radicals originated at the 
surface of the catalyst by each absorbed photon, i.e., the number of molecules degraded by 
each photon. If every absorbed photon induces a molecular transformation, then Φ = 1; if 
Φ < 1, it means there are deactivation processes or other reactions competing with the 
target one; if Φ > 1, then it indicates there is taking place a series of reactions whose 
promoter has been excited by a photon (3).  
The experimental determination of the quantum yield is rather difficult, forcing the 
application of indirect methods, which consequently bring in some error.  
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Apparent kinetic constants constitute another way to assess photocatalysts’ efficiency for 
the degradation of organic compounds, since the great majority of the reactions follow a 
pseudo-first order kinetic model:  
  Ct = Co e-kapp t       (15) 
where Ct is the concentration of the substrate at different reaction times (t), Co is the 
initial substrate concentration for t = 0 (the instant when illumination is turned on) and 
kapp is the apparent pseudo-first order kinetic rate constant (47). 
Nonetheless, in order for comparison between artificial UV sources (lamps) and natural 
solar UV radiation to be possible (Paper 3), time (t) was replaced by another parameter: 
the accumulated UV energy (QUV, kJ L-1). 
In the case of the medium pressure mercury lamp Heraeus TQ150W, with the purpose of 
calculating the accumulated UV energy as a function of time, it was first necessary to have 
knowledge of its photon flux. The UV lamp photon flux was determined at different 
wavelengths with the use of the Hatchard-Parker actinometer (47, 48), one of the most 
reliable and practical actinometers for UV and visible light up to 500 nm. Under light 
excitation the potassium ferrioxalate decomposes, according to the following equations: 
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(17) 
The quantity of ferrous ions formed during the irradiation period is monitored by 
conversion to the coloured trisphenanthroline complex (ε = 11,100 L mol-1 cm-1 at λmax = 
510 nm) (Fig. 4.9). The original ferric ions are not appreciably complexed by 
phenanthroline and the complex does not absorb at 510 nm. 
 
 
Fig. 4.9. Chemical structure of the complex Fe2+ -1,10-phenanthroline (ratio 1:3). 
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However, it should be noticed that the lamp photon flux (Einstein s-1) corresponds to its 
total emission spectrum, whereas only radiation with λ ≤ 390 nm is capable of photo-
activating TiO2. Thus, bearing in mind the main emission line intensities up until 390 nm, 
partial photon fluxes were calculated for each wavelength and the corresponding radiant 
energy (E≤390 nm, J) was determined according to Eq. (18): 
 λ
chNE A=
       
(18) 
where E is the energy of electromagnetic radiation, NA is the Avogadro constant (6.022E23 
mol-1), h is the Planck constant (6.626E-34 J s), c is the speed of light in the vacuum (3E8 
m s-1) and λ is the respective wavelength. The radiant flux (also known as radiant power) 
obtained was 15 J s-1, i.e., 15 W. 
Afterwards, calculations regarding the accumulated UV energy (QUV,n) took into account 
the lab-scale photochemical reactor geometry/dimensions and the volume of 
solution/suspension (surface contact area of ~233 cm2 and 850 mL of sample, as 
aforementioned), as well as the time duration of each experiment, according to the 
following equation: 
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(19) 
where tn is the time corresponding to n-water sample(s), Vt is the total reactor volume, Ar 
is the illuminated surface area and nGUV ,  is the average UV radiation measured in the time 
interval Δtn. 
Results showed that the UV mercury lamp provided a constant QUV(total) dose of 
approximately 3.5 kJ L-1 min-1 (QUV(300–400 nm) ≈ 1 kJ L-1 min-1), except in the first ca. 2 min 
of lamp warming up (Fig. 4.10). 
 
Similar calculations were performed for the LYNX S11W blacklight blue lamp. However, 
instead of the actinometrical determination of the photon flux, the average UV radiation 
intensity was measured with an UV portable radiometer (Kipp & Zonen, model CUV5), 
which provided the result of 10 WUV m-2. 
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Fig. 4.10. Lab-scale prototype LsTQUV: graphic representation of the accumulated UV 
energy per litre of solution, as a function of the time after turning the UV lamp on [obs.: 
insert picture represents the emission spectrum of the medium pressure mercury lamp 
Heraeus TQ 150W]. 
 
Ultimately, some considerations shall be made regarding the CPC solar pilot plant. Besides 
the composition of the material used for its construction (the abovementioned borosilicate 
glass, with a cut-off at 280 nm), the design of solar photoreactors conceived for 
photochemical applications is of no less importance.  
The original photochemical reactors were based on line-focus parabolic-trough 
concentrators (PTCs) (Fig. 4.11 (b)). PTCs made an efficient use of direct solar radiation 
and, as an additional advantage, the thermal energy collected from the concentrated 
radiation could simultaneously be used with other purposes. Nevertheless, they presented 
three main disadvantages: i) the use of only direct radiation; ii) the high cost; iii) the low 
optical and quantum efficiencies for TiO2 applications (49). On the other hand, one-sun 
(non-concentrating) collectors (Fig. 4.11 (a)) were cheaper than PTCs, since they were 
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static and had no solar tracking devices.  Moreover, they did not concentrate radiation, 
thus the efficiency of the process was not reduced by factors associated with concentration 
and solar tracking (50). Finally, compound parabolic concentrators (CPCs) (Fig. 4.11 (c)) 
appeared as an interesting cross between trough concentrators and one-sun systems. They 
are considered by many the choice for optimal possibilities (51). CPCs are static collectors 
with an involute reflective surface around a cylindrical reactor tube. The reflector design 
enables almost all UV radiation arriving at the CPC aperture to be collected and available 
for the photochemical process taking place inside the reactor. These static collectors 
provide the best optics for low concentration systems and present the advantages of both 
PTCs and one-sun collectors, since they can capture both direct and diffuse UV sunlight 
(Fig. 4.12) (52, 53).   
 
 
Fig. 4.11. Design of photocatalytic reactors used for water treatment: (a) one-sun system; 
(b) parabolic-trough concentrator (PTC); (c) compound parabolic collector (CPC). 
 
  
Fig. 4.12. Ray tracing example for a CPC collector (from Ajona et al. (51)). 
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The intensity of solar UV radiation is measured by radiometers. In our work, a global UV 
radiometer (ACADUS 85-PLS) was mounted on the pilot plant, tilted at the same angle 
(41º), providing data in terms of incident WUV m-2. 
 
4.1.2.1.5.  Analytical Determinations 
In order to accompany the degradation of target and non-target emerging compounds 
over the phototreatment experiments (Paper 3, Paper 4 and Paper 5), several 
analytical determinations were carried out, two of which deserve special attention: LC-
tandem MS and the determination of dissolved organic carbon (DOC). 
While the utilized LC-tandem MS methodology preceded by a cleanup/SPE step, in order 
to purify and concentrate the samples on target analytes, was part of our initial work 
(described in Chapter 2), the identification of transformation products (TPs) and the 
elucidation of the mechanisms involved in the attenuation of a particular xenobiotic – 
lorazepam, required a completely different approach. A lot of effort was devoted to this 
issue and the adopted strategy and achieved results are presented in the following chapter 
(Chapter 5, including Paper 5).  
The mineralization state of a sample can be determined by its DOC content. Thus, DOC 
was also followed throughout photodegradation experiments, showing, as expected, a 
considerable decrease along the reactions. 
Notwithstanding, one main conclusion which can be withdrawn from this work relates to 
the fact that both natural and artificial remediation processes are potential sources of TPs 
for the environment, should total mineralization be not attained. 
 
Herein follow the two papers (Paper 3 and Paper 4) encompassing the experimental 
work and achieved results in the field of AOPs applications for contaminated water photo-
remediation. Another publication, involving the use of combined biological treatment and 
AOPs for the decontamination of pesticide-containing wastewaters, resulted from a 
collaboration work with the Faculty of Engineering of the University of Porto, and is 
included in the present thesis as Annex IV. 
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4.2. Paper 3 – Photolytic and TiO2-Assisted Photocatalytic 
Oxidation of the Anxiolytic Drug Lorazepam (Lorenin® 
pills) under Artificial UV Light and Natural Sunlight: A 
Comparative and Comprehensive Study 
 
Published Scientific Paper: 
 
Sousa, M.A., Gonçalves, C., Pereira, J.H.O.S., Vilar, V.J.P., Boaventura, R.A.R. and 
Alpendurada, M.F., Photolytic and TiO2-Assisted Photocatalytic Oxidation of the 
Anxiolytic Drug Lorazepam (Lorenin® pills) under Artificial UV Light and Natural 
Sunlight: A Comparative and Comprehensive Study. Solar Energy, 2013. 87: 219-228. 
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4.3. Paper 4 – Suspended TiO2-Assisted Photocatalytic 
Degradation of Emerging Contaminants in a Municipal 
WWTP Effluent using a solar Pilot Plant with CPCs 
 
Published Scientific Paper: 
 
Sousa, M.A., Gonçalves, C., Vilar, V.J.P., Boaventura, R.A.R. and Alpendurada, M.F., 
Suspended TiO2-Assisted Photocatalytic Degradation of Emerging Contaminants in a 
Municipal WWTP Effluent using a Solar Pilot Plant with CPCs. Chemical Engineering 
Journal, 2012. 198-199: 301-309. 
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" Municipal WWTP effluent contaminated with pharmaceuticals and earthy-musty compounds.
" CPC pilot plant for TiO2-solar photocatalysis as a complementary tertiary treatment.
" Complete removal of 19 out of 22 pharmaceuticals with ca. 32 kJ L1 solar UV energy.
" Zahn–Wellens test indicates many pharmaceuticals are refractory to biotreatment.
" V. fischeri bioassay revealed no toxicity increase during photocatalytic treatment.a r t i c l e i n f o
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Emerging pollutants, such as pharmaceuticals, are widely disseminated in the aquatic media. Though in
low concentrations in the environment, they still pose concerns mainly over potential chronic toxicity
effects. Consequently, this work reports on the successful attempt to develop a photocatalytic treatment
method, using suspended TiO2 in a concentration of 200 mg L1 and solar UV radiation as the photon
source, firstly designed for lorazepam (Lorenin pills) degradation and further applied to the treatment
of a real municipal WWTP effluent, containing several other emerging contaminants (ECs).
Initial effluent physicochemical characterization revealed the presence of 22 pharmaceutical com-
pounds in moderate concentrations (maximum of 680 ng L1, except for diclofenac 24 lg L1 and
hydrochlorothiazide 3 lg L1) and a low dissolved organic carbon (DOC) content. Therefore, the main
purpose of the work was not to increase the effluent’s biodegradability, but to improve the removal rates
of the several present ECs.
Pharmaceuticals’ degradation kinetics, using a solar pilot plant with CPCs, were thoroughly studied. A
pseudo-first order kinetic model was able to successfully predict the experimental data. The overall treat-
ment was considered efficient, with a complete removal of the majority of these micropollutants, except
for ciprofloxacin (35%), ketoprofen (61%) and bisoprolol (77%). Nevertheless, a small increase in the reac-
tion time could easily accomplish their total degradation.
Zahn–Wellens biodegradability assay allowed withdrawing some conclusions about which pharmaceu-
ticals could be degraded by means of biotreatment, thus avoiding the need to apply a photocatalytic treat-
ment.
Finally, Vibrio fischeri acute toxicity test showed that the effluent itself presented no significant toxicity
and that the intermediate oxidation compounds, possibly formed during phototreatment, did not reflect
any significant increase of toxicity.
 2012 Published by Elsevier B.V.1. Introduction quality, whose environmental impact is not yet sufficiently studiedEmerging pollutants are defined as compounds that are not
currently covered by the existing legislation in the field of waterElsevier B.V.
x: +351 22 936 42 19.
endurada).and which are thought to be potentially harmful to environmental
ecosystems and human health. They encompass a wide range of
products, including pharmaceuticals, personal care products, fra-
grances, detergents, plasticizers, flame retardants, pesticides and
several other classes [1].
Concerns about the hazards associatedwith long-term exposure to
pharmaceutically active compounds for non-target organisms and for129
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___________________________________________ Chapter 4 ________________________________________human health are rising. One of the best known detrimental effects of
thesecompounds in theenvironment is thedisruptionof theendocrine
system in wild species, affecting their growth, physiology and repro-
duction. The selectionofmulti-resistant strains of pathogenicmicroor-
ganisms is also a threat to humans and ecosystems, resulting from the
uncontrolled use of antibiotics and deficient treatment of effluents
fromwastewater treatment plants (WWTPs) [2,3].
In fact, WWTPs’ effluents are considered a major source of envi-
ronmental pharmaceutical contamination, since they are not pre-
pared for the complete removal or degradation of such
micropollutants, as mentioned in several studies [4–6]. They can,
therefore, reach the aquatic media, where they have been found in
concentrations ranging from 0.1 to 20 lg L1, among treatedwaste-
waters, surface and groundwater and even drinking water [7–11].
Recently, there has been a research outbreak in the field of ad-
vanced water treatment technologies, designed to become part of
the solution to this problem. They include the advanced oxidation
processes (AOPs) (using the combination of strong oxidants, e.g. O3
or H2O2, with high energy sources, such as ultraviolet (UV), ultra-
sound (US) or electron beam (EB), and catalysts, e.g. Fe2+, and phot-
ocatalysts, e.g. TiO2, to produce hydroxyl radicals), membrane
based technologies (microfiltration, ultrafiltration, nanofiltration
and reverse osmosis) and adsorption/ion exchange processes (acti-
vated carbon, resins), each one presenting their own advantages
and disadvantages [12].
Special attentionhasbeengiven toAOPs, inwhichhydroxyl radicals
(OH)are the responsible agents for theoxidationandmineralizationof
almost any organic molecule, yielding CO2 and inorganic ions as final
products, due to their strong unselective oxidative power [13]. Among
AOPs, theheterogeneous photocatalysiswithUV/TiO2 has shown to be
a promising technique forwastewater detoxification [12]. In heteroge-
neous photocatalysis, dispersed solid particles absorb efficiently larger
fractions of the UV spectrum and generate chemical oxidants in situ
from dissolved oxygen or water. Regarding the catalyst choice, TiO2
has generally been demonstrated to be the most active, whenever
tested against other semiconductor materials, under comparable con-
ditions [14]. When illuminated with light energy higher than their
bandgap, semiconductors like TiO2 (BGE = 3.2 eV) produce excited
high-energy states of electron and hole pairs (e/h+) [12]. TiO2 is also
technologically interesting due to its chemical and photocorrosion
resistance, its safetyandlowcostand, specially, to itscapabilityofusing
natural and renewable solar UV energy (since the energetic separation
between its valence and conduction bands can be surpassed by the en-
ergy content of a solar photon) [14].
The purpose of this work was to study the application of heteroge-
neous photocatalysis with solar UV/TiO2 to the degradation of an anx-
iolytic drug – lorazepam – which is frequently detected in WWTPs’
effluents and surface waters [1]. To the authors’ knowledge, never
has thisdrugbeenstudiedunderacceleratedphototransformationpro-
cesses (photo-induced structural alterations). To do so, a solar pilot
plant with compound parabolic collectors (CPCs) designed for solar
photo(cata)lytic applicationswasused, takingprofitof solar renewable
energy. Besides, lorazepamwas tested in one of its most commercial-
ized dosage forms in Portugal – Lorenin pills, 1 mg (Wyeth) – in order
to simulate amore realistic scenario. The optimized treatment process
was further applied toa realWWTPeffluent containing, apart from lor-
azepam, several other emerging contaminants.2. Experimental
2.1. Contaminated water samples
TiO2 (P25 Degussa, 80% anatase and 20% rutile) concentration
optimization was performed using a ca. 200 lg L1 lorazepam
solution, obtained by dissolving 1 mg Lorenin pills (Wyeth) in dis-130tilled water [15]. Lorazepam’s photodegradation (photo-induced
structural simplification) was furthermore evaluated on a real
wastewater effluent, where several other emerging contaminants
were as well present.
Table 1 presents the main characteristics of the effluent sample
collected at Febros WWTP. This WWTP discharges its treated efflu-
ent into Febros River, a southern bank small tributary of Douro Riv-
er, located in the north of Portugal. Moreover, a 2 mg L1
lorazepam spiked effluent sample was also submitted to photocat-
alytic treatment. This concentration was obtained by dissolving 40
Lorenin pills (1 mg of lorazepam each) in 20 L of the real effluent
sample. Besides assuring a proper kinetic characterization and pos-
sible future identification of some lorazepam’s degradation prod-
ucts (LDPs) formed during photodegradation, this procedure also
simulates a more realistic scenario, where lorazepam is among
several other compounds, also present in pharmaceutical formula-
tions (numerous excipients, including titanium dioxide itself).
2.2. Analytical determinations
pH, temperature and conductivity were measured using a pH
meter HANNA HI8424 and a conductivity meter HANNA HI4522;
turbidity was determined in a Merck Turbiquant 3000 R; dis-
solved oxygen was measured using a multi-parametric YSI probe;
oxidability was determined according to ISO 8467:1993 [16] and
total suspended solids (TSSs) and volatile suspended solids (VSSs)
were determined according to the standard methods book [17]. Ni-
trate, nitrite, bromide, chloride, fluoride and sulphate were quanti-
fied by ion chromatography (Dionex DX-120), using a Dionex
Ionpac AS9-HC 4  250 mm column. The program for anions deter-
mination comprises a 20 min run using 9 mMNa2CO3 as eluent at a
flow rate of 1.0 mL min1. Ammonium and phosphate were mea-
sured with Merck Spectroquant kits. Metals were analyzed and
quantified using an ICP-MS (X-Series, Thermo Elemental). Dis-
solved organic carbon (DOC) was measured in a TC-TOC-TN ana-
lyzer (Shimadzu, model TOC-VCSN) provided with a NDIR detector
and calibrated with standard solutions of potassium phthalate.
Dissolved nitrogen was measured by thermal decomposition and
NO detection by a chemiluminescence method in the same TC-
TOC-TN analyzer coupled with a TNM-1 unit (Shimadzu, model
TOC-VCSN) calibrated with standard solutions of potassium nitrate.
Absorbance at 254 nm was determined using an Unicam spectro-
photometer (model Super Sipper), in order to indirectly evaluate
the content in aromatic compounds. Finally, the concentration pro-
file of several pharmaceutical compounds was obtained by solid-
phase extraction followed by liquid chromatography coupled to
mass spectrometry (SPE-LC-tandem MS), according to the proce-
dure thoroughly described by Sousa et al. [1], while some fra-
grances and earthy–musty compounds were also quantified by
gas chromatography–mass spectrometry (scan or MS/MS mode),
as detailed in Machado et al. [18].
During the photocatalytic experiment, pH, temperature, absor-
bance, total nitrogen (TN) andDOCwere followed, giving indications
about the mineralization state. Finally, all different emerging con-
taminants detected in the original effluent samplewere also contin-
uously followed through the entire photo-treatment process.
2.3. Solar CPC pilot plant
The solar TiO2-photocatalytic experiments were performed in a
pilot plant with compound parabolic collectors (CPCs) installed in
the roof of the Chemical Engineering Department of the Faculty
of Engineering, University of Porto (FEUP), Portugal (Fig. 1) [19].
The plant is composed by one CPC unit (0.91 m2) of four borosili-
cate tubes (Schott-Duran type 3.3, Germany, cut-off at 280 nm,
external diameter 50 mm, length 1500 mm and thickness
Table 1
Physicochemical characterization of the effluent sample collected at Febros WWTP and used for the solar photocatalytic experiment.
Parameter (units) Febros WWTP effluent (18/03/2011) ELVa Dec. Lei no. 236/98, de 1 de Agosto 1998 (portuguese legislation)
Color Pale yellow; n.db at dil.1:20 n.d. For dilution 1:20
Odor n.d. (dil.1:20) n.d. For dilution 1:20
pH 7.3 6.0–9.0
Temperature (C) 20.0 3 C Increasec
Turbidity (NTU) 115 –
Conductivity (lS cm1) 555 –
Dissolved oxygen (mg L1) 2.2 –
Oxidability (mg L1) 56.2 –
Total dissolved carbon (mg L1) 37.5 –
Inorganic carbon (mg L1) 25.4 –
Dissolved organic carbon (mg L1) 12.1 –
Absorbance at 254 nm (AU) 0.07 –
Total suspended solids (mg L1) 363 60
Volatile suspended solids (mg L1) 223 –
Ammonium – NHþ4 (mg L
1) 1.2 10
Nitrate – NOÞ3 (mg L1) 23.3 50
Nitrite – NO2 (mg L
1) <0.5 –
Bromide – Br (mg L1) <0.5 –
Chloride – Cl (mg L1) 78.5 –
Fluoride – F (mg L1) <0.5 –
Phosphate – PO34 (mg L
1) 7 –
Sulphate – SO24 (mg L
1) 59.8 2000
Phosphorus – 31P (mg L1) 3.0 10,000
Metals
Sodium – 23Na (mg L1) 78.8 –
Potassium – 39K (mg L1) 21.1 –
Calcium – 44Ca (mg L1) 274.8 –
a ELV – Emission limit value.
b n.d. – Not detected.
c Comparatively to the receptor medium.
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CPC mirrors in anodized aluminum, supported by an aluminum
structure and tilted 41 (local latitude). The pilot plant has also
two recirculation tanks (10 L and 20 L), two recirculation pumps
(maximum 20 L min1), two flow rate meters, five polypropylene
valves and an electric board for process control. The pilot plant is
operated in batch mode and can be used in two ways: using the to-
tal CPCs area (0.91 m2) or using 0.455 m2 of the CPCs area individ-
ually, giving the possibility to carry out two distinct experiments at
the same time and at the same solar radiation conditions.
The intensity of the solar UV radiation is measured by a global
radiometer (ACADUS 85-PLS), placed at the same inclination angle,
which provides the data in terms of instantaneous UV radiation
(Wm2). According to Eq. (1), one is able to calculate the accumu-Fig. 1. Solar Pilot Plant with CPCs where the TiO2-photocatalytic treatment of the
WWTP effluent was performed.lated UV energy (QUV,n, kJ L1) received on any surface in the same
position with regard to the sun, per unit of water volume inside the
reactor, in a given time interval Dt:
QUV ;n ¼ QUV ;n1 þ DtnUVG;n
Ar
Vt
; Dtn ¼ tn  tn1 ð1Þ
where tn is the time corresponding to n-water sample (s), Vt,n is the
total volume of wastewater at n-water sample (L), Ar is the illumi-
nated collector surface (m2), and UVG;n is the average solar UV radi-
ation (Wm2) measured in the time interval Dtn.
2.4. Experimental set-up
Photocatalytic processes were conducted during sunny days,
using the solar CPC pilot plant described in Section 2.3.
Experiments using the WWTP effluent started with the addition
of 20 L to one recirculation tank and 25 L to the other recirculation
tank of the CPC units, followed by homogenization by turbulent
recirculation during 15 min, in the darkness (a first control sample
was taken for characterization). Thegoalwas toperformtwoparallel
experiments, onewith the real effluent and anotherwith lorazepam
spiked effluent, under the same solar irradiation conditions, taking
profit of the two independent CPC units (see Section 2.3.). Then,
TiO2 was added to both reservoirs, up to a final concentration of
0.2 g L1 – optimal determined concentration [15,20]. Next, Lore-
ninpillswere dissolvedonly in the reservoir supplying theCPCunit
containing the 20 L of WWTP effluent, in order to achieve a loraze-
pam spiking concentration of 2 mg L1. After 15 min of turbulent
recirculation in the dark, another control sample was taken from
each tank to evaluate the contaminants’ adsorption onto the TiO2
surface and, finally, the solar collectors were uncovered and the
experiments began.
Samples were taken at pre-defined times, from each recircula-
tion tank, with several purposes: degradation kinetics evaluation
(by SPE-LC-MS/MS [1] and GC–MS [18]) of the different emerging131
304 M.A. Sousa et al. / Chemical Engineering Journal 198-199 (2012) 301–309
___________________________________________ Chapter 4 ________________________________________contaminants, including lorazepam, DOC, TN and absorbance
(254 nm) measurements, biodegradability and toxicity assays.
2.5. Biodegradability test
A 28 days Zahn–Wellens biodegradability test was carried out,
according to the OECD standards [21], for biodegradability evalua-
tion of all samples, collected at different phototreatment times,
from the experiment with 2 ppm lorazepam spiked effluent.
240 mL of each sample were added to an open glass flask, along
with some mineral nutrients (KH2PO4, K2HPO4, Na2HPO4, NH4Cl,
CaCl2, MgSO4 and FeCl3) and activated sludge from Freixo WWTP
(Porto, Portugal), previously centrifuged and added in proportion
to the DOC of the sample. A control and a blank experiment were
performed in parallel, using glucose as carbon source (highly bio-
degradable) and distilled water, respectively. All vessels were kept
in the dark, inside a thermostatic chamber at 25 C, under contin-
uous magnetic stirring, for a 28 days period.The percentage of bio-
degradation (Dt) can be determined by Eq. (2):
Dt ¼ 1 ðCt  CBÞðCA  CBAÞ
 
 100 ð2Þ
where CA and CBA are the DOC (mg L1) in the mixture and in the
blank experiment, respectively, measured 3 h after the beginning
of the experiment, Ct and CB are the DOC (mg L1) in the mixture
and in the blank experiment, measured at the sampling time t. Sam-
ples are considered biodegradable only when Dt is higher than 70%.
After the 28 days experiment, the levels of lorazepam, as well as of
all other pharmaceuticals previously detected, were determined by
SPE-LC-MS/MS [1] and compared to those obtained prior to the bio-
degradability assay.
2.6. Toxicity assessment
The toxicity test herein used for acute toxicity measurements is
based on the bioluminescence inhibition of Vibrio fischeri NRRL B-
111 77 by means of the ToxAlert 100 system from Merck. It is a
well-established test, extensively described in literature [21–24]
and similar in principle to the better-known Microtox test.
It is based on the fact that toxic substances will cause changes
either in cell structures and/or metabolic pathways of the marine
bacteria V. fischeri, consequently reflected in a decrease of biolumi-
nescence. This inhibition, caused by the toxic effect of the sample,
can be calculated against the response given by a saline control solu-
tion, which accounts for the natural decrease in light emission. Data
were collected after 15 and 30 min of time exposure of the bacteria
to all non-spiked effluent samples, collected over the photocatalytic
treatment, after a tonicity adjustment corresponding to 2% NaCl.
Phenol (20 mg L1) and potassium dichromate (40 mg L1) were
used as positive controls.
3. Results and discussion
3.1. Lorazepam and TiO2 concentrations
Experimental variables were previously optimized in distilled
water, including lorazepam/catalyst’s concentrations and UV light
source [15], in order to achieve a maximal removal efficiency at
the least reagents/energy expenses, so that the process becomes
economically viable and potentially applicable at a larger scale.
Different criteria were taken into account for decision making
regarding which lorazepam’s concentration ought to be used. The
concentration of ca. 200 lg L1 (obtained by dissolving 1 mg Lore-
nin pills) was adopted, bearing in mind a compromise between a
concentration value simulating real conditions in WWTP effluents
and the concentration required for a proper kinetic characteriza-132tion, according to instrumental quantification limits (LC–MS). Un-
der these conditions, and using the Solar Pilot Plant with CPCs
described in Section 2.3., the required TiO2 concentration for opti-
mal performance was ca. 200 mg L1 [15].
3.2. WWTP effluent physicochemical characterization
The performance of the optimized photo-oxidation treatment
process was further assessed using a real municipal WWTP efflu-
ent. Some physicochemical properties of this grab effluent sample
are summarized in Table 1.
Results of the analyzed parameters were compared to the legal
emission limit values (ELVs) ofwastewaters’ discharge into the aquatic
environment, as stated in the LawDecree 236/98 [25]. However, these
discharge values are only established for monthly averages, consider-
ingdaily averagevaluesof representative24 hcomposite samples, col-
lected and analyzed over the respective month.
Nevertheless, all analyzed parameters were within/below the
respective legal interval/limit value, with the exception of TSS –
363mg L1, far above the legally imposed 60 mg L1. With regard
to the DOC content, it was low (12.1 mg L1), as expected, since we
are dealing with a municipal WWTP effluent. A low DOC indicates
that some recalcitrant organic compounds that might still exist,
namely pharmaceuticals (see Table 2), shall be in low concentrations.
Regardingmetals’ composition, apart fromthosepresented inTa-
ble 1 (which are below the respective ELV), several others were
investigated (including arsenic, lead, mercury, cadmium, iron and
aluminum), but all showed to be below the respectivemethodquan-
tification limit (MQL), already in agreement with legal limit values.
Therefore, AOPs’ application, and in this particular case TiO2-
photocatalysis, may be seen as an alternative or complementary
method to the already existing/applied technologies, in order to
improve the removal rates of some refractory compounds, such
as pharmaceuticals. These compounds are usually present at low
levels, though which may be high enough to induce several chronic
toxicity effects.
3.3. Heterogeneous TiO2-photocatalytic treatment
In this work, the photon source used for the phototreatment of
the municipal WWTP effluent was the sunlight radiation, a renew-
able energy source and, therefore, more economically attractive
and sustainable.
Samples collected from both experiments, at pre-defined times,
were analyzed with several purposes. From DOC analysis (Fig. 2a),
it can be deduced that the significant difference between the
spiked and non-spiked effluent samples is mainly due to lactose,
the only water-soluble excipient present in Lorenin formulation.
The excipients constitute the major portion of each Lorenin pill
(100 mg), in which there is only 1 mg of lorazepam. Fig. 2a also
shows that a considerable DOC reduction (37% and 41% for
spiked and non-spiked effluents, respectively) took place still in
the dark phase of the experiment, due to adsorption on the catalyst
surface, as described in literature [26]. Total mineralization per-
centages achieved at the end of the photocatalytic reaction were
approximately 50% for spiked and 59% for non-spiked effluents.
These results allowed deriving two main conclusions: on the one
hand, and regarding the non-spiked effluent, there was still a sig-
nificant amount of organic compounds not totally degraded by
the phototreatment – though chemical toxicants, including phar-
maceuticals, may have ceased to exist, possible oxidation interme-
diates still remained; on the other hand, regarding the spiked
effluent, the major components of the pills (excipients) are also
refractory to complete mineralization (i.e. leading to H2O and
CO2 as sole final products), since the final DOC value was still very
distant from the initial DOC of the non-spiked effluent sample.
Table 2
Initial concentration values (Ci) and first order degradation kinetic parameters (Ct = C0  ekt) determined for all emerging contaminants (pharmaceuticals, fragrances and earthy–
musty compounds) quantified in the WWTP effluent sample (value ± standard error).
Emerging Pollutant MQLa
(ng L1)
Ci
b
(ng L1)
C0
c
(ng L1)
kd (L kJ1) r0e (ng L1) r2f S2r
g
(ng L1)
Pharmaceutical compounds Fluoxetine 9 24 29 1.2 ± 0.3 34 ± 8 0.8873 14
Paroxetine 3 29 38 0.8 ± 0.02 29 ± 9 0.7331 58
Diclofenac 79 24,256 10,473 0.48 ± 0.03 4991 ± 320 0.9888 217570
Clotrimazole 7 12 16 0.40 ± 0.08 6 ± 1 0.8176 4
Azithromycin 5 631 680 0.37 ± 0.03 250 ± 19 0.9834 1402
Lorazepam 6 682 640 0.33 ± 0.05 208 ± 35 0.9143 6465
Propanolol 17 52 30 0.26 ± 0.05 8 ± 1 0.9371 4
Furosemide 35 492 448 0.26 ± 0.03 117 ± 16 0.9331 1539
Hydrochlorothiazide 58 3051 2740 0.256 ± 0.033 701 ± 92 0.9434 80,508
Carbamazepine 7 417 399 0.21 ± 0.02 82 ± 6 0.9888 642
Bisoprolol 2 132 119 0.17 ± 0.01 20 ± 2 0.9730 59
Fenofibrate 7 53 39 0.16 ± 0.02 6.3 ± 0.9 0.9091 20
Ofloxacin 33 101 90 0.14 ± 0.01 13 ± 1 0.9430 29
Losartan 6 149 78 0.117 ± 0.008 9.1 ± 0.6 0.9598 19
Ketoprofen 7 410 317 0.10 ± 0.01 33 ± 3 0.9569 519
Norfloxacin 33 138 112 0.10 ± 0.01 11 ± 2 0.8364 167
Lorazepam spkh 6 1.21  106 1.08  106 0.094 ± 0.003 1.0  105 ± 0.4  105 0.9912 1  109
Carvedilol 7 95 78 0.06 ± 0.01 4.5 ± 0.8 0.8933 75
Fluconazole 25 110 82 0.049 ± 0.003 4.0 ± 0.2 0.9658 3
Ciprofloxacin 4 254 229 0.040 ± 0.002 9.2 ± 0.4 0.9660 33
Gemfibrozil 36 215 223 0.035 ± 0.002 7.8 ± 0.4 0.9675 26
Alprazolam 4 244 89 0.026 ± 0.004 2.3 ± 0.4 0.8917 34
Terbinafine 15 37 34 – – – –
Fragrances & earthy–musty
compounds
2,4,6-Trichloroanisole 7 226 170 0.56 ± 0.02 95 ± 4 0.9958 19
Galaxolide 7 3604 206 0.24 ± 0.04 49 ± 9 0.9245 548
Musk ketone 10 134 33 0.15 ± 0.01 5.0 ± 0.4 0.9536 2
Tonalide 13 703 55 0.12 ± 0.02 6 ± 1 0.8285 63
a MQL – Method quantification limit.
b Ci – Concentration before the addition of TiO2.
c C0 – Concentration after the addition of TiO2.
d k – Reaction rate constant.
e r0 – Initial reaction rate.
f r2 – Determination coefficient.
g S2r – Estimation of variance.
h spk – Spiked.
M.A. Sousa et al. / Chemical Engineering Journal 198-199 (2012) 301–309 305
________ Photo-Remediation of Contaminated Waters using Advanced Oxidation Processes (AOPs) __________Concerning total nitrogen content, it did not vary significantly
during the photocatalytic process for both experiments.
Temperature and pH variations were also accompanied over the
phototreatment experiments (Fig. 2b). Firstly, it should be re-
marked that the photocatalytic experiments took place mainly
during one day – only the last sample (at ca. 32 and 42 kJ L1 of
accumulated UV energy for non-spiked and spiked effluent sam-
ples, respectively) was collected at the end of the following day.
Bearing in mind that temperature usually rises from morning
start-up (15–20 C) to an almost constant value for several hours
until 2 pm, decreasing again over the afternoon, depending on
the sunlight intensity, the maximum temperature achieved during
the phototreatment was approximately 28 C, what discards the
hypothesis of any thermo-mediated degradation [27]. Since pH is
‘‘temperature-dependent’’, pH variations accompanied tempera-
ture fluctuations over the day. Nevertheless, pH values were in
compliance with the Law Decree 236/98 (between 6.0 and 9.0)
during the entire experiment.
Finally, the aromatic content followed a similar trend to the
DOC, decreasing 94% for the non-spiked effluent, while for the
spiked sample it only diminished ca. 64%. Additionally, special
attention was given to the degradation kinetics, over the photo-
treatment, of each emerging contaminant (EC) detected in the ini-
tial WWTP effluent sample.
As already pointed out in the Introduction section, conven-
tional WWTPs are not specifically prepared for the complete
removal1 of such micropollutants as pharmaceuticals. These can1 The term ‘‘removal’’ is always used in this article referring to the conversion of the
pollutant to compounds other than the parent compound.still remain in the effluents due to their low tendency to adsorb
onto the activated sludge or because their microbial degradation
is not fast enough to be completed within the respective WWTP
hydraulic retention time [6]. Therefore, this photocatalytic ap-
proach was a promising attempt to increase pharmaceuticals’ re-
moval rates.
Table 2 presents the initial concentration values (Ci) obtained
for the 22 pharmaceuticals, 3 fragrances and 1 earthy–musty
compound (2,4,6-Trichloroanisole – 2,4,6-TCA) detected in the
effluent sample, prior to phototreatment. As previously men-
tioned, these Ci values may differ from the concentrations mea-
sured at QUV = 0 (C0) due to adsorption to the catalyst surface
(in the dark). Apart from some exceptions (fluoxetine, paroxetine,
clotrimazole, norfloxacin, carvedilol, alprazolam and tonalide), the
majority of the degradation profiles of the detected ECs follows
well a first order kinetic model, with r2 above 0.90. Table 2 also
compiles the kinetic constant (k) and the initial reaction rate
(r0) estimated for each compound, when submitted to the de-
scribed TiO2-photocatalytic reaction. In Table 2, all pharmaceuti-
cal compounds are ordered from the highest to the lowest rate
constant value (k). Interestingly, if we compare the k value of na-
tive lorazepam (naturally present in the effluent sample) with
that of total lorazepam, achieved after spiking with Lorenin pills,
we can observe that the first one is higher
(0.33 ± 0.05 > 0.094 ± 0.003). Since the only difference relates to
the presence of the pills’ excipients in the spiked sample, it can
be concluded that they might be competing for the hydroxyl rad-
icals, leading to a lower lorazepam degradation rate. Please note
that the DOC content in the spiked sample was much higher than
the unspiked one.133
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Fig. 2. Physicochemical parameters followed throughout the photocatalytic reac-
tion: (a) DOC (dissolved organic carbon) and TN (total nitrogen) and (b) absorbance
at 254 nm, temperature and pH variation represented as a function of the amount of
accumulated UV energy per liter of effluent.
Fig. 3. Graphic representation of the concentration evolution of the 22 pharma-
ceutical compounds present in the WWTP effluent, over the phototreatment
process, as a function of the amount of accumulated UV energy per liter of effluent.
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mized photocatalytic method to the treatment of a real WWTP
effluent, since wastewaters are more complex mixtures. Interfer-
ence of other oxidizable compounds and scavengers such as car-
bonates, which typically occur in high concentrations in
wastewaters [28,29], could influence the method’s efficiency. Nev-
ertheless, except for ciprofloxacin and a small amount of ketopro-
fen and bisoprolol, all pharmaceuticals initially quantified in the
effluent sample decreased to concentration levels below the
respective MQLs, attesting therefore the method’s practical appli-
cability (Fig. 3). Even lorazepam, a recalcitrant compound whose
removal improvement has never been tested by means of acceler-
ated oxidation processes, showed a complete degradation.
Nonetheless, and still regarding the three remaining pharma-
ceuticals, they presented already much lower concentrations at
the end of the phototreatment (corresponding to a total accumu-
lated UV energy of approximately 32 kJ L1). A small increase in
the UV irradiation exposure (time/intensity) could easily allow
their complete removal (up to 38 kJ L1, except for ciprofloxacin
– 101 kJ L1 necessary). Otherwise, and depending on the local
weather conditions, a proper management of the combination with
a complementary artificial UV [30] source could also be an eco-
nomically viable solution.
Furthermore, and according to Gros et al. [6], the anti-epileptic
carbamazepine usually presents a low removal percentage, or
sometimes even a concentration increase, after leaving the WWTP,
due to conversion of carbamazepine glucuronides and other134conjugated metabolites to the parent compound by enzymatic
reactions occurring over the treatment processes. With the applied
photocatalytic treatment, its removal was complete, which is in
agreement with previous results obtained by Miranda-García
et al. [31] and Rizzo et al. [32]. The same occurred with the mod-
erately removed antibiotics norfloxacin and ofloxacin, the diuretic
furosemide and the lipid regulators bezafibrate and gemfibrozil
[1,6].
3.4. Biodegradability assay
Zahn–Wellens biodegradability test is considered to be espe-
cially accurate, as it involves a long contact period (28 days) be-
tween the effluent sample and the sludge, in order to allow some
adaptation of the microorganisms.
This assay was performed at different stages of the photocata-
lytic treatment of the Lorenin spiked effluent, with the purpose
of determining the optimal phototreatment time to reach a biode-
gradable effluent (Dt > 70%). It is however important to highlight
that it would not be reasonable to perform such a test over the
non-spiked effluent, since it was collected at the exit of the WWTP
(itself including the treatment by conventional activated sludge)
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Fig. 4. Representation of the concentration evolution of all pharmaceutical compounds (except for terbinafine) present in the spiked WWTP effluent, over the phototreatment
process, as a function of the amount of accumulated UV energy per liter of effluent: d – before Zahn–Wellens test; s - after Zahn–Wellens test; H – lorazepam already
present in the effluent sample, before spiking with Lorenin pills.
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decreased to ca. 5 mg L1 at the end of the phototreatment (refer to
Section 3.2.).
Zahn–Wellens’ results showed that none of the spiked effluent
samples collected over the photocatalytic process presented a Dt
value >70%, therefore the phototreatment did not significantly im-
prove the effluent’s biodegradability. Nevertheless, all samples
were again analyzed in terms of pharmaceutical content, with
the aim of understanding which pharmaceutical compounds
would already be biodegradable in the first place. This aspect is
particularly important considering that biological treatments are
usually more interesting than phototreatments (when efficient),
due to economic reasons.Fig. 4 demonstrates that the majority of the analyzed pharma-
ceuticals seems refractory to biological treatment, since the con-
centrations before and after Zahn–Wellens test are quite similar.
Nonetheless, some pharmaceuticals such as fluoxetine, paroxetine,
azithromycin, furosemide, bisoprolol, fenofibrate, losartan, keto-
profen, norfloxacin, carvedilol and gemfibrozil look susceptible to
the microorganisms present in the sludge, as their concentrations
significantly decreased after the Zahn–Wellens biodegradability
test. After thorough analysis of the removal rates of several phar-
maceuticals and personal care products by different biological
wastewater treatment processes, Sui et al. [33] reported that in
the case of gemfibrozil, conventional activated sludge treatment
could reach an 80% removal efficiency, which is in agreement with135
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Fig. 5. Vibrio fischeri inhibition percentage, after 15 and 30 min, for two positive
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spiked effluent samples collected over the phototreatment process; EF – effluent; i –
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(overnight) correspond to the sunlight exposure time (following TiO2 addition) after
which each sample was collected, during the photocatalytic reaction.
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refractory compound carbamazepine, despite not being biodegrad-
able, presented a ca. 95% removal rate after photocatalytic treat-
ment with TiO2, which again reinforces our results/conclusions.
3.5. Toxicity outcome
According to Rizzo [35], despite the fact that AOPs are being
widely used in wastewater treatment for the removal of both or-
ganic and inorganic contaminants, as well as to increase effluents’
biodegradability, a partial oxidation may result in the formation of
intermediates more toxic than parent compounds.
Therefore, and to prevent this potential drawback in cases
where complete mineralization is not achieved, AOPs are expected
to be carefully monitored and, consequently, toxicity tests must be
used to evaluate whether effluents’ detoxification is accomplished.
In this work, the acute toxicity of the non-spiked effluent sam-
ple was followed over the photocatalytic treatment, by means of %
inhibition ofV. fischeri’s bioluminescence, after 15 and 30 min. Two
positive controls (phenol and potassium dichromate) were used to
assure bacteria viability.
Results given in Fig. 5 show that inhibition percentages were
already low (<15%) from the beginning of the experiment,
therefore indicating that the effluent presented no significant
toxicity. Nevertheless, these results are still of great importance
to attest that no toxicity increase occurred over the phototreat-
ment process, contrarily to the examples reported by Klamerth
et al. [36].
Although acute toxicity tests give a fast and preliminary infor-
mation on the hazard of the sample, these tests may not always
be the most suitable to evaluate the ecotoxicological hazard of
micropollutants such as pharmaceuticals, due to their usually
low environmental concentrations [37]. Thus, studies on chronic
effects should be used in environmental studies, but due to their
duration they are not appropriate to be used as toxicity checks in
photocatalytic experiments.
4. Conclusions
The optimized TiO2-photocatalytic treatment, using a solar pilot
plant with CPCs, proved to fit its purpose of removal/degradation of136several ECs, among which are lorazepam and other pharmaceuti-
cals, present in a real WWTP effluent. With a total accumulated
UV energy of approximately 32 kJ L1, 19 out of the 22 pharmaceu-
tical compounds present in the effluent sample were completely
removed. Regarding the three remaining pharmaceuticals, cipro-
floxacin, ketoprofen and bisoprolol, their removal percentages
were 35%, 61% and 77%, respectively.
In addition to the almost complete pharmaceuticals’ removal
through phototreatment, a Zahn–Wellens biodegradability test
allowed to distinguish, among the present pharmaceutical com-
pounds, between the ones that could be removed through biological
treatment and those probably refractory to biotreatment, therefore
requesting the photocatalytic treatment.
The acute toxicity assay using the marine bacteria V. fischeri re-
vealed that, despite the initial effluent itself presented no signifi-
cant toxicity, it did not increase over the photocatalytic process,
thus discarding the possibility of formation of more toxic interme-
diate oxidized compounds.
In conclusion, this photocatalytic treatment proved to be a
promising tool with practical future applicability, since it requires
the use of solar renewable energy.
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Chapter 5 
Phototreatment Mechanisms and By-
Products Structural Elucidation 
 
Identifying pollutants’ degradation products in environmental matrices is a very complex 
task faced by researchers. However, it is also fundamental to know the identity of these 
compounds, in order to further assess their environmental impact and potential 
individual/mixture toxicity. 
In this context, the present chapter includes the study of the photodegradation treatment 
of lorazepam, a recalcitrant anxiolytic drug frequently detected in environmental water 
samples. To the best of our knowledge, this work was never undertaken before. 
Herein follows Paper 5, which presents the work carried out with the aim to elucidate 
lorazepam photodegradation mechanism. The phototreatment was performed via 
different processes, including solar UV radiation vs. artificial UV radiation sources, as well 
as photolytic vs. photocatalytic pathways. Moreover, the identification of the main 
photoproducts was carried out by ultra performance liquid chromatography–quadrupole-
time-of-flight-mass spectrometry (UPLC/QqToF-MS), as previously described in chapter 
2. 
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5.1. Paper 5 – Lorazepam Photofate under Photolysis and 
TiO2-assisted Photocatalysis: By-products’ 
Identification and Evolution Profiles during 
Phototreatment of a Contaminated WWTP Effluent 
 
Scientific Paper: 
 
Sousa, M.A., Lacina, O., Hrádková, P., Pulkrabová, J., Vilar, V.J.P., Gonçalves, C., 
Boaventura, R.A.R., Hajšlová, J. and Alpendurada, M.F., Lorazepam Photofate under 
Photolysis and TiO2-assisted Photocatalysis: By-products’ Identification and Evolution 
Profiles during Phototreatment of a Contaminated WWTP Effluent. Submitted for 
publication in Environmental Science and Technology, September 25, 2012. 
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ABSTRACT: This manuscript reports on the study of Lorazepam (LZP) 
phototransformation pathways under artificial UV and natural solar irradiation, through 
photolytic and TiO2-assisted photocatalytic processes. Three experimental set-ups were 
employed: two lab-scale photoreactors, each provided with an UV lamp (one medium 
pressure mercury lamp and one blacklight blue lamp), and a pilot-scale Solar Plant with 
Compound Parabolic Collectors (CPCs). Samples collected along the different 
phototreatment experiments were analyzed by ultra-high performance liquid 
chromatography–quadrupole-time-of-flight–mass spectrometry (UHPLC/QqToF-MS). The 
key assumption of the analytical approach was that related compounds (LZP and its by-
products (LBPs)) provide identical “diagnostic fragment ions”. Identification was also 
based on the chlorine atoms specific isotopic pattern, as well as accurate masses. Six major 
LBPs were identified and elucidated, with nominal [M+H]+ masses of 337, 303, 319, 275, 
291 and 293 Da. The proposed LZP photodegradation mechanism included the initial 
opening of the diazepinone seven-membered ring, followed by a rearrangement into a 
highly stabilized six-membered aromatic ring and subsequent cleavage and/or 
hydroxylation reactions. LBPs’ evolution profiles were described for each of the three 
experimental prototypes and the CPCs Solar Pilot Plant proved to be the most efficient 
one. Finally, LZP photocatalytic degradation was further assessed on a contaminated 
municipal effluent, where the photoproducts generated showed to be more persistent than 
LZP itself. 
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INTRODUCTION  
Pharmaceuticals have become prominent emerging contaminants due to their demonstrated 
presence and persistence in environmental waters, as well as for the potential toxicological 
effects they may induce on non-target organisms. Some major concerns have been raised 
regarding their possible estrogenic effects, not to mention the development of different 
bacterial resistances (creation of “Super Bugs”). It is currently estimated that 
approximately 3000 different compounds are used as pharmaceutically active substances, 
including analgesics, antibiotics, anxiolytics, antidepressants, β-blockers, lipid regulators, 
antidiabetics, neuroleptics, contraceptives and impotence drugs. Nevertheless, still only a 
rather small subset of these compounds has been investigated in environmental studies.1   
Due to the growing competitiveness installed in modern society, the consumption of 
anxiolytic drugs has recently shown a remarkable increase. Within these drugs are 
benzodiazepines (BDZ), a family of compounds which enhance the effect of the 
neurotransmitter gamma-aminobutyric acid (GABA), thus resulting in anxiolytic (anti-
anxiety) and sedative activities, as well as hypnotic (sleep-inducing), anticonvulsant, 
muscle relaxant and amnesic effects.2 According to the International Narcotics Control 
Board,3 in 2008 a total of 30 billion S-DDD (defined daily doses for statistical purposes) of 
BDZ were manufactured, the highest amount registered up until today.  
Moreover, Portugal was considered one of the countries with the highest anxiolytics 
consumption rate.3 Amongst the most marketed anxiolytic drugs in Portugal, Lorazepam 
(LZP) highlights with a quite elevated sales value over the past 5 years, according to 
unpublished data provided by the Portuguese National Authority of Medicines and Health 
Products, IP (INFARMED). 
Pharmaceutical compounds in general reach the aquatic media, where they have been 
found in concentrations ranging from < 0.1 to ca. 20 µg L-1, among treated wastewaters, 
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surface and groundwater and even drinking water.4-8 LZP, in particular, has already been 
quantified in levels ranging from approximately 0.040 µg L-1 in river waters to ca. 0.200 
µg L-1 in effluent wastewaters.9-11 The environmental aquatic pollution by such persistent 
organic pollutants is commonly attributed either to point-source contaminations or 
following the incomplete removal in wastewater treatment plants (WWTPs). In fact, 
WWTPs are not prepared for the complete degradation of such micropollutants, as 
mentioned in several studies.12-14  
The limitations of conventional wastewater treatments for the remediation of emerging 
pollutants require the development and application of advanced tertiary/quaternary 
treatment processes. In this field, special attention has been given to Advanced Oxidation 
Processes (AOPs), in which hydroxyl radicals (•OH) are the responsible agents for the 
oxidation and mineralization of almost any organic molecule, due to their strong 
unselective oxidative power, yielding CO2 and inorganic ions as final products.15 Common 
techniques already reported in the literature include the use of UV alone, UV/TiO2, 
UV/H2O2, UV/Fe3+, UV/H2O2/Fe3+, UV/S2O82-, UV/chlorine and UV in combination with 
other photocatalysts.16,17 Among them, the heterogeneous photocatalysis with UV/TiO2 
showed to be a promising technique for wastewater detoxification.18 TiO2 has generally 
been considered the most active catalyst, whenever tested against other semiconductor 
materials, under comparable conditions.19 However, despite the fact that AOPs are being 
widely used in wastewater treatment for the removal of both organic and inorganic 
contaminants, as well as to increase effluents’ biodegradability, a partial oxidation may 
result in the formation of intermediates more toxic than parent compounds.20 For this 
reason, it becomes indispensable to identify the resulting photoproducts, in order to allow 
the study of their individual/mixture toxicity.  
The work herein described aims the elucidation of the photodegradation mechanism of 
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Lorazepam. LZP phototreatment was performed via different processes, including solar 
UV light vs. artificial UV radiation sources, as well as photolytic vs. photocatalytic 
pathways. The identification of the main photoproducts was carried out by ultra 
performance liquid chromatography–quadrupole-time-of-flight–mass spectrometry 
(UHPLC/QqToF-MS) and their formation was followed up concomitantly with the 
degradation of the parent compound. To the best of the authors’ knowledge, this work has 
never been undertaken before. Furthermore, LZP photodegradation products were also 
analyzed over the phototreatment of a real contaminated municipal WWTP effluent. 
 
EXPERIMENTAL 
Chemicals and Materials. 
LZP structural formula and some chemical characteristics are presented in Fig. S1 
(Supporting Information). LZP used in the experiments was in the form of standard 
solution 1 mg mL-1 supplied by LGC Standards (Barcelona, Spain) and Lorenin® pills (1 
mg) were from Wyeth. The pills were also composed of lactose monohydrate, 
microcrystalline cellulose, polacrilin potassium and magnesium stearate (ca. 100 mg). 
Consequently, a more realistic scenario was simulated using the pills, and any possible 
interference due to the presence of the 4 excipients has not been disregarded. TiO2 catalyst 
(P25 Degussa, 80% anatase and 20% rutile) was purchased from Degussa Portuguesa. 
Demineralized and ultrapure water, used in the phototreatment experiments, were obtained 
with a reverse osmosis system (Panice®) and a Millipore® system (Direct-Q model), 
respectively. Methanol (LiChrosolv®) for UHPLC/QqToF-MS analyses was LC gradient 
grade purchased from Merck. Ultrapure water was obtained using a Milli-Q system 
(Millipore Corporation, Bedford, MA, USA). Formic acid (~98% purity) and ammonium 
acetate (>99.9% purity) were both purchased from Sigma-Aldrich (Germany). Nylon 
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syringe filters (0.2 µm) were provided by VWR International. Temperature and pH data 
were collected using a pH meter HANNA HI8424. 
 
Photodegradation Systems 
 In this work, three distinct experimental set-ups were used to induce LZP 
photodegradation. A first lab-scale experimental apparatus consisted of a glass immersion 
photochemical reactor with a water column of 8 cm diameter and 16 cm height. The 
reactor was loaded with 850 mL of solution, with constant stirring for the total reaction 
period. It was equipped with a medium pressure mercury lamp Heraeus TQ 150W, with a 
dominant emission line at 366 nm, placed axially and held in a quartz immersion tube with 
a surface contact area of ~233 cm2 - LsTQUV (Lab-scale TQ150W-UV prototype) (Fig. 
S2a). This system was refrigerated by a continuous tap water flow, which allowed 
temperature to be properly controlled below 30 ºC. The second employed lab-scale 
prototype was composed by a 5 L beaker, loaded with 4.5 L of solution constantly stirred, 
and an immersed pyrex glass cylinder placed axially, holding a LYNX S 11W blacklight 
blue lamp with maximal emission at 365 nm. The surface contact area between the pyrex 
cylinder and the solution was approximately 456 cm2. The water column was 23.5 cm high 
with 11 cm diameter - LsBLBUV (Lab-scale Blacklight Blue-UV system) (Fig. S2b).  
Furthermore, photocatalytic experiments were also performed, during sunny days, in a 
Solar Pilot Plant with Compound Parabolic Collectors (CPCs) installed in the roof of the 
Chemical Engineering Department of the Faculty of Engineering, University of Porto 
(FEUP), Portugal. This CPC solar collector (0.91 m2) was composed of four borosilicate 
tubes (Schott-Duran type 3.3, Germany, cut-off at 280 nm, external diameter 50 mm, 
length 1500 mm and thickness 1.8 mm) connected in series by polypropylene junctions 
with their CPC mirrors in anodized aluminum, supported by an aluminum structure and 
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tilted 41º (local latitude) - SPP-CPCs (Solar Pilot Plant with CPCs) (Fig. S2c).  
More detailed information regarding the characteristics of the used UV lamps and the 
design/functioning of the described phototreatment experimental set-ups can be found in 
previous publications.21,22  
 
UHPLC/QqToF-MS Analysis. 
Ultra-high performance liquid chromatography analyses, carried out to resolve LZP and its 
phototransformation products, were performed by Dionex UltiMate 3000 RS UHPLC 
system (Thermo Fisher Scientific, Waltham, USA), equipped with a 100 mm × 2.1mm i.d., 
1.8 µm particle size Acquity UPLC® HSS T3 column (Waters, Milford, MA, USA), 
maintained at 40 ºC. The mobile phases consisted of (A) 0.010 M formic acid in Milli-Q 
water for ESI(+) mode and 0.005 M ammonium acetate in Milli-Q water for ESI(–) 
analyses, and (B) methanol, with the following multi-step elution gradient: 0 min (98% A; 
0.30 mL min-1), 8.0 min (0% A; 0.45 mL min-1), 10.0 min (0% A; 0.45 mL min-1), 10.1 min 
(98% A; 0.40 mL min-1) and a short column reconditioning period up to 12.0 min (98% A; 
0.40 mL min-1). Nevertheless, this gradient was later adjusted to an initial methanol 
concentration of 20%, in order to better separate the many co-eluted peaks between ca. 5 – 
8 min. The sample injection volume was 10 µL, in all experiments, and the autosampler 
temperature was fixed at 5 ºC.  
For the identification of LZP photoproducts, high-resolution MS analyses were performed 
using an ABSCIEX TripleTOF® 5600 (Toronto, ON, Canada), provided with a Duo 
SprayTM ion source, operated in positive mode. The ion source was set at the following 
conditions: ion-spray voltage floating (ISVF) 4 kV, temperature (TEM) 600 ºC, ion source 
gases (GS1 and GS2) 60 psi, curtain gas (CUR) 35 psi and a declustering potential (DP) of 
60 V. 
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LZP By-products Elucidation Strategy 
The initial screening method consisted of two TOF MS (+) scan simultaneous experiments, 
the second with induced fragmentation (collision energy (CE) of 35 V). Acquired m/z 
values ranged between 50 and 650 Da, with an accumulation time of 0.25 s and a total 
acquisition time of ca. 12 min. The chosen samples for these primary analyses were 
selected from an intermediate phototreatment time, so that they were likely to contain a 
significant amount of some LZP degradation products. Afterwards, with the attained 
information regarding LZP characteristic/diagnostic fragment ions, associated to exact 
mass results, it was possible to determine a great variety of molecular ions. Subsequently, 
information dependent acquisition (IDA) method was employed to collect full scan MS 
and MS/MS information simultaneously and allow their following quantitative analysis. 
The method consisted of a survey TOF MS (+) experiment from m/z 100 to m/z 650 and 
product ion (PI) spectra for the eight most intense ions of the survey spectra throughout the 
chromatographic run. Dynamic background subtraction was activated to automatically 
acquire PI spectra of co-eluting compounds. PI spectra were collected only ions from m/z 
150 to m/z 400, moreover the isotopes within 1 Da and the former precursor ion were 
excluded for 5 s (mass tolerance of 30 mDa) and totally excluded after three occurrences. 
This setting allowed acquisition of thousands of unique m/z / tR combinations. The 
collision energy of 35 V with a collision energy spread of ±15 V was used for the PI 
spectra. The collision energy spread resulted in more characteristic MS/MS spectra since 
both low and high energy fragment ions were present in a single spectrum. Since the total 
cycle (survey scan and 8 PI spectra) took only 0.55 s, at least 12 points per peak were 
always achieved for accurate quantitation.  
An automatic m/z calibration was performed every ten samples with the positive APCI 
calibration solution, using the calibration delivery system (CDS), and each set of samples 
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was preceded by two blank controls: Milli-Q water and methanol. In the end, the same MS 
approach was conducted in ESI(–) mode, though the resulting chromatograms presented no 
relevant additional information. The MS detector was used, in both ESI(+) and ESI(–) 
modes, the resolving power was > 31,000 (m/z 321.0192) full width at half maximum 
(FWHM). Since the PI spectra were measured in high sensitivity mode, half resolution was 
obtained. 
Instrument control and data acquisition were carried out with the AnalystV1.5.1TF 
software (ABSciex) and the qualitative analysis was performed using PeakView, also 
equipped with the XIC Manager and Formula Finder tools. All identified LZP degradation 
products were further quantitatively processed using MultiQuantV2.1 software. 
 
Photodegradation Experiments and Procedure. 
Irradiation experiments of LZP were performed using the three described systems: 
LsTQUV, LsBLBUV and SPP-CPCs (refer to section 2.2.). Prior to use, Lorenin® pills were 
ground using a porcelain pestle and mortar.  
For the LsTQUV experiment, 5 Lorenin® pills were dissolved in 100 mL Milli-Q water. 
LZP was first extracted with 100 mL ethyl acetate (solubility of 30 mg mL-1 in ethyl 
acetate and 0.08 mg mL-1 in water),23 using a separatory funnel, ethyl acetate was then 
completely evaporated and LZP redissolved in Milli-Q water, up to a final volume of 850 
mL ([LZP]final ~ 6 mg L-1). After constant stirring of the solution, in the dark (lamp-off) for 
approximately 15 min, using the described LsTQUV system, a first sample was collected 
(time 0); following, the photolytic process began by turning the UV light on and different 
samples were taken, every minute during 20 min. Moreover, a similar experiment was 
performed with the total Lorenin® pills (LZP plus excipients). In this case, a dark control 
experiment under analogous experimental conditions was also conducted. In the case of the 
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LsBLBUV experiment, 22 Lorenin® pills were dissolved in 4.5 L of Milli-Q water 
([LZP]final ~ 5 mg L-1) and further submitted to a photocatalytic treatment with 200 mg L-1 
of TiO2 (in suspension). Likewise, the suspension was continuously stirred during the 
whole experiment and several samples were collected, at different time intervals, after 
turning the UV light on. According to previous results,24 LZP undergoes no significant 
hydrolysis nor adsorption onto the catalyst surface, thus in the present work no control 
sample was collected after the catalyst addition and prior to the beginning of irradiation. 
Lastly, in the case of the SPP-CPCs system, 30 Lorenin® pills were dissolved in 15 L of 
distilled water ([LZP]final ~ 2 mg L-1) and photocatalytic experiments were performed with 
200 mg L-1 of TiO2 (experimentally determined optimal TiO2 concentration).24 The 
suspension was constantly mixed by turbulent recirculation (~0.3 min residence time, 
~40% illuminated volume). Finally, experiments began by uncovering the CPCs and 
different aliquots were collected at pre-defined times. Afterwards, a similar experiment was 
performed over a real municipal WWTP effluent sample, further spiked with Lorenin® pills 
in order to attain a final LZP concentration of ca. 2 mg L-1. No pH adjustments were 
performed in any of the photodegradation processes. Temperature and pH were 
continuously monitored along all experiments. 
Previous to LC–MS/MS analysis, all sample aliquots containing TiO2 were pre-filtered 
through 0.2 µm membrane filters. Afterwards, LZP and its photoproducts were analyzed 
using the UHPLC/QqToF-MS system at the established settings described in section 2.3. 
 
RESULTS AND DISCUSSION 
According to previous results described by Sousa et al.,24 using the LsTQUV apparatus, 
LZP highest degradation yield is obtained through photolysis, while with the SPP-CPCs 
system the best degradation performance is achieved through a photocatalytic process, 
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using a TiO2 concentration of 200 mg L-1. Besides, the degradation kinetic constant 
determined for the optimized method using the SPP-CPCs system (k = 1.49±0.03 L kJ-1) 
was higher than the one calculated for the LsTQUV set-up (k = 0.131±0.006 L kJ-1). In the 
case of the LsBLBUV apparatus, photocatalysis with a TiO2 concentration of 200 mg L-1 
was elected as well, since LZP photolytic degradation was still quite lengthy (data not 
shown). Building on these grounds, the purpose of the present work was to clarify LZP 
photodegradation pathway(s) and accurately identify the different resulting photoproducts, 
rather than to characterize its degradation kinetics. In order to achieve so, the tested LZP 
concentrations were in the low ppm range (2 - 6 mg L-1), despite significantly higher than 
the already reported aquatic environmental values (ca. 40 - 200 ng L-1). 
As aforementioned, the employed non-target screening approach initially consisted of two 
TOF MS (+) scan simultaneous experiments, one with and one without in-source 
fragmentation. This interesting strategy, based upon the concept of “diagnostic fragment 
ions”, was first described by Ferrer and Thurman.25 Applied to the present case-study, the 
key assumption is that LZP photodegradation products will still present a basic structure 
analogous to that of the parent compound and, consequently, a similar in-source 
fragmentation pattern. The resulting diagnostic fragment ions were then selected bearing in 
mind the presence of the chlorine atom specific isotopic pattern (Fig. S1), as well as 
accurate masses. Subsequently, the corresponding molecular ions were identified in the 
respective non-fragmented sample chromatogram, using background subtraction at the 
corresponding retention times (tR) and taking into account peaks with identical shape.26 
Afterwards, MS/MS spectra of every [M+H]+ ions were acquired by IDA product ion (+) 
MS analysis, as previously mentioned in section 2.3. Finally, with the help of the Formula 
Finder tool, from the PeakView software, the structural enlightening of several LZP 
photoproducts was possible, taking into account LZP structural formula and respective 
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tandem MS spectra, as well as some of the software proposed fragments with 
corresponding spectra fitting probabilities. 
 
 
Structural Elucidation of LZP By-products and Mechanism Proposal. 
As previously mentioned, the samples selected for preliminary UHPLC/QqToF-MS 
analyses were chosen from an intermediate phototreatment time, in order to potentially 
contain a higher amount of most LZP photoproducts, and the selected system was the 
LsTQUV, since it allowed to start with higher LZP concentrations. Nevertheless, all 
compounds herein identified were later confirmed in most samples obtained in the 
remaining photocatalytic systems (LsBLBUV and SPP-CPCs), bearing in mind the same 
exact masses and tR, in addition to comparable MS2 spectra. 
Initially, several molecular ions were included in the group of potential LZP by-products 
(LBPs), though some of them were later identified as corresponding to either 35Cl/37Cl 
isotopes or Na+/K+ adducts of other [M+H]+ ions. Such examples were the cases of LZP 
itself (m/z 321.0196 (35Cl) / 323.0167 (37Cl)), presenting a sodium adduct at m/z 343.0014 / 
344.9984 and a potassium adduct at m/z 358.9749 / 360.9723, as well as LBP291 (m/z 
291.0088 / 293.0058), with a sodium adduct at m/z 312.9906 / 314.9877, or LBP319 (m/z 
319.0034 / 321.0007), with a sodium adduct at m/z 340.9862 / 342.9828 (Fig. S3). For 
these preliminary identifications, besides taking into account the two chlorine atoms 
typical isotopic pattern, both isotopes exact masses (35Cl isotope – 34.9689 and 37Cl 
isotope – 36.9659) were also considered. Thus, the selected ions were those corresponding 
to an isotope m/z difference slightly inferior to 2 Da. Furthermore, chromatographic data 
was also found to be an indispensable tool to enable the distinction between true LZP 
photoproducts and some potentially formed LZP in-source fragments. For instance, at first 
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sight, the 303.0085 m/z fragment could be considered a LBP, since it fitted all MS 
requisites imposed by the adopted analytical strategy. However, when comparing its 
chromatographic profile with LZP’s, the obtained peaks were overlapping (i.e., similar 
shapes and tR), leading to the conclusion that this compound was merely the result of in-
source fragmentation and not of the phototreatment process. Moreover, it was later 
confirmed that there was actually a LBP with a nominal mass of 303 Da, but its exact 
monoisotopic mass was still significantly higher (303.0560 m/z). 
Finally, fourteen compounds (excluding structural isomers) were identified as presumable 
LBPs and none of the corresponding peaks was detected in either of the used control 
blanks. All TOF MS scan extracted ion chromatograms (XICs) are presented in Fig. S4. 
Herein, one can observe that these putative LBPs were mostly eluted in the narrow range 
between 4-7 min, even after some preliminary improvements in the chromatographic 
elution gradient (refer to section 2.3.). Nonetheless, the QToF still afforded sufficient 
selectivity to record good quality product ion spectra for the majority of these compounds: 
LBP257, LBP266, LBP275, LBP282, LBP291, LBP293, LBP303, LBP319 and LBP337. 
Their respective MS2 XICs and mass spectra are displayed, along with LZP’s, in Fig. S5. 
Other less abundant LBPs included LBP156, LBP223, LBP230, LBP239 and LBP273. Fig. 
S5 illustrates some examples of the use of diagnostic ions for the identification of non-
target by-products obtained after phototreatment of the (targeted) parent compound LZP. 
One example was the case of the fragment ion 275.0171 m/z, identified in the mass 
spectrum of LBP319. Other fragment ions such as 229.0547 m/z and 163.0064 m/z were 
identified as well in the mass spectra of LBP303 and LBP257/LBP275/LBP291, 
respectively. However, despite constituting a rather useful tool for finding structurally 
related compounds, namely degradation products, the applicability of the diagnostic 
fragment ions concept is slightly limited and many exceptions exist.26 Therefore, other 
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important pieces of information such as chlorine isotopic pattern, exact masses, 
cleavage/oxidation and energetically favored reactions were considered when trying to 
establish some LBPs’ structures. 
In Fig. S5, the detected ion with a nominal mass of 319 Da was rationalized as being the 
product of the opening of the diazepinone seven-membered ring, followed by a 
rearrangement into a highly stabilized six-membered aromatic ring (LBP319).27 The 
resulting exposed carboxylic function is then likely to be cleaved, yielding an ion with 275 
Da (LBP275) – neutral loss of 44 Da, corresponding to the carboxylic group. It should be 
highlighted that this photoproduct with monoisotopic mass of ca. 275.0175 m/z 
corresponds also to a LZP in-source fragment, as one can observe on LZP PI spectrum and 
corroborated by the presence of the small peak at 5.76 min (LZP tR) in LBP275 
chromatogram. This aspect stresses, once again, the importance of good resolution of the 
parent compound/photoproducts. 
Concerning the remaining proposed LBPs, their structures were put forward based on the 
common reactions taking place in photocatalysis, namely oxidative processes mediated by 
•OH species. Consequently, from a mechanistic point of view, different hydroxylation 
reactions could be predicted. Regarding LBP337 and LBP303, they were considered side 
products of LZP phototreatment and interpreted as the result of the addition of a hydroxyl 
group to one of LZP’s benzene rings and the substitution of one chlorine atom by the 
hydroxyl group, respectively. However, these hydroxylation reactions could take place at 
different carbons of LZP skeleton, leading to the formation of distinct isomeric hydroxyl 
derivates and, thus, different chromatographic peaks.26 As one can observe in Fig. S5, in 
the case of LBP337, it was possible to distinguish between two potential structural 
isomers, each one derived from hydroxylation of a different aromatic ring, leading to the 
identification of ions at m/z 154.0078 and 179.0040 and corresponding putative structures. 
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Still, the exact position of the –OH substituent in the benzene ring remains undetermined. 
On the other hand, in the case of LBP303, it was possible to pinpoint exactly which 
chlorine atom was being substituted by the hydroxyl group, thanks to the structures 
tentatively attributed to ions at m/z 145.0388 and 153.0204 These ions were separately 
identified in the spectrum of each of the two most intense peaks, located at tR 3.65 and 5.92 
min. With reference to the probable LBP291, also shown in Fig. S5, the three observed 
peaks were interpreted as three different structural isomers: the most intense peak at 6.92 
min, most likely corresponding to the hydroxyl addition in the middle ring (LBP291(b)) 
according to the proposed structure for the 179.0009 Da ion, and two others at 6.05 and 
6.46 min (LBP291(a)), matching the hydroxylation on each of the two additional aromatic 
rings. Nevertheless, the latter two structures were again indistinguishable. According to 
some results reported by Calisto et al.,27 LBP266 was also identified in the present work, 
showing some common MS2 fragments with another proposed LZP photoproduct - 
LBP282 (ions with the nominal mass of 154 and 126 Da) (Fig. S5). Thus, it was our belief 
that LBP282 may result from the hydroxylation of LBP266 in one of the aromatic rings. 
Finally, the structure proposed for the putative LBP257 differs significantly from that 
previously presented by Calisto et al.27, consisting of a fused tricyclic structure, while our 
suggestion is more coherent with earlier stage photoproducts. Besides, Calisto et al.27 have 
only simulated the environmental degradation of BDZ, including LZP, in the laboratory 
i.e., they disregarded accelerated photodegradation processes such as TiO2-driven 
photocatalysis, as well as any mechanistic elucidation. 
Considering the importance of having an holistic overview of LZP photofate in the 
environment, in the present work a photodegradation pathway is proposed (Scheme 1), 
based on the results discussed so far. As it can be observed, the suggested scheme is 
divided in three main stages: a first one, leading to the formation of key LBP275, through 
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the intermediate LBP319, including as well some LBP275 side products resulting from the 
hydroxylation of the central diamino-ring; a following stage, comprising LBP291, LBP257 
and LBP273, corresponding to –OH addition, –Cl substitution and both, respectively; a 
third stage encompassing different photoproducts resulting from probable cleavage and/or 
hydroxylation reactions (LBP266, LBP282, LBP239, LBP230, LBP223 and LBP156). 
In conclusion, the unambiguous identification and confirmation of some LZP 
photoproducts was enabled taking into account the parent compound structural formula 
and performing an accurate mass analysis of the protonated molecules, together with that 
of additional characteristic fragment ion(s), including characteristic isotopic signals and 
retention times. 
 
Comparison Between LsTQUV, LsBLBUV and SPP-CPCs Experiments. 
The evolution profiles of the above enumerated LZP photoproducts and whether or not 
they were produced using the three employed experimental systems was then investigated. 
Since authentic standards are not commercially available for these LBPs, their 
concentrations in the several collected samples could not be accurately calculated. Thus, in 
Fig. 1 we illustrated their evolution in terms of peak area (i.e., ratio At/Amax.) in relation to 
the accumulated UV energy (QUV), calculated for each experimental set-up. All data used 
for the determination of peak area values are given in Table S1. The normalization attained 
with the QUV parameter allowed the comparison of the different LBPs increase/decrease 
profiles between the three experimental systems. On the overall, it is also worth noting that 
since in most cases the different isomers could not be distinguished, their respective peak 
areas were presented as a global value. Exception noted for LBP291, for which isomeric 
structures (a) and (b) were displayed separately. 
As preliminary conclusions two main aspects must be highlighted: first, the SPP-CPCs 
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photocatalytic system seemed to be the most efficient one amongst the three tested, since a 
faster LZP decrease was observed and the increase/decrease variations of several LBPs 
appeared at an earlier stage (Fig. 1); second, using this experimental system, some 
compounds such as LBP291(a), LBP257, LBP266, LBP282 and LBP230 were never 
detected. Remains to be clarified if this was due to the fact that the initial LZP 
concentration used in these experiments was lower than in the other two systems (2 ppm 
for SPP-CPCs vs. 6 and 5 ppm for LsTQUV photolysis and LsBLBUV photocatalysis, 
respectively), or if the efficient degradation of LZP didn’t allow isolating some 
intermediates.  
Lastly, the obtained evolution profiles for LBP337, LBP303, LBP319 and LBP275, 
regarding all three experimental set-ups, showed a noticeable increase as soon as light 
exposure began, which further reinforces the aforeproposed LZP photodegradation 
pathway. Moreover, their respective peak areas (data not shown) corresponded to the 
highest initial absolute values among all proposed LBPs’ structures. Though we are 
perfectly aware that such comparison is not flawless, since different compounds will most 
likely present different MS responses, it is likely that the signal intensities should fall in a 
rather similar range, given that the basic structure is still maintained. 
 
LZP Photodegradation in a Real Contaminated WWTP Effluent 
The experimentally confirmed most effective LZP photodegradation system – 200 mg L-1 
TiO2-assisted photocatalysis using the Solar Pilot Plant with Compound Parabolic 
Collectors (SPP-CPCs) – was finally used to envisage LZP photofate in a real effluent 
sample. A preliminary physicochemical characterization (including some emerging 
pollutants) of this sample was performed and the results are displayed in Table S2. The 
effluent was further spiked with 2 mg L-1 LZP, in order to facilitate the identification of 
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potential LZP photoproducts. pH and temperature were constantly measured over the 
experiment, never falling outside the range of 6.35-7.10 and 18.5-28.5 ºC (normal within-
day variation), respectively. 
The evolution profiles of the most abundant LBPs were then monitored and the charts 
obtained are presented in Fig. 2. It is well-known that nitrates, humic and fulvic acids 
present in wastewaters can act as sensitizers, giving rise to highly reactive species such as 
hydroxyl-radicals, singlet oxygen or H2O2 and thus promoting indirect photolysis.28 On the 
other hand, humic acids can also exert an optical filter effect, thereby attenuating the direct 
photolysis process. These two competing mechanisms are widely recognized and the 
overall effect is considered to be dependent on the analyte being investigated.29,30 
However, even taking these aspects into consideration, no quantitative comparison with the 
results obtained for distilled water (Fig. 1) was possible. This holds true mainly due to the 
fact that the dissolved organic matter, present in the effluent sample, can render the 
analytes prone to different matrix effects. Nevertheless, from an overall analysis of Fig. 2, 
it can be observed that the photoproducts generated seem to be more persistent than LZP 
itself, requiring higher QUV amounts to achieve their photodegradation. Consequently, 
some ecotoxicity tests would be quite relevant to further assess their environmental impact. 
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Figure 1.    Graphical representation of LZP and respective LBPs evolution profiles, over 
the photo-treatment process, in terms of ratio At/Amax. (peak area at time t / maximal peak 
area) as a function of the amount of accumulated UV energy per liter of sample: ■ - Lab-
scale TQ150W-UV prototype (LsTQUV); ● - Lab-scale Blacklight Blue-UV system 
(LsBLBUV); ▲ - Solar Pilot Plant with CPCs (SPP-CPCs). 
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Figure 2. Graphical representation of LZP and respective LBPs evolution profiles, over the 
photo-treatment using the SPP-CPCs set-up, in terms of ratio At/Amax. (peak area at time t / 
maximal peak area) as a function of the amount of accumulated UV energy per liter of 
effluent.  
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IUPAC name:  
(RS)-9-chloro-6-(2-chlorophenyl)-4-hydroxy-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one 
 
 
 
Figure S1. LZP structural formula, IUPAC designation, pharmaceutical and chemical characteristics 
(from Rang, H. P.; Dale, M. M.; Ritter, J. M.; Moore, P. K. Pharmacology; Bath Press: U.K., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therapeutic group Anxiolytics 
Molecular formula C15H10N2Cl2O2 
Molecular weight 321.2 
CAS no. 846-9-1 
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Figure S2. Experimental systems used for LZP phototreatment tests: (a) Laboratory-scale Photoreactor 
with UV medium pressure mercury lamp (1) and emission spectrum of the lamp Heraeus TQ 150W 
(2); (b) Laboratory-scale Photoreactor with blacklight blue lamp (1) and LYNX S 11W lamp emission 
spectrum (2) (http://www.intertronics.co.uk/products/iuv026.htm, last accessed September 20, 2012); 
(c) Solar Pilot Plant with CPCs (1) and solar radiation spectrum (2) (http://org.ntnu.no/solarcells/ 
pages/Chap.2.php?part=1, last accessed September 20, 2012).      
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Figure S3. Illustration of some examples of sodium and potassium adducts: LZP321 and Na+/K+-
adducts; LBP291 and LBP319 and respective Na+-adducts.  
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Figure S4. UHPLC/QqToF extracted ion chromatograms obtained for the sample corresponding to 
QUV = 13.5 kJ L-1 / LsTQUV prototype. 
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Figure S5. (+)ESI-MS2 extracted ion chromatograms and mass spectra of LZP and its photoproducts, 
obtained with sample QUV = 13.5 kJ L-1 / LsTQUV prototype. For each MS spectrum, some putative 
structures are presented for the higher intensity signals. 
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Name Formula Mass (Da) 
Adduct / 
Modifications 
Extraction 
Mass (Da) 
Width 
(Da) 
Found at 
Mass (Da) 
Error 
(ppm) 
Expected 
RT (min) 
RT Width 
(min) 
Found at 
RT (min) Intensity 
LBP156_2.76 C7H6ClNO 155.01380 +H 156.02107 0.01 156.02050 -3.7 2.76 0.5 2.76 8944 
LBP230_6.06 C13H8ClNO 229.02944 +H 230.03672 0.02 230.03641 -1.3 6.06 0.5 6.06 102238 
LBP230_6.66 C13H8ClNO 229.02944 +H 230.03672 0.02 230.03617 -2.4 6.66 0.5 6.66 336100 
LBP230_6.76 C13H8ClNO 229.02944 +H 230.03672 0.02 230.03617 -2.4 6.76 0.5 6.76 336100 
LBP230_7.11 C13H8ClNO 229.02944 +H 230.03672 0.02 230.03638 -1.5 7.11 0.5 7.11 44250 
LBP257_4.75 C14H9ClN2O 256.04034 +H 257.04762 0.01 257.04722 -1.5 4.75 0.5 4.75 14055 
LBP257_5.27 C14H9ClN2O 256.04034 +H 257.04762 0.01 257.04755 -0.2 5.27 0.5 5.27 23726 
LBP257_6.30 C14H9ClN2O 256.04034 +H 257.04762 0.01 257.04762 0 6.30 0.5 6.30 20081 
LBP266_6.76 C13H9Cl2NO 265.00612 +H 266.01340 0.02 266.01352 0.5 6.76 0.5 6.76 1090835 
LBP273_4.27 C14H9ClN2O2 272.03526 +H 273.04253 0.01 273.04190 -2.3 4.27 0.5 4.27 6379 
LBP275_6.94 C14H8Cl2N2 274.00645 +H 275.01373 0.01 275.01403 1.1 6.94 0.5 6.94 1638425 
LBP275_7.32 C14H8Cl2N2 274.00645 +H 275.01373 0.01 275.01394 0.8 7.32 0.5 7.32 11583 
LBP282_5.84 C13H9Cl2NO2 281.00103 +H 282.00831 0.01 282.00769 -2.2 5.84 0.5 5.84 5781 
LBP282_5.98 C13H9Cl2NO2 281.00103 +H 282.00831 0.01 282.00832 0 5.98 0.5 5.98 38613 
LBP282_6.16 C13H9Cl2NO2 281.00103 +H 282.00831 0.01 282.00821 -0.4 6.16 0.5 6.16 38613 
LBP282_6.22 C13H9Cl2NO2 281.00103 +H 282.00831 0.01 282.00821 -0.4 6.22 0.5 6.22 38613 
LBP282_6.45 C13H9Cl2NO2 281.00103 +H 282.00831 0.01 282.00821 -0.4 6.45 0.5 6.45 38613 
LBP291_6.07 C14H8Cl2N2O 290.00137 +H 291.00864 0.01 291.00861 -0.1 6.07 0.5 6.07 126219 
LBP291_6.21 C14H8Cl2N2O 290.00137 +H 291.00864 0.01 291.00861 -0.1 6.21 0.5 6.21 126219 
LBP291_6.49 C14H8Cl2N2O 290.00137 +H 291.00864 0.01 291.00852 -0.4 6.49 0.5 6.49 15167 
LBP293_4.85 C14H10Cl2N2O 292.01702 +H 293.02429 0.01 293.02441 0.4 4.85 0.5 4.85 7944 
LBP293_6.66 C14H10Cl2N2O 292.01702 +H 293.02429 0.01 293.02403 -0.9 6.66 0.5 6.66 13170 
LBP303_3.66 C15H11ClN2O3 302.04580 +H 303.05310 0.02 303.05276 -1.1 3.66 1 3.66 16585 
LBP303_4.71 C15H11ClN2O3 302.04582 +H 303.05310 0.02 303.05238 -2.4 4.71 1 4.71 3256 
LBP303_5.94 C15H11ClN2O3 302.04582 +H 303.05310 0.02 303.05307 -0.1 5.94 1 5.94 17491 
LBP319_6.30 C15H8Cl2N2O2 317.99628 +H 319.00356 0.01 319.00359 0.1 6.30 0.5 6.30 24727 
LBP319_6.46 C15H8Cl2N2O2 317.99628 +H 319.00356 0.01 319.00359 0.1 6.46 0.5 6.46 24727 
LBP337_4.90 C15H10Cl2N2O3 336.00685 +H 337.01412 0.01 337.01400 -0.4 4.90 0.5 4.90 8765 
LBP337_5.21 C15H10Cl2N2O3 336.00685 +H 337.01412 0.01 337.01427 0.4 5.21 0.5 5.21 18793 
LBP337_5.36 C15H10Cl2N2O3 336.00685 +H 337.01412 0.01 337.01427 0.4 5.36 0.5 5.36 18793 
LBP337_5.56 C15H10Cl2N2O3 336.00685 +H 337.01412 0.01 337.01409 -0.1 5.56 0.5 5.56 18793 
LZP321_4.09 C15H10Cl2N2O2 320.01193 +H 321.01921 0.01 321.01909 -0.4 4.09 0.5 4.09 1939 
LZP321_5.78 C15H10Cl2N2O2 320.01193 +H 321.01921 0.01 321.01934 0.4 5.78 0.5 5.78 1253349 
LZP321_6.09 C15H10Cl2N2O2 320.01193 +H 321.01921 0.01 321.01935 0.4 6.09 0.5 6.09 21202 
LZP321_6.28 C15H10Cl2N2O2 320.01193 +H 321.01921 0.01 321.01935 0.4 6.28 0.5 6.28 21202 
LZP321_6.76 C15H10Cl2N2O2 320.01193 +H 321.01921 0.01 321.01913 -0.2 6.76 0.5 6.76 8162 
 
Table S1. Calculated, extracted and observed mass, mass error, expected and found RT (Retention Time) and intensities determined for the predicted formulas of the identified 
LBPs, using the sample corresponding to QUV = 13.5 kJ L-1 and the LsTQUV prototype - the designation of the photoproducts is in accordance with Fig. 1 
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Table S2. Physicochemical characterization of the WWTP effluent sample used for the solar 
photocatalytic experiment and concentration of every emerging pollutant therein quantified 
Parameter (units) 
WWTP  
Effluent 
ELV a 
Dec. Lei nº236/98, 1 de Agosto 1998 
(Portuguese Legislation) 
Color pale yellow; n.d.b at dil.1:20 n.d. for dilution 1:20 
Odor n.d. (dil.1:20) n.d. for dilution 1:20 
pH 7.3 6.0-9.0 
Temperature (ºC) 20.0 3 ºC increase c 
Turbidity (NTU) 115 - 
Conductivity (µS cm-1) 555 - 
Dissolved Oxygen (mg L-1) 2.2 - 
Oxidability (mg L-1) 56.2 - 
Total Dissolved Carbon (mg L-1) 37.5 - 
Inorganic Carbon (mg L-1) 25.4 - 
Dissolved Organic Carbon (mg L-1) 12.1 - 
Absorbance at 254 nm (AU) 0.07 - 
Total Suspended Solids (mg L-1) 363 60 
Volatile Suspended Solids (mg L-1) 223 - 
Ammonium - NH4+ (mg L-1) 1.2 10 
Nitrate - NO3- (mg L-1) 23.3 50 
Nitrite - NO2- (mg L-1) <0.5 - 
Bromide - Br- (mg L-1) <0.5 - 
Chloride - Cl- (mg L-1) 78.5 - 
Fluoride - F- (mg L-1) <0.5 - 
Phosphate - PO43- (mg L-1) 7 - 
Sulphate - SO42- (mg L-1) 59.8 2,000 
Phosphorus - 31P (mg L-1) 3.0 10,000 
Sodium - 23Na (mg L-1) 78.8 - 
Potassium - 39K (mg L-1) 21.1 - 
Calcium - 44Ca (mg L-1) 274.8 - 
Emerging Pollutants (ng L-1) 
Alprazolam                                                                               24 - 
Azythromycin 29 - 
Bisoprolol 24,256 - 
Carbamazepine 12 - 
Carvedilol 631 - 
Ciprofloxacin 682 - 
Clotrimazole 52 - 
Diclofenac 492 - 
Fenofibrate 3,051 - 
Fluconazole 417 - 
Fluoxetine 132 - 
Furosemide 53 - 
Gemfibrozil 101 - 
Hydrochlorothiazide 149 - 
Ketoprofen 410 - 
Lorazepam 138 - 
Losartan 95 - 
Norfloxacin 110 - 
Ofloxacin 254 - 
Paroxetine 215 - 
Propanolol 244 - 
Terbinafine                                     37 - 
a ELV – Emission Limit Value. b n.d. – not detected. c Comparatively to the receptor medium. 
 
 Occurrence of Emerging Pollutants’ By-Products in Water Resources 
 
183 
 
Chapter 6 
Occurrence of Emerging Pollutants’ 
By-Products in Water Resources 
 
 
 
 
 
 
 
 
 
This chapter will focus on the occurrence of transformation products (TPs) of different 
classes of emerging compounds (e.g., pharmaceuticals, hormones, personal care products, 
pesticides, alkylphenols, etc.) in environmental matrices (surface waters, groundwaters, 
drinking waters, sea waters, wastewaters and sewage sludge) from a geographical 
perspective, seeking to present an integrated account of the characteristics, impacts and 
activities across Europe. 
By-products are often detected in the environment in the absence of the parent 
compounds and may be more noxious and less biodegradable than their counterparts, 
therefore they must be taken into account in risk assessment studies. As stated in the 
previous chapter, using lorazepam as example, the identification of other emerging 
pollutants TPs, which will now be reviewed, is only the first step towards the further 
assessment of their potential toxicity effects and consequent environmental impact.  
 
 
 
This chapter represents a résumé of the following book chapter: C. Gonçalves, M.A. Sousa and M.F. 
Alpendurada: Occurrence of Transformation Products of Emerging Contaminants in Water 
Resources. In: Transformation Products of Emerging Contaminants in the Environment: Analysis, 
Processes, Occurrence, Effects and Risks. Book to be edited by Dimitra A. Lambropoulou and Leo M.L. 
Nollet, John Wiley & Sons Inc. (2013). 
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6.1. Brief Introduction on the Sources of Transformation 
Products of Emerging Contaminants 
The first step on the transformation of chemicals used for therapeutic purposes can soon 
take place inside living organisms, giving rise to metabolites. Parent substances and 
metabolites then undergo further transformations in the environment, through biotic and 
abiotic processes, and the cascade of transformation products (TPs) is exponentially 
magnified until total mineralization is achieved. The identification of a huge number of 
unknown TPs in environmental matrices is complicated by their diverse physico-chemical 
properties, which make their determination difficult with one analytical procedure, and 
the absence, in most cases, of analytical standards to confirm their chemical structure. 
Nevertheless, a lot of progress has been made in recent years with the use of sophisticated 
analytical instrumentation, predictive tools and simulated laboratory assays (1).  
Biochemical transformations of organic toxicants are governed by specific enzyme-
mediated pathways, thus reasonably predictable and limited. On the other hand, abiotic 
processes are extremely diverse and non-specific (e.g., catalyzed by radicals), resulting in 
myriads of products with different predominance (2). Abiotic transformations comprise 
chemical hydrolysis, oxidation/reduction, isomerisation, photolysis, etc., influenced by 
chemical and physical factors such as temperature, pH, salinity, chemical sensitizers that 
make part of the water and soil composition, and sunlight radiation with different 
intensity and wavelength, depending on the latitude, altitude and season of the year (2-4). 
Different TPs with diverse environmental behaviour and ecotoxicological profile can be 
formed depending on the predominant chemical or biochemical process taking place, as 
well as the surrounding media where it occurs (surface water, groundwater, soil, sediment, 
wastewater effluents, etc.) (4, 5). 
Fatta-Kassinos et al. (2) carried out a review on degradation products resulting from 
advanced oxidation processes (AOPs) used for water and wastewater treatment, aiming at 
the destruction of recalcitrant organic substances but which usually fail to achieve total 
mineralization. The disappearance of the original substance does not guarantee the 
complete efficacy of the process and the intermediates formed may preserve the mode of 
action of the parent compound or even be biologically more active (3). 
As long as the identification of all TPs is excessively challenging, attempts can be made to 
assess the final biological activity, but the assays must be relevant for human or 
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environmental toxicology. Following this strategy, we enter another field of prospect since 
a large battery of assays has to be used to arrive to valid conclusions. Valid assays should 
tackle both real targets and real concentration levels, which is not always the case (6).  
A review published by Farré et al. (1) is a good background work for this chapter and gives 
an account of the levels of several emerging pollutants and respective TPs in wastewaters 
(influent and effluent) and surface waters, until 2008. Nevertheless, it is discernible from 
the present literature review that a lot of progress has been made on this subject in these 
last 4 years. 
 
6.2. Transformation Products in Natural Waters: from 
Contamination Sources to Drinking Water Production 
Natural waters are the most relevant environmental compartment as regards the impact of 
pollution by emerging contaminants and their TPs, being the first to be endangered. 
Indeed, natural waters are the habitat of numerous species, give support to important 
human activities and are source of environmental services (as the supply of fish and raw 
water for the production of drinking water), which ought to be protected and preserved.   
Horvat et al. (5) have studied the occurrence and fate of anthelmintics and their TPs in the 
environment based on their high applicability in animal husbandry and aquaculture. 
Benzimidazoles, the most popular group of anthelmintics, may undergo sulfide oxidation 
in the environment as well as in human metabolism. As a result, albendazole is converted 
into albendazole sulfoxide, also known as ricobendazole, the major active metabolite 
responsible for albendazole efficacy. Some of the sulfoxide is further transformed to 
albendazole sulfone which does not appear to have any anthelmintic activity. Similarly, 
flubendazole is transformed into active fenbendazole sulfoxide, known as oxfendazole. 
Benzimidazoles undergo ester-group demethylation followed by decarboxylation of the 
carbamic group giving rise to the amine-derivative, which has been reported to be the 
main photodegradation product and also the major metabolite of these drugs (7). 
Ricobendazole amine has been identified. 
The information available on the levels of anthelmintics in the environment is very limited 
and even scarcer for metabolites and TPs. Although levels of flubendazole and 
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thiabendazole were measured in wastewaters (in the range 19.9–89.7 µg L-1 for influent 
and 55.0–671 ng L-1 for effluent) and surface waters (3.9 to 27.3 ng L-1), respectively, no 
metabolites are reported. On the other hand, 22,23-dihydroavermectin B1a was found in 
sediments under a fish farm where ivermectin has been administered, at the mean 
concentration of 5.0 ng g-1 in the top 3 cm (8). 
Gonçalves et al. (9) have studied the behaviour of oseltamivir carboxylate (OC), the active 
metabolite of oseltamivir (OE, Tamiflu), in the context of the past predicted pandemia of 
influenza virus H1N1. The levels measured in the Ebro River basin during fall/winter 2009 
reached maximum concentrations in Sástago, downstream the city of Zaragoza (OC 50 
and OE 100 ng L-1), Miranda de Ebro (OC 46 and OE 83 ng L-1) and El Bocal (OC 42 and 
OE 83 ng L-1). Photolysis TPs of OE identified as TP330 (photo-induced hydration) and 
TP312 (photo-isomerisation) were found in the above sites at vestigial levels, which could 
not be quantitated due the absence of pure standards. Also some tributaries presented 
levels of antivirals: River Huerva contained a concentration of OC of 46 and OE of 73 ng L-
1 while the concentrations in River Segre amounted to OC 22 and OE 35 ng L-1 (9). 
Jongh et al. (10) studied the fate and levels of pharmaceuticals and degradation products 
along the water cycle, from source to finished drinking water. Concentrations in pre-
treated surface waters by such simple treatments as fast sand filtration, infiltration in 
dunes or sole storage in large reservoirs generally reduced the concentrations by one order 
of magnitude. This was observed for tramadol, venlafaxine and carbamazepine and its 
TPs, but other compounds kept similar concentrations. Notably, the river bank filtrate 
concentrations of phenazone and 1-acetyl-1-methyl-2-phenylhydrazide (AMPH) 
significantly exceeded the concentrations in surface waters by almost one order of 
magnitude. This finding was explained by the authors as possibly historical contamination 
due to phenazone and dimethylaminophenazone high usage rates in the River Meuse and 
Rhine catchments some decades ago (10). The concentrations of degradation products 
rarely exceed 100 ng L-1, with average values of several tens of ng L-1. The concentrations 
of O-desmethyltramadol in the surface water samples ranged between 27 to 73% of its 
parent compound tramadol, which corresponds to the ratio of the excreted human 
metabolite via urine. In a different way, the concentrations of carbamazepine-10,11-
epoxide were also below the parent compound carbamazepine (about 13% to 37%) despite 
the main human metabolite being carbamazepine-10,11-diol, to which the epoxide is 
transformed. Nevertheless, a study on wastewater showed that the rations of 
carbamazepine-10,11-epoxide to carbamazepine formed are preserved in surface waters 
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(12-13%) (10). Conversely, the concentrations of O-desmethylvenlafaxine were higher than 
its parent venlafaxine in the surface water samples (between 128 and 208%) (10).  
Pesticides TPs in the environment are a particularly concerning group of substances 
because of their potential acute toxicity.   Hernandez et al. (11) carried out the entire job of 
elucidation, identification and quantitation of several of these substances in surface and 
groundwaters of Valencia, Spain, an agricultural area much affected by the use of 
pesticides. TPs were detected in higher number than the parent substances and at 
concentration levels reaching some µg L-1, which exceed the respective parent compounds. 
These concentrations surpasse the 0.1 µg L-1 limit generally established for natural waters, 
which would pass uncovered if the degradation products were not monitored. 
The environmental contamination with polybrominated diphenyl ethers (PBDEs) poses a 
singular scenario. Although less brominated PBDEs have been phase-out, it has been 
shown that heavier ones, like deca-BDE, degrade by photolytic cleavage into lighter ones 
(debromination), including penta-BDE. This last substance is not only more toxic but also 
more stable and more easily transported in the atmosphere crossing long distances to 
remote regions. Schenker et al. (12) have estimated that about 13% of the penta-BDE and 
about 2% of the tetra-BDE homologues found in the environment arise from the 
degradation of deca-BDE. Although, this study focused on the air compartment, 
deposition in rainfall leads to contamination of water bodies. 
Qu et al. (13) carried out an extensive protocol aiming the identification of neurotoxic 
brominated flame retardants (BFRs) and their by-products in environmental samples near 
a BFR-manufacturing plant, in China. Tetrabromobisphenol A diallyl ether was identified 
as a key developmental neurotoxicant in the most potent fraction of sediments where it 
was also measured in huge concentrations (around 10 mg Kg-1). This compound partitions 
to the water phase in the ng L-1 concentration range and it was detected 3.1 km farther 
downstream the BFR manufacturing plant (13). 
Alkylphenol ethoxylates (APEOs) constitute one of the main non-ionic surfactant groups 
with particular environmental relevance, since some of their possible metabolites 
(nonylphenol (NP), A9PEO1 and A9PEO2) have shown to be endocrine disrupting 
compounds. Nonylphenol polyethoxylates are large volume production chemicals used as 
detergents, emulsifiers and dispersing agents during the last 4 decades, both for domestic 
and industrial purposes (1, 14-16). The whole chain of degradation products is found in 
surface waters with concentrations ranging from hundreds of ng L-1 to several µg L-1 and 
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different toxic burden (14). Because all of these compounds exist together as mixture in 
the environment a risk assessment of the overall mixture is required. 
Despite a reasonable amount of data is currently available concerning the occurrence of 
APEOs in fresh waters, the knowledge about their subsequent fate in saline waters is still 
limited. Maximum estuarine and sea concentrations reported in literature are around 1 µg 
L-1, with some exceptions such as 10 µg L-1 in Spain and 25 µg L-1 in Israel. These values are 
found to be roughly one order of magnitude lower than those in fresh waters (17, 18). 
Jonkers et al. (19) elaborated a field study on surface waters, sediments and suspended 
particulate matter, with the goal to determine the sources and levels of A9PEOs, NP and 
the carboxylated metabolites (A9PECs) on the Dutch coastal zone, as well as their fate. 
According to different sampling campaigns, A9PEO1,2 and A9PEO>2 maximum 
concentrations varied between 0.14-0.73 and 0.27-35 µg L-1, respectively, while NP and 
A9PEC maximum levels ranged from 0.031-1.7 and 0.11-0.63 µg L-1, respectively. On the 
other hand, on the fresh water side of the locks at the mouth of the North Sea canal, 
slightly higher concentrations of metabolite compounds were obtained: 0.042 µg L-1 for 
NP and 0.31 µg L-1 in the case of A9PEC.  
Poly- and perfluoroalkyl substances (PFAs) comprise a diverse range of high production 
volume chemicals that have been used in industrial and consumer products for the last 5 
decades (in metal plating, fire-fighting foams and oil/water repellents). Chemicals like 
perfluorooctanosulfonates (PFOS) and perfluoroalkylcarboxylates (PFCA) are themselves 
better well-known than their chemical precursors of industrial origin (ammonium 
perfluorooctanoate (A-PFO); and fluorotelomer alcohols (FTOHs) and perfluoroalkane 
sulfonamidoethanols (PFASEs), respectively) (20). These compounds are so persistent 
and ubiquitous that could be found in sea waters of remote regions, most surface waters 
and also in wildlife (20, 21). Maclachlan et al. (22) conducted a survey of perfluorinated 
carboxylates (PFCA) in 14 major rivers including the Rhine, Danube, Elbe, Oder, Seine, 
Loire, and Po. The highest concentrations measured were 200 ng L-1 for 
perfluorooctanoate (PFOA) in the Po River followed by 32 ng L-1 of perfluorohexanoic acid 
(PFHxA) in Thames River. In most other cases the levels of PFAs substances remain below 
10 ng L-1. The Po River accounted for two-thirds of the total PFOA discharge in the studied 
rivers, which the authors attributed to a fluoropolymer manufacturing facilities in the Po 
watershed (22). In recent years attention has been expanded from environmental 
monitoring of acidic PFAs to include neutral compounds such as fluorotelomers (olefins, 
alcohols, acrylates), fluoroalkylsulfonamides, and fluoroalkylsulfonamidoethanols (23). 
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6.3. Wastewaters as Major Source of Transformation 
Products 
Fatta-Kassinos et al. (2) stress that the knowledge on the biodegradation products of 
pharmaceuticals, i.e., TPs formed during biological wastewater treatment is currently only 
little, therefore studies focusing on this topic should be undertaken so that the possible 
hazards related to the biotransformation products released in the environment can be also 
assessed. One should bear in mind that effluents from municipal wastewater treatment 
plants are a major source of emerging contaminants (e.g., hormones, pharmaceuticals and 
personal care products) and their degradation products, which affect particularly small 
water streams in dry seasons. 
Applying a systematic approach named “fragmentation-degradation relationship”, Gomez-
Ramos et al. (3) identified eight TPs in wastewaters out of 147 precursor compounds that 
were established in the database. The most frequent TPs in eight samples collected from 
four WWTPs in Spain were erythromycin anhydride, cleaved azithromycin and 4-
aminophenol. Erythromycin anhydride (m/z 716) quantified in effluent samples in the 
range from 27 to 159 ng L-1, using a commercial authentic standard. A hydrolysis product 
of erythromycin, erythralosamine (m/z 540), was also identified. The authors recall 
particular attention to the presence of 4-aminophenol in wastewaters, as degradation 
product of acetaminophen. Levels of this TP in the µg L-1 range were quantified, raising 
ecotoxicological concerns as 4-aminophenol has been described as very toxic to aquatic 
organisms, causing long term adverse effects (3). 
TPs of carbamazepine, an ubiquitous, persistent and abundant drug in the aquatic 
environment were also detected: the monohydroxylated product with m/z 255 was 
assigned as 10,11-dihydro-10,11-hydroxycarbamazepine, while the dihydroxylated product 
was also evidenced with m/z 271, corresponding to 10,11-dihydro-10-
dihydroxycarbamazepine, corroborating a previous report (24). Carbamazepine 10,11- 
epoxide, which is said to be frequently detected in wastewater samples, was also identified. 
Ghosh et al. (25) have measured oseltamivir carboxylate at a maximum concentration of 
293 ng L-1 in effluents from conventional activated sludge-based WWTPs, but the 
concentration decreased to 37.9 ng L-1 when an advanced WWTP with ozonation as a 
tertiary treatment was used. The levels of oseltamivir carboxylate measured by Prasse et 
al. (26) in two German WWTPs were 42.7 and 17.3 ng L-1 in the influent and effluent of 
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WWTP1 and 29.4 and 12.2 ng L-1 in WWTP2, respectively, while the levels of oseltamivir 
were constantly inferior to the metabolite, in agreement with the human excretion rate of 
about 80% in the carboxylate form. 
A TP of amoxicillin, a commonly used antibiotic belonging to the group of penicillins, was 
recognized as being (5R) amoxicillin diketopiperazine-2´.5´ (m/z 366), recently reported 
in both wastewater and surface waters (27, 28). 
Jia et al. (29) investigated the occurrence of six tetracyclines (TCs) and ten of their 
degradation products wastewaters and surface waters in China. They elicit ecotoxicity on 
fresh water species such as the cyanobacteria Micocystis aeruginosa and phytotoxicity on 
aquatic higher plants as Lemna gibba (30, 31). Tetracycline abiotical degradation is 
known to occur depending on pH, redox and light conditions, through epimerization, 
dehydration and proton transfer reaction pathways (32). 4-Epi-TCs can be formed in the 
aquatic medium under mildly acidic conditions (pH 2-6) and reversed back to their active 
form in specific alkaline conditions and in the presence of a complexing metal. Such are 
the cases of 4-epitetracycline (ETC) and 4-epioxytetracycline (EOTC), originated from TC 
and oxytetracycline (OTC), respectively. On the other hand, anhydro-TCs such as 
anhydrotetracycline (ATC) and anhydrochlortetracycline (ACTC) are formed under 
strongly acidic conditions (pH < 2). These compounds can also epimerize to form epi-
analogues (29). 
Jia et al. (29) then applied the developed method to the analysis of wastewaters and 
surface waters in China, using commercial standards for the clear identification of every 
compound. Apart from TC and OTC, the main analyte quantified in an influent sample at 
72.5 ng L-1, also several degradation products were detected at low nanogram per litre 
levels. Such were the examples of ETC, EOTC, ATC, isochlortetracycline (ICTC) and 4-
epianhydrochlortetracycline (EACTC), mostly eliminated through the WWTP treatment; 
besides TC and OTC, only ICTC and EACTC were quantified in effluent samples ranging 
from 1.9 to 7.6 ng L-1. 
Metformin is a highly consumed antidiabetic drug worldwide, which partially justifies its 
release in significant amounts (low µg L-1 range) to environmental recipient waters. On the 
other hand, this compound is not metabolized in humans (33). Measured concentrations 
of metformin in Belgian WWTP influents went up to 94 µg L-1 (34), while Scheurer et al. 
(35) published values for German WWTP influents as high as 129 µg L-1. It is also known 
that metformin is biologically degraded to guanylurea in WWTPs. Due to high metformin 
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concentrations in influents and its high yet incomplete removal during the treatment 
process, both compounds reach surface waters in considerable amounts of up to several 
tens of µg L-1 (36).  
Although a study from Trawtwein et al. (37) indicated guanylurea as the only recalcitrant, 
aerobic, bacterial degradation product of metformin, the detected concentrations of 
guanylurea in the effluent samples did not completely account for the corresponding 
removed fraction of metformin. Information is also scarce concerning the ecotoxicological 
relevance of both these compounds. Therefore, Scheurer et al. (36) recently published a 
systematic study aiming to clarify the direct transformation of metformin into guanylurea 
in WWTPs, evaluating the effectiveness of different treatment techniques applied in 
waterworks. In the five WWTPs comprised in the study, guanylurea ranged from 
undetectable levels to 3 µg L-1 in influent samples, reaching a concentration of 99 µg L-1 in 
an effluent sample corresponding to an influent with 105 µg L-1 of metformin. This 
observed widespread occurrence of guanylurea reinforces the environmental relevance of 
metabolites. 
To better assess the impact of emerging pollutants and their TPs in the environment and 
human health, there is the need to better understand the chemical and physical 
transformations occurring at the treatment plants, in order to determine their capacity to 
remove the contaminants or turn them into more persistent and toxic compounds. 
Gagnon et al. (38) reported on the influence of different wastewater treatment processes 
on the fate of some pharmaceutical compounds. During this study, 2-hydroxy-ibuprofen 
was identified as a metabolite of ibuprofen. This TP was quantified in effluent samples in 
concentrations ranging from ca. 300 to 3,500 ng L-1, depending on the WWTP where the 
sample was collected and the treatment technique therein employed. The relatively high 
concentrations of 2-hydroxy-ibuprofen helped justifying the low concentration of 
ibuprofen after treatment (38). 
Iodinated contrast media TPs were also detected in a municipal WWTP effluent with 
concentrations as high as 660 ng L-1 for iomeprol TP791. While the concentration levels 
measured were the highest among all environmental matrices analysed, less TPs (only 10) 
were detected (39). 
In another work, Bueno et al. (40) described the development of an enhanced liquid 
chromatography-mass spectrometry (LC-MS) strategy for the analysis of a selected group 
of 56 organic pollutants in wastewaters composed by 38 pharmaceuticals and 10 of their 
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most frequent metabolites, 6 pesticides and 2 disinfectants. Since target analysis based on 
LC-MS provides a great performance for quantitative analysis, but fails in the 
determination of compounds not initially included in the multiresidue methods (non-
target compounds), the latest trends to increase methods scope include the combination of 
two complementary LC-MS techniques or the use of hybrid systems with different 
analyzer designs. Therefore, Bueno and co-workers adopted a LC-MS methodology based 
in the use of a hybrid triple-quadrupole linear ion trap mass spectrometer (QTRAP), for 
accurate quantification, in combination with time-of-flight mass spectrometry (TOF-MS), 
providing unequivocal confirmation. The developed methodology was then successfully 
applied to a monitoring study of six WWTPs, in Spain. Herein, a group of pharmaceutical 
compounds metabolites were detected and quantified: carbamazepine-10,11-epoxide (13-
110 ng L-1), 1,7-dimethylxanthine (or paraxanthine) (131-80,875 ng L-1), clofibric acid (67-
81 ng L-1), fenofibric acid (14-349 ng L-1), and the metabolites of the antipyretic drug 
dipyrone, 4-methylaminoantipyrine (4-MAA, 9-9,253 ng L-1), N-acetyl-4-aminoantipiryne 
(4-AAA, 2,109-25,030 ng L-1), N-formyl-4-aminoantipiryne (4-FAA, 40-10,114 ng L-1), 4-
dimethylaminoantipiryne (4-DAA, 122 ng L-1), 4-amino-antipiryne (4-AA, 131-9,286 ng L-
1) and antipyrine (17-2,760 ng L-1) (40). The authors also recalled particular attention to 
the fact that paraxanthine and 4-AAA were present at the highest levels in the effluent 
samples collected in the WWTP of Almeria, possibly due to the proximity of a hospital. 
Moreover, the group of metabolites of dipyrenone was also detected at quite high 
concentrations (40). 
Concerning the group of sulphonamides, widely used synthetic antibiotics, García-Galán 
et al. (41) studied the behaviour of sulfapyridine (SPY), typically used in human therapies, 
and the veterinary sulphonamide sulfamethazine (SMZ), as well as their acetylated 
metabolites, AcSPY and AcSMZ, in wastewater matrices under artificial irradiation 
conditions. Compounds as SPY and SMZ are amongst the sulphonamides most frequently 
detected in effluent wastewaters and surface waters, respectively. Results showed that the 
photolysis of SPY produced a total of 10 different TPs, 4 major compounds (M) and 6 
other minor products (m), upon irradiation for 30 h: the hydroxylated metabolite 
(C11H12N3O3S), m/z 266.0599 (M); the SO2 extrusion product, N-(pyridin-2-yl)benzene-
1,4-diamine (C11H12N3), m/z 186.1031 (M); the hydroxylated moiety of this desulfonated 
product, N-hydroxy-N-(pyridin-2-yl)benzene-1,4-diamine (C11H12N3O), m/z 202.0980 
(m); a compound resulting from the reduction of the hydroxylamine in the N4 position of 
the hydroxylated product (C11H10N3O3S), m/z 264.0443 (M); pyridine-2-amine (C5H7N2), 
m/z 95.0609 (M); hydroquinone (m); aniline (m); sulphanilamide (m); sulfanilic acid (m); 
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aminosulfonic acid (pyridin-2-ylsulfamic acid) (C5H7N2O3S), which resulted from the 
cleavage of the bond between the aniline ring and the sulfonic group, followed by an -OH 
addition to the SO2 group, m/z 175.0177 (m). On the other hand, the photodegradation of 
N4-acetylsulfapyridine yielded a new molecule with a predicted elemental composition 
C13H14N3O (m/z 228.1137), through the loss of the sulfonate group. Regarding SMZ, eight 
different TPs were identified: similarly to what happened with SPY, a desulfonated 
product of SMZ was detected, presenting two different signals corresponding to the same 
mass (m/z 215.1297) and yielding the same mass spectra – stereoisomers with the 
elemental composition C12H15N4; its hydroxylated moiety C12H15N4O, m/z 231.1246, and 
the desaminated product C12H14N3, m/z 200.1188; 4,6-dimethylpyrimidin-2-amine 
(C6H10N3), m/z 124.0875; the hydroxylated product of SMZ (m/z 295.0865) and 
desaminated moiety (m/z 264.0807) of SMZ; a compound resulting from the reduction of 
the hydroxylamine in the N4 position of the hydroxylated product (C12H13N4O3S), m/z 
293.0708; (4,6-dimethylpyrimidin-2-yl) sulfamic acid (C6H10N3O3S), m/z of 204.0443. 
Finally, AcSMZ photodegradation yielded 3 TPs: one resulting from the loss of SO2 and the 
methyl group from the acetylated moiety (C13H14N4O), m/z 243; a second one as the result 
of a desulfonation reaction (m/z 257); a third TP attributed to a structural rearrangement 
of the desulfonated photoproduct (C15H19N4O), m/z 271.  
Benzodiazepines (BZPs) are prescribed in high amounts worldwide and constitute 
potentially new emerging contaminants. However, the environmental persistence and fate 
of these pharmaceuticals, as well as their degradation products is, yet, scarcely 
understood. Hence, a study by Kosjek et al. (42) addressed this gap by monitoring 
environmental concentrations of several benzodiazepine residues and studying their 
removal during biological and photochemical water treatment, including the identification 
of stable TPs. As a result, the elucidation of eight novel diazepam (DZP) TPs and four 
novel oxazepam (OXA) TPs was performed. DZP biodegradation results in the formation 
of OXA, nordazepam (NRZ) and temazepam (TMZ), which are also human metabolites of 
DZP and marketed as individual pharmaceuticals. NRZ is formed by N-demethylation on 
N-1 of DZP, TMZ by hydroxylation of the C-3 atom and OXA comprises both 
transformation reactions. The newly discovered DZP TPs included 5 isomers with 
elemental composition C16H14N2O2Cl and nominal mass of 300 Da, resulting from one 
single hydroxylation of DZP, and 2 isomers with elemental composition C16H14N2O3Cl and 
nominal mass of 316 Da, resulting from double hydroxylation of DZP, all obtained by 
photocatalysis; the last TP identified, resulted from biotransformation of DZP and 
presented the elemental composition C16H16N2O2Cl and a nominal mass of 302 Da. 
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Regarding OXA, 1 degradation product with elemental composition C15H12N2OCl and 
nominal mass 270 Da was originated by biotransformation reactions, while other 3 
hydroxylated isomers, presenting the elemental composition C15H12N2O3Cl and a nominal 
mass of 302 Da, were the result of photocatalysis at pH 2.  
In another study by Calisto et al. (43), the relevance of photodegradation processes on the 
environmental persistence of four benzodiazepines - OXA, DZP, lorazepam (LZP) and 
alprazolam (ALP), was investigated. These benzodiazepines were irradiated under 
simulated solar conditions, together with three different fractions of humic substances. A 
total of nineteen TPs were identified by electrospray mass spectrometry, 7 for OXA, 4 for 
DZP, 6 in the case of LZP and finally 2 for ALP.   
Sousa et al. (44) also studied LZP phototransformation pathways under artificial UV and 
natural solar irradiation, through photolytic and TiO2-assisted photocatalytic processes. 
Herein, fourteen compounds (excluding structural isomers) were identified as presumable 
LZP TPs. The proposed photodegradation mechanism included the initial opening of the 
diazepinone seven-membered ring, followed by a rearrangement into a highly stabilized 
six-membered aromatic ring and subsequent cleavage and/or hydroxylation reactions. 
LZP photocatalytic degradation was further assessed on a contaminated municipal 
effluent, where the photoproducts generated showed to be more persistent than LZP itself. 
Estrogens high potency at the nanogram per litre level makes it important to assess their 
fate in the urban environment and evaluate the effectiveness of different processes of the 
urban sewer infrastructure in removing or lowering their estrogenic potential. Other 
chemicals such as octylphenol, nonylphenol, nonylphenol ethoxylates, bisphenol A and 
phthalates also express estrogenicity, even though to a lesser extent (15, 45). Limpiyakorn 
et al. (46) recently published a review work summarizing data collected from a total of 130 
full-scale WWTP distributed over 14 countries and focusing on the fate of estrogens and 
estrogen potentials in the sewerage system, starting from human excretion until municipal 
sewage treatment facilities. Humans generally excrete 90-95% of estrogens via urine, 
preferentially in the conjugated forms. Conjugated estrogens usually found in female urine 
include estrone 3-(β-D-glucuronide) (E1–3G), estrone 3-sulfate (E1–3S), 17β-estradiol 3-
glucoronide (E2–3G), 17β-estradiol 17-glucoronide (E2–17G), 17β-estradiol 2-sulfate (E2–
3S), estriol 3-(β-D-glucuronide) (E3–3G), estriol 16α (β-D-glucuronide) (E3–16G) and 
estriol 3-sulfate (E3–3S). Glucuronide estrogens are found to be the most predominant 
form (47, 48). Afterwards, in the septic tanks, the dominant transformation mechanism 
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appears to be conjugation, with sulphate estrogens concentrations to the total conjugated 
estrogens, increasing from 22% in the influent to 55% in the effluent. In sewers, 
conjugated estrogens E1–3S, E1–3G, E2–3S, E2–17G, E2–3G, E3–3S, E3–16G, and E3–
3G were found to be reduced by about 64%, 84%, 100%, 0%, 100%, 84%, 100% and 0%, 
respectively (47). Finally, D’Ascenzo et al. (47) were able to quantify E1–3G, E1–3S and 
E3–3S in municipal WWTPs samples, of which 0.7 ng L-1, 9.0 ng L-1 and 2.2 ng L-1, 
respectively, remained in the effluent. In another study conducted by Isobe et al. (49), E1–
3S and E2–3S were found in the concentrations of 0.3-2.2 ng L-1 and 1.0 ng L-1, 
respectively, in the effluent of WWTPs in Japan. On the other hand, in a batch study 
performed by Ternes et al. (50), the conjugated estrogen E2–17G was found to be totally 
cleaved under aerobic conditions by activated sludge in a German WWTP. 
Moving to pesticides TPs group, Gomez-Ramos et al. (3) have identified unequivocally, 
with the help of a pure standard, the 2-isopropyl-6-methyl-4-pyrimidinol (IMP - m/z 153) 
as a TP of diazinon, an organophosphorous pesticide widely used in urban and agricultural 
applications. This TP was quantified in 2 samples from 2 different WWTPs at the 
concentrations of 288 and 630 ng L-1. It had already been reported in surface waters and 
referenced as one of the major degradation products of diazinon, showing a higher 
genotoxic potential than diazinon itself (24, 51). 
As previously mentioned, nonylphenol polyethoxylates (NPEOs) give rise to a great variety 
of dicarboxylic degradation products (CAPECs), particularly those containing five to eight 
carbon atoms (CA5-8PECs). Their demonstrated presence and possible persistence in 
several environmental compartments is raising concern worldwide (52). However, reports 
on CAPECs environmental occurrence and behaviour, including their possible eco- and 
human toxicological effects, are still very scarce. In this context, Hoai et al. (52) 
investigated four model compounds of dicarboxylic metabolites (dm-CA5-8P1EC) and other 
dicarboxylic metabolites (CA5-8P1ECs) of nonylphenol polyethoxylates in wastewater, river 
and pure water. The dicarboxylic metabolites referred as dm-CA5-8P1EC present an α,α-
dimethyl configuration (expressed as “dm”), five to eight carbon atoms and a carboxyl 
group in the alkyl chain, besides an ethoxy acetic acid group. 
Though dm-CA5-8P1ECs metabolites were not detected in the collected water samples, 
Hoai et al. (52) could identify 21 isomers of CA5-8P1ECs by CI-MS in surface and 
wastewater effluents in Japan: 2 isomers of the CA5P1EC metabolite, 5 isomers of the 
CA6P1EC metabolite, 6 isomers of the CA7P1EC metabolite and 8 isomers of the CA8P1EC 
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metabolite. The metabolites of CA6P1EC and CA8P1EC were identified as the dominant 
compounds, at µg L-1 level, from 2-15 times higher than CA5P1EC and CA7P1EC 
metabolites, leading to the conclusion that nonyl chains degradation occurs mainly 
through the elimination of two carbon units. Hoai et al. (52) also highlighted that 
dicarboxylic degradation products should play an important role when studying the 
behaviour of NPEOs in WWTPs, due to the high concentrations of CA5-8P1ECs metabolites 
in the studied river and WWTP effluents. Moreover, the obtained results for surface and 
wastewaters in Japan were compared to previous ones reported in Italy and Taiwan, 
where CA5-8P1ECs concentrations were about one and two orders of magnitude higher, 
respectively.  
 
6.4. Origin and Presence of Transformation Products in 
Drinking Water 
In their review, Mompelat et al. (4) highlighted the human health risk associated with the 
occurrence of pharmaceuticals and degradation products in drinking water, even at low 
concentrations. According to these authors, drinking water is the least studied when it 
deals with the occurrence, fate and behaviour of emerging pollutants’ by-products, 
compared to environmental matrices.  
Lee et al. (53) have studied the fate of steroid estrogens upon chlorination. Ortho-
substituted derivatives were identified as the main by-products which displayed 
considerably weaker estrogenic potency. In the presence of increased levels of bromine in 
the raw water and low concentration of dissolved organic matter and ammonia, secondary 
products of 17α-ethinylestradiol (EE2) were identified, containing one or two bromine 
atoms in both positions (2- and 4-) of the phenolic ring. These products can be further 
transformed either by chlorine or bromine into a cleaved phenolic moiety (53). During the 
chlorination process (at pH 7) and under typical concentrations of 17α-ethinylestradiol at 
ng L-1 levels and bromine between 10-100s µg L-1, the predominant products are the 
brominated ones (4-Br- and 2,4-diBr-17α-ethinylestradiol) until total depletion of 
bromine. The formation of chlorinated by-products of 17α-ethinylestradiol is faster at pH 
from 7-9 with higher accumulation of 2,4-dichloroderivatives. The authors advocate that 
the same behaviour can be extrapolated for other steroid estrogens, such as 17β-estradiol 
(E2), estrone (E1) and estriol, and other phenol-containing endocrine disrupting 
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compounds such as bisphenol A and nonylphenol, in which the presence of bromine 
accelerates the transformation and gives rise to less potent by-products (53). 
Under ozonation conditions in water treatment works the primary oxidation end-products 
of metformin were identified as the hydroperoxide of metformin, methylbiguanide and 2-
amino-4-imino-5-methyl-1,3,5-triazine (36). Under chlorination both substances 
metformin and guanylurea should undergo similar reactions. Dimethylamine was 
identified as the prime chlorination product but others such as: N-chlorourea, NCl3, 
NHCl2 and NH2Cl can be formed by hydrolysis of the amine group and further 
chlorination (36). The presence of guanylurea in finished drinking water seems, however, 
to be unlikely if a underground passage is part of the raw water treatment train (36). 
Illicit drugs have been recognized in recent years as a new group of water contaminants 
and a sufficient pool of data exists already on their ubiquity around the world (54). 
Huerta-Fontela et al. (54) have demonstrated in previous works that most illicit drugs and 
respective metabolites can be removed during the steps of drinking water production. 
Nevertheless, they can give rise to the formation of disinfection by-products. A common 
chlorinated by-product (3-chlorobenzo)-1,3-dioxole, was identified for both 4-
methylenedioxyamphetamine (MDA) and 3,4-methylenedioxyethamphetamine (MDEA) 
while for 3,4-methylenedioxymethamphetamine (MDMA), 3-chlorocatechol was found 
(54). The chemical (3-chlorobenzo)-1,3-dioxole was found after the first chlorination step, 
in concentrations from 1.2 to 3 ng L-1, and was eliminated after ozone and graphitic 
activated carbon filtration. On the other hand, 3-chlorocatechol, generated mainly after 
the post-chlorination step, showed to be recalcitrant and it was found in final treated 
waters at concentrations ranging from 0.5 to 5.8 ng L-1 (54). 
 
6.5. Ubiquity and Regio-Specificity of Transformation 
Products  
After all the information regarding the occurrence and fate of pharmaceuticals and their 
TPs is gathered, one of the most difficult issues is to prioritize them and extend these finds 
to other environmental scenario. Indeed, a great variability may be found in terms of 
geographical consumption, seasonal and environmental climatic conditions, contexts of 
water treatment, flora and fauna exposed individuals and water safety regulations.  
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According to the results given in the review by Mompelat et al. (4) and our own literature 
review most of the studies on degradation products of emerging contaminants have been 
produced in Germany followed by France and UK, which is not surprising as these 
countries lead the environmental research and host the most renowned researchers in the 
field. Spain and Switzerland also devote great effort to environmental research which was 
reflected in the present literature survey. 
A variety of studies on PDBEs and respective degradation products have taken place in 
Asia, namely in China (55). The fast growth of the electronics manufacturing capacities for 
the global market and the accumulation of a large fraction of electronic waste (E-waste) 
from developed countries, which are submitted to uncontrolled recycling, endangered the 
environment with PBDEs and their by-products (55). The results presented in the 
previous section regarding the detection of tetrabromobisphenol A diallyl ether in an 
industrial area attest the relevance of brominated flame retardants contamination in 
China (13).  
As far as ubiquity is concerned, one of the main gaps hampering wider/global perception 
is the lack of data in “younger” European and accession countries. The studies conducted 
by Loos et al. (21, 56) at the European Union Joint Research Centre (JRC) are exceptions 
and they proved the ubiquity of NPE1C and NP in surface- and groundwaters which were 
even detected at remote areas. 
It is obvious from the present review that results on emerging pollutants and degradation 
products is mainly available from Mediterranean and Central European countries as well 
as from Asiatic (China and Japan) and American countries (Brazil, Canada and USA). 
Eastern countries contribute very little to this awareness; however, it is believed that 
today’s global economy and globalized habits may give rise to similar (qualitative if not 
quantitative) contamination problems. In other words, with due exceptions, the ubiquity 
or regio-specificity may be more a matter of availability of studies rather than 
environmental reality. Furthermore, Europe is crossed by big water streams which 
conduct organic micropollutants from industrialized/populated areas to far distances that 
suffer the indirect impact of these substances. 
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6.6. Transformation Products of Emerging Contaminants: 
Fate and Behaviour 
Transformation reactions mediated by biotic and abiotic factors often lead to smaller, 
more polar, and thus less hydrophobic molecules, which are in turn less toxic and less 
bioaccumulative. However, in some instances (e.g., when polar or charged parts of a 
molecule are cleaved off, or heteroatoms are included in the molecule), hydrophobicity is 
increased leading to increased toxicity. The toxic mechanism (e.g., genotoxicity) may also 
be altered, as often verified in disinfection by-products (6). In evaluating the toxicity of a 
TP, two dimensions should be appreciated: the toxicokinetics meaning the behaviour of a 
substance in terms of uptake, distribution, metabolism and excretion; and the 
toxicodynamics respecting the type and potency of interaction with the target site which 
prompts for a biological effect. This two components may differentiate the behaviour of 
parent compounds and TPs (6). 
Using an effect-driven approach, Dodd et al. (57) conducted several toxicity studies with 
antibiotics during the oxidation by ozone, a process frequently employed in water 
treatment works. Similarly to roxithromycin, other antibiotics (macrolides, β-lactams, 
fluoroquinolones, tetracyclines, aminoglycosides, etc.) oxidized by ozone and hydroxyl 
radicals either did not give rise to TPs in significant amounts and/or their toxicity was 
much smaller than that of the parent compounds. Exception is noted for penicillin G and 
cephalexin, which form sulfoxides as first generation TPs retaining antibacterial activity, 
though further transformation leads to loss of antibacterial activity (57). In such cases 
where toxicity is eliminated concomitantly with the parent compounds degradation, no 
further identification and characterization of the TPs should be needed. 
Escher and Fenner (6) compiled several reports on the toxicity of emerging pollutants and 
degradation products, mainly pharmaceuticals, under accelerated oxidation conditions 
(simulated photodegradation, photocatalysis and ozonation), where Vibrio fischeri and 
Daphnia magna were the preferred test species. Under photocatalysis with TiO2 
sulfacetamide, sulfathiazole, sulfamethoxazole, and sulfadiazine don’t give rise to 
toxicologically relevant TPs. Under hypochlorite oxidation the mutagenicity of frazolidone 
has disappeared while the mutagenicity of nitrofurazone has been reduced. The 
isomerisation and polymerization of isoamylmethoxycinnamate and 
ethylhexylmethoxycinnamate under irradiation led to decrease in toxicity. The initial 
degradation 2-ethylhexyl-4-(dimethylamino) benzoate maintained the same toxicity, but 
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further degradation decreased toxicity. Dipyrone and three degradation products (4-
methylaminoantipyrine, 4-formylaminoantipyrine, 4-acetylaminoantipyrine) were 
submitted to simulated solar irradiation giving rise to increased toxicity of the reaction 
mixture after photolysis. Similar behaviour was observed for sulfamethoxazole whose TPs 
displayed higher toxicity for Daphnia magna. The ozonation of a solution containing 
clofibric acid gave rise to an initial increase in toxicity. The often studied and ubiquitous 
anti-inflammatory drug in the environment diclofenac photodegrades to 2-[2-
(chlorophenyl)amino]benzaldehyde which is more toxic than diclofenac itself due to 
higher bioconcentration potential (6). 
Triazines in the environment generally give rise to dealkylated and hydroxy degradates 
which, with some exceptions, tend to be less frequently detected than the parent 
herbicides and occur at lower concentrations. Conversely, two well-known classes of 
chloroacetamide degradates, the ethane sulfonic acid (ESA) and oxanilic acid (OA) 
derivatives, are normally encountered at concentrations much higher than the parent 
herbicides. The array of possible degradation products is also much larger (58). Some 
studies indicate that the principal hydrolysis products that are formed have long 
persistence in the environment. Besides, some neutral chloroacetamide derivatives have 
revealed toxic attributes. Just to mention, 2-hydroxy-2’,6’-diethylacetanilide and 2-chloro-
2’,6’-diethylacetanilide, have demonstrated mutagenic activity and the later can bind 
DNA. Both 2-ethyl-6-methylaniline and 2,6-diethylaniline are more teratogenic than their 
parent compounds (metolachlor and alachlor, respectively) while aniline metabolites, such 
as 2,6-dialkylbenzoquinoneimine and 2-ethyl-6-methylbenzonquinoneimine displayed 
genotoxic activity (58). 
Nonylphenol polyethoxylates are ubiquitous pollutants whose pathway of degradation in 
the environment depends on the actual conditions. If there is enough oxygen present, as is 
the case in surface water and upper soil layers, the carboxylation of NPnEO to NP1EC and 
NP2EC is favoured and nonylphenol is expected to mineralize quickly. Otherwise, 
nonylphenol formed out of NP1EC or NP1EO may be more persistent (14, 59). 
Carboxylated ethoxy chains AP2ECs and AP1ECs have been observed in aerobic 
biodegradation. Anaerobically treated sewage sludge favours the formation of 
alkylphenols (59). Nonylphenol ethoxylates are known to cause estrogenic responses in 
aquatic organisms at concentrations similar to those at which chronic effects occur. It is 
believed however that, short chain analogues have increased toxicity, the highest 
belonging to nonylphenol (14). In a risk assessment study including degradation products 
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performed by Fenner et al. (14) under a typical Swiss scenario, although none of the 
degradation products exhibited a significant risk alone, the mixture risk quotient was 2.2 
(>1). The biggest contributions to the overall risk stem from the three most toxic 
compounds, namely nonylphenol, NP2EO and NP1EO (14). The acids NP2EC and NP1EC 
exhibit lower single risks. For the special case of nonylphenol polyethoxylates, whose TPs 
are more toxic than the parent compound itself, the TPs account for 89% of the overall 
risk, according to Fenner et al. (14) estimations. 
Prevedouros et al. (60) reviewed the behaviour and fate of perfluorinated compounds, 
concluding that these chemicals are primarily emitted to water which is their major 
reservoir in the environment and transport media and that they accumulate in surface 
waters, being carried from rivers to sea, due to their very high persistence. 
 
6.7. Conclusions 
In this section we will discuss the gaps in knowledge, needs of further research and future 
trends. A major conclusion highlights from the present review of the literature, building 
on the remarks expressed by Escher and Fenner (6): the presence of TPs in the aquatic 
environment is not negligible and clearly contributes to the environmental and human 
health risk of organic micropollutants. Based on the results of a monitoring study of 
surface and drinking waters which revealed similar concentrations of transformations and 
parent drugs with equivalent pharmacological activity, Jongh et al. (10) strengthened the 
relevance of monitoring TPs and including them in risk assessment.  
Furthermore, there is a need to study the evolution of TPs spatially and temporarily in 
water streams. Also much deeper research is needed targeting the distribution of TPs in 
the environmental compartments, namely sediments and biota which may be regarded as 
sinks for toxic compounds or an alternative entrance route in the trophic chain, 
respectively. Monitoring of TPs in environmental matrices so far have mostly been 
restricted to major known by-products due to the limited availability of authentic 
standards both for unequivocal identification and quantification. Several authors just give 
qualitative or semi-quantitative information on TPs occurrence, while others have 
circumvented this limitation purifying degraded solutions to be used as standards. 
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One of the options to address the extensive work to be done on the risk assessment of TPs 
might be the use of a battery of bioassays including one targeting the specific mode of 
action of the parent compound, complemented by a nonspecific bioassay sensitive to TPs 
which has developed high nonspecific toxicity or a new mode of toxic. Nevertheless, 
chromatographic/mass spectrometric techniques remain essential tools in the elucidation 
of TPs due to their superior sensitivity and accuracy. In specific cases, nuclear magnetic 
resonance (NMR) technique is necessary for ultimate identification/confirmation of 
degradation products, however this technique is not yet widely available, requires purified 
samples and its sensitivity is inadequate for environmental levels. Hyphenation of NMR to 
LC instruments is rarely found in environmental laboratories. 
To tackle the lack of spectra libraries and of efficient common strategies for the 
identification of new compounds NORMAN has established a web-based accurate mass 
spectra database for environmental contaminants, named MassBank database, which is 
open for contributions and freely accessible (61). 
In the future, prioritization of the degradation products which merit inclusion in the 
monitoring lists of pollutants is a paramount need, as it is already being attempted for the 
parent emerging pollutants (62). All efforts of environmental science including analytical 
tasks (identification of TPs and occurrence levels), fate and behaviour studies and risk 
assessment should converge to supply the data to turn this goal feasible. A strong 
emphasis on the thorough study of the environmental behaviour of new synthetic 
substances, as required by REACH (Registration, Evaluation, Authorization and 
Restriction of Chemical substances) policy, will alleviate the work load that is left for 
characterizing threats perceived just once they are already established. 
With the aim of anticipating the risk posed by synthetic chemicals, opposite to delayed 
perception of dangerous xenobiotics already widely distributed, the Environmental 
Specimen Banks (ESB) are being regarded as tools for retrospective evaluation of toxic 
substances, eventually degradation products (63).  Studies of the Swedish ESB on archived 
guillemot eggs from the Baltic Sea allowed describing the concentration trends of 
brominated flame retardants and perfluorinated compounds. This ESB are also useful to 
gauge the success of banning uses of chemicals (63). 
As noted in the workshop “Mixtures and metabolites of chemicals of emerging concern” 
organized by NORMAN in Amsterdam, 2009, pesticides and pharmaceuticals degradation 
products still remain the most studied chemicals. Research should be enlarged to other 
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groups. Fatta-Kassinos and Kalavrouziotis (64) highlighted the presence of degradation 
products of xenobiotics as a current concern related to wastewater reuse. 
As an overall conclusion, the study of degradation products requires more clever and 
productive strategies, in order to overcome the challenge of characterizing a massive 
number of possible substances with uncertain human health and environmental relevance.  
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Final Conclusions and Remarks: Work 
Novelty, Knowledge Gaps and Future 
Research  
 
Over the last few decades, the so called “emerging pollutants” have been raising increasing 
awareness, due to their widespread environmental occurrence and many times 
unpredictable (eco)toxicological effects. These pollutants are not necessarily new 
chemicals, but only the development of new highly sensitive analytical tools has enabled 
their detection, in often significantly low concentration levels. Among all emerging 
substances in water, special attention has been given to pharmaceutical products, owe to 
their demonstrated presence and persistence in environmental waters, as well as for the 
potential toxicological effects they may induce on non-target organisms.  
In order to build knowledge on the environmental occurrence and fate of pharmaceutical 
compounds, our work began with the development of a multiresidue analytical method for 
the concurrent determination of 23 pharmaceuticals of diverse chemical nature, among 
the most consumed in Portugal, in wastewater samples. The main overall conclusions 
related to the better performance achieved with Oasis MAX cartridges, when compared to 
all other tested extraction adsorbents (e.g., normal-phase, ion exchange and mixed 
composition), allowing recovery rates generally higher than 60%. Moreover, these 
cartridges allowed the simultaneous extraction and cleanup of the sample, thus 
accelerating the experimental procedure before sample injection into the LC-tandem MS 
system, while reducing the variability of the results.   
In a subsequent work, the developed, optimized and validated method was then applied to 
evaluate the impact caused by the discharge of a municipal WWTP on Febros river, a small 
tributary of Douro river, located in the northern region of Portugal, regarding 
pharmaceutical content only. Febros WWTP implication on the pharmaceutical input to 
Febros river was evidenced by the higher pharmaceutical load in samples collected 
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immediately downstream the WWTP discharge point, when compared to upstream 
sampling sites. Moreover, the performance of the method was assessed through the 
participation in two European level inter-laboratory exercises, promoted by EU-JRC and 
PHARMAS FP7. Most of our results fell in a satisfactory z-score range, which further 
confirmed the reliability of the developed procedure for monitoring pharmaceuticals in 
water samples. 
The limitations of conventional wastewater treatments for the remediation of emerging 
pollutants have potentiated the development and application of advanced 
tertiary/quaternary treatment processes. In this field, special attention has been given to 
Advanced Oxidation Processes, in which hydroxyl radicals (•OH) are the responsible 
agents for the oxidation and mineralization of almost any organic molecule, due to their 
strong unselective oxidative power, yielding CO2 and inorganic ions as final products. 
Therefore, subsequent work approaching the use advanced photodegradation processes 
for the removal of a rather recalcitrant anxiolytic drug – lorazepam, allowed to withdraw 
several conclusions. Firstly, when comparatively evaluating the performance of three 
distinct experimental phototreatment systems, lorazepam highest degradation yield was 
obtained by TiO2-driven photocatalysis, using the solar pilot plant with CPCs (k = 
1.49±0.03 L kJ-1, for 200 mg L-1 TiO2). To the best of our knowledge, never was lorazepam 
studied under accelerated photodegradation treatment processes. In order to provide 
knew information concerning lorazepam degradation mechanism, studies proceeded using 
high-resolution and high accuracy instrumentation, such as UHPLC/QqToF-MS, to allow 
the structural elucidation of lorazepam by-products, according to the concept of 
“diagnostic fragment ions”, besides the acquisition of accurate masses. This work main 
conclusions included the identification of six major lorazepam degradation products, with 
nominal [M+H]+ masses of 337, 303, 319, 275, 291 and 293 Da. Moreover, the proposed 
photodegradation mechanism consisted on the initial opening of the diazepinone seven-
membered ring, followed by a rearrangement into a highly stabilized six-membered 
aromatic ring and subsequent cleavage and/or hydroxylation reactions.  
Since the photocatalytic treatment proved to be quite efficient for lorazepam removal, it 
was further applied to the treatment of a real municipal WWTP effluent, containing 
several other emerging contaminants. Initial effluent physicochemical characterization 
revealed the presence of 22 pharmaceutical compounds in moderate concentrations 
(maximum of 680 ng L-1, except for diclofenac ~24 µg L-1 and hydrochlorothiazide ~3 µg L-
1). A pseudo-first order kinetic model was able to successfully predict all pharmaceuticals’ 
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degradation kinetics, while the overall treatment was considered efficient, with a complete 
removal of the majority of these micropollutants, except for ciprofloxacin (35%), 
ketoprofen (61%) and bisoprolol (77%).  
However, one main issue regarding water treatment processes leading to incomplete 
mineralization of contaminants, is that the resulting intermediate oxidation compounds 
possibly formed may present even more significant toxicity, individually or in more or less 
complex mixtures, than parent compounds themselves. Therefore, it is crucial to always 
support phototreatment processes with solid toxicity results. In our case, an acute toxicity 
test with the species V. fischeri was performed, in order to confirm that the effluent 
toxicity did not increase significantly over the photodegradation process. 
There is still a lot of missing information regarding several aspects of this environmental 
problematic. From occurrence data to fate in the aquatic compartment, from 
contamination prevention strategies to the development of end-of-pipe phototreament 
technology and engineering, several lacunas and doubts have to be first clarified, in order 
reach an agreement on the most efficient strategies to antagonize this increasing pollution 
trend. New legislation including these emerging contaminants must be created, but this 
will only be possible once provided accurate and high quality data, which in turn has to be 
based upon well developed and validated analytical methodologies, always associated to 
high performance instrumentation. 
Studies on identification of degradation products are vital for proper assessment of the 
environmental impact. However, a question remains on how these studies can 
substantially contribute to the understanding of their overall fate under field conditions 
where “cocktail” effects in aqueous environments are much more complex with numerous 
organic and inorganic chemicals, including nutrients and suspended solids interacting 
simultaneously. 
Finally, several exercises have now been running, with the purpose to prioritise the most 
critical questions raised concerning this pollution issue, to aid in the development of 
future research programs on the topic. From specific workshops regarding the 
environmental contamination by pharmaceutical compounds and personal care products, 
the “top 3” of the most relevant questions were as follows: 
1) What approaches should be used to prioritise pharmaceutical compounds and 
personal care products for research on environmental and human health exposure 
and effects? 
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2) What are the environmental exposure pathways for organisms (humans included) 
to pharmaceuticals in the environment, and are any of these missed in current risk 
assessment approaches? 
3) How can the uptake of ionisable pharmaceuticals into aquatic and terrestrial 
organisms and through food chains can be predicted? 
In conclusion, methodologies must be harmonised, strategies must be concerted and 
efforts must be gathered, in order to achieve the common goal of (aquatic) environmental 
pollution containment and future regression. 
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Annex I – NORMAN list of emerging substances (most 
frequently discussed) (latest update approved March 2011) (8) 
List built upon the data collected by NORMAN Associates, after several European surveys. 
Category / class CAS Individual substances 
Algal toxins 
101043-37-2 Microcystin-LR 
111755-37-4 Microcystin-RR 
101064-48-6 Microcystin-YR 
Anticorrosives 
95-14-7 1,2,3-Benzotriazole 
Other 4-/5-Tolyltriazole (TTri) 
29878-31-7 4-Methyl-1H-benzotriazole 
4184-79-6 5,6-Dimethyl-1H-benzotriazole 
136-85-6 5-Methyl-1H-benzotriazole 
302-01-2 Hydrazine 
29385-43-1 Methyl-1H-benzotriazole / Tolyltriazole 
29385-42-1 Methylbenzotriazole 
Antifoaming agents 126-86-3 Surfinol-104 
Antifouling compounds 
1002-53-5 Dibutyl tin ion 
1135-99-5 Diphenyltin ion 
28159-98-0 Irgarol 
78763-54-9 Monobutyl tin ion 
1461-25-2 Tetrabutyl tin ion 
668-34-8 Triphenyltin ion 
Antioxidants 
128-39-2 2,6-Di-tert-butylphenol 
98-54-4 4-tert-Butylphenol 
25013-16-5 BHA 
1948-33-0 BHQ 
128-37-0 BHT 
Biocides 
120-32-1 Chlorophene 
1085-98-9 Dichlofluanide 
01-01-4640 Methyl triclosan 
3380-34-5 Triclosan 
Bio-terrorism / sabotage agents 76-06-2 Chloropicrin 
Complexing agents 
67-43-6 DTPA 
60-00-4 EDTA 
139-13-9 NTA 
10543-57-4 TAED 
Annexes 
212 
 
 
Detergents 
 
 
 
20427-84-3 4-Nonylphenol di-ethoxylate (NPE2O) 
104-35-8 4-Nonylphenol mono-ethoxylate (NPE1O) 
3115-49-9 4-Nonylphenoxy acetic acid (NPE1C) 
Other 
4-Nonylphenoxyethoxy acetic acid 
(NPE2C) 
4-Octylphenol di-ethoxylate (OPE2O) 
2315-67-5 4-Octylphenol mono-ethoxylate (OPE1O) 
15234-85-2 4-Octylphenoxy acetic acid (OPE1C) 
Other 4-Octylphenoxyethoxy acetic acid (OPE2C) 
69669-44-9 C10-C14-LAS 
25155-30-0 C12-LAS 
120-18-3 Naphthalene sulphonic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disinfection by-products 
(drinking water) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1768-31-6 1,1,1,3,3-Pentachloropropanone 
16995-35-0 1,1,1,3-Tetrachloropropanone 
632-21-3 1,1,3,3-Tetrachloropropanone 
921-03-9 1,1,3-Trichloropropanone 
867-54-9 1,1-Dibromopropanone 
534-07-6 1,3-Dichloroketone 
683-72-7 2,2-Dichloroacetamide 
74039-30-8 2,3,5-Tribromopyrrole 
79-07-2 2-Chloroacetamide 
95-57-8 2-Chlorophenol 
106-48-9 4-Chlorophenol 
62872-35-9 Acetamide, 2-chloro-2-iodo- 
590-17-0 Bromoacetonitrile 
98136-99-3 Bromochloroacetaldehyde 
62872-34-8 Bromochloroacetamide 
5589-96-8 Bromochloroacetic acid 
83463-62-1 Bromochloroacetonitrile 
34970-00-8 Bromochloroiodomethane 
74-97-5 Bromochloromethane 
135531-25-8 Bromochloronitromethane 
71133-14-7 Bromodichloroacetic acid 
918-02-5 Bromodichloronitromethane 
557-95-9 Bromodiiodomethane 
62872-36-0 Bromoiodoacetamide 
563-70-2 Bromonitromethane 
107-20-0 Chloroacetaldehyde 
107-14-2 Chloroacetonitrile 
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Disinfection by-products 
(drinking water) 
638-79-9 Chlorodiiodomethane 
1794-84-9 Chloronitromethane 
4471-47-0 Cyanoformaldehyde 
84852-53-9 Decabromodiphenyl ethane 
598-70-9 Dibromoacetamide 
3252-43-5 Dibromoacetonitrile 
5278-95-5 Dibromochloroacetic acid 
1184-89-0 Dibromochloronitromethane 
594-18-3 Dibromodichloromethane 
593-94-2 Dibromoiodomethane 
74-95-3 Dibromomethane 
598-91-4 Dibromonitromethane 
79-02-7 Dichloroacetaldehyde 
3018-12-0 Dichloroacetonitrile 
594-04-7 Dichloroiodomethane 
7119-89-3 Dichloronitromethane 
5875-23-0 Diiodoacetamide 
25637-99-4 Hexabromocyclododecane (HBCD) 
116-16-5 Hexachloropropanone 
144-48-9 Iodoacetamide 
64-69-7 Iodoacetic acid 
624-75-9 Iodoacetonitrile 
75-47-8 Iodoform 
87-56-9 Mucochloric acid 
77439-76-0 Mutagen X (MX) 
79-15-2 N-Bromoacetamide 
924-16-3 NDBA 
62-75-9 NDMA 
59-89-2 NMOR 
55-18-5 N-nitrosodiethylamine (NDEA) 
86-30-6 N-Nitrosodiphenylamine (NDPA) 
10595-95-6 N-nitrosomethylethylamine (NMEA) 
100-75-4 N-Nitrosopiperidine (NPIP) 
930-55-2 N-Nitrosopyrrolidine (NPYR) 
115-17-3 Tribromoacetaldehyde 
594-47-8 Tribromoacetamide 
75-96-7 Tribromoacetic acid 
464-10-8 Tribromonitromethane 
594-65-0 Trichloroacetamide 
545-06-2 Trichloroacetonitrile 
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Drugs of abuse 
50-36-2 Cocaine 
125-28-0 Dihydrocodeine 
561-27-3 Heroin 
57-27-2 Morphine 
76-42-6 Oxycodone 
Flame retardants 
3194-55-6 1,2,5,6,9,10-Hexabromocyclododecane (HBCD) (5 isomers - alpha to epsilon) 
1163-19-5 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 
207122-16-5 2,2',3,4,4',5',6-Heptabromodiphenyl ether (BDE-183) 
68631-49-2 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 
207122-15-4 2,2',4,4',5,6'-Hexabromodiphenyl ether (BDE-154) 
5436-43-1 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 
Other 
Long chain polychlorinated alkanes (l-
PCAs, C>17) 
Medium chain polychlorinated alkanes 
(m-PCAs, C14-17) 
32536-52-0 Technical octabromodiphenyl ether 
Other Technical polychlorinated alkanes products 
79-94-7 Tetrabromo bisphenol A (TBBPA) 
21850-44-2 Tetrabromo bisphenol A bis (2,3 dibromopropylether) 
13674-87-8 Tri-(dichlorisopropyl)phosphate 
78-40-0 Triethylphosphate 
126-73-8 Tri-n-butylphosphate 
115-86-6 Triphenylphosphate 
115-96-8 Tris(2-chloroethyl)phosphate 
78-42-2 Tris(2-ethylhexyl)phosphoric acid 
78-43-3 Tris(dichloropropyl)phosphate 
Food additives 
56038-13-2 Sucralose 
102-76-1 Triacetin 
77-93-0 Triethylcitrate 
 
Fragrances 
 
 
4455-13-4 2-Ethylthioacetic acid ethylester 
67-71-0 2-Methylthioacetic acid ethylester 
646-01-5 3-Methylthiopropionic acid 
32388-55-9 Acetylcedrene 
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Fragrances 
13171-00-1 ADBI (Celestolide) 
15323-35-0 AHDI (Phantolide) 
1506-02-1 AHTN (Tonalide) 
68140-48-7 ATII (Traseolide) 
140-11-4 Benzylacetate 
118-58-1 Benzylsalicylate 
76-22-2 Camphor 
106-02-5 Cyclopentadecanolide 
6028-61-1 Dipropyltrisulfide 
5989-27-5 d-Limonene 
105-95-3 Ethylene brassylate 
1222-05-5 Galaxolide 
127-51-5 g-Methylionone 
34902-57-3 Habanolide 
101-86-0 Hexylcinnamaldehyde 
124-76-5 Isoborneol 
125-12-2 Isobornylacetate 
119-65-3 Isoquinoline 
24851-98-7 Methyldihydrojasmonate 
119-36-8 Methylsalicylate 
83-66-9 Musk ambrette 
81-14-1 Musk ketone 
81-15-2 Musk xylene 
54464-57-2 OTNE 
80-54-6 p-t-Bucinal (Lilial) 
98-55-5 Terpineol 
Gasoline additives 1634-04-4 Methyl-tert-butyl ether (MTBE) 
 
 
 
 
 
 
 
Industrial chemicals 
 
 
 
 
 
 
 
 
79-00-5 1,1,2-Trichloroethane 
75321-20-9 1,3-Dinitropyrene 
42397-64-8 1,6-Dinitropyrene 
42397-65-9 1,8-Dinitropyrene 
17164-77-1 2-(2-Naphthalenyl)benzothiophene 
149-30-4 2-Mercapto-benzothiazole 
108-42-9 3-Chloroaniline 
106-47-8 4-Chloroaniline 
17117-34-9 4-Nitrobenzanthrone 
75-07-0 Acetaldehyde 
62-53-3 Aniline 
82-05-3 Benzanthrone 
98-10-2 Benzenesulfonamide 
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Industrial chemicals 
56-55-3 Benzo(a)anthracene 
941-57-1 Benzothiazol-2-sulfonic acid 
95-16-9 Benzothiazole 
92-52-4 Biphenyl 
101-83-7 Dicyclohexylamin (DCHA) 
122-39-4 Diphenylamine 
78-51-3 Ethanol, 2-butoxy-, phosphate (3:1) 
50-00-0 Formaldehyde 
68002-20-0 Hexa(methoxymethyl)melamine 
2082-79-3 Irganox 1076 
100-61-8 N-methyl-Aniline 
90-30-2 N-phenyl-naphthylamine 
1336-36-3 Polychlorinated biphenyls (PCBs) - Total 
100-42-5 Styrene 
51805-45-9 TCEP 
56-23-5 Tetrachloromethane 
108-88-3 Toluene 
791-28-6 Triphenyl phosphine oxide 
13674-84-5 Tris(2chloroisopropyl)phosphate (TCPP) 
1330-20-7 Xylene 
 
 
 
 
 
 
 
 
 
 
 
Nanoparticles 
 
 
 
 
 
 
 
 
 
 
 
 
7429-90-5 
Aluminium fiber (nanoparticles) 
Aluminium metal (nanoparticles) 
1344-28-1 Aluminium oxide (powder) (nanoparticles) 
99685-96-8 Buckyballs (Fullerene C-60) 
115383-22-7 Buckyballs (Fullerene C-70) 
1317-65-3 Calcium carbonate (nanoparticles) 
1344-95-2 Calcium silicate (nanoparticles) 
1333-86-4 Carbon black (nanoparticles) 
308068-56-6 / 
308068-63-0 
Carbon nanotubes - coated 
Carbon nanotubes - multi-wall 
Carbon nanotubes - single-wall 
9004-34-6 Cellulose (nanoparticles) 
7440-50-8 Copper (nanoparticles) 
1302-74-5 Emery (nanoparticles) 
60676-86-0 Fused silica (nanoparticles) 
10101-41-4 Gypsum (nanoparticles) 
1317-65-3 Limestone (nanoparticles) 
546-93-0 Magnesite (nanoparticles) 
1309-48-4 Magnesium oxide (nanoparticles) 
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Nanoparticles 
1317-65-3 Marble (nanoparticles) 
12001-26-2 Mica (nanoparticles) 
17069-72-6 Silica (crystalline) (nanoparticles) 
7631-86-9 Silica (SiO2 amorphous) (nanoparticles) 
7440-21-3 Silicon (nanoparticles) 
409-21-2 Silicon carbide (nanoparticles) 
13463-67-7 Titanium dioxide (nanoparticles) 
557-05-1 Zinc distearate (nanoparticles) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1634-36-2 (1-Hydroxy-iso-propyl)acetophenone 
619-33-0 1,1-Dichloro-2,2-diethoxyethane 
151-05-3 1,1-Dimethyl-2-phenethylacetate 
96-19-5 1,2,3-Trichloropropene (TRCP) 
4773-83-5 1,2,3-Trimethyl-1H-indene 
118-12-7 1,3,3-Trimethyl-2-oxoindol 
1014-60-4 1,3-Bis(1,1-dimethylethyl)-benzene 
793-23-7 1,4-Bis(phenylmethyl) benzene 
106-46-7 1,4-Dichlorobenzene 
112-30-1 1-Decanol 
8047-67-4 1H-Indole 
111-87-5 1-Octanol 
3910-35-8 1-Phenyl-1,3,3-trimethylindane 
615-22-5 2-(Methylthio)benzothiazol 
85688-81-9 2,3-Diethyl-2,3-dimethylsuccinonitrile 
61-70-1 2,3-Dihydro-1-methyl-1H-indol 
607-99-8 2,4,6-Tribromoanisole 
118-79-6 2,4,6-Tribromophenol 
21702-84-1 2,4-Dibromoanisole 
615-58-7 2,4-Dibromophenol 
120-83-2 2,4-Dichlorophenol 
3149-12-0 2,6-Diethoxytetrahydropyran 
10396-80-2 2,6-Di-tert-butyl-4-hydroxy-4-methyl-2,5-cyclohexadien-1-one 
719-22-2 2,6-Di-tert-butylquinone 
71758-44-6 2-[(2-Chlorophenyl)amino]benzaldehyde 
704-00-7 2-Acetylacetophenone 
95-56-7 2-Bromophenol 
100-86-7 2-Methyl-1-phenylpropan-2-ol 
2444-37-3 2-Methylthioacetic acid 
88-75-5 2-Nitrophenol 
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Other 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1929-29-9 3-(Bromo-4-methoxyphenyl)propionic acid 
14035-33-7 3,5-Di-tert-butyl-4-hydroxyacetophenone 
3964-56-5 4-Bromo-2-chlorophenol 
104-92-7 4-Bromoanisole 
106-41-2 4-Bromophenol 
445-03-4 4-Chloro-2-(trifluoromethyl)aniline 
06-04-5359 4-iso-Propenylacetophenone 
645-13-6 4-iso-Propylacetophenone 
832-64-4 4-Methyl-phenanthrene 
98-52-2 4-tert-Butylcyclohexanol (2 isomers) 
98-53-3 4-tert-Butylcyclohexanone (2 isomers) 
2719-62-2 6-Phenyldodecane 
82304-66-3 7,9-Di-tert-butyl-1-oxaspiro(4,5)deca-6,9-diene-2,8-dione 
4273-98-7 Aminodiphenylsulfone 
18339-16-7 Androstenone 
84-65-1 Anthrachinone 
54460-96-7 Bis(chloropropyl)ethers 
91-22-5 Chinoline 
91-19-0 Chinoxaline 
14866-68-3 Chlorate 
88-04-0 Chlorodimethylphenol (Chloroxylenol) 
7205-98-3 Chloromethylphenylsulfone 
25167-93-5 Chloronitrobenzene (2 isomers) 
486-56-6 Cotinine 
57-12-5 Cyanides 
506-77-4 Cyanogen chloride 
3173-53-3 Cyclohexylisocyanate 
91-17-8 Decahydronaphtalene (Dekalin) 
608-27-5 Dichloroaniline 
133-53-9 Dichlorodimethylphenol (2,4-Dichloro-meta-xylenol) 
4253-89-8 Di-iso-propyldisulfide 
2078-54-8 Di-iso-propylphenol 
2591-86-8 Formylpiperidine 
74-90-8 Hydrogen cyanide 
28179-44-4 Ioxithalamique acid 
108-62-3 Metaldehyde 
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Other 
529-19-1 Methylbenzonitrile 
614-68-6 Methylphenylisocyanate 
3112-85-4 Methylphenylsulfone 
761-65-9 N,N-Dibutylformamide 
686-07-7 N,N-Diethyldithiocarbamic acid methyl ester 
85-98-3 N,N'-Diethyl-N,N'-diphenylurea 
4128-37-4 N,N'-Di-iso-propylurea 
1696-20-4 N-Acetylmorpholine 
103-69-5 N-Ethylaniline 
5022-29-7 N-Ethylphthalimide 
26914-52-3 N-Ethyltoluenesulfonamide 
4394-85-8 N-Formylmorpholine 
98-95-3 Nitrobenzene 
1678-25-7 N-Phenylbenzenesulfonamide 
1087-02-1 p-Dicyclohexylbenzene 
127-18-4 Perchloroethylene 
85-01-8 Phenanthrene 
103-71-9 Phenylisocyanate 
529-34-0 Tetralinone 
7695-91-2 Tocopherolacetate 
634-67-3 Trichloroaniline 
13463-41-7 Zincpyrithione 
 
 
 
 
 
 
 
 
 
 
 
Perfluoroalkylated substances 
and their transformation 
products 
 
 
 
 
 
865-86-1 10:2 FTOH 
39239-77-5 12:2 FTOH 
1691-99-2 2-(N-ethylperfluorooctanesulfonamido)-ethyl alcohol (N-Et-FOSE) 
24448-09-7 
2-(N-
methylperfluorooctanesulfonamido)-
ethyl alcohol (N-Me-FOSE) 
2043-47-2 4:2 FTOH 
425670-75-3 6:2 Fluorotelomer sulfonate (6:2 FTS) 
647-42-7 6:2 FTOH 
678-39-7 8:2 FTOH 
4151-50-2 N-ethylperfluorooctanesulfonamide (N-EtFOSA) 
31506-32-8 N-methylperfluorooctanesulfonamide (N-MeFOSA) 
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Perfluoroalkylated substances 
and their transformation 
products 
25268-77-3 
N-
methylperfluorooctanesulfonamidoethyl 
acrylate (N-MeFOSEA) 
29420-49-3 Perfluorobutanesulfonate anion (PFBS) 
335-77-3 Perfluorodecane sulfonate (PFDS) 
335-76-2 Perfluorodecanoic acid (PFDA) 
307-55-1 Perfluorododecanoic acid (PFDoA) 
375-85-9 Perfluoroheptanoic acid (PFHpA) 
432-50-7 Perfluorohexane sulfonate (PFHS) 
307-24-4 Perfluorohexanoic acid (PFHxA) 
375-95-1 Perfluorononanoic acid (PFNA) 
2058-94-8 Perfluoro-n-undecanoic acid (PFUnA) 
754-91-6 Perfluorooctane sulfonamide (PFOSA) 
1763-23-1 Perfluorooctane sulfonate (PFOS) 
45298-90-6 Perfluorooctane sulfonate (PFOS) - anion 
307-35-7 Perfluorooctanesulfonyl fluoride (POSF) 
335-67-1 Perfluorooctanoic acid (PFOA) 
376-06-7 Perfluorotetradecanoic acid (PFTDA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Personal care products 
 
 
 
 
 
 
 
 
36861-47-9 4-Methylbenzylidene camphor 
1125-21-9 4-Oxoisophorone 
658051-75-3 Bayrepel 
119-61-9 Benzophenone 
87075-14-7 Butyl methoxydibenzoylmethane 
8024-53-1 Cineole 
23726-91-2 Damascone 
541-02-6 Decamethylcyclopentasiloxane (D5) 
141-62-8 Decamethyltetrasiloxane (MD2M) 
37172-53-5 Dihydromethyljasmonate 
540-97-6 Dodecamethylcyclohexasiloxane (D6) 
141-63-9 Dodecamethylpentasiloxane (MD3M) 
2400-22-4 Drometrizole 
155633-54-8 Drometrizole trisiloxane (INCI) 
5466-77-3 Ethylhexyl methoxycinnamate 
120-47-8 Ethyl-paraben 
588-68-1 Eusolex 
107-46-0 Hexamethyldisiloxane (HM or HMDS) 
118-56-9 Homosalate 
03-02-4247 Isobutyl-paraben 
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Personal care products 
 
 
6485-40-1 Methyl-iso-propylcyclohexenone, Carvone 
99-76-3 Methyl-paraben 
134-62-3 N,N-Diethyltoluamide (DEET) 
556-67-2 Octamethylcyclotetrasiloxane (D4) 
107-51-7 Octamethyltrisiloxane (MDM) 
80135-31-5 Octocrylene 
84-15-1 o-Terphenyl 
131-57-7 Oxybenzone 
94-13-3 Propyl-paraben 
92-94-4 p-Terphenyl 
101-48-4 Viridine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pesticides 
 
 
 
 
 
 
 
 
 
 
 
 
 
542-75-6 1,3-Dichloropropene 
58-90-2 2,3,4,6-Tetrachlorophenol 
94-75-7 2,4 D 
95-95-4 2,4,5-Trichlorophenol 
87-40-1 2,4,6-Trichloroanisole 
88-06-2 2,4,6-Trichlorophenol 
553-82-2 2,4-Dichloroanisole 
1984-65-2 2,6-Dichloroanisole 
934-32-7 2-Aminobenzimidazole 
578-57-4 2-Bromoanisole 
84-54-8 2-Methylanthraquinone 
83-05-6 4,4?-DDA 
2642-80-0 4,4?-DDMS 
530-48-3 4,4?-DDNU 
95975-55-6 4,4?-DDOH 
74070-46-5 Aclonifen 
116-06-3 Aldicarb 
1646-88-4 Aldicarb sulfone 
834-12-8 Ametryn 
1066-51-9 Amino Methyl Phosphoric Acid (AMPA) 
61-82-5 Amitrole 
2642-71-9 Azinphos-ethyl 
25057-89-0 Bentazone 
42576-02-3 Bifenox 
314-40-9 Bromacil 
4824-78-6 Bromofos-ethyl 
1689-99-2 Bromoxynil octanoate 
63-25-2 Carbaryl 
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Pesticides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86-74-8 Carbazole 
10605-21-7 Carbendazim 
5234-68-4 Carboxin 
1698-60-8 Chloridazon 
1897-45-6 Chlorothalonil 
15545-48-9 Chlorotoluron 
1982-47-4 Chloroxuron 
101-21-3 Chlorpropham 
5598-13-0 Chlorpyriphos methyl 
1861-32-1 Chlorthal-dimethyl 
1702-17-6 Clopyralid 
21725-46-2 Cyanazine 
36576-43-9 Cyanazine acid 
52315-07-8 Cypermethrin 
90-98-2 DBP 
62-73-7 d-Dichlorvos 
52918-63-5 Deltamethrin 
6190-65-4 Desethylatrazine 
30125-63-4 Desethylterbutylazine 
1007-28-9 Desisopropylatrazine 
13684-56-5 Desmedipham 
1014-69-3 Desmetryn 
333-41-5 Diazinon 
1918-00-9 Dicamba 
1194-65-6 Diclobenil 
115-32-2 Dicofol 
83164-33-4 Diflufenican 
108-18-9 Diisopropylamine 
87674-68-8 Dimethenamid 
60-51-5 Dimethoat 
1420-07-1 Dinoterb 
563-12-2 Echio 
1031-07-8 Endosulfan-sulfate 
26225-79-6 Ethofumesate 
13194-48-4 Ethoprophos 
60168-88-9 Fenarimol 
55-38-9 Fenthion 
142459-58-3 Flufenacet 
69377-81-7 Fluroxypyr 
85509-19-9 Flusilazole 
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Pesticides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76674-21-0 Flutriafol 
65907-30-4 Furathiocarb 
1071-83-6 Glyphosate 
76-44-8 Heptachlor 
1024-57-3 Heptachlor epoxide 
23560-59-0 Heptenophos 
51235-04-2 Hexazinone 
138261-41-3 Imidacloprid 
18181-70-9 Iodofenphos 
330-55-2 Linuron 
121-75-5 Malathion 
94-74-6 MCPA 
94-81-5 MCPB 
93-65-2 MCPP (Mecoprop) 
16484-77-8 Mecoprop-P 
57837-19-1 Metalaxyl 
41394-05-2 Metamitron 
67129-08-2 Metazachlor 
2032-65-7 Methiocarb 
01-10-2635 Methiocarb sulfoxide 
16752-77-5 Methomyl 
72-43-5 Methoxychlor 
51218-45-2 Metolachlor 
19937-59-8 Metoxuron 
7786-34-7 Mevinphos 
96180-79-9 Microcystin-LA / Cyanoginosin-LA 
2212-67-1 Molinate 
825629-31-0 N-Ethyl-2-tolylsulfonamide 
53-19-0 o,p'-Dichlorodiphenyldichloroethane (o,p'-DDD) 
1113-02-6 Omethoate 
34622-58-7 Orbencarb 
19666-30-9 Oxadiazon 
77732-09-3 Oxadixyl 
76738-62-0 Paclobutrazol 
56-38-2 Parathion ethyl 
298-00-0 Parathion methyl 
40487-42-1 Pendimethalin 
52645-53-1 Permethrin 
13684-63-4 Phenmedipham 
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Pesticides 
14816-18-3 Phoxim 
29232-93-7 Pirimiphos methyl 
67747-09-5 Prochloraz 
1610-18-0 Prometon 
7287-19-6 Prometryn 
1918-16-7 Propachlor 
709-98-8 Propanil 
139-40-2 Propazine 
60207-90-1 Propiconazole 
23950-58-5 Propyzamide 
90717-03-6 Quinmerac 
124495-18-7 Quinoxyfen 
26259-45-0 Secbumeton 
35507-37-0 Sulfonyl urea 
886-50-0 Terbutryn 
5915-41-3 Terbutylazine 
148-79-8 Thiabendazole 
59669-26-0 Thiodicarb 
57018-04-9 Tolclofos methyl 
731-27-1 Tolylfluanid 
43121-43-3 Triadimefon 
2303-17-5 Tri-allate 
52-68-6 Trichlorfon 
101-20-2 Triclocarban 
 
 
 
 
 
 
 
 
 
Pharmaceuticals 
 
 
 
 
 
 
 
 
 
123050-98-6 (R)-O-Desmethyl Naproxen 
57-91-0 17-alpha-Estradiol 
57-63-6 17-alpha-Ethinylestradiol 
50-28-2 17-beta-Estradiol 
37517-30-9 Acebutolol 
77-66-7 Acecarbromal 
89796-99-6 Aceclofenac 
53164-05-9 Acemetacin 
103-90-2 Acetaminophen (paracetamol) 
59-66-5 Acetazolamide 
50-78-2 Acetylsalicylic acid (aspirin) 
59277-89-3 Acyclovir 
18559-94-9 Albuterol 
51022-70-9 Albuterol sulfate 
22131-79-9 Alclofenac 
52-43-7 Allobarbital 
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Pharmaceuticals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28981-97-7 Alprazolam 
50-48-6 Amitryptiline 
57-43-2 Amobarbital 
26787-78-0 Amoxicillin 
69-53-4 Ampicillin 
635-12-1 Anthracen-1,4-dione 
37321-09-8 Apramycin 
77-02-1 Aprobarbital 
29122-68-7 Atenolol 
83905-01-5 Azithromycin 
1134-47-0 Baclofen 
102280-35-3 Baquiloprim 
378-44-9 Betamethasone 
83-46-5 Beta-sitosterol 
63659-18-7 Betaxolol 
41859-67-0 Bezafibrate 
66722-44-9 Bisoprolol 
1812-30-2 Bromazepam 
77-26-9 Butalbital 
58-08-2 Caffeine 
57775-29-8 Carazolol 
298-46-4 Carbamazepine 
10206-21-0 Cefacetrile 
15686-71-2 Cefalexin 
5575-21-3 Cefalonium 
21593-23-7 Cefapirin 
25953-19-9 Cefazolin 
62893-19-0 Cefoperazone 
302-17-0 Chloral hydrate 
56-75-7 Chloramphenicol 
57-15-8 Chlorobutanol 
57-62-5 Chlortetracycline 
57-88-5 Cholesterol 
85721-33-1 Ciprofloxacin 
59729-32-7 Citalopram 
81103-11-9 Clarithromycin 
37148-27-9 Clenbuterol 
882-09-7 Clofibric acid 
23593-75-1 Clotrimazole 
7081-44-9 Cloxacillin 
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Pharmaceuticals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76-57-3 Codeine 
8064-90-2 Cotrimoxazole 
483-63-6 Crotamiton 
50-18-0 Cyclophosphamide 
75526-90-8 Cyclophosphamide (anhydrous form) 
112398-08-0 Danofloxacin 
7261-97-4 Dantrolene 
80-08-0 Dapsone 
20830-81-3 Daunorubicin 
50-02-2 Dexamethasone 
117-96-4 Diatrizoate 
439-14-5 Diazepam 
15307-86-5 Diclofenac 
3116-76-5 Dicloxacillin 
56-53-1 Diethylstilbestrol 
98106-17-3 Difloxacin 
88637-37-0 Diphenhydramine 
57808-66-9 Domperidone 
1668-19-5 Doxepine 
25316-40-9 Doxorubicin 
94088-85-4 Doxycycline (anhydrous) 
564-25-0 Doxycycline (monohydrate) 
74011-58-8 Enoxacin 
93106-60-6 Enrofloxacin 
56420-45-2 Epirubicin 
114-07-8 Erythromycin 
128196-01-0 Escitalopram 
119141-88-7 Esomeprazole 
50-27-1 Estriol 
53-16-7 Estrone 
481-97-0 Estrone sulphate 
77-67-8 Ethosuximide 
56775-91-8 Etofibrate 
76824-35-6 Famotidine 
458-24-2 Fenfluramine 
49562-28-9 Fenofibrate 
26129-32-8 Fenofibric acid 
31879-05-7 Fenoprofen 
53746-45-5 Fenoprofen calcium salt dihydrate 
03-12-1944 Fenoterol 
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Pharmaceuticals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5250-39-5 Flucloxacillin 
42835-25-6 Flumequine 
51-21-8 Fluorouracil 
54910-89-3 Fluoxetine 
54739-18-3 Fluvoxamine 
54-31-9 Furosemide 
25812-30-0 Gemfibrozil 
1403-66-3 Gentamicin 
10238-21-8 Glyburide (glibenclamid; glybenzcyclamide) 
56-29-1 Hexobarbital 
58-93-5 Hydrochlorothiazide 
125-29-1 Hydrocodone 
15687-27-1 Ibuprofen 
53949-53-4 Ibuprofen 1-hydroxy 
51146-55-5 Ibuprofen 2-hydroxy 
3778-73-2 Ifosfamide 
50-49-7 Imapramine 
256-96-2 Iminostilbene 
53-86-1 Indomethacin 
66108-95-0 Iohexol 
78649-41-9 Iomeprol 
60166-93-0 Iopamidol 
73334-07-3 Iopromide 
70288-86-7 Ivermectin 
16846-24-5 Josamycin 
08-07-8063 Kanamycin sulfate 
22071-15-4 Ketoprofen 
84057-84-1 Lamotrigine 
103577-45-3 Lansoprazole 
102767-28-2 Levetiracetam 
137-58-6 Lidocaine 
859-18-7 Lincomycin 
554-13-2 Lithium carbonate 
79794-75-5 Loratadine 
846-49-1 Lorazepam 
75330-75-5 Lovastatin 
115550-35-1 Marbofloxacin 
07-06-3625 Mebeverine 
644-62-2 Meclofenamic acid 
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06-12-2898 Medazepam 
61-68-7 Mefenamic acid 
57-53-4 Meprobamate 
72-33-3 Mestranol 
657-24-9 Metformin 
61-32-5 Methicillin 
115-38-8 Methylphenobarbital 
37350-58-6 Metoprolol 
73573-88-3 Mevastatin 
13614-98-7 Minocycline 
42200-33-9 Nadolol 
985-16-0 Nafcillin 
434-22-0 Nandrolone 
22204-53-1 Naproxen 
1404-04-2 Neomycin B 
7298-73-9 N-Methylphenacetine 
1088-11-5 Nordiazepam 
70458-96-7 Norfloxacin 
1476-53-5 Novobiocin 
82419-36-1 Ofloxacin 
3922-90-5 Oleandomycin 
73590-58-6 Omeprazole 
66-79-5 Oxacillin 
14698-29-4 Oxalinic acid 
604-75-1 Oxazepam 
6452-71-7 Oxprenolol 
79-57-2 Oxytetracycline 
61869-08-7 Paroxetine 
61-33-6 Penicillin G 
87-08-1 Penicillin V 
76-74-4 Pentobarbital 
06-05-6493 Pentoxifylline 
60-80-0 Phenazone 
50-06-6 Phenobarbital 
50-33-9 Phenylbutazone 
57-41-0 Phenytoine 
13523-86-9 Pindolol 
1893-33-0 Pipamperon 
81093-37-0 Pravastatin 
50-24-8 Prednisolone 
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125-33-7 Primidone 
525-66-6 Propranolol 
479-92-5 Propyphenazone 
66357-35-5 Ranitidine 
80214-83-1 Roxithromycin 
35763-26-9 Salbutamol 
98105-99-8 Sarafloxacin 
76-73-3 Secobarbital 
309-43-3 Secobarbital sodium 
79617-96-2 Sertraline 
79902-63-9 Simvastatin 
3930-20-9 Sotalol 
1695-77-8 Spectinomycin 
8025-81-8 Spiramycin 
57-92-1 Streptomycin 
68-35-9 Sulfadiazine 
122-11-2 Sulfadimethoxine 
2447-57-6 Sulfadoxine 
127-79-7 Sulfamerazine 
57-68-1 Sulfamethazine 
723-46-6 Sulfamethoxazole 
144-83-2 Sulfapyridine 
25451-15-4 Taloxa 
846-50-4 Temazepam 
23031-25-6 Terbutaline 
60-54-8 Tetracycline 
55297-95-5 Tiamulin 
108050-54-0 Tilmicosin 
91524-16-2 Timolol 
13710-19-5 Tolfenamic acid 
27203-92-5 Tramadol 
738-70-5 Trimethoprime 
1401-69-0 Tylosin 
101312-92-9 Valnemulin 
99-66-1 Valproic acid 
52-53-9 Verapamil 
82626-48-0 Zolpidem 
 
Plasticizers 
 
131-56-6 2,4-Dihydroxybenzophenone 
7425-14-1 2-Ethylhexanoic acid 2-ethylhexyl ester 
85-68-7 Benzylbutylphthalate (BBP) 
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Plasticizers 
80-05-7 Bisphenol A 
84-66-2 Diethylphthalate (DEP) 
68515-49-1, 
26761-40-0 Di-isodecyl-phthalate (DIDP) 
68515-48-0, 
28553-12-0 Di-isononyl-phthalate (DINP) 
131-11-3 Dimetylphthalate (DMP) 
84-74-2 Di-n-butylphthalate (DBP) 
117-84-0 Di-n-octylphthalate (DOP) 
38640-62-9 DIPN 
947-19-3 Methanone, Irgacure 184 
3622-84-2 NBBS 
872-50-4 NMP 
77-90-7 Tributylacetylcitrate 
126-71-6 Tri-iso-butylphosphate (TIBP) 
6846-50-0 TXIB 
Trace metals and their 
compounds 
7440-38-2 Arsenic 
7440-47-3 Chromium 
7440-50-8 Copper 
03-05-7440 Palladium 
12595-26-5 Silver 
74-00-2 Tetraethyllead 
75-74-1 Tetramethyllead 
7440-66-6 Zinc 
Wood preservatives 
51-28-5 2,4-Dinitrophenol (DNP) 
106-44-5 para-Cresol 
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Analysis of acidic, basic and neutral pharmaceuticals in river waters:
clean-up by 1, 2 amino anion exchange and enrichment using an
hydrophilic adsorbent
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A fast and sensitive LC-MS/MS method suitable to monitor a set of 24
pharmaceuticals belonging to 9 therapeutical families was developed using an
analytical column of reduced dimensions and an appropriate SPE procedure for
acidic, basic and neutral analytes. Furthermore, a preliminary assessment of the
occurrence and levels of these substances in surface waters of the Lec¸a and Douro
rivers, located in the north of Portugal, was conducted. Among 17 different SPE
adsorbents tested, some of them often neglected, the JTBaker H2Ophilic provided
the best recoveries (average 86%). When compared to the amino and quaternary
ammonium adsorbents, the 1, 2 amino proved the most suitable clean-up media
for surface water samples prior to enrichment by SPE. The overall method
provided limits of detection generally below 5ngLÿ1 and a precision below or
around 10% RSD in three non-consecutive days at 500 ngLÿ1 and around 12% at
50 ngLÿ1 concentration levels. The confirmatory capabilities of the method
developed are especially welcome either through the MS3 spectra or the isotopic
pattern.
The first known results regarding the occurrence of pharmaceuticals in Lec¸a
river confirmed its expected high contamination load and the successful selection
of the target pharmaceuticals. Concentrations up to 770 ngLÿ1 of bezafibrate,
925 ngLÿ1 of paracetamol, 389 ngLÿ1 of hydrochlorothiazide and 283 ngLÿ1 of
furosemide were measured. The most ubiquitous in both seasons, February and
June 2009, were bisoprolol, furosemide, bezafibrate and gemfibrozil. In Douro
river the abundance and contamination level of pharmaceuticals was much lower
which gives a clear indication that the hydraulic features of the river provide
enough attenuation of the several contamination sources whereas Lec¸a is highly
impacted by insufficiently treated anthropogenic effluents.
Keywords: pharmaceuticals; surface water; LC-MS/MS; hydrophilic SPE; anion
exchange clean-up; Lec¸a and Douro rivers
1. Introduction
A number of studies beginning in the 1990s have reported the presence of pharmaceuticals
in surface water, groundwater and drinking water in concentrations ranging from a
*Corresponding author. Email: mfalpendurada@iaren.pt
Intern. J. Environ. Anal. Chem., 2013
Vol. 93, No. 1, 1–22, http://dx.doi.org/10.1080/03067319.2012.702272
© 2013 Taylor & Francis
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few ngLÿ1 to tens of mgLÿ1 [1–4]. Generally, these pollutants are amenable to biotic and/
or abiotic degradation; however, the world-wide dissemination and frequent release
sources, which often exceed their degradation rate, turn them into pseudo-persistent
pollutants [5,6]. The most important entry sources in the environment are household
residues, waste water treatment plants (WWTPs), hospitals, industrial units, land
application of biosolids and intensive animal-breeding farms [6–11].
The presence of pharmaceuticals in the environment raises particular awareness since
they are bioactive substances produced to modulate the functioning of vital organs and
systems in living organisms [7]. Therefore the growth, physiology and reproduction of
exposed individuals may be impaired. Among the best characterized detrimental effects
of this sort are the disruption of the endocrine system in wildfowl originated by estrogens
and a wide range of other chemicals (pesticides, phthalates, alkyphenols, fragrances, etc.)
and the selection of multi-resistant strains of pathogenic microorganisms that results
from uncontrolled use of biocides (antibiotics and antivirals) and deficient treatment
of anthropogenic effluents [12–15]. Nonetheless, pollution by cocktails of parent substances,
metabolites and degradation products is even more worrying than pharmaceuticals
considered individually because mixture toxicity effects are virtually unforeseeable [5].
Often, pharmaceuticals are found in surface waters with higher frequency and
concentration levels than other recognized priority pollutants (see data in [16]). Besides, in
the preparatory stage of Directive 2008/105/EC several pharmaceuticals were subject to
review for the identification as priority substances (carbamazepine, clotrimazole,
diclofenac, amidotrizoate and lopamidol) and currently an Impact Assessment of the
Review of the Priority Substances list including diclofenac, ibuprofen, 17 --ethinylestra-
diol and 17 --estradiol is ongoing [17].
Against this background, research is urgently needed to build up knowledge on the
occurrence of pharmaceuticals as well as for monitoring of the removal, partition and
ultimate fate of these pollutants in the environment allowing to uncover their potential
ecotoxicological and human health impact [1,5,18]. Reliable, high throughput and
multiresidue analytical methods based on powerful equipments (namely liquid chromato-
graphy-tandem mass spectrometry (LC-MS/MS) and efficient enrichment materials for
pharmaceuticals in water (such as hydrophilic polymeric adsorbents) are indispensable
tools to this aim [1–3,12,13]. Furthermore, pharmaceuticals, in particular, are char-
acterised by ranging from acidic (carboxylic acids, e.g. bezafibrate, diclofenac) to basic
(secondary amines e.g. bisoprolol, paroxetine), therefore inclusive methodologies yet
selective against interferences must be developed to analyse the most environmentally
relevant pharmaceuticals.
The challenge of managing conflictive properties embraces not only the sample
pre-treatment protocol (extraction and clean-up), considered the bottleneck step, but also
separation, ionization and detection [16]. Solid-phase extraction (SPE) is particularly well
adapted to multi-residue analysis, because of the great variety of sorbents available, their
larger capacity as compared to microextraction techniques, moderate consumption of
organic solvents and easy automation [18]. Hypercrosslinking, functionalization and
copolymerisation of styrene-divinylbenzene materials have been exploited to improve the
extraction of polar analytes along with a few novel polymers [19,20]. A definitive trial
including the largest array of adsorbents ever tested (seventeen, some of them often
neglected) for the extraction of acidic, neutral and basic pharmaceuticals from water was
2 C.M.O. Gonc¸alves et al.
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undertaken in this work. The following adsorbents were tested, among others: Abselut
Nexus, Chromabond Easy, Bakerbond H2Ophilic, StrataX, Evolute ABN and
Resprep RDX.
The clean-up procedure constitutes a critical step for the accurate determination of
pharmaceuticals and has been addressed by some authors to tackle matrix effects [6,8].
A previous work where a systematic evaluation of clean-up strategies was carried out
demonstrated the complexity of this task [21]. The options may range from using normal
phase, ion exchange or mixed-mode retention but the final decision ought to take into
account the diverse nature of the analytes and the load of the matrix, in order to eliminate
the unwanted substances while preserving the target analytes. Often the most efficient
cleaners also eliminate the pharmaceuticals [21]. Therefore, a clean-up protocol targeted
for acidic, basic and neutral pharmaceuticals in surface water of medium matrix load is
proposed considering the best sorbent material and its application stage.
In summary, this work was mentored by two objectives: (i) developing a fast and
sensitive LC-MS/MS method suitable to monitor a set of important pharmaceutical
substances using an analytical column of reduced dimensions and an appropriate SPE
procedure (extraction and clean-up) for acidic, basic and neutral analytes, and
(ii) preliminary assessment of the occurrence and levels of these substances in surface
waters of the Lec¸a and Douro rivers, located in the north of Portugal. A list of 24 most
consumed pharmaceuticals in Portugal belonging to 9 different therapeutic categories was
selected as representative compounds.
2. Experimental
2.1 Reagents and chemicals
The pharmaceuticals determined in this work and respective therapeutic categories were
the following: zolpidem, bromazepam, lorazepam, alprazolam, diazepam (anxiolytics);
paracetamol, naproxen, ketoprofen, ibuprofen, diclofenac, nimesulide, (analgesic/antipy-
retics); amoxicillin, ciprofloxacin, azithromycin (antibiotics); bezafibrate, gemfibrozil,
simvastatin (lipid regulators); hydrochlorothiazide, furosemide (diuretics); fluoxetine,
paroxetine (anti-depressives), omeprazol (anti-ulcer agent); indapamide (anti-diabetic) and
bisoprolol (cardiotonic). The analytical standards were purchased from Fluka, Sigma
and Riedel-de-Hae¨n (Sigma-Aldrich, Spain), except the benzodiazepines which were
supplied by LGC Standards (Barcelona, Spain). Two isotopically labelled compounds
were used as external standards: paracetamol-D4 (LGC Standards) and fluoxetine-D5
(Sigma-Aldrich).
Individual stock standard solutions were prepared in methanol at a concentration
around 500mgLÿ1 of the free acid or base and stored at ÿ18C in the dark and renewed
yearly. A mixture of all pharmaceuticals with a concentration of 5mgLÿ1 was prepared as
needed in methanol, at least every four months. A working solution at 500 mgLÿ1
concentration was prepared daily in methanol : water (25 : 75, v/v) and analysed to assess
the separation efficiency and response.
LC mobile phases were prepared with ultrapure Milli Q water (Millipore, Molsheim,
France), methanol LC-MS analyzed reagent (JTBaker, Deventer, The Netherlands) and
formic acid 50% (Fluka, Buchs, Switzerland).
International Journal of Environmental Analytical Chemistry 3
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2.2 Solid phase extraction procedure
SPE was performed using an automated device ASPEC XL from Gilson (Middleton,
USA) fitted to accommodate 6mL cartridges. The set of adsorbents tested for extraction
(see Table 1) include C18, modified polystyrene-divinylbenzene and proprietary polymeric
materials specially designed for the analysis of polar pharmaceutical substances.
The characteristics of some of the adsorbents can be found in Weigel’s paper [19].
Comparison trials were performed under basic conditions for conditioning (8mL of
methanol), percolation (10mLminÿ1) and elution (8mL of methanol). For clean-up of
environmental samples weak anion exchange (WAX, amino and primary/secondary
(1, 2) amino), strong anion exchange (SAX, quaternary ammonium) and normal phase
(diol) on silica substrate were evaluated (see Table 1).
Under the optimised conditions, conditioning of the extraction cartridges was
performed with 3mL of methanol followed by 3mL of acidified Milli Q water at pH 2
with HCl. 200mL of standards and samples acidified at pH 2 were percolated through the
JTBaker H2Ophilic cartridge at a flow rate of 10mLmin
ÿ1. The adsorbent was allowed to
dry under vacuum in an Analytichem International SPE manifold (Varian). The analytes
were then eluted with 6mL of methanol, the deuterated external standards were added to
obtain a final concentration of 500 mgLÿ1, the extract was evaporated to dryness under a
gentle stream of nitrogen and redissolved in 200mL of methanol : water (25 : 75, v/v) for
LC-MS/MS analysis. Samples requiring clean-up were acidified at pH 2 and percolated
Table 1. Set of adsorbents tested for the preconcentration of pharmaceuticals and clean-up of
environmental samples.
Adsorbents for
preconcentration
Mass
(for 6mL) Supplier
Abselut Nexus 200mg Varian
Bond Elut ENV 1000mg Varian
Bond Elut PPL 500mg Varian
Bakerbond H2OPhilic 200mg JTBaker
Bakerbond H2OPhobic 200mg JTBaker
Bakerbond SDB-1 200mg JTBaker
Chromabond C18 500mg Macherey-Nagel
Chromabond Easy 500mg Macherey-Nagel
Chromabond HRX 500mg Macherey-Nagel
Chromabond HRP 500mg Macherey-Nagel
Evolute ABN 200mg Biotage/IST
Isolute ENVþ 200mg Biotage/IST
Lichrolut EN 500mg Merck
Oasis HLB 200mg Waters
Oasis MCX 150mg Waters
Resprep RDX 500mg Restek
Strata X 500mg Phenomenex
Adsorbents for clean-up Mass (for 3mL) Supplier
Bakerbond Amine 500mg JTBaker
Bakerbond 1, 2 Amino 500mg JTBaker
Bakerbond quaternary ammonium 500mg JTBaker
Diol 500mg JTBaker
4 C.M.O. Gonc¸alves et al.
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directly through Bakerbound 1, 2 Amino adsorbent before enrichment in the SPE
material. The clean-up procedure was done manually under vacuum with 3mL cartridges
packed with 200mg of adsorbent.
2.3 Protocol for LC-MS/MS analysis
Analysis of pharmaceuticals was performed using a LC-MS/MS system composed of two
Varian 210 HPLC pumps, a Varian 500 MS ion trap mass spectrometer and a ProStar 410
autosampler, all from Varian (Walnut Creek, CA, USA). The system was mounted with an
analytical column of short dimensions, Pursuit UPS C18 (2.1mm i.d. 50mm, 2.4 mm)
from Varian and a guard column of the same characteristics (2.1mm i.d. 10mm, 3mm).
The equipment was fitted with a 10 mL sample loop.
Chromatographic separation was achieved using an elution gradient of LC-MS grade
methanol and 10mM formic acid in Milli Q water as mobile phases. The program started
with 25% methanol, rising to 75% methanol in 8min without delay, then rising to 100%
methanol at 10min and holding until 13min run time. The program returned to the initial
conditions in 1min and the column was allowed to stabilize for 8min. The flow rate was
0.3mLminÿ1 and the column temperature was 35C.
The ESI source parameters (ionization polarity, drying gas temperature, needle voltage
and capillary voltage) and the detector storage and fragmentation conditions (RF loading
voltage and collision induced dissociation (CID) voltage) were optimized on a per analyte
basis by infusion of authentic standards. The purpose was accumulating the maximum
amount of precursor ion in the detector followed by CID fragmentation until a few percent
of the precursor ion was remaining. Positive electrospray ionization was selected whenever
possible since it gave better sensitivity in this instrument and ionization is favoured under
acidic mobile phase. Table 2 assembles the instrumental conditions employed.
Confirmation of positive results in real samples was made by comparison of the MS/
MS spectra against authentic standards and also by setting two to three qualifiers and 20%
tolerance criteria. Isotopic ratios in halogenated compounds were also used to improve
confirmation. Nevertheless for several compounds just one product ion is generated, e.g.
paracetamol, bisoprolol, furosemide, nimesulide, ketoprofen, bezafibrate, diclofenac,
ibuprofen and gemfibrozil. Therefore, pharmaceuticals occurring in real samples were also
confirmed by MS3 spectra. The instrumental conditions for the analysis of azithromycin
were such to accumulate the double charged ion and fragment it to a single charged
product which is possible for a few molecules improving the analytical confidence and the
sensitivity. Instrumental control and data processing was performed by a personal
computer running the Varian MS Workstation version 6.9.1.
2.4 Method validation
After the optimization of the method in the extraction and analysis perspectives, full
validation was performed encompassing sensitivity, linear range, precision and accuracy
features. The limits of detection (LODs) were estimated as the concentration giving a
signal-to-noise ratio of 3 (S/N 3) and the LOQs a S/N 10. Precision was studied as
repeatability and intermediate precision (on three non consecutive days) with a spiking
level of 500 ngLÿ1 in Milli Q water and two surface waters. Accuracy was determined
calculating the method’s recoveries and through a detailed study of matrix effect along the
International Journal of Environmental Analytical Chemistry 5
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analytical procedure. Unless otherwise stated, (absolute) recoveries means the ratio
expressed in percentage of the signal obtained in a sample (subjected to SPE and
eventually clean-up) relative to the signal expected without any interference of any sort
(direct injection of a standard). Matrix effect observed when analyzing real samples is
probably the major source of inaccuracy of the results, therefore the extension of this
phenomenon was assessed in two ways: effect on recoveries and ionization suppression
effect. To estimate this effect four types of solutions were analyzed: standard solution
(StdSol), SPE extract of spiked Milli Q water (SPESol), SPE extract of spiked real samples
(SampSol) and spiked extract (after SPE) of real sample (ExtrSol). Spiking with
pharmaceuticals was always performed at 500 ngLÿ1 concentration level.
Absolute recoveries in Milli Q water and real samples were determined as:
Re c ¼
SPESol ðorSamplSol Þ  100
StdSol
ð1Þ
Ionization effect in the electrospray source (ESI) was determined as:
IonizEffect ¼
ðExtrSolÿ StdSol Þ  100
StdSol
ð2Þ
Matrix effect on recoveries was determined as:
EfectRe c ¼
SampSol
ExtrSol
ÿ
SPESol
StdSol
 
 100 ð3Þ
Additionally the loss of analyte in the clean-up step was determined comparing the
response of Milli Q water solutions submitted to clean-upþSPE and just SPE and;
samples spiked before and after clean-up. These trials also allowed investigating if
acidification ought to be performed before or after clean-up. The physico-chemical
characteristics of four river water matrices tested (1 Ave river, 2 Lec¸a river and 1 Douro
river) are given in Table 3. Lec¸a Reg. is a clean matrix, Ave and Douro are medium loaded
and Lec¸a Pte Pedra is a highly polluted river water sample.
2.5 Sampling scheme in Lec¸a and Douro rivers
The assessment of the occurrence of pharmaceuticals in surface waters was carried out in
two very distinct rivers in the north of Portugal. Lec¸a river is a small water stream of 45 km
Table 3. Physico-chemical characteristics of the river waters matrices tested in the clean-up and
matrix effect studies.
Ave
river
Lec¸a
river Reg.
Lec¸a river
Pte Pedra
Douro
river
TOC (mgLÿ1) 1.96 1.41 22.23 2.30
NH4þ (mgLÿ1) 0.512 0.107 43.35 0.032
NO2ÿ (mgLÿ1) 0.042 0.03 0.094 0.235
NO3ÿ (mgLÿ1) 9.50 8.8 17.00 6.4
Conductivity (mS cmÿ1) 146 94.4 371.5 310
pH 6.83 6.16 7.44 7.79
Turbidity (NTU) 1.71 0.81 16.35 4.64
Dissolved Oxygen (mgLÿ1) 7.34 6.84 2.21 7.89
International Journal of Environmental Analytical Chemistry 7
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long and average flow of 3.4m3 sÿ1 that receives in its path different inputs of agricultural
and industrial origin as well as domestic effluents from a large urban population in the
neighbourhood of Oporto, contributing to its high contamination status. Douro river is an
international river with headwaters in Spain and mouth in Oporto with a stream of
average 450m3 sÿ1 (ranging from 200 to 710m3 sÿ1) running a 927 km course. It is source
of drinking water for the population living in the metropolitan area of Oporto.
The monitoring scheme in Lec¸a river included ten sampling stations, one in the
headwaters, as control, and so forth until the mouth before and after every contamination
source (villages, tributaries, WWTPs). The same rationale was applied in Douro river with
a total of 12 sampling stations beginning from 45 km towards the mouth. Samples were
collected in 1L amber glass bottles and transported to the laboratory in a refrigerated
environment. Samples were processed immediately or at latest three days after sampling
and were kept always at 4C. The samplings took place in the 23February and 15 June
2009 in Lec¸a river and 4March and 16 June 2009 in the case of Douro river.
3. Results and discussion
3.1 LC-MS/MS optimization
Instrumental optimization began by setting up the appropriate electrospray ionization
source parameters, MS/MS conditions and the chromatographic gradient to analyse a
mixture of acidic, basic and neutral pharmaceuticals at the maximum sensitivity and
resolution. Just the most critical aspects will be discussed, briefly, which derive from the
challenge of analysing the above analytes in the same run. After an initial optimization by
direct infusion of the standards, two observations highlighted: some analytes gave an
extremely broad chromatographic peak under methanol/water mobile phase while others
required better fine tuning for improving the sensitivity. The former group include,
noticeably, ciprofloxacin, azithromycin, bisoprolol, paroxetine and fluoxetine. Aqueous
mobile phases buffered at the pH of 2.9, 3.2, 3.7 and 4.6 were tested using formic acid and
ammonium formate as additives in a concentration of 5 and 10mM. A mobile phase
composed of formic acid 10mM in water (pH 2.9) revealed essential for obtaining good
peak shape and resolution of the abovementioned pharmaceuticals. The tremendous
improvement in peak shape is demonstrated in Figure S1. In general, peak widths at half
height (W0.5) of the studied pharmaceuticals ranged then from 4.5–11.2 s. Acidification of
the mobile phase also contributed to improve the ionization efficiency of several analytes,
therefore ESIþ was the preferred ionization mode, namely for amoxicillin, paracetamol,
ketoprofen and naproxen, which are normally analysed under ESIÿ. A representative MS/
MS chromatogram of a 500 mgLÿ1 standard solution obtained under the above conditions
is given in Figure 1. A fast and efficient separation was achieved with a total
chromatographic time of 13min and a 22min cycle time, owing to the use of a 50mm
and 2.4mm particle size column. MS/MS segments with the least number of analytes (5)
were scheduled to keep the required number of data points per peak. To address the
improvement of sensitivity for some compounds, further optimization was attempted
changing the precursor m/z isolation window and the high mass ejection factor. These
conditions were given as footnote to Table 2. It should be noted that a larger isolation
window also allowed collecting the isotopic pattern of some halogenated benzodiazepines
in the precursor ion and MS/MS spectra, providing better confirmation quality.
8 C.M.O. Gonc¸alves et al.
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Figure 1. Representative LC-MS/MS chromatogram of a standard solution of the 23 relevant
pharmaceuticals at 500 mgLÿ1 concentration.
International Journal of Environmental Analytical Chemistry 9
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3.2 Comprehensive adsorbent comparison
Surface modification of styrene-divinylbenzene and synthesis of divinylbenzene-N-
vinylpyrrolidone and methacrylate-divinylbenzene co-polymers have been pursued to
better retain polar environmental pollutants, such as pharmaceuticals, in SPE cartridges
[20]. We have performed a comprehensive evaluation of 17 SPE materials available
nowadays, some of them neglected in previous studies [19], for the enrichment of a wide
array of pharmaceuticals. Irrespective of their order, the five adsorbents that performed
worst in a first round were: Chromabond C18 and HRP, Lichrolut EN, Bond Elut ENV
and Isolute ENVþ. The remaining 12 were then systematically compared in four replicates
with an average relative standard deviation (RSD) per cartridge of 5.7 to 20% and the
ranking of average recoveries/median recoveries at 500 ngLÿ1 concentration level was as
follows: JTBaker H2Ophilic (89/92%), JTBaker H2Ophobic (86/96%), Abselut Nexus
(86/90%), Resprep RDX (80/87%), Oasis HLB (80/85%), JTBaker SDB1 (73/77%), Bond
Elut PPL (69/78%), Strata X (67/67%), Oasis MCX (66/81%), Chromabond HRX
(62/61%), Chromabond Easy (58/62%) and Evolute ABN (56/64%). Of these, the best
five are represented in Figure 2 for the whole group of test compounds. For the majority of
pharmaceuticals the five adsorbents are comparable, namely for antidepressives and
anxiolytics, nevertheless five cases must be highlighted: paracetamol and simvastatin are
extracted much more efficiently by JTBaker H2Ophilic and H2Ophobic while for
ciprofloxacin the H2Ophilic is just superpassed by Abselut Nexus with an abnormally
high recovery rate. On the contrary, hydrochlorothiazide and ibuprofen are better
extracted by Oasis HLB and Resprep RDX. The efficiency obtained for simvastatin,
paracetamol and ciprofloxacin has driven the selection of JTBaker H2Ophilic as the most
appropriate for the set of pharmaceuticals. The full results for the 12 best adsorbents are
given in Table S1 (Supplementary Information).
According to the literature survey performed by Kostopoulou and Nikolaou until 2008
[6], the most effective SPE adsorbents for the enrichment of pharmaceuticals in aqueous
samples were Isolute ENVþ, Oasis HLB, Oasis MAX, Oasis MCX, Strata-X, LiChrolut
C18 and LiChrolut EN. The most popular pre-concentration technique is undoubtedly
SPE with a few applications of solid-phase microextraction (SPME) using fibres coated
with polyacrylate and carbowax/divinylbenzene [6]. Nevertheless, the limits of detection
never rival those of SPE [6]. On the other hand, van de Steene concluded that among Oasis
HLB, C8, Phenyl, Strata-X and Strata SCX, the former was the best cartridge for the
extraction of nine basic pharmaceuticals, mostly antimycotics, but it also led to intense
matrix effect (non selective extraction) [8]. The study of Weigel et al. [19] also included
some specialized polystyrene-divinylbenzene based adsorbents and co-polymers with
noteworthy similarities to our results. The extraction efficiencies of Abselut Nexus,
Chromabond Easy and JTBaker SDB1 for the commonly tested pharmaceuticals,
although different in the figures, follow the same trend. The recoveries we obtained
were generally higher probably because the samples were acidified. That can be important
for acidic substances such as bezafibrate, diclofenac and ibuprofen but also for fluoxetine
and related analytes as it will be demonstrated later. The above references show that most
of the tested cartridges in the present work, namely the most efficient ones JTBaker
H2Ophilic, H2Ophobic and Resprep RDX, are usually disregarded.
Hierarchical cluster analysis (HCA) of the recoveries achieved by the twelve adsorbents
revealed that JTBaker H2Ophilic, H2Ophobic and Abselut Nexus have a similar extraction
profile, so as Oasis HLB and Resprep RDX. JTBaker SDB1 and Bond Elut PPL cluster
10 C.M.O. Gonc¸alves et al.
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together and at a later stage a link is formed with the previous two. The two Chromabond
phases HRX and Easy also link together and at a much farther stage they join the
remaining group other than the JTBaker H2Ophilic’s. The respective dendrogram is given
in Figure S2. This information can be useful when deciding from different brands since it
shows how the adsorbents compare among them for a representative list of pharmaceu-
ticals. Not to undervalue, of course, the other way round of how the substances behave
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Figure 2. Recovery rates of the five most efficient SPE adsorbents for the enrichment of
pharmaceuticals in Milli Q water at 500 ngLÿ1 concentration (n¼ 5). Error bars represent the
standard deviation. Omeprazole was not represented since it is not extracted at pH 2 and amoxicillin
gives erratic results due to its unstable character.
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regarding the different adsorbents. The respective dendrogram is given in Figure S3.
Chemical family affinity is apparent for anti-inflammatories (Group 1) and antidepressives
(Group 2), however benzodiazepines scatter between two major groups where anti-
inflammatories and lipid regulators are present (Groups 1 and 3). Bromazepam clusters in
a more heterogeneous group (Group 4) composed of hydrochlorothiazide, azithromycin
and indapamide. Two aspects should be noted: chemical variability is also present among
benzodiazepines expressed in their different chromatographic retention times (from 6.37 to
8.97min) and; the similar or dissimilar behaviour of bromazepam with the other group
members is not clearly seen in Figure 2 because only five adsorbents are displayed whereas
HCA encompassed all of them. For Group 1 all five adsorbents present in Figure 2 are
equally good with average recoveries above 95%. For Group 3 JTBaker H2Ophilic,
H2Ophobic and Nexus are preferred giving average recoveries between 88 and 92%. For
Group 4, Nexus is the most suitable with average recovery of 83%. Group 2 approaches
the case of Group 1 except that Oasis MCX is totally unsuitable (Table S1). Of superior
evidence, HCA demonstrated that simvastatin, paracetamol and ciprofloxacin showed the
most dissimilar pattern thus outweighed the selection of JTBaker H2Ophilic as the most
suitable adsorbent.
3.3 Effect of sample pH, flow rate and breakthrough volume of the adsorbents
Sample pH is a very important parameter when enriching substances containing diverse
chemical moieties, such as the pharmaceuticals, in SPE adsorbents by reversed-phase
interaction. This assumption was proved by testing the following sample pHs: 2, 3, 4, 7.3
and natural pH 5.4. The results obtained are given in Figure 3. The antibiotics
azithromycin and ciprofloxacin require acidification to the lowest pH (pH 2) to improve
recovery rates while paroxetine and fluoxetine are efficiently extracted at a moderately acid
pH (pH 4). Bisoprolol benefits from acidification in a much smaller scale. On the contrary,
omeprazole becomes ionized at low pH and extraction is reduced to complete loss. The
extraction of the remaining pharmaceuticals is not significantly affected by sample pH and
they well tolerate a pH of 2, therefore this value was considered the most appropriate to
undertake the analysis, although omeprazole cannot be analysed.
The flow rate of sample percolation was studied between 5 and 20mLminÿ1.
Generally, the extraction efficiency was independent of the flow rate except for selected
compounds. A continuous loss in retention capacity was observed for azithromycin,
ciprofloxacin, paroxetine and fluoxetine, with a more intense drop changing from 5 to
10mLminÿ1 for antibiotics (18 and 22%, respectively) than antidepressives (7 and 9%,
respectively). Bisoprolol and bromazepam lost retention strength just at 15 and
20mLminÿ1 flow rate. Interestingly, the retention efficiency of simvastatin increased
three fold at 20 compared to 5mLminÿ1. It has not been proved whether simvastatin
degrades during 40min of sample extraction or if adsorption to tubing is reduced at
20mLminÿ1. A 10mLminÿ1 flow rate was finally chosen corresponding to 25min sample
processing time compared to 45min at 5mLminÿ1.
Subsequently, the breakthrough volume was determined under the conditions above.
The results in Figure 4 show a good proportionality between the extracted volume and the
analytical response at a constant concentration of pharmaceuticals for the majority of
analytes. Therefore, the breakthrough volume is above 1000mL and the retention capacity
is independent of the volume of sample. Nevertheless, paracetamol starts leaking from the
12 C.M.O. Gonc¸alves et al.
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cartridge at sample volumes around 200mL, which is related to its hydrophilicity.
Omeprazole, on the other hand, is not possible to enrich on the adsorbent under acidic
conditions and the recovery is low at 100mL volume and is further lost. In view of the
above results and the necessary sensitivity of pharmaceutical analysis in surface waters,
200mL of sample are SPE processed and eluted in 2 steps of 3mL of methanol (1min-.
waiting time in between). The dry residue is redissolved in 200 mL of a mixture of
methanol/water 35 : 65 and injected for LC-MS/MS analysis.
3.4 Clean-up procedure to overcome matrix effects
Evaluating matrix effects is very important when developing an LC–MS/MS method. The
results of van de Steene et al. [8] prove that matrix effects are very difficult to tackle and
combined multiple approaches are necessary to reduce their impact in precision and
accuracy. Normalization of erroneous analyte response, either signal suppression or
enhancement, caused by co-eluting compounds originated from the matrix can be
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Figure 3. Effect of sample pH on the retention of some critical and representative pharmaceuticals
in the JTB H2Ophilic adsorbent (n¼ 4). Error bars represent the standard deviation of the mean.
Tests were performed at a concentration level of 500 ngLÿ1 in Milli Q water.
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endeavoured by several methods: use of isotopically labelled internal standards, removal
of interfering substances by clean-up, selective extraction of different types or standard
addition for calibration and calculation of recoveries. Selective extraction, and clean-up in
particular, extend the life-time of the chromatographic column [22]. Sample to sample
variability is another issue to keep in mind: compensation by recoveries calculated for each
sample or use of isotopically labelled internal standards are the best options to achieve
accurate results.
The pharmaceuticals most affected by matrix effect (mainly ionization suppression
rather than interference in enrichment efficiency) with average (relative) recovery
reduction above 30% were: hydrochlorothiazide, azithromycin, furosemide, indapamide,
fluoxetine, alprazolam, naproxen and diclofenac, considering the four matrices in Table 4.
Signal enhancement was observed for lorazepam (18%). More detailed information on the
type of matrix effect (either ionization suppression or effect on recoveries) obtained
according to the calculations explained in section 2.4 can be found in Table S2).
Indeed, ionization suppression could reach 46% signal reduction in the dirtiest sample.
Additionally, azithromycin and bisoprolol suffered peak broadening and increase of
retention time whereas paroxetine and fluoxetine were just affected by retention time
deviation. Retention time shifting is critical in MS/MS methods scheduled in segments.
Fluoxetine D5 was used to monitor retention time variation of antidepressives while
paracetamol D4 was used for compensation of matrix effect on the native paracetamol.
For the remaining pharmaceuticals correction by recoveries on related matrix was used
spiking the sample with pharmaceuticals at 500 ngLÿ1 concentration. Additionally,
clean-up was employed in the dirtiest samples.
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Figure 4. Study of breakthrough volume of the JTBaker H2Ophilic adsorbent for several
pharmaceuticals in a concentration of 500 ngLÿ1 in Milli Q water.
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Conversely to Vieno et al. [22], in our studies selective wash of the cartridge did not
reduce significantly matrix effects, even with 20% methanol in water (data not shown).
Clean-up of the extract with normal phase adsorbents was attempted however florisil
retains irreversibly the majority of analytes, as mentioned by Weigel et al. [19] and
Fontanals et al. [20], while diol is quite inefficient. Much effort was then put in sample
clean-up with anion exchange gathering from the previous knowledge on this strategy [21].
The results of the assays performed on river water samples can be found in Table 4. Lec¸a
Pte Pedra is the most loaded matrix since it is located downstream two WWTPs. As a first
remark, adjustment of the sample to pH 2 has to be performed prior any clean-up
otherwise azithromycin (16%), paroxetine (9%) and fluoxetine (17%) do not percolate
quantitatively (% loss) the ion exchange adsorbents. The quaternary amine (SAX)
clean-up prior to JTBaker H2Ophilic enrichment was the least efficient: visually and
analytically the clean-up was the weakest and a specific study also demonstrated that
undesired retention of some analytes takes place. The 1, 2 amino (WAX) clean-up
showed advantage over the NH2, which was demonstrated by better recoveries and less
breakthrough of dirty material. Although the gain in analytical response is not
outstanding (10% higher recoveries in Lec¸a river and 8% in Douro river, on average),
the clean-up has a very positive impact on chromatographic stability, thus reducing the
possibility of false negatives, and obviously protecting the column from deterioration due
to bulk material. Besides, an individual recovery improvement of 51, 37, 28 and 22% was
observed for azithromycin, sinvastatin, indapamide and paroxetine, respectively, in Lec¸a
river and 38, 37, 21 and 21% for nimesulide, ciprofloxacin, furosemide and indapamide,
respectively, in Douro river. The described strategy with 1, 2 amino might imply a loss in
the adsorbent of furosemide, indapamide, bezafibrate between 4-9% calculated in Milli Q
water while for the remaining analytes it is meaningless. In Table S2 results are given for
Douro river sample. The mass of adsorbent to be used should be as little as required (200
mg) to prevent the above effect and no better clean-up was achieved with 500mg. As
mentioned by van de Steene et al. [8] sample clean-up for pharmaceutical analysis is very
tricky and a more exhaustive procedure may vanish also the analytes. Therefore we
preferred a softer procedure with anion exchange. The several approaches tested by the
above authors gave divergent results for different analytes, thus an overall good
methodology was not clearly found [8]. These authors propose a clean-up based on
NH2 adsorbent but the option was to perform SPE first and then WAX on the extract in
chloroform/methanol (80 : 20) solvent, conversely to our strategy. Subsequent elution with
an organic solvent may carry interferences alongside with the analytes.
If acidification of the sample to pH 2 was not a requisite, the anion exchange retention
of organic acids composing the dissolved organic matter would be improved and their
subsequent enrichment on the H2Ophilic cartridge would be minimized. However, proper
recovery of some selected pharmaceuticals forced ex ante acidification, by several reasons
already discussed.
3.5 Evaluation of the method performance
The extraction efficiency of the method expressed as recoveries in Milli Q and surface
water, with or without clean-up with 1, 2 amino adsorbent was already given in Table 4.
Matrix effects were also already discussed. Additionally, the following figures of merit are
given in Table 5: precision (as repeatability and intermediate precision in three non
16 C.M.O. Gonc¸alves et al.
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consecutive days), limits of detection (LODs) and linear range. Recoveries in Milli Q water
were generally above 80%, exceptions noted for hydrochlorothiazide and paracetamol due
to their water solubility and, furosemide and indapamide which apparently are more
sensitive analytes. For some unknown reason, the recovery of simvastatin never exceeded
50%. Tests on adsorption to tubing, incomplete elution and insufficient redissolution of
the dry extract didn’t provide any clue. Degradation by interconversion of the cyclic and
open ester form is an hypothetic explanation.
Limits of detection verified in real samples were generally below 5 ngLÿ1. The LOD of
ciprofloxacin was raised to highlight from a small background peak. The sensitivity in
ESIþ is typically better than in ESIÿ. The fragmentation of ibuprofen is very erratic,
therefore no CID energy was applied to be able to collect the [M–H]ÿ ion and the high
LOD is a consequence of this limitation. The precision of the method is very good and
typical of a SPE procedure. Repeatablity in Milli Q water varied between 4 and 17.3%
RSD, except ibuprofen (24%), with an average value of 8.4% RSD while intermediate
precision varied between 4.5 and 27.2% RSD with an average value of 13.2% RSD. No
relevant difference was observed in spiked surface waters at both spiking levels (500 and
50 ngLÿ1, except for analytes detected in ESIÿ (furosemide, indapamide, nimesulide,
bezafibrate, diclofenac, gemfibrozil) and simvastatine, which display worse precision. At
50 ngLÿ1 precision is worse about 3% relative to 500 ngLÿ1 level.
The linear range evaluated from the determination coefficients of the linear regression
model (average of eight calibrations) is generally very good in the LOQ-500 ngLÿ1
concentration range, particularly for the benzodiazepines, bisoprolol and the phenylpro-
panoic acid anti-inflammatories. Two compounds deserve special attention: ciprofloxacin
gives a concave calibration plot while nimesulide gives a convex one therefore linear range
is reduced to LOQ-100 ngLÿ1. The linearity was also tested in a surface water sample
(Lec¸a Reguenga) and the determination coefficients are similar to those found in Milli Q
water, so the linearity was not prejudiced by matrix effect. These figures of merit are
perfectly adapted for monitoring acidic, basic and neutral pharmaceuticals in surface
waters that can range from tens to hundreds ngLÿ1. Conversely to our strategy, Vieno
et al. have discriminated the analysis of acidic [23] and base/neutral pharmaceuticals [22]
into two separate methods.
3.6 Assessment of pharmaceuticals in surface water
To demonstrate the applicability of the developed method and assess the presence of those
pharmaceuticals in surface waters, Lec¸a and Douro rivers were sampled in February/
March and June, 2009. The results obtained are presented in Table 6. An illustrative
chromatogram of sample Pte Moreira collected in June is shown in Figure 5.
The samples of Lec¸a river upstream Pte Ermesinde didn’t contain any quantifiable
amount of pharmaceuticals. Paracetamol was present in downstream stations in
considerable amounts in February while azithromycin and hydrochlorothiazide appeared
in June. Bisoprolol and furosemide appeared in both seasons, generally at higher
concentrations in June than in February, the former pharmaceutical in a 10-times lower
concentration. Vieno et al. reported removal rates of -blockers in WWTPs from 11%, for
metoprolol, up to 76%, for atenolol [22], therefore these pharmaceuticals reach the
receiving waters, as occurred with bisoprolol. On the other hand, ciprofloxacin only
appeared in one sample due to its breakdown in the WWTPs, as documented by the same
18 C.M.O. Gonc¸alves et al.
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authors [22]. Lipid regulators are a class with high prevalence in Lec¸a river. A considerable
concentration of bezafibrate (from 256–770 ngLÿ1) was quantified in February decreasing
15–70 times in June while gemfibrozil was always present at around 35–90 ngLÿ1.
Ketoprofen, diclofenac and simvastatin appeared sporadically. Rodil et al. have reported
levels of four pharmaceuticals in effluents discharged to surface waters at levels above
500 ngLÿ1, associated with low removal rates in the WWTPs: diclofenac (23%),
bezafibrate (54%), naproxen (63%) and ibuprofen (85%) [18]. Despite the different
removal rates of ibuprofen and ketoprofen (10%) the levels in one effluent were not
Figure 5. Extracted ion chromatogram of the sample Pte Moreira collected in June 2009 showing
the quantified pharmaceuticals. The insert represents the total ion chromatogram (TIC).
20 C.M.O. Gonc¸alves et al.
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so distinct. In Douro river none of the pharmaceuticals was measured in February while in
June one sample collected in the outskirts of Oporto contained hydrochlorothiazide
(31 ngLÿ1) and another collected in the estuary contained paracetamol (63 ngLÿ1) and
ketoprofen (11 ngLÿ1).
As noted by Madureira et al. [7] the concentrations of pharmaceuticals are typically
higher in dry seasons rather than in winter, especially in the small stream of Lec¸a river that
carries a considerable portion of WWTP effluents in dry periods. Two punctual cases
depart from this trend: paracetamol, that is normally removed by the biological treatment
in WWTPs [6] and bezafibrate which was infrequent in later samplings.
To clarify whether the presence of pharmaceuticals in Lec¸a river is just apportioned by
the WWTPs, the monitoring network will be complemented by sampling the three
tributaries: Leandro, Boi Morto and Arquinho streams. High levels of paracetamol
conjugated with a high ratio of caffeine/carbamazepine may be an indication of untreated
domestic sewage [24–26]. Although agricultural and domestic pollution sources are
convened to both rivers the dimension of Douro provides a much higher dilution capacity.
Lec¸a is critically affected by pharmaceuticals since: (i) current WWTPs are not prepared to
remove completely such organic substances [22], (ii) some of them are recalcitrant in the
environment, (iii) they are intensively discharged in the river and (iv) the dilution ratio is
scarce. The presence of the reported pharmaceuticals was unequivocally confirmed by MS/
MS and MS3 complemented with isotopic ratios.
4. Conclusions
The aim of this work consisting of the simultaneous analysis of acidic, basic and neutral
pharmaceuticals was successfully attained with a judicious selection of the most appropriate
SPE adsorbent, which turned out to be JTBaker H2Ophilic. Paracetamol, ciprofloxacin
and simvastatin have driven this option. Acidification was demonstrated to be essential
for efficient extraction and chromatographic resolution of the set of pharmaceuticals.
A tailor-made clean-up for the reduction of matrix effects in medium/high loaded surface
waters was accomplished with the 1, 2 amino adsorbent that provided a satisfactory
clean-up without irreversible retention of the analytes. The employed clean-up benefited
recoveries and was essential for the consistency in peak shape and retention time of
antibiotics, antidepressives and bisoprolol. The developed method provided limits of
detection generally below 5 ngLÿ1 and precision generally below 15% RSD. Amoxicilin is
a very unstable compound that although much consumed is not likely to appear in
environmental samples whereas omeprazol cannot be determined under acid conditions.
Eleven out of twenty two pharmaceuticals were quantified in Lec¸a river. Diuretics and
lipid regulators are categories of concern. Paracetamol was atypically present and
lorazepam is also scarcely reported in surface water. Douro river revealed much lower
levels of pharmaceuticals although several anthropogenic pollution sources are present,
which can be attributed to its hydraulic features.
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Abstract 
An inter-laboratory exercise was organized under the PHARMAS EU project, by the 
Advanced School of Public Health (EHESP), in order to evaluate the reproducibility of 
analytical method for the measurement of antibiotics (ATB) in waters. For the first time, this 
type of exercise has been organized in Europe, and using different kind of analytical methods 
and devices. In this exercise thirteen laboratories from five countries (Canada, France, Italy, 
the Netherland and Portugal) participated, and a total number of 78 samples were distributed.  
During the exercise, 2 testing samples (3 bottles of each) prepared from tap water and river 
water respectively, spiked with ATB, were sent to the participants and analyzed along one 
month. 
A final number of 77 (98.7 %) testing samples were analyzed. Depending on substances 
analysis by each participant, 305 values in duplicate were collected, and the results for each 
sample were expressed as the target concentration. 
A statistical study was initiated using 611 results. The mean values, standard deviations (σ), 
variances (σ2) and, upper and lower warning limits (UWL and LWL) between concentration-
result from the participant laboratory at different intervals were obtained. 
In this exercise, 24 results (3.93 % of accounted values) were outliers according with the 
Zscore values and the Dixon test. The outlier results were excluded.  
In order to establish the stability of testing samples along the exercise, differences between 
variances obtained for every type of sample at different intervals were evaluated. The results 
showed not significant variations and can be considered that all samples were stable during 
the exercise. 
The goals of this inter-laboratory study were to evaluate the repeatability (r) and 
reproducibility (R) when different laboratories conduct the analysis, the influence of different 
matrix samples, the variability between different methods, and to determine the rate at which 
participating laboratories successfully completed the tests initiated. 
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1. Introduction 
The presence of antibiotics in environmental samples has been reported extensively. 
Antibiotic are among the most investigated class of pharmaceuticals in the environment. More 
recently, they have been detected in drinking water (Bruchet et al., 2005; Ye et al., 2007; 
Focazio et al., 2008; Benotti et al., 2009, Vulliet et al., 2009; Watkinson et al., 2009). 
However, concentrations are very low and accurate and analytical methods need to be 
controlled in order to insure a good uncertainty of the data obtained required for a robust 
assessment of exposure scenarios of human people.  
In this context, an inter-laboratory comparison exercise (announcement and recommendation 
have been reported in annex 1) was conducted among thirteen laboratories covering different 
EU countries. 2 samples were analyzed along one month. The samples correspond to 3 glass 
bottles of tap water for the first and 3 glass bottles of river water (filtered sample from La 
Vilaine river in Brittany, France ) for the second.  
The principal aims of the interlaboratory study were: 
- To evaluate the variability of results between different laboratories 
- To evaluate the rate at which participating laboratories successfully completed the 
exercise 
- To evaluate the capacity and variability in front of complex real samples 
 
2. Participants profile 
Interlaboratory exercise is an opportunity for one laboratory to assess their performances by 
comparison with several other laboratories and to quantify the modification necessary to 
improve them. 
 13 laboratories (annexe 2) participed to the exercise. 5 countries are represented (Canada, 
France, Italy, The Netherland, Portugal). 1 (one) laboratory used two analytical methods and 
was considered as 2 different ones. Then 14 “labs” have been considered. For reasons of 
anonymity, they have been numbered randomly from lab1 to lab14. 
50% have already participated to EIL 
1/3 of laboratories have less than 2 years of experience in the analysis of ATB in water 
25% have more than 6 years of experience in the analysis of ATB in water 
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40% have between 3 and 5 years of experience in the analysis of ATB in water 
 
92% perform routine analysis of ATB in their lab (83% of which several times a week and 
17% at least once every 6 months). 
 
Analytical know-how: Figure 1 show the % of laboratories being able to analysis the ATB 
proposed. 
 
Figure 1 : Analytical Know-how of the participating laboratories  
 
Performances of the whole consortium are reported in the Table 1. They take into account the 
limit of detection of each laboratory. Min and Max correspond to the lower and higher value 
of LOD among the laboratories. Median and mean have been calculated on the basis on the 
average of the 14 values of LOD declared by the laboratories. n is the number of laboratories 
analyzing the corresponding substance. 
 
Table 1: Analytical performances of the participating laboratories 
  LOD repartition (ng/L) 
 n Min Max Mean Median 
Erythromycin (ERY) 10 1 500 80.3 10 
Trimethoprim (TMP) 10 1 50 16.6 5.5 
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Sulfamethoxazole (SMX) 9 1 50 13 10 
Ciprofloxacin (CIP) 8 1 100 32.13 20.5 
Oxytetracycline (OXY) 7 1 50 26.9 25 
Ofloxacin (OFL) 7 1 20 12.2 11 
Tetracycline (TET) 6 1 100 39.5 37.5 
Chlortetracycline (CHL) 5 1 200 48.4 11 
Doxycycline (DOX) 3 5 100 51.7 50 
Levofloxacin (LEV) 2 5 50 27.5 27.5 
Cefuroxim (CFU) 1   50  
Ceftriaxone (CFT) 0     
 
When available, the substances were analyzed by non accredited method except ERY in three 
laboratories and SMX in two laboratories. Only one laboratory is accredited for 8 substances.  
 
Considering the different performances and capabilities of the participating laboratories and 
the capacity of the host laboratory to produce the reference samples, the following antibiotics 
were chosen (Table 2) 
Table 2 : Final substances studied during the exercise 
Class of antibiotic Molecule Acronym 
CAS registry 
number 
Fluoroquinolones 
Ofloxacin OFL 83380-47-6 
Ciprofloxacin CIP 85721-33-1 
Sulfonamide Sulfamethoxazole SMX 723-46-6 
Pyrimidin (associated 
to sulfonamide) 
Trimethoprim TMP 738-70-5 
Macrolide Erythromycin ERY 114-07-8 
 
  
3. Material preparation  
3.1. Standard preparation   
Acetonitrile (HPLC gradient, Baker), methanol (HPLC gradient, Baker), formic acid (Baker), 
NH4OH 25% (Carlo Erba), sodium nitrite 99% (ACS Reag. PhEur, Merck) and ultrapure 
water were used for the preparation of standards solution.  
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Standards are commercialized under powder form with purity between 97 to 99,9%. 
Trimethoprim standard was purchased from VWR (certified quality,Dr. Ehrenstorfer GmbH, 
Bgm.-Schlosser-Str. 6 A, 86199 Augsburg, Germany) 
Standards of other antibiotics were purchased from Sigma Aldrich. Life durations are not 
certified by the provider but 3 years of preservation are insured by a certificate.  
 
Mother solutions are solutions of individual compounds prepared in Methanol. CIP and OFL 
solutions are prepared as 0.5 g/L; the other ones at 1g/L. CIP solution requires addition of 
formic acid for a better solubility. 
 
Daughter solutions (DS) are prepared in acetonitrile. A first DS (DS1) at 10mg/L followed by 
a second DS (DS2) at 0.5mg/L are prepared by dilution of the mother solutions. 
DS are preserved at -20°C. 
 
The characterization (stability and homogeneity test) of the reference sample has been 
conducted by UPLC/MS/MS using internal standard.  
Internal standard solutions have been produced from the following marked molecule: 
Ofloxacin-d3, Trimethoprim-13C, Ciprofloxacin-13C-15N, Sulfamethoxazole-13C, 
Erythromycin-13C purchased from Sigma Aldrich (TMP, ERY and CYP are solutions in 1.2 
ml flask) 
Mother solutions of OFL-d3 and SMX-13C are prepared in Methanol (1g/L) followed by a 
dilution in acetonitrile up to solution at 10mg/L. 
ERY-13C, TMP-13C, CIP-13C-15C are prepared directly in acetonitrile (12pp). 
 
A solution standard of reference marked compound at 0.5 mg/L is finally prepared in 
acetonitrile.  
 
 
3.2. Reference sample preparation  
Two reference samples (called sample A and sample B) were prepared. Sample A and sample 
B correspond to treated and filtrated surface water respectively spiked with the 5 antibiotics of 
interest. The characteristics of the matrices are presented in Table 3. 
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Table 3: Characteristics of the matrices used to prepared sample A and B 
Parameters 
Raw water after 
filtration (0.7µ) 
Distributed water 
(LERES tap) 
pH at 20 °C  7.95 7.85 
Conductivity at 25 °C 
(µS/cm) 
516 697 
TOC (mg/L) 7.3 1.3 
DOC (mg/L) 7.0 1.3 
Total chlorine (mg/L) < 0.1 0.2 
Free chlorine (mg/L) < 0.1 < 0.1 
In order to minimize sources of variation, samples A and B were collected, homogenized and 
prepared at EHESP-LERES, Rennes, France. River water (70L) was collected and transported 
to the laboratory where it was filtered through 0.7 μm glass fibre filters. Treated water (70L) 
was directly collected at the tap of laboratory. Afterwards, waters were homogenized, spiked 
and sub-sampled for homogeneity and stability testing.  
Samples A and B were then transferred into 1 L polyethylene bottles (approx. 900 mL of each 
sample); 3 bottles of each samples for each laboratories. They were shipped on dry-ice to the 
participant laboratories on October, 5
th
, 2011. A total number of 39 bottles was sent to 13 
participants (3 of each sample). The samples arrived to participant laboratories in 24 to 72 hrs 
in frozen state. 
 
4. Homogeneity of samples 
To assure and confirm the quality of reference sample preparation, homogeneity tested by 
following the guidelines of the ISO 13528. Treated (sample A) and surface water (sample B), 
were sub-sampled after the spiking and homogenisation, where ten subsamples per sample 
were taken from different layers in the container. Two parallels were analysed per each 
sample, in total 30 samples were analysed per each sample. The homogeneity was statistically 
evaluated by using the comparison of the between-sample standard deviation to total standard 
deviation. According to the ISO 13528 standard, the ratio of the between-samples standard 
deviation to the total standard deviation must be below 0.3.  
The between-sample standard deviation has been calculated as follow: 
- xt,k are the data (t represent the sample and k the parallel) 
- the mean of the samples is defined as xt, = (xt,1 + xt,2)/2 
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- the range of the duplicate as wt =  xt,1 - xt,2  
- the general mean is given by:           
- the standard deviation of the mean of the samples:                        
- the standard deviation of the samples:          
        
 
Finally, between-sample standard deviation can be calculated as follow 
          
   
 
  
 
Table 4 represents the calculation of the between-sample standard deviation for each target in 
both samples. 
 
Table 4 : Ratios between Ss* (between-samples standard deviation) and σ (standard deviation 
of the round calculated from the results of the laboratories) for all the homogeneity controls  
Target Sample A Sample B 
 ss  ss / ss  ss / 
ERY 7.1 43.1 0.16 11.7 252.9 0.04 
OFL 2.7 21.6 0.13 9.6 83.1 0.12 
CIP ND   11.0 62.4 0.18 
SMX 2.6 6.8 0.38 2.8 26.7 0.1 
TMP 4.5 12.8 0.35 0.8 33.0 0.02 
* details of the calculation are shown in annex 3 
 
Thus, the results of the controls showed that the samples are not significantly different for that 
homogeneity target. It can be concluded that the reference samples A and B may be 
considered homogeneous; this means that all the manufactured samples may be considered 
homogeneous for a given proficiency test. It can be noted that, since homogeneity between 
the samples depends largely on the nature of the product. 
 
Ciprofloxacin was not detected in sample A 
 
5. Stability of samples 
The verification of the stability was assessed by using the same protocol as for the verification 
of the homogeneity. Temperature preservation and storage time were assessed for the 
evaluation of the stability of the reference samples. 
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3 sub-samples of each type of water were randomly selected and preserved at room 
temperature (20°C ± 2) and +4°C during two, seven and ten days (total of 18 samples) 
Each antibiotic were measured in each sub-samples in duplicate. The average concentration 
(   is compared with the average concentration of all sub-samples used for the stability and 
homogeneity tests (  ). The total standard deviation has been calculated from the results of the 
exercise for each antibiotic (Table 5 and Table 6). Detail of calculation is given in annex 3 
 
Table 5 : Values for verification of stability in treated water  
SAMPLE A: Treated Water 
  OFL TMP SMX ERY 
   28.63 43.76 26.81 43.03 
  21.6 12.8 5.7 43.1 
  Room T° Day 2 33.81 40.67 24.29 44.74 
 Room T° Day 7 28.43 43.04 24.45 38.04 
 Room T° Day 10 30.43 42.36 23.87 41.81 
 4°C Day 2 25.86 42.42 25.47 46.97 
 4°C Day 7 26.13 43.23 25.19 41.92 
 4°C Day 10 20.33 41.8 24.45 41.79 
 
Table 6: Values for verification of stability in treated water 
SAMPLE B: Surface Water 
  OFL TMP CIP SMX ERY 
   208.96 121.06 179.35 116.21 164.85 
  83.1 33 62.4 26.7 252.9 
  Room T° Day 2 234.2 106 211.44 104.48 162.09 
 Room T° Day 7 200.81 120.63 156.5 112.07 171.81 
 Room T° Day 10 207.27 117.77 168.3 104.59 162.02 
 4°C Day 2 234.65 117.94 215.3 112.41 169.14 
 4°C Day 7 205.91 123.7 169.1 119.72 184.86 
 4°C Day 10 206.37 120.48 168.24 118.14 178.04 
 
The stability of the reference sample is correct if               
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The results showed that the reference samples can be considered as stable, both at room 
temperature and at +4°C. The relation mentioned above has been verified in 80% of the 
measurement.  
 
6. Sample distribution  
The reference samples were dispatched on October 5
th
 2011 by express service. 
 
7. Analytical methods 
No standard recommendations have been sent to the participants neither for the sample 
treatment (extraction, preconcentration) nor for the analytical method. 
Table 7 lists the participant laboratories as well as the main characteristics (when sent) of the 
analytical methods used  
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Table 7 : Methods used by the different participants 
Participant Pre-treatment Extraction Extraction solvent Internal standard Chromatography column 
1 
before extraction 2.5 
mL EDTA solution of 
2.5 g/L added (pH8), 
and pH changed to 3.2 
with 100 uL formic 
acid 
SPE Oasis 
HLB 
n.c 
Ciprofloxacin 13C3 
Sulfamethoxazole 
13C6 
 
UHPLC-MS-MS 
Acquity BEH  
50x2.1 mm; 1.7 
um 
2 none 
SPE Oasis 
HLB 
MeOH/ Ethyl acetate (50/50) 13 C compound UPLC-MS/MS 
Hypersil Gold 
1.9µm-
2.1*100mm 
3 none 
SPE reverse 
phase 
n.c none LC-MS/MS 
Acquity HSS-
T3 
4 none 
SPE ENVI 
CHROM-P 
250mg 
MeOH Carbamazepine D10 HPLC-MS/MS 
XBridge C18 
3.5 um, 2.1*150 
mm Column 
5 acidification pH2 
SPE JTBaker 
H2Ophilic 
n.c none HPLC-MS-MS 
Varian Pursuit 
UPS (2.1 mm x 
50 mm x 2,4 
um) 
6 n.c n.c n.c n.c HPLC-MS/MS 
Zorbax eclipse 
plus C18 
7 n.c 
SPE Oasis 
HLB 
acetone/méthanol/acétonitrile yes HPLC-MS/MS 
Acquity BEH 
C18, 
2.1*150mm, 
1.7µm 
8 n.c 
Polymeric 
reversed phase 
n.c yes HPLC-MS/MS C18 
9 n.c 
SPE Oasis 
HLB (pH 7) 
MeOH Yes HPLC-MS/MS 
Agilent 
ZORBAX 
eclipse plus C18 
(3,5 um 
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2,1*100mm) 
10 n.c 
SPE Oasis 
HLB 
acetonitrile Carbamazepine D  Polaris 
11 cooling + dark SPE Polymer n.c yes HPLC-MS C18 
12 cooling + dark SPE Polymer n.c yes HPLC-MS/MS C18 
13 pH 6.95+/- 0.2 
SPE water 
HLB 
n.c 13C3-analog HPLC-MS/MS 
Thermo Betasil, 
2.1x100m 
14 pH 7 
SPE Oasis 
HLB 
methanol 13 C compound RLC-MS/MS  
n.c : not communicated 
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8. Evaluation procedure 
 The statistical evaluation was executed according to ISO 13528 “Statistical methods 
for use in proficiency testing by interlaboratory comparisons”. 
For each series the mean value (X), the standard deviation (σ), coefficient of variation (CV), 
standard error of the mean (M), median (M), the minimum (Min) and maximum (M) values 
of each series as well as the 95% confidence interval have been calculated or reported. 
As an acceptance criteria for each result were used the z-score function according with the 
“Laboratory Accreditation & Audit Protocol: Food Inspection Directorate”3,4, following the 
AOAC & ISO & IUPAC directives. 
 
 The Z values where calculated according to the following expression: 
   
      

 
Where: 
Xlab= result for a laboratory 
X = mean values between all laboratories 
σ = Standard deviation in the correspondent population (accounting the results obtained for 
the different laboratories in this series in front of this sample) 
 
The results whose Z value was over 3 was directly excluded and when the Z-score value was 
between 2 and 3 was applied the Dixon Test with a 5% of Significance Level.  
 
 In addition, laboratory biases (D) were estimated for each results (or average of 
results) reported by each participants. D corresponds to the difference between the value (or 
average value) of laboratory (x) with the reference value (X) 
D = x – X 
According to ISO 13528, the biases were classified into three categories: D≥3.0 indicating 
an “action signal”, 2.0≤D<3.0 considered as “warming signal” and -2.0 
≤D<2.0indicating “acceptable value”. The outlier results were excluded from the 
calculation of D. 
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 Distribution of data produced by the participants for each substance was displayed in 
box plot (a.k.a. tuckey and whisker diagram). This standardized representation is based on 
five numbers: minimum, first quartile, median, third quartile, and maximum. In the simplest 
box plot the central rectangle spans the first quartile to the third quartile. A segment inside the 
rectangle shows the median and "whiskers" above and below the box show the locations of 
the minimum and maximum values (Figure 2: General scheme of simple Box plot).  
 
Figure 2: General scheme of simple Box plot 
 
  Degree of variation of the data obtained between the different participants but also 
obtained in a same laboratory was estimated by the calculation of the coefficient of variation. 
It is expressed in % and represents the ratio of the standard deviation to the mean. 
        

 
 
 
9. Results 
A total number of 13 participants took place of this study, by using the methods detailed in 
Table 7. One participant using two analytical methods, we have considered 14 series of data. 
Each participant received 3 bottles of sample A (spiked treated water) and 3 bottles of sample 
B (spiked surface water). Statistical analysis was performed by considering the spiking value 
as the reference value of the antibiotic of concern (Table 8). 
 
Table 8 : Reference value for each antibiotic in the two matrices 
 Sample A : treated water 
 
Sample B : Surface Water 
 ERY OFL SMX TMP 
 
ERY CIP OFL SMX TMP 
Spiking level 
(ng/L) 
55 40 30 50 
 
200 180 200 100 150 
 
The five anibiotics have not been measured by all laboratories. Table 9 shows the repartitions 
of the antibiotics of interest by laboratories.  
Maximum value
Minimum value
Median
First quartile
Third quartile
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Table 9 : Substances and laboratories 
         Lab 
Subst. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
ERY                
CIP                
OFL               
SMX               
TMP               
 
A total number of 611 results were collected (annex 4). The mean values, standard deviations 
(), coefficient of variation, standard error of mean, median, lower and higher values between 
results from the participant laboratories at different intervals were calculated. 
Notice that ciprofloxacin in sample A was determinate only in two laboratories. The number 
of data is too weak to be considered in the statistical analysis. Consequently, CIP in sample B 
(surface water) have been only investigated. 
 
9.1. z score 
z score values were used to calculate the outliers within the results. The calculation gave 24 
outliers (3.9% of the total number of results, see Table 10). The outliers were not distributed 
evenly across all labs. Only 4 labs produced outliers and only on one substance.  
 Figure 3 presents the absolute values of z score after exclusion of the outliers. According to 
the difference of the analytical protocols used, the number of outliers obtained in this exercise 
can be considered low. The sample matrix with the higher number of outlier was treated 
water. 
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Figure 3 : z score absolute values 
 
The outlier values were excluded for the final data treatment and the statistical parameters 
(mean values, standard deviation, variance, coefficient of variation) were calculated. Table 10 
shows the corrected statistical values (after outlier exclusion) obtained for each compound in 
the different samples.  
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Table 10 : Statistical values corrected after outlier exclusion for each compound in the different types of water: mean (x), standard deviation (), 
coefficient of variation (CV), standard error of mean (M), median (M), minimum value (Min), maximum value (Max). 
Substance  
Matrix  
Spiking 
level 
(ng/L) 
Nbr of 
accepted 
results 
x 
(ng/L) 

(ng/L)
CV 
M
(ng/L) 
M 
(ng/L) 
Min 
(ng/L) 
Max 
(ng/L) 
95% confidence 
interval Nbr of 
outlier from to 
Cyprofloxacin 
Surface Water (B) 180 55 137.96 62.44 0.45 8.42 135.03 22.59 298.54 121.12 154.80 0 
Erythromycin 
Treated water (A) 55 60 58.64 34.66 0.59 4.47 45.73 13.66 145.45 49.70 67.59 6 
Surface water (B) 200 58 296.87 252.89 0.85 33.21 170.47 54.74 1048 230.46 363.28 6 
Ofloxacin 
Treated water (A) 40 54 45.20 21.64 0.48 2.95 40.43 6.19 93.05 39.31 51.09 0 
Surface Water (B) 200 54 211.51 83.12 0.39 11.31 197.78 57.49 433.0 188.89 234.14 0 
Sulfamethoxazole 
Treated water (A) 30 70 20.0 5.67 0.28 0.68 19.83 5.64 30.51 18.64 21.35 6 
Surface water (B) 100 76 87.06 26.73 0.31 3.07 89.28 26.86 127.07 80.96 93.16 0 
Trimetoprim 
Treated water (A) 50 80 39.91 12.77 0.32 1.43 39.43 18.86 74 37.05 42.76 4 
Surface water (B) 150 80 105.79 32.98 0.31 3.69 110.70 30 178 98.41 113.16 2 
Total  587          24 
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9.2. Results by molecules and matrices 
 
Results for the different samples expressed in ng/L, mean and reference values are plotted in 
Figure 4. 
For all molecules, the tendency is the same in the two matrices concerning the comparison of 
the mean of all values and the reference value. Two behaviors can be distinguished: ERY and 
OFL show higher mean than the reference value; SMW, TMP and CIP show the contrary.  
The deviation between the two values (calculated by the ration between the observed mean 
concentration and the reference one) is important for ERY in surface water (148%) and SMX 
in treated water (66%). It corresponds to 106%, 88% 71%, 77% in surface water for OFL, 
SMX, TMP, CIP respectively and to 106%, 113%, 80% in treated water for ERY, OFL, TMP.  
This difference can be considered as representative in the case of SMX in treated water and 
TMP in surface water because the value is higher than the standard deviation (Table 10).  
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Figure 4: Results obtained for each participant for Erythromycin, Ofloxacin, 
Sulfamethoxazole, Trimethoprim and Ciprofloxacin expressed in ng/Lin the different 
samples, and mean values of results. 
These data can be represented by using Tuckey diagram representing the different 
characteristics of the values for each molecule in the two matrices (Figure 5) illustrating the 
distribution of the data. 
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Figure 5 : Tuckey diagram for the repartition of the value for treated water and surface water 
 
9.3. Coefficients of variation 
 
A comparison of the CV values (Figure 6) in both matrices (surface and treated water) for all 
laboratories resulted in a weak difference. The highest CV was observed for erythromycin in 
both matrices. It is particularly high in surface water (highest concentration). 
The lowest CV was observed for sulfamethoxazole and trimethoprim and is similar in the two 
matrices in spite of a difference in the spiked concentration. 
According to the heterogeneity of the methods employed we can consider the CV relatively 
low for the targets except for erythromycin  
  
Figure 6 : Coefficient of variation for all laboratories 
 
Several laboratories have used the same methodology in particular, same extraction cartridges 
(Oasis HLB) and chromatography techniques (HPLC/MS/MS). CV between such laboratories 
has been calculated (Figure 7). Except for ciprofloxacin in surface water, and trimethoprim in 
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treated water, CV is lower than considering all laboratories, showing an influence of the 
analytical procedure in the representativity of the results. 
 
Figure 7: CV of laboratories using oasis HLB and HPLC/MS/MS as extraction cartridge and 
chromatography techniques respectively 
 
9.4. Laboratory performances 
 
Intralaboratory repeatability has been evaluated for each substance in the two matrices and for 
each laboratory by the calculation of the coefficient of variation (Figure 8 and Figure 9).  
 
Figure 8: Intralaboratory repetability in sample A (tap water) 
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Figure 9: Intralaboratory repetability in sample B (surface water) 
 
Good intralaboratory reproducibility has been observed. CV varies from 0.5 to 25.5 % 
(median 6.6%) and to 0.8 to 19.8 % (median 5.6%) for sample A and B respectively. This 
result illustrates the important capability of the different laboratories to produce representative 
data. 
 
On the second hand, the difference between the produced values by each laboratory and the 
reference value was estimated by the calculation of the bias.  
By considering all values, the ISO 13528 classification of the laboratory biases resulted in 
85% of acceptable values, 11% of value to be survey and 5% of not acceptable values  
 
Furthermore, the average performance of the laboratories can be divided up the following 
(Table 11). The detail of the calculation is reported in annex 5.  
- 43% of the laboratories have the whole result considered as acceptable 
- 36% of the laboratories have at minimum one value to be survey 
- 14% of the laboratories have at minimum one value not acceptable 
- 7 % of the laboratories have at minimum one value to be survey and one value not 
acceptable 
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Table 11 : Laboratory biases for each values reported by the participant laboratories in the 
two matrices (surface (SW) and treated (TW) water). 0, 1 and 2 correspond to acceptable 
values, warming signal and action signal respectively (grey boxes correspond to non produced 
data) 
 
ERY CIP. OFL TMP SMX 
 
TW SW SW TW SW TW SW TW SW 
Lab 1 0 1 0 0 1 0 0 0 0 
Lab 2 0 0 
   
0 0 0 0 
Lab 3 
  
0 0 0 0 0 
  
Lab 4 
     
0 0 2 0 
Lab 5 
 
0 0 0 0 0 0 1 0 
Lab 6 0 0 0 0 0 0 2 2 0 
Lab 7 0 0 0 0 0 0 0 0 0 
Lab 8 0 0 0 0 1 1 2 2 1 
Lab 9 0 0 0 0 0 0 0 0 0 
Lab 10 
  
1 1 0 0 0 
 
0 
Lab 11 0 0 
   
0 0 1 1 
Lab 12 0 0 
   
0 0 1 0 
Lab 13 0 
 
0 
  
0 0 0 0 
Lab 14 0 0 0 0 0 0 0 0 0 
 
 
10. Conclusion 
Thirteen participants from five different countries took part in the interlaboratory exercise 
organized in the frame of Pharmas Project. 77 testing samples were analyzed to determine 
concentration of selected antibiotics and 611 results (including parallels, excluding <LOD) 
were collected for the data evaluation. The final number of 587 values was pooled out for 
further data analysis, where 24 of them (3.9 %) were determined as outliers according to 
classical approach (z score).  
 
The sample matrix yielding the highest number of outliers was, treated water (66%) 
 
According to the scheme of the ILE (no recommendation of the analytical procedure), the 
global coefficients of variation between the participants are relatively low except for 
erythromycin in the two matrices and ofloxacin in treated water. 
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The intralaboratory coefficients of variation (repeatability) show better result for each lab for 
the two matrices (below than 20%). 
 
The estimation of the laboratory biases (D) showed 5 results outside the range -3.0 σ < D <3.0 
σ (“action signals”), while 11 were “warning signals”, falling outside the range -2.0 σ< D < 
2.0 σ. 
Between the 14 participating laboratories 6 laboratories showed an excellent performance (5 
out of 6 using internal standard), never reaching the range outside -2.0 σ < D < 2.0 σ, 2 
laboratories with only one warming signal. Only three laboratories showed action signals (2 
out of 3 using internal standard). 
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Annex IV – Treatment of a pesticide-containing wastewater 
using combined biological and solar-driven AOPs at pilot 
scale 
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